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Introduction
What is population health and why is its measurement 
important?
As recently attested by the Millennium Declaration (United Nations, 2000), 
the health of populations is a concern for both governments and civil society: 
three of the eight Millennium Development Goals are defined in terms of 
health objectives. It is therefore reasonable to enquire what it means when we 
claim population health improves or declines. We should also know how to 
measure such changes. Since the Millennium Declaration does not answer 
these questions, we infer that concern for population health on the part of 
governments and civil society is not necessarily accompanied by clear concepts 
regarding its definition and measurement.
Nevertheless, substantial technical progress on population health measurement 
has been made recently (see, for example, Murray and Lopez, 1996). In 
addition, there is a substantial body of older work on life expectancy and related 
measures (for an overview, see Keyfitz and Caswell, 2005). Life expectancy, 
in addition to being one of the oldest population health measures, might 
also be the only one to have successfully established itself in popular and 
political conceptions. As we argue in the following, this very success conceals 
subtle technical points that have confounded, at least to some degree, further 
developments in population health measurement.
The large literature on the “burden of disease”, and the widespread use of 
concepts such as the QALY (see, for example, Drummond et al., 1987), 
the DALY (Murray and Lopez, 1996), the HeaLY (Hyder et al., 1998) and 
the healthy life expectancy (Sullivan, 1971) testify to a sustained scientific 
interest in population health measurement. Notably, this interest has fuelled 
the development and distribution of a number of related software tools (e.g. 
Barendregt et al., 2003; Gunning-Schepers, 1989; Gunning-Schepers, 1999; 
Kruijshaar et al., 2002; Mooy and Gunning-Schepers, 2001; Naidoo et al., 
1997; van Baal et al., 2008). However, progress in the technical dimensions 
of health measurement has not been matched by progress in political and 
popular concepts. 
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The central role of time and age
In addition to technical barriers, we propose that a lack of consensus regarding 
a central issue of population health measurement has limited the diffusion 
of modern concepts. We believe the principal disagreement centers around 
how to understand and represent the time and age dimensions of population 
health. Although human lifespan is limited in time, and age is the most 
obvious measure of its progress, disagreements about how to represent age and 
time in health measurement reflect divergent views. A corollary disagreement 
is whether data collected for the purpose of population health measurement 
should be time- or age-oriented. 
The need for a model
Measurement requires a model: to measure length, a model of length is 
necessary. Since population health is considerably harder to define than length, 
a model for its measurement is arguably even more necessary. By “model” we 
refer to a mathematical structure defining a measurement scale (e.g. a “ruler”). 
To be a valid model, the scale defined should permit the fundamental algebraic 
operations of addition, subtraction, multiplication and division (Krantz et al., 
1971). The population health model implicit in the life table is technically and 
conceptually simple. As for the model of length, it may be simple enough even 
to escape notice as a model. 
A model requires an interpretation. The interpretation makes explicit a 
correspondence between the structures and assumptions of the model and the 
reality it is intended to represent (the correspondence is usually expressed in 
terms of a “theory”). Since a simple population health model cannot support 
a detailed correspondence to complex reality, it requires more elaborate 
assumptions for its interpretation.
Terminology for population health measurement
We briefly review some terms related to population health measurement that 
are important for the research presented here. Because the terms implicitly 
express an orientation towards time and age, they define (or at least suggest) 
corresponding population health models. We discuss examples in the context 
of births and mortality.
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As noted in Keiding (2000), the years around 1870 witnessed an explosion, in 
German-speaking Europe, in the use of sophisticated graphical representations for 
population health measurement as well as in the underlying mathematical concepts. 
We begin by introducing the Lexis diagram, so called for its inventor W. Lexis 
(1875). Although there are different versions (Keiding, 2000), the Lexis diagram is 
fundamentally a two-dimensional graph with age and time dimensions (Figure 1).
This simple diagram admits several interpretations, not all of them simple. For 
example, the life line of an individual can be represented as a ray of a certain 
length. Different individuals will show different rays, always parallel, but of 
differing lengths reflecting age at death and with different starting points 
reflecting year of birth. In brief, vital events like birth and death have a unique 
(a, t) coordinate in two dimensions.
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Figure 1:  Lexis diagram showing individual life lines.
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blue curves), showing for a p pulation the number of 
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Now, if a third dimension (e.g. orthogonally out of the page) represents the 
number of individuals alive at coordinate (a, t), or some other related quantity 
of interest, this quantity defines a surface, called the Zeuner surface, after G. 
Zeuner (Keiding, 2000) (Figure 2). For simplicity, in the following we usually 
do not represent the surface, although it is important to understand that it is 
implicitly present. 
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Figure 3: The AC set of observations classified by age (age between a and a + 2) and cohort 
(born between t − a and t + 1 − a). 
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Figure 3: The AC set of obs rvations cl ssified by age (age 
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The Lexis diagram also defines three distinct two-factor classification schemes. 
These schemes, present at the birth of population health measurement, are at 
the heart of current disagreements about time and age. Notice, for example, 
that population observations classified by age and birth cohort (i.e. year of 
birth) may not show the precise timing of vital events. Such a classification of 
observations defines a set in Lexis space that is similar to the parallelogram 
shown in Figure 3. Conversely, observations classified by co ort an  period 
(an interval of time) may not indicate the precise age of the individuals 
experiencing the events. The set defined by such a classification of observations 
is similar to the parallelogram shown in Figure 4.
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Finally, the classification of observations by age and period will generally 
conceal the exact cohort of the individuals experiencing the events. The 
set corresponding to such a classifica ion of observations  is shown by the 
rectangle in Figure 5. Since the cohort is concealed, observations classified 
by age and period, such as those belonging to a set like that shown in Figure 
5, can be called synthetic. The meaning of synthetic is that such observations 
combine (literally, “put together”, but also, in practice, “confound”) the health 
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experience of more than one birth cohort. One can construct a synthetic 
cohort from the observations made of two or more “natural” cohorts. A set of 
observations corresponding to a synthetic cohort, which might be constructed 
from age−period classified data, is shown in Figure 6 by the diagonal series 
of grey squares. The synthetic cohort contains part of the vital experience of 
each of two natural cohorts: one above and the one below the bold diagonal 
line. Notice that observations of vital events occurring in the light grey-
shaded regions, which belong to these two cohorts, are not included in the set 
corresponding to the synthetic cohort.
Cross-sectional population health measures refer to measures constructed 
from observations of vital events from a single time period, such as those 
corresponding to the set shown in Figure 5. Within the measurement interval, 
period is fixed (i.e. constant). Thus, cross-sectional measures are also called 
period measures. In contrast, age is often variable in period measures, in the 
sense that the observations of different age classes (cohorts) are referenced 
(see Figure 5). Cross-sectional measures typically define a population made 
up of several different cohorts (hence, a synthetic population). Notice that, 
in this particular terminology, “synthetic population” is identical to what in 
non-technical language is usually referred to simply as the “population”. By 
showing how health experience varies by age in a given period, cross-sectional 
measures can be said to promote an “age-oriented” view of population 
health. 
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Perhaps the best-known example of a cross-sectional population health 
measure is the ordinary period life expectancy. Period life expectancy is 
a synthetic measure derived from observations of the vital experience of 
different birth cohorts. As such, unless special conditions pertain, period life 
expectancy cannot be said to be the life expectancy of any single member of 
the population.
In contrast, longitudinal population health measures are based on a time (or 
age) series of vital rates (see Figures 3, 4 and 6). Note that the time series 
may refer either to a single birth cohort (Figures 3 and 4) or to different 
ones (Figure 6). In either case, longitudinal series of measures have a cohort 
interpretation. Further, if we assume that the distribution of vital events is 
uniform in time, longitudinal observations in the cohort−age classification 
(Figure 3) can be easily transformed into the cohort−period classification 
(Figure 4). Since, in the latter classification, age is not explicit, longitudinal 
population health measures of the cohort−period type can be said to promote 
a "time-oriented" view of population health.
The longitudinal version of period life expectancy is cohort life expectancy. 
Cohort life expectancy is the life expectancy of a particular birth cohort (for 
example, that of individuals born in 1964). By definition, measuring cohort 
life expectancy requires information on the full mortality experience of the 
cohort, which in this example can only be obtained after the last person born 
in 1964 has died. It will likely be many years before it is possible to compile 
complete mortality data for this cohort. Thus, cohort life expectancy can be 
calculated only for cohorts that are no longer members of the population. 
In this respect, cohort life expectancy is like period life expectancy: apparently, 
neither is an estimate of the life expectancy of any living member of the 
population. Thus, both measures conceal problems: either of measurement 
(cohort life expectancy) or of interpretation (both life expectancies). The naive 
interpretations of life expectancy that are in common use in popular and 
political discussions are therefore incorrect (since they do not admit a valid 
correspondence with what we understand about reality); other, potentially valid, 
interpretations require elaborate and potentially unrealistic assumptions. 
The time dimension in measurements of population health
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As an example of the latter sort of interpretation is known as the stationary 
population interpretation. The interpretation derives its name from the fact that, 
when the population is “stationary”, in the sense that the health experience in 
all age classes is constant with respect to time, the population’s cross-sectional 
health measures are numerically identical to its longitudinal measures. The 
stationary population interpretation is an example of a set of assumptions 
about how a population model corresponds to what we understand about the 
reality it is supposed to measure.
Multi-state models
The preceding discussion has centered around the observation and modelling 
of vital events, and the principal focus has been on mortality. Although the 
history of population health measurement has mostly been concerned with 
mortality-based measures, in early days, Lexis and Zeuner already presented 
sophisticated multi-state descriptions of population processes, in which events 
for marriage and disability, as well as emigration and immigration, were 
represented (Keiding, 2000). In a single-state model, such as the ordinary life 
table, transitions are only to an absorbing state, such as death. For a model to be 
a multi-state model, it must represent at least one transition to a non-aborbing 
state. As in the early models of Zeuner and Lexis, non-absorbing transitions 
can be events such as marriage (and divorce), emigration (and immigration), 
or entry to (and exit from) various health conditions. 
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If transition rates are constant, the multi-state model defines a system of 
ordinary differential equations, with solutions in terms of standard exponential 
formulas. If transition rates are stratified by age, the multi-state model defines 
a multi-state life table. Figure 7 depicts a graphical representation of a multi-
state, constant-rate model with four non-absorbing states and one absorbing 
state. Transition rates are represented as arrows, where i is incidence, r remission, 
m disease-specific mortality and μ other (“background”) mortality. Note that 
transition to an absorbing state (i.e. death) is equivalent to exiting the model, 
and births are entries. Since multi-state life tables allow for calculation of 
quantities such as the average population time spent with disability or disease, 
they are of considerable interest for population health measurement, and there 
is a long tradition of their use (see, for example, Keyfitz and Caswell, 2005).
Types of population health measures
The research presented here mainly uses examples of a class of population health 
measures known as summary measures, since they summarize (usually in a single 
number) the impact of fatal and non-fatal health events on population health 
(Murray et al,. 2002). Several subfamilies of summary measures have been 
described. Health gaps  (e.g. DALYs) compare actual population health to some 
reference standard. Health expectancies (essentially multi-state generalizations 
of the life expectancy; Robine et al., 1993) summarize population health by 
means of a weighting function applied to non-fatal outcomes (non-absorbing 
states). Such a function sometimes purports to quantify the health of the 
modelled states relative to a state of perfect health (Murray et al., 2002). If 
the weighting function is simply a tabulation of numerical values by health 
state, the values are called disability weights, or health-state valuations (Murray 
et al., 2002). 
Static versus dynamic models
In conventional usage, dynamic models (such as longitudinal models) measure 
change in an outcome variable with respect to time. Similarly, static models are 
understood to be models without a time dimension. Since, as we have noted, 
time is fixed in cross-sectional models, such models are often understood to 
be synonymous with static models. 
The time dimension in measurements of population health
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In the context of the age, period and cohort classification, the question arises 
whether a population health model should not be capable of accounting for 
all three tabulation variables. A class of models designed with this criterion 
in mind has been referred to as dynamic life tables (Murray et al., 2002). A 
dynamic life table is usually described as a period life table augmented by an 
independent time dimension. More directly, in the spirit of Zeuner and Lexis, 
a dynamic life table is a model of the function N(a, t) indicated in Figure 2.
In terms of that figure, a dynamic life table could be represented by a two-
factor (e.g. age/time) table of values for N. Typical summary measures are 
derived from a dynamic life table are integrals (sums) and weighted integrals 
(weighted sums) of the function N, for example ∫a∫t N(a, t). Appropriate limits 
of integration need to be defined. When N is a tabular function (e.g. because 
it is computed numerically), the integral is simply a sum ∑a∑t N(a, t), again, 
taken over appropriate intervals of age and time. In the multi-state case, N 
itself is a (possibly weighted) sum of other populations, such as S,  X, C, and 
X&C (cf. Figure 7): N = S + X + C + X&C.
Another common term for a dynamic life table is simply a population model. In 
the ecology literature, however, such a model is usually referred to as a meta-
population model, meaning a model containing more than one population 
(Caswell, 2001). When additional precision is required, or to emphasize the 
presence of an independent time dimension, we shall frequently use the term 
“longitudinal population model”. When we wish, on the other hand, to 
emphasize the continuity of dynamic population models with classical life 
table methods, we say “longitudinal population life tables”. 
A longitudinal population model can be cast in either discrete or continuous 
time, and the choice of one or the other is often a question of convenience. For 
example, since demographic data are often reported as proportions (in terms 
of some initial at-risk population), it may be natural to cast the corresponding 
population model in discrete time, where the observed proportions are directly 
used as model parameters. Particularly in animal or plant biology, where 
mortality and reproduction are limited to specific periods, there may be clear 
subject-matter reasons to prefer discrete-time over continuous-time models 
(Caswell, 2001). Nevertheless, at least mathematically, a discrete-time model 
13
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can always be recast as a continuous-time one, and vice versa. Sometimes, as 
here, tradition plays a role; consistent with life-table methods from population 
demography, the longitudinal population health models discussed in this 
thesis are all of the continuous-time type. 
Requirements of longitudinal population models
As longitudinal population models represent a greater level of complexity 
than the ordinary period or cohort life tables, it is useful to consider whether 
they make additional demands in terms of either the technical sophistication 
required of the user or the kinds of data required for input parameters. A 
corollary question is whether any additional data requirements can be satisfied 
by the sort of data that are typically available in practice.
In reply to the first question, the technical demands made by longitudinal 
population models are modest compared with those of other technical fields, 
for example engineering or actuarial science. In addition, computational 
barriers that in the past made a simple one-dimensional single-state life table 
an attractive option for population health measurement can no longer be 
considered relevant. Finally, the would-be user of longitudinal population 
models has access to a body of publications, some of which are referred to 
here, that explain in detail their methods and concepts. Therefore, technical 
complexity cannot be considered an important barrier to the use of longitudinal 
population life tables.
On the other hand, to supply the parameters required by a longitudinal 
population model, especially the multi-state kind, can be more challenging. 
To start, population data corresponding to the age classes used in the model 
are required. Although it is possible in principle to use age classes of any 
width, it is common practice as well as conceptually simple to define one-year 
age classes as the unit of analysis (Caswell, 2001). So data on population size 
and population vital rates are required in terms of one-year age groups. Since 
most applications typically need to distinguish outcomes by sex, sex-specific 
data on population size and vital rates by year of age comprise a minimum 
set of required data. For the multi-state population model, basic information 
about different disease states of interest is also required, usually in the form 
of an incidence, prevalence, mortality (IPM) model (Kruijshaar et al., 2002). 
The time dimension in measurements of population health
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Finally, to define the distribution of the total population across subpopulations 
at the start of the simulation, information on the prevalence of each modelled 
condition is required.
Some of these data may be routinely estimated and made available in disease 
registries, or published by health agencies. Some of the additional data required, 
especially those required for disease-specific outcomes, will either be difficult to 
obtain or possibly difficult even to observe. For example, disease mortality and 
remission rates frequently differ according to disease severity, or according to the 
presence or absence of comorbidities. In addition, there may be several distinct 
disease stages, each with its own particular transition rates. Such complexities 
require additional data. If all the required data are not available, it may be 
possible to obtain the necessary parameter estimates by employing methods 
that more fully make use of the data that are available. For example, as in the 
IPM model, it may be possible to assume the existence of systematic relations 
between disease parameters; these relations can then be used to estimate missing 
parameters. In a few cases, merely changing denominators appropriately (e.g. to 
transform population-level mortality estimates to estimates for subpopulations) 
can yield estimates of parameters that are not directly observed. Yet other 
parameter estimates may be obtained by unit analysis of observed parameters, 
such as by obtaining the recovery rate as the inverse of disease duration.
However, all such indirect approaches require assumptions. In particular, 
the unobserved parameters need to be representable in a model whose form 
is simple enough to facilitate indirect estimation (e.g. the IPM model) yet 
complex enough to provide a convincing representation of the relevant process. 
The assumptions required for inference (characterized mainly by simplicity) 
may be in conflict with the needs of validity and realism. Moreover, estimates 
resulting from indirect methods depend on the validity of the assumptions 
used, such as the degree of simplification or approximation involved. 
Given the significant demands for data that are made by population health 
modelling, especially in a longitudinal and multi-state framework, the 
availability of the required data can become a central concern. Indeed, 
embarking on a project of multi-state longitudinal population health 
modelling can involve a constant struggle to meet the ambitious demands 
15
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of the model for parameters using only the scarce supply of data available in 
practice. Despite the required assumptions and limitations of such methods, 
the demand for parameters can typically be met only by the creative use of 
indirect methods of estimation,. 
Stationary population interpretation
One of the more powerful methods of indirect estimation is the stationary 
population interpretation referred to above. As we describe subsequently, 
applying this interpretation allows us to identify a number of “implicit” dynamic 
methods. These methods mitigate, to a certain extent, the need for data inherent 
in multi-state longitudinal population modeling. In addition to the life table, a 
number of other simple models admit the stationary population interpretation. 
Unlike life tables, however, these other models are not purpose-built population 
health models but are rather descriptive and statistical models in wide use in 
epidemiology, econometrics, ecology and related fields. In the body of the thesis 
we discuss the implications of some of these models, and show examples of how 
they can be employed for population health measurement in the absence of 
complete information about the required model parameters. 
Perhaps the most fundamental implicit dynamic model is the logistic model, 
which includes the exponential model as a special case. Taken together, these 
two models have extremely wide scope of application in the study of growth 
processes and epidemics. They can in turn be embedded in a richer set of 
related models such as generalized logistic growth models (Tsoularis and 
Wallace, 2002) and models for the so-called GS-distributions (generalized 
S-distributions; Muiño et al., 2006). With the exception of the models for 
GS-distributions, which have a more statistical formulation, all of these 
models are fundamentally longitudinal models of dynamic processes; thus, 
under the assumption of population equilibrium in the model covariates, the 
dynamics are reproduced in cross section.
Research questions addressed by this thesis
The research presented in this thesis can be described in terms of a number 
of related research questions, some general and others more specific. The 
individual chapters in the body of the thesis are designed to shed light on 
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these questions, which thus form the unifying themes of the research. By 
general questions we have in mind questions that can be considered of general 
importance for scientific work in the field of population health measurement. 
Another feature is that such questions typically do not permit completely 
determined and discrete answers. The general questions that we examine can 
be formulated as follows:
Should we care about the longitudinal (i.e. time) dimension of population G1. 
health? To motivate this question, we have argued above that population 
time dynamics are an essential concern for the measurement of population 
health. 
Do longitudinal measures allow us to answer questions about population G2. 
health better than other measures? To address this question we focus, in 
particular, on an important set of questions of the form “What is the 
impact on population health of a given course of action?”, i.e. we examine 
how longitudinal measures can be applied in answering questions about 
quantifying risks to health as well as in quantifying the benefits of 
interventions designed to improve health. 
Are standard models from other scientific fields relevant to questions of G3. 
population health measurement? In relation to this question, we apply some of 
these models to addressing questions of population health measurement.
Inherent in the approach adopted here is an effort to illustrate general questions 
through related subsidiary questions which, as they are more specific in their 
formulation, offer the possibility of more tightly circumscribed answers. 
The subsidiary questions we address here concern, on the one hand, the 
practicability and feasibility of the methods inspired by the general questions. 
On the other hand, they also concern the nature and usefulness of the results 
that can be obtained by application of these methods. Two of the specific 
questions addressed here are as follows:
Is it possible to develop an easy-to-use, reasonably generic, longitudinal S1. 
model that can be used for population health measurement with generally 
available epidemiologic and demographic data?
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Is it feasibile to apply a generic, longitudinal model to quantify population S2. 
health risks, or to quantify the benefits of interventions to improve health, and 
what sort of insights can be obtained through its application?
These specific questions (S1, S2) are related to the first two general questions 
(G1, G2) identified above. The third general question (G3) is explored through 
the following specific questions:
Does the logistic family of models offer an approach relevant to longitudinal S3. 
population health measurement? 
Is it feasibile to apply logistic models to quantify real population health S4. 
risks and what sort of insights can be obtained through their application?
In tabular form, the specific questions relate to the general questions as 
follows:
(S1, S2) → (G1, G2)
(S3, S4) → (G3).
Contents of thesis and relation to research questions
With the exception of Chapter 8, the chapters in the body of the thesis relate 
to one of the specific questions. The present introductory chapter, Chapter 
1, motivates the research and introduces the research questions. The final 
chapter, Chapter 9, discusses answers to the research questions, highlights 
areas for additional research and proposes conclusions and recommendations. 
We also attach two technical appendices that discuss in detail two of the areas 
for further research. A description of the chapters in the body of the thesis, 
and their relation to the research questions, follows.
Chapter 2 looks at the technical aspects of constructing a generic multi-state 
longitudinal population model. In that chapter, the technical feasibility of such 
a model is demonstrated, which is relevant for question S1. In addition, some 
of the issues related to the availability and use of data are also touched upon; 
however, these questions are also addressed in the subsequent two chapters. 
Chapter 3 describes a particular application of the model described in Chapter 
2 to the cost-effectiveness analysis of interventions to lower blood pressure 
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and cholesterol. In much the same spirit, Chapter 4 describes an application 
of the model to the cost-effectiveness analysis of malaria control strategies. 
Both chapters respond primarily to question S2, which concerns the feasibility 
of applying a generic longitudinal model to quantify real population health 
interventions and risks; these chapters also illustrate questions concerning the 
use and availability of the sort of data required for a multi-state longitudinal 
population model.
Chapter 5 examines how the logistic model, one of the most widely used 
models in epidemiology, ecology and related fields, can be derived from 
basic processes that are relevant for standard applications of the model. An 
examination of these processes shows their importance for population health 
measurement (question S3).
Chapter 6 and Chapter 7 discuss an application of the logistic model to questions 
of population health measurement; specifically, these chapters demonstrate 
the feasibility of using the logistic model (relevant to S4) to infer missing 
epidemiological parameters relevant to the measurement of exposure to a risk 
factor. Chapter 6 addresses the technical aspects of prevalence estimation; 
Chapter 7 uses the resulting exposure estimates to estimate the impact of 
the risk factor on population health using the framework of population 
attributable fraction. As such, Chapter 7 is the only chapter that does not use 
an explicitly dynamic (longitudinal) method to estimate population health. 
Although this was originally done for comparability with similar estimates 
published in the World health report 2002 (WHO, 2002), it also allows for a 
discussion of the advantages and disadvantages of cross-sectional methods.
Chapters 5, 6 and 7 thus all relate to the third general question, regarding 
the use of models from other fields in population health measurement. In 
adopting an econometric time-series model for panel data to analyse the 
determinants of health care utilization in a group of developed countries, 
Chapter 8 also relates to this question. That chapter provides a detailed 
opportunity to compare directly longitudinal and cross-sectional estimates of 
the same phenomenon. Chapter 9 concludes.
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Abstract
This article provides a description of the population model PopMod, which 
is designed to simulate the health and mortality experience of an arbitrary 
population subjected to two interacting disease conditions as well as all other 
“background” causes of death and disability. Among population models with 
a longitudinal dimension, PopMod is unique in modelling two interacting 
disease conditions; among the life-table family of population models, PopMod 
is unique in not assuming statistical independence of the diseases of interest, 
as well as in modelling age and time independently. Like other multi-state 
models, however, PopMod takes account of “competing risk” among diseases 
and causes of death.
PopMod represents a new level of complexity among both generic population 
models and the family of multi-state life tables. While one of its intended uses 
is to describe the time evolution of population health for standard demographic 
purposes (e.g. estimates of healthy life expectancy), another prominent aim 
is to provide a standard measure of effectiveness for intervention and cost-
effectiveness analysis. PopMod, and a set of related standard approaches 
to disease modelling and cost-effectiveness analysis, will facilitate disease 
modelling and cost-effectiveness analysis in diverse settings and help make 
results more comparable. 
The time dimension in measurements of population health
26
Introduction
Historical background and analytical context
Measuring population health has been inseparable from modelling population 
health for at least three hundred years. The first accurate empirically based life 
table − a population model, albeit a simple one − was constructed by Edmund 
Halley in 1693 for the population of Breslau, Germany.[1] However, the 1662 
life table of John Graunt, while less rigorously based on empirical mortality 
data, represented a reasonably good approximation of life expectancy at 
birth in the seventeenth century.[2] Indeed, because of Graunt’s strong a 
priori assumptions about age-specific mortality, his life table could be said to 
represent the first population model. Recently, multi-state life tables, which 
explicitly model several population transitions, have become a common tool 
for demographers, health economists and others, and a considerable body of 
theory has been developed for their use and interpretation.[3-5] Despite the 
substantial complexity of existing multi-state models, a recent publication has 
highlighted the advantages of so-called “dynamic life tables”, in which age 
and time would be modelled independently.[6] 
Mathematical and computational constraints are no longer serious obstacles 
to solving complex modelling problems, although the empirical data required 
for complex models are. In particular, multi-state models present data 
requirements that can rapidly exceed empirical knowledge about real-world 
parameter values, and in many cases, the input parameters for such models 
are therefore subject to uncertainty. Nevertheless, even with substantial 
uncertainty, such models can provide robust answers to interesting questions. 
Indeed, the work of John Graunt demonstrates the practical value of results 
obtained with even purely hypothetical parameter values.
PopMod, one of the standard tools of the WHO-CHOICE programme 
(http://www.who.int/evidence/cea), is the first published example of a multi-
state dynamic life table. Like other multi-state models, PopMod takes 
account of “competing risk” among diseases, causes of death and possible 
interventions. However, PopMod represents a new level of complexity among 
both generic population models and the family of multi-state life tables. 
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Among population models with a longitudinal dimension, PopMod is unique 
in modelling two distinct and possibly interacting disease conditions; among 
the life-table family of population models, PopMod is unique in not assuming 
statistical independence of the diseases of interest, as well as in modelling age 
and time independently. 
While one of PopMod’s intended uses is to describe the time evolution of 
population health for standard demographic purposes (e.g. estimates of 
healthy life expectancy), another prominent aim is to provide a standard 
measure of effectiveness for intervention and cost-effectiveness analysis. 
PopMod, and a related set of standard approaches to disease modelling and 
cost-effectiveness analysis used in the WHO-CHOICE programme, facilitate 
disease modelling and cost-effectiveness analysis in diverse settings and help 
make results more comparable. However, the implications of a tool such as 
PopMod for intervention analysis and cost-effectiveness analysis is a relatively 
new area with little published scholarship. Most published cost-effectiveness 
analysis has not taken a population approach to measuring effectiveness, 
and when studies have done so they have generally adopted a steady-state 
population metric.[7] Relatively little published research has noted the biases 
of conventional approaches when used for resource allocation.[8] 
Despite similarities in some of the mathematical techniques,[9] this paper 
does not consider transmissible disease modelling. 
Basic description of the model 
PopMod simulates the evolution in time of an arbitrary population subject to 
births, deaths and two distinct disease conditions. The model population is 
segregated into male and female subpopulations, in turn segmented into age 
groups of one-year span. The model population is truncated at 101 years of 
age. The population in the first group is increased by births, and all groups 
are depleted by deaths. Each age group is further subdivided into four distinct 
states representing disease status. The four states comprise the two groups 
with the individual disease conditions, a group with the combined condition 
and a group with neither of the conditions. The states are denominated for 
convenience X, C, XC and S, respectively. The state entirely determines health 
status and disease and mortality risk for its members. For example, X could 
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be ischaemic heart disease, C cerebrovascular disease, XC the joint condition 
and S the absence of X or C.
State members undergo transitions from one group to another, they are 
born, they get sick and recover, and they die. The four groups are collectively 
referred to as the total population T, births are represented as the special 
state B, and deaths as the special state D. A diagram for the first age group 
is shown in Figure 1 (notation used is explained in the section Describing 
states, populations and transitions between states). In the diagram, states are 
represented as boxes and flows are depicted as arrows. Basic output consists 
of the size of the population age-sex groups reported at yearly intervals. From 
this output further information is derived. Estimates of the severity of the 
states X, C, XC and S are required for full reporting of results, which include 
standard life-table measures as well as a variety of other summary measures 
of population health. 
There now follows a more technical description of the model and its 
components, broken down into the following sections: describing states, 
populations and transitions between states; disease interactions; modelling 
mechanics; and output interpretation.  The article concludes with a discussion 
of the relation of PopMod to other modelling strategies, plus a consideration 
of the implications, advantages and limitations of the approach. 
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Describing states, populations and transitions 
between states
Describing states and populations
In the full population model depicted in Figure 1, six age-and-sex specific 
states (X, C, XC, S, B and D) are distinguished. However, births B and deaths 
D are special states in the sense that they only feed into or absorb from other 
states (while the states X, C, XC and S both feed into and absorb from other 
states). Special states are not treated systematically in the following, which 
focuses on the “reduced form” of the model consisting of the states X, C, XC, 
and S. 
B
X
C
S
XC
D
rx→xc
m
rs→crc→srxc→x
rc→xc
rx→s
rxc→c
rs→x
m +
fc
m + fx
m + fxc
bin 0
T
Figure 1: The differential equations model.
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States are not distinguished from their members; thus, “X” is used to mean 
alternatively “disease X” or “the population group with disease X”, according 
to context. The second meaning is equivalent to the prevalence count for the 
population group. 
For the differential equation system, states/groups are always denoted in the 
strict sense: “X” means “state X only” or “the population group with only 
X”. However, in deriving input parameters (described more fully below in 
the section Disease interactions) from observed populations, it is convenient 
to describe groups in a way that allows for the possibility of “overlap”. For 
example in Figure 2, the area “X” might be understood to mean either “the 
population group with X including those members with C as well” (i.e. the 
entire circle X) or the “the population group with only X” (i.e. the circle 
minus the region overlapping with circle C).       
   
     
Figure 2
A schematic for describing observed populations.
Table 1: Alternative ways to describe populations.
Logical expression Meaning Differential equations expression
~ X~ C Population group with neither X nor C S
X~ C Population group with X but not C, i.e. with X only X
~ XC Population group with C but not X, i.e. with C only C
~ X Population group without X S + C
~ C Population group without C S + X
X Total population group with X X + XC
C Total population group with C C + XC
S Susceptible population S
XC Population with both X and C XC
T Total population T
Figure 2: A schematic for describing observed populations.
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Since these two valid meanings imply different uses of notation, the following 
conventions are adopted:
The differential equations expressions X, C, XC and S refer only to disjoint 	
states (or groups).
The logical operator “~”means “not”, thus “~X” is the state “not X”  (or 	
“the group without X”).
The logical expressions denoted in the left-hand column of Table 1 have 	
the meaning and alternative description indicated in the two right-hand 
columns.
       
   
     
Figure 2
A schematic for describing observed populations.
Table 1: Alternative ways to describe populations.
Logical expression Meaning Differential equations expression
~ X~ C Population group with neither X nor C S
X~ C Population group with X but not C, i.e. with X only X
~ XC Population group with C but not X, i.e. with C only C
~ X Population group without X S + C
~ C Population group without C S + X
X Total population group with X X + XC
C Total population group with C C + XC
S Susceptible population S
XC Population with both X and C XC
T Total population T
       
   
     
Prevalence rates (p) describe populations (i.e. prevalence
counts) as a proportion of the total, for example:
pX = X/T, pC = C/T, pXC = XC/T, pS = S/T.  (1)
Here, prevalence is presented in terms of the disjoint pop-
ulations X, C and XC, and the notation from the right-
hand column of Table 1 is used. In the section Disease
interactions, we discuss the case of overlapping
populations.
A prevalence rate is always interpretable as a probability,
but a probability is not always interpretable as a preva-
lence. The lower-case Greek letter pi () is used through-
out this article to denote probability. Probabilities can be
used to describe populations as noted in Table 2.
Describing transitions between states
In the differential equation system, transitions (i.e. flows)
between population groups are modelled as instantane-
ous rates, represented in Figure 1 as labelled arrows. In-
stantaneous rates are frequently called hazard rates, a
usage generally adopted here (demographers tend to refer
to instantaneous rates as "hazards" or as "forces" – e.g.
force of mortality – although epidemiologists commonly
use the term "rate" with the same meaning). A transition
hazard is labelled here h, frequently with subscript arrows
denoting the specific state transition.
In PopMod terminology, the transitions XD, CD and
XCD are partitioned into two parts, one of which is the
cause-specific fatality hazard f due to the condition X, C or
XC, and the other which is the non-specific death hazard
(due to all other causes), called background mortality m:
hXD = fX + m  (2a)
hCD = fC + m  (2b)
hXCD = fXC + m  (2c)  (2)
hSD = m.  (2d)
PopMod consequently allows for up to twelve exogeneous
hazard parameters (Table 3).
Transition hazards
A time-varying transition hazard is denoted h(t). The haz-
ard expresses the proportion of the at-risk population (dP/
P) experiencing a transition event (i.e. exiting the popula-
tion) during an infinitesimal time dt:
h(t) = - (1/P)·dP/dt.  (3)
"Instantaneous rate" means the transition rate obtaining
during the infinitesimal interval dt, that is, during the in-
stant in time t. If an instantaneous rate does not vary, or
its small fluctuations are immaterial to the analysis, Pop-
Mod parameters can be interpreted as average hazards
without prejudice to the model assumptions.
Average hazards can be approximated by counting events
P during a period t and dividing by the population time
at risk. If for practical purposes the instantaneous rate
does not change within the time span, the approximate
average hazard can be used as an estimate for the underly-
ing instantaneous rate:
- (1/P)·dP/dt  -dP / Pdt  - P / (P·t),  (4)
where P = dP is the cumulative number of events occur-
ring during the interval t, and Pdt  P·t is the
corresponding population time at risk. Time at risk is ap-
proximated by multiplying the mid-interval population
(P) by the length of the interval t.
For example, if ten deaths due to disease X (P = 10) occur
in a population with approximately one million years of
time at risk (P·t = 1,000,000), an approximation of the
instantaneous rate hXD(t) is given by:
hXD (t)  P / P·t = 10 / 1,000,000 = 0.00001.  (5)
Note that while eq. (3) and eq. (4) are equivalent in the
limit where t0, the approximation in eq. (4) will result
in large errors when rates are high. This is discussed in the
section Proportions and hazard rates, and an alternative for-
mula for deducing average hazard is proposed in eq. (9).
The quantity in eq. (4) has units "deaths per year at risk",
and is often called a "cause-specific mortality hazard". For
the same population and deaths, but restricting attention
Table 2: Probability of finding members of population groups in PopMod.
Symbol Description
X Probability of finding a member of T that is a member of X with random selection.
C Probability of finding a member of T that is a member of C with random selection.
XC Probability of finding a member of T that is a member of XC with random selection.
Table 1: Alternative ways to describe populations.
Table 2:  Probability of finding members of population groups 
in PopMod.
Prevalence rates (p) describe populations (i.e. prevalence counts) as a proportion 
of the total, for example:
 pX = nX/nT, pC = nC/nT, pXC = nXC/nT, pS = nS/nT. (1)
Here, prevalence is presented in terms of the disjoint populations X, C and 
XC, a d the notation from the ight-hand column of T ble 1 is used. In the 
section Disease interactions, we discuss the case of overlapping populations. 
A prevalence rat  is always interpretable as a robability, but a probability is 
not always interpretable as a prevalence. The lower-cas  G eek letter pi (π) is 
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used throughout this article to denote probability. Probabilities can be used 
to describe populations as noted in Table 2.
Describing transitions between states
In the differential equation system, transitions (i.e. flows) between population 
groups are modelled as instantaneous rates, represented in Figure 1 as labelled 
arrows. Instantaneous rates are frequently called hazard rates, a usage generally 
adopted here (demographers tend to refer to instantaneous rates as “hazards” 
or as “forces” - e.g. force of mortality - although epidemiologists commonly 
use the term “rate” with the same meaning). A transition hazard is labelled 
here h, frequently with subscript arrows denoting the specific state transition. 
In PopMod terminology, the transitions X→D, C→D and XC→D are 
partitioned into two parts, one of which is the cause-specific fatality hazard 
f due to the condition X, C or XC, and the other which is the non-specific 
death hazard (due to all other causes), called background mortality m:
hX→D = fX + m
hC→D = fC + m
hXC→D = fXC + m
hS→D = m.
(2a)
(2b)
(2c)
(2d)
(2)
PopMod consequently allows for up to twelve exogeneous hazard parameters 
(Table 3). 
Transition hazards
A time-varying transition hazard is denoted h(t). The hazard expresses the 
proportion of the at-risk population, P (dP/P), experiencing a transition event 
(i.e. exiting the population) during an infinitesimal time dt:
h(t) = −(1/P) · dP/dt. (3)
“Instantaneous rate” means the transition rate obtaining during the 
infinitesimal interval dt, that is, during the instant in time t. If an instantaneous 
rate does not vary, or its small fluctuations are immaterial to the analysis, 
PopMod parameters can be interpreted as average hazards without prejudice 
to the model assumptions. 
33
Chapter 2 PopMod: a longitudinal population model with two interacting disease states
Average hazards can be approximated by counting events ∆P during a period 
∆t and dividing by the population time at risk. If for practical purposes the 
instantaneous rate does not change within the time span, the approximate average 
hazard can be used as an estimate for the underlying instantaneous rate:
 −(1/P) · dP/dt ≈ −∫dP / ∫Pdt ≈ −∆P / (P · ∆t), (4)
where ∆P = ∫dP is the cumulative number of events occurring during the 
interval ∆t, and ∫Pdt ≈ P · ∆t is the corresponding population time at risk. 
Time at risk is approximated by multiplying the mid-interval population (P) 
by the length of the interval ∆t. 
For example, if ten deaths due to disease X (∆P = 10) occur in a population 
with approximately one million years of time at risk (P · ∆t  = 1,000,000), an 
approximation of the instantaneous rate hX→D (t) is given by:
hX→D (t) ≈ ∆P / P · ∆t = 10 / 1,000,000 = 0.00001 . (5)
Note that while eq. (3) and eq. (4) are equivalent in the limit where ∆t→0, 
the approximation in eq. (4) will result in large errors when rates are high. 
This is discussed in the section Proportions and hazard rates, and an alternative 
formula for deducing average hazard is proposed  in eq. (9).
The quantity in eq. (4) has units “deaths per year at risk”, and is often called 
a “cause-specific mortality hazard”. For the same population and deaths, but 
restricting attention to the group with disease X (where, for example, P · ∆t = 
10,000) the calculated hazard will be larger:
hX→D (t) ≈ ∆P / P · ∆t = 10 / 10,000 = 0.001. (6)
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   
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to the group with disease X (where, for example, P·t =
10,000) the calculated hazard will be larger:
hXD (t)  P / P·t = 10 / 10,000 = 0.001.  (6)
The quantity i  eq. (6) has the s me units as that in eq.
(5), but is a "case fatality hazard". Note that the same tran-
sition events (e.g. "dying of disease X") can be used to de-
fine different hazard rates depending on which
population group is considered.
Proportions and hazard rates
Integration by parts of eq. (3) shows that the proportion
of the population experiencing the transition in the time
interval t (i.e. the "incident proportion") is given by:
If the hazard is constant, that is, if h(t) = h(t0) = h, dt = t
and the integral collapses. The incident proportion is then
written:
The incident proportion can always be interpreted as the
average probability that an individual in the population
will experience the transition event during the interval
(e.g. for mortality, this probability can be written PD =
P/P). The qualification "average" is dropped if individu-
als in P are homogeneous with respect to transition risk
during the interval.
Even if the hazard is not constant, eq. (8) can be rear-
ranged to give an alternative (exact) formula for calculat-
ing the equivalent constant hazard h yielding P
transitions in the interval t:
However, if the true hazard is constant during the interval,
the "equivalent constant hazard" equals the "average haz-
ard" and the "instantaneous rate". The same identity ap-
plies when fluctuations in the underlying hazard are of no
practical importance. PopMod requires the assumption
that hazards are constant within the unit of its standard re-
porting interval, defined by convention as one year.
Note that series expansion of exp{-h·t} or ln{1-P/P}
shows that, for values f h·t << 1 nd P/P << 1, the
equivalent constant hazard is well approximated by the
time-normalized incident proportion, and vice versa, as in
eq. (4):
Case-fatality hazards
Case-fatality hazards fX, fC, and fXC are defined with re-
spect to the specific populations X, C and XC, respectively:
Table 3: Transition hazards in the population model.
Hazard Description State transition
hSX incidence hazard SX
hXS remission hazard XS
hSC incidence hazard SC
hCS remission hazard CS
hXD case fatality hazard XD
hCD case fatality hazard CD
hXCD case fatality hazard XCD
hTD background mortality hazard TD
hCXC incidence hazard CXC
hXCC remission hazard XCC
hXXC incidence hazard XXC
hXCX remission hazard XCX
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Table 3: Transition hazards in the population model.
The time dimension in measurements of population health
34
The quantity in eq. (6) has the same units as that in eq. (5), but is a “case fatality 
hazard”. Note that the same transition events (e.g. “dying of disease X”) can 
be used to define different hazard rates depending on which population group 
is considered. 
Proportions and hazard rates
Integration by parts of eq. (3) shows that the proportion of the population 
experiencing the transition in the time interval ∆t (i.e. the “incident 
proportion”) is given by:
∫
∆+
−−=∆
tt
t
tth
tP
P 0
0
d)(exp1
)( 0
(7)
If the hazard is constant, that is, if ht hth == )()( 0 , tt ∆=∫d  and the 
integral collapses. The incident proportion is then written:
th
P
P ∆⋅−−=∆ e1
.
(8)
The incident proportion can always be interpreted as the average probability 
that an individual in the population will experience the transition event during 
the interval (e.g. for mortality, this probability can be written πP→D = ∆P/P). 
The qualification “average” is dropped if individuals in P are homogeneous 
with respect to transition risk during the interval.
Even if the hazard is not constant, eq. (8) can be rearranged to give an 
alternative (exact) formula for calculating the equivalent constant hazard h 
yielding ∆P transitions in the interval ∆t:
t
P
Ph ∆



 ∆−−= /1l  n
.
(9)
However, if the true hazard is constant during the interval, the “equivalent 
constant hazard” equals the “average hazard” and the “instantaneous rate”. 
The same identity applies when fluctuations in the underlying hazard are 
of no practical importance. PopMod requires the assumption that hazards 
are constant within the unit of its standard reporting interval, defined by 
convention as one year.
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Note that series expansion of { }th ∆⋅−exp  or { }PP∆−1ln  shows that, for 
values of 1<∆⋅ th  and 1/ <∆ PP , the equivalent constant hazard is well 
approximated by the time-normalized incident proportion, and vice versa, as 
in eq. (4):
P
P
t
h ∆
∆
≈ 1
.
(10)
Case-fatality hazards
Case-fatality hazards fX, fC, and fXC are defined with respect to the specific 
populations X, C and XC, respectively:
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(13)
Mortality hazards
Mortality hazards are defined with respect to the entire population, where 
cause-specific mortality hazards are conditional on cause of death:


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(16)
The background mortality rate m is defined as the instantaneous rate of 
deaths due to causes other than X or C. 
/
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Disease interactions
PopMod is typically used to simulate the evolution of a population subjected to 
two disease conditions, where health status, health risk and mortality risk are 
conditional on disease state. Health status, health risk and mortality risk are 
plausibly conditional on disease state when the two primary disease conditions 
X and C interact. Such interactions can be analysed from various perspectives, 
for example, common risk factors, common treatments, common prognosis; 
however, the primary perspective adopted here for the pupose of analysis 
is that of “common prognosis”, by which is meant that the two conditions 
mutually influence prevalence, incidence, remission and mortality risk. 
A previously cited example was that of ischaemic heart disease (X) and 
cerebrovascular disease (C): it is well known that individuals with either heart 
disease or stroke history have lower health status and higher mortality risk 
than individuals with neither of these conditions, and that individuals with 
heart disease are at increased risk for stroke and vice versa. 
Furthermore, individuals with history of both heart disease and stroke (XC) 
are known to have higher mortality risk and lower health status than either 
individuals with only one of the disease histories or those with neither. 
However, in this example as in many others, information about the joint 
condition (heart disease and stroke) is scarce relative to information about the 
two individual conditions (heart disease or stroke). The obvious reason for 
this is that the population group with the joint condition is smaller in size and 
has a lower life expectancy, reducing opportunities for data collection. 
The presimulation problem
One of PopMod’s guiding principles, therefore, is that while an analyst has 
access to information about basic parameter values for the conditions X and 
C (i.e. prevalence rates and incidence, remission and either case-fatality or 
cause-specific mortality hazards), the same is not generally true for the joint 
condition XC. Thus, more or less by construction, the modelling situation is 
one in which data for the joint condition are scarce or unavailable, and must 
consequently be derived from data known for the individual conditions. 
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An important implication is that the data available for the individual 
conditions (X and C) will be reported in terms of overlapping populations. 
Where specifically noted, therefore, the notation in the left-hand column of 
Table 1 (Logical expressions) is used in the following, with the particular 
implication that “X”, for example, means “the population group with 
X including those members with C as well” (i.e. “X + XC” in differential 
equations terminology).
Once parameter values for the joint condition are determined, the minimum 
set of parameters required for population simulation are known. This 
parameter-value problem – referred to here as the presimulation problem, 
since its solution must precede population simulation per se – can be divided 
into two principal parts: one concerning the prevalence rates defining the 
intial conditions (stocks) of the differential equations system, and the other 
the transition hazards defining its flows. These stocks and flows together make 
up the initial scenario of the population model. A cross-sectional approach is 
adopted in which deriving these two kinds of parameters values for the initial 
scenario are treated as separate problems. 
The analytics of these derivations largely depend on which of a range of 
possible assumptions is made about the interactions of the two principal 
conditions. The simplest possible assumption is essentially an assumption of 
non-interaction (statistical independence). Since an understanding of the non-
interacting case is an essential starting point for more complex interactions, 
it is discussed first.
The independence assumption
Prevalence for the joint group
When conditions X and C are statistically independent, the joint prevalence 
is the product of the individual (marginal) prevalences:
pXC = pX · pC. (17)
Transition hazards for the joint group
Independence implies that the hazards for the group with X or C are equal 
to the corresponding hazards for the group without X or C (in eq. (18) 
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populations are denoted in differential equations (disjoint) notation from the 
right-hand column of Table 1):
hXC→C = hX→S
hXC→X = hC→S
hC→XC = hS→X
hX→XC = hS→C
(18)
Joint case fatality hazard
The probabilities 
DX X→π  and D→CCπ  for an individual in group X or C to 
die of cause X or C, respectively, during an interval t∆ are:
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So the joint probability D → Cor  XXCπ  for someone in the group XC dying of either X or C is given by the laws of probability:
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(20)
Although individuals in the joint group XC are at risk of death from either X or 
C, or from other causes, the probability framework requires the assumption that 
they do not die of simultaneous causes (i.e. there is no cause of death “XC”). 
The combined case-fatality rate fXC is thus: 
CXXC fff += . (21)
This simple addition rule can be generalized to situations with more than two 
independent causes of death.
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Background mortality hazard
The “background mortality hazard” m expresses mortality risk for population 
T due to any cause of death other than X and C. The “independence 
assumption” claims m is independent of these causes, in other words, that 
m acts equally on all groups (in eqs. (22−25) populations are denoted in 
differential equations notation from the right-hand column of Table 1): 
XCmCmXmSmXCCXSmTm ⋅+⋅+⋅+⋅=+++⋅=⋅ )( . (22)
The total (“all cause” or “crude”) death hazard for the population is written 
mtot. The following identity expresses the constraint that deaths in population 
T equal the sum of deaths in populations S, X, C and XC: 
XCfmCfmXfmSmTm ⋅++⋅++⋅++⋅=⋅ )()()( XCCXtot . (23)
Thus:
).()(
)(
)(
CX
CXCX
XCCXtot
XCCfXCXfTm
XCffCfXfTm
XCfCfXfXCCXSmTm
+⋅++⋅+⋅=
⋅++⋅+⋅+⋅=
⋅+⋅+⋅++++⋅=⋅
(24)
Since by definition group X  or C contributes no deaths due to cause C or X, 
respectively, we can write the system of equations: 
TmXCCf ⋅=+⋅ CC )( ,
TmXCXf ⋅=+⋅ XX )( ,
(25)
so:
TmTmTmTm ⋅+⋅+⋅=⋅ CXtot . (26)
and:
CXtot mmmm −−= . (27)
Likewise, this rule is generalizable to scenarios with more than three (m, X, 
C) independent causes of death.
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Relaxing the independence assumption
As noted in the introduction, one of the primary reasons for the introduction of 
PopMod was to model disease interactions in a longitudinal population model. 
Modelling interactions requires relaxing the assumption of independence. 
In the presimulation (see p. 36) of the “stocks and flows” required for the 
initial scenario, three areas of interaction for the health states X and C can be 
distinguished. Having X (C) may make it more or less likely to:
 
have C (X), (1) 
acquire or recover from C (X), (2) 
die from C (X). (3) 
Note that  while interaction (1) could alternatively be considered the cumulative 
result of interactions (2) and (3)  in the past, this is not the approach adopted 
here. 
Interaction (1): Prevalence of the joint group
In this and subsequent sections except where noted, we revert to the notation 
from the left-hand column of Table 1. Table 4 shows six possible cases for 
calculating prevalence of the joint group depending on the type of information 
known about the disease interaction. The probability notation π is used for 
prevalence, where πX|C is the probability of having disease X among those who 
have disease C and πX and πC are short forms for πX|T and πC|T. Relative risk 
(RR) is defined here as a ratio of probabilities (risk ratio), for example, RRC|X 
= πC|X / πC|~X is the probability of having C if X is present over the probability 
of having C if X is not present.
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     
In the presimulation of the "stocks and flows" required for
the initial scenario, three areas of interaction for the
health states X and C can be distinguished. Having X (C)
may make it more or less likely to:
(1) have C (X),
(2) acquire or recover from C (X),
(3) die from C (X).
Note that while interaction (1) could alternatively be con-
sidered the cumulative result of interactions (2) and (3) in
the past, this is not the approach adopted here.
Interaction (1): Prevalence of the joint group
In this and subsequent sections except where noted, we re-
vert to the notation from the left-hand column of Table 1.
Table 4 shows six possible cases for calculating prevalence
of the joint group depending on the type of information
known about the disease interaction. The probability no-
tation  is used for prevalence, where X|C is the probabil-
ity of having disease X among those who have disease C
and X and C are short forms for X|T and C|T. Relative
risk (RR) is defined here as a ratio of probabilities (risk ra-
tio), for example, RRC|X = C|X / C|~X is the probability of
having X if C is present over the probability of having X if
C is not present.
Calculations for case 1 follow directly from the assump-
tion of independence. Cases 2 and 3 follow directly from
the definition of conditional probability. Cases 4 and 5
are derived as follows. Since the probability of belonging
to the joint group is independent of which disease group
is conditioned on, it is clear that:
XC = X|C·C = C|X·X.  (28)
Using the definition of conditional probability, we write:
X = X|C·C + X|~C·~C, and
C = C|X·X + C|~X·~X.  (29)
Now supposing RRX|C or RRC|X is known, solving either
for X|C or C|X and substituting the result into eq. (29)
and solving again for X|C and C|X yields:
X|C = X / (C + ~C / RRX|C), and
C|X = C / (X + ~X / RRC|X).  (30)
So again using the definition of conditional probability:
XC = X·C / (C + ~C / RRX|C), and
XC = C·X / (X + ~X / RRC|X).  (31)
Recalling 1 - X = ~X and 1 - C = ~C, the required expres-
sions in Table 4 are obtained.
The factor k in case 6 is an arbitrary multiplier that increas-
es or reduces the prevalence of group XC compared to
what would be obtained under independence, and lies be-
tween 0 and 1 if having one disease reduces the probabil-
ity of having the other, and between 1 and MAX(1/C, 1/
X) if having one disease makes it more likely to have the
other. Upper bounds on k are easy to derive using the fact
that XC = X = C when X and C are obligate symbiotes.
The six cases span a range of information availability
about interaction of X and C on the prevalence of the joint
condition:
• Case 1 assumes independence (no interaction).
• Case 2 and 3 assume conditional prevalence is known.
• Case 4 and 5 assume relative risk is known.
• Case 6 assumes a potentiation (or protection) factor can
be defined.
Interaction (2): Incidence and remission for the joint group
For incidence hazard, we write i and for remission hazard,
r. Consistent with "overlapping populations", unless spe-
cifically noted, hazards are understood as "total hazards",
Table 4: Options for calculating overlap probability XC.
Case XC calculated as Comment
1 C·X C and X are independent
2 C|X·X C and X interact and C|X or X|C is known.
3 X|C·C
4 C·X / [C + (1 - C) / RRX|C] C and X are dependent and the relative risk RRX|C or RRC|X is known.
5 X·C / [X + (1 - X) / RRC|X] X (C) either potentiates, or protects from, C (X).
6 X·C·k
Table 4: Options for calculating overlap probability πxc
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Calculations for case 1 follow directly from the assumption of independence. 
Cases 2 and 3 follow directly from the definition of conditional probability. Cases 
4 and 5 are derived as follows. Since the probability of belonging to the joint 
group is independent of which disease group is conditioned on, it is clear that: 
XXCCCXXC πππππ ⋅=⋅= . (28)
Using the definition of conditional probability, we write: 
.
and,
~~
~~
XXCXXCC
CCXCCXX
πππππ
πππππ
⋅+⋅=
⋅+⋅=
(29)
Now supposing RRX|C or RRC|X is known, solving either for πX|C or πC|X 
and substituting the result into eq. (29) and solving again for πX|C and πC|X 
yields:
( )
( ).
and ,
~
~
XCXXCXC
CXCCXCX
RR
RR
ππππ
ππππ
+=
+=
(30)
So again using the definition of conditional probability:
( )
( ).
and ,
~
~
XCXXXCXC
CXCCCXXC
RR
RR
πππππ
πππππ
+⋅=
+⋅=
(31)
Recalling 1 − πX = π~X and 1 − πC = π~C, the required expressions in Table 4 
are obtained. 
The factor k in case 6 is an arbitrary multiplier that increases or reduces 
the prevalence of group XC compared to what would be obtained under 
independence, and lies between 0 and 1 if having one disease reduces the 
probability of having the other, and between 1 and MAX(1/πC, 1/πX) if 
having one disease makes it more likely to have the other. Upper bounds on k 
are easy to derive using the fact that πXC = πX = πC when X and C are obligate 
symbiotes. 
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The six cases span a range of information availability about interaction of X 
and C on the prevalence of the joint condition:
Case 1 assumes independence (no interaction).	
Case 2 and 3 assume conditional prevalence is known. 	
Case 4 and 5 assume relative risk is known.	
Case 6 assumes a potentiation (or protection) factor can be defined. 	
Interaction (2): Incidence and remission for the joint group
For incidence hazard, we write i and for remission hazard, r. Consistent with 
“overlapping populations”, unless specifically noted, hazards are understood 
as “total hazards”, that is, iX includes all incidence to X regardless of whether 
C is also present in the population at risk. Conditional hazards are denoted 
iX|~C or iX|C to signify “incidence to X in the group without C” and “incidence 
to X in the group with C”, respectively.
Consider total incidence iX for the initial scenario. The product of total 
incidence to X and the total population without X (~X) must be equal to 
the sum of the products of the conditional incidences (iX|~C, iX|C) and the 
conditional populations (~X~C, ~XC): 
)(~)~(~)(~ CX|CX|~X XCiCXiXi ⋅+⋅=⋅ . (32)
Dividing by total population T yields:
)(
)(~
)(
)~(~
)(
)(~
CX|CX|~X T
XCi
T
CXi
T
Xi ⋅+⋅=⋅ , (33)
and replacing population ratios by the corresponding prevalence rates yields:
XC~C|XC~X~C|~XX~X πππ ⋅+⋅=⋅ iii . (34)
Dividing both sides by π~X yields the following expression for iX:
X~
XC~
C|X
X~
C~X~
C|~XX π
π
π
π ⋅+⋅= iii , (35)
where:
XC~C~X~X~ πππ += . (36)
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It is therefore clear that total incidence to X is a weighted average of the 
conditional incidences, where the weights are the proportions of the population 
without X partitioned according to C status. 
Recall that, in terms of the differential equations notation from the right-
hand column of Table 1, π~X = πC + πS, π~X~C = πS and π~XC = πC, the values 
of which are determined according to one of the six cases defined above in 
interaction (1).  Thus, when total hazard iX is known, eq. (34) has only two 
unknowns (iX|~C and iX|C). Clearly, if information on one or both conditional 
hazards is available, interaction (2) with respect to iX is fully characterized for 
the initial scenario. 
However, the guiding principle of the presimulation problem was that 
information on the non-overlapping populations (e.g. direct observation of 
the conditional hazards) is relatively scarce. When this is true, the unknown 
conditional hazards must remain undetermined unless one of the following 
three rate ratios (RR) is known or can be approximated: 
.)(or  ,)(,)(
X
CX
3X
X
C~X
2X
C~X
CX
1X i
i
iRR
i
i
iRR
i
i
iRR ===
   
(37)
A similar situation applies to the total hazards iC, rC, and rX for the initial 
scenario, that is, eq. (34) is one of a family of equations representing the 
relation between the total disease hazards and the corresponding conditional 
hazards for subpopulations:
.XCXCXC~X~CCC
XCCXC~XC~XXX
C~XXCC~X~X~CC~C
XC~CX|C~X~CX|~X~X
πππ
πππ
πππ
πππ
⋅+⋅=⋅
⋅+⋅=⋅
⋅+⋅=⋅
⋅+⋅=⋅
rrr
rrr
iii
iii
(38)
Note that, with respect to the initial scenario, eq. (38) forms a simultaneous system 
with eq. (31) – or one of the other methods of calculating πXC noted in Table 4 
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– and the system has a unique numerical solution whenever enough parameter 
values are known, that is, assuming the four total hazards are known, if one of the 
three following rate ratios (or its inverse) is known for each hazard:
.)(or  ,)(,)(
and ,)(or  ,)(,)(
and ,)(or  ,)(,)(
and ,)(or  ,)(,)(
C
XC
3C
C
X~C
2C
X~C
XC
1C
X
CX
3X
X
C~X
2X
C~X
CX
1X
C
XC
3C
C
X~C
2C
X~C
XC
1C
X
CX
3X
X
C~X
2X
C~X
CX
1X
r
r
rRR
r
r
rRR
r
r
rRR
r
r
rRR
r
r
rRR
r
r
rRR
i
i
iRR
i
i
iRR
i
i
iRR
i
i
iRR
i
i
iRR
i
i
iRR
===
===
===
===
(39)
Interaction (3): Mortality for the joint group
This interaction concerns causes of death. We assume that the all-cause 
mortality hazard mtot and the total (i.e. overlapping) case-fatality hazards fX 
and fC are known. It follows that:
.
and ,
XCXCXC~X~CCC
XCCXC~XC~XXX
πππ
πππ
⋅+⋅=⋅
⋅+⋅=⋅
fff
fff
(40)
Following a derivation similar to that in eqs (19) – (21), one can show that, 
given total case-fatality hazards fX and fC, the case-fatality hazard for the joint 
condition is the sum of the conditional hazards:
XCCXXC fff += (41)
Further, since: 
),()(~
and ),()~(
XCX~CC
CXC~XX
XCfXCfTm
XCfCXfTm
⋅+⋅=⋅
⋅+⋅=⋅
(42)
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so:
XCCXC~XC~XX ππ ⋅+⋅= ffm , (43)
and: 
XCXCXC~X~CC ππ ⋅+⋅= ffm . (44)
In other words, the cause-specific mortality hazards are weighted averages of 
the conditional case-fatality hazards, where weights are the proportions of the 
total population according to disease status regarding the other condition. 
It remains true that: 
CXtot mmmm −−= , (45)
as in eq. (27). 
Other interactions
Another interaction might involve relaxing the assumption of independence 
between background mortality hazard m and case-fatality hazards fX and fC. 
However, in cases where such dependence is suspected or known, it may be 
possible to “work around” it by choosing appropriate definitions for X and C. 
For example, to take the ischaemic heart disease (X) and stroke (C) example, 
suppose it is important for the research question to account for the fact that 
individuals with X or C are also at increased risk of mortality from other 
selected causes of death such as cardiac failure. While one approach might 
be to introduce a new box for cardiac failure, within the current structure 
of PopMod, the onus is effectively on the analyst to take into account such 
increased risk of background mortality by modifying the way state C is 
defined and by adjusting the corresponding incidence and case-fatality rates. 
For example, state C could be defined as “stroke and all other conditions 
(including cardiac failure) at increased risk due to heart disease”. Another 
type of exception to the general rule of independence between background 
mortality and cause-specific mortality would be the existence of any common 
causal modifiers of m, fX and fC, for example, the allocation of health-care 
expenditure.
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Modelling mechanics
Initial conditions
PopMod describes population evolution conditional on initial conditions that 
define the state of the system at some initial time. These initial conditions consist 
of the population distribution in non-overlapping terms. If potentially overlapping 
populations (i.e. descriptions from the left hand side of Table 1) are considered, 
when the total prevalences pX and pC are known the non-overlapping population 
distribution can be fully determined by determining the prevalence of the joint 
group. Methods for this are discussed in the section Disease interactions. 
Runge-Kutta method
The differential equation system is determined by its initial conditions and its 
parameters. An algebraic description of PopMod differential equation system 
– using notation from the right-hand side of Table 1 – is:
dS/dt = −( hS→X + hS→C + hS→D )·S + (hX→S)·X + (hC→S)·C
dX/dt = −( hX→S + hX→XC + hX→D )·X + (hS→X)·S + (hXC→X)·XC
dC/dt = −(hC→X + hC→XC + hC→D )·C + (hS→C)·S + (hXC→C)·XC
dXC/dt = −( hXC→X + hXC→C + hXC→D )·XC + (hX→XC)·X + (hC→XC)·C
dD/dt = ( hS→D )·S+( hX→D )·X + ( hC→D )·C + ( hXC→D )·XC
(46a)
(46b)
(46c)
(46d)
(46e)
(46)
where S, X, C and XC are unknown. Under specified conditions, which apply 
here, such a differential equation system has a unique, exact and analytical 
solution, and the solution can be expressed in terms of the eigenvalues and 
eigenvectors of the 5 x 5 coefficient matrix.[10] 
Since finding the required eigenvalues and eigenvectors is here equivalent to 
solving a fifth-degree polynomial equation, specialized solution algorithms – 
and access to a substantial amount of processor time – will generally be required. 
An attractive alternative is therefore the use of numerical techniques, since 
they yield solutions more cheaply, and without requiring custom routines. 
47
Chapter 2 PopMod: a longitudinal population model with two interacting disease states
In PopMod, the evolution of the population in time is approximated by a 
4th-order Runge-Kutta method, or, optionally, by a 5th-order Runge-Kutta 
method.[10, please consult reference for further information] The relevant time 
step is defined as a fraction of the standard reporting interval (the number of 
divisions of the basic reporting interval must in principle be divisible by 3, but 
to allow for the possibility of starting with mid-year values in the first year, 
the number of divisions must be divisible by 6 and the minimum number 
of divisions is fixed at 12). Note that an nth-order numerical method will in 
general provide useful results so long as the differentials are smaller than nth-
order in the chosen time step. 
Each population age- and sex group is modelled as a separate system, and age 
is updated by taking end-of-year solution values for the “age = α” system as 
the initial values for the “age =  α + 1” system in the subsequent model year. 
A 4th-order Runge-Kutta method provides solutions to differential equations 
of the type:
dyi(x)/dx = fi(x, yi(x)), (47)
and is defined by the ansatz (Euler method) that:
yi(x + ∆x) = yi (x) + ∆x · fi (x, yi(x)), (48)
where:
yi(x + ∆x) = yi(x) + (k1i + 2k2i + 2k3i + k4i)/6 + O(∆x5), and
k1i = ∆x · fi(x, yi)
k2i = ∆x · fi(x + ∆x/2, yi +  k1i/2)
k3i = ∆x · fi(x + ∆x/2, yi +  k2i/2)
k4i = ∆x · fi(x + dx, yi +  k3i).
(49)
Note that here x = t, yi = S, X, C, XC and D and that the differential equations 
(46a-46e) are not explicitly time dependent, that is, fi(t, yi(t)) = fi(yi(t)).[10]
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Output interpretation
Standard PopMod output reports P(t) for each population group as end-of-
interval (e.g. year-end) values, corresponding to the standard life table quantity 
lx. An important derived quantity also included in output is the time at risk 
experienced by the group during the interval (∫P(t) dt), corresponding to the 
life table quantity Lx (sometimes called “life-years” or “person-years”).
For a constant population, population time at risk is calculated tP ∆⋅ . 
For PopMod populations, population time at risk for the interval b – a is 
calculated:
( )∫=
b
a
LY ttPP d
 
, for example
 
( )∫=
b
a
LY ttXX d . (50)
When the quantity resulting from eq. (50) with units “person-years” is divided 
by the length of the time interval with units “years”, average population size 
for the interval ( Pˆ , with units “persons”) is obtained:
∫−=
b
a
ttP
ab
P d)(1ˆ . (51)
Pˆ  thus conforms to the definition of the expected value of the function P(t) 
on the interval b−a. Since b−a is by convention one year (or “chronon” etc.), 
the normalization to the interval b−a means dividing by 1. Thus, since in this 
case the numerical quantity is unchanged, substituting different reporting 
units yields two equally valid interpretations for the same output:
the average population size(1)  Pˆ = E[P(t)] during the interval t∆ , or
the population time at risk(2)  PLY experienced during the interval t∆ .
Interpretation (1) also corresponds to average (count) prevalence for the 
population. 
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When transition rates are “small” (i.e. the differentials are approximately 
linear), average population can be interpreted as mid-interval population. 
Under the same assumptions, mid-year population provides a good estimate 
of population time at risk. 
PopMod numerically evaluates PLY with a standard Newton-Cotes formula 
for 4-point closed quadrature, sometimes also called Simpson’s 3/8-rule.[11] 
The quadrature formula relies on the values of P(t) determined by the Runge-
Kutta method at multiples of the chosen time step. Since these values involve 
numerical estimation error, there is no simple expression for the order of 
accuracy of the different output values reported in PopMod.[10] 
Discussion
Advantages of the approach
PopMod combines features of existing models (see below) with the possibility 
to analyse several disease states. It explicitly analyses time evolution and, even 
more importantly, abandons the constraint of independence of disease states. 
A primary advantage of the approach adopted in PopMod is the separate 
modelling of age and time, and the type of bias inherent in models that do not 
do so has been previously pointed out.[7] Moreover, it has been independently 
noted that, without this feature, life-table measures are constrained to adopt 
– somewhat artificially – either a “period” or a “cohort” perspective.[6] The 
other chief advantage of PopMod is the ability to deal with heterogeneity of 
disease and mortality risk by modelling up to four disease states. No previous 
published generic population model has combined both these features. Note, 
however, that if disease conditions are independent, and population-dependent 
effects are not of interest, a multi-state life-table approach should probably be 
adopted.[20] 
A further advantage of PopMod is the introduction of a systematic analytical 
approach to the modelling of disease interactions. This by itself represents a 
relatively important advance, as modellers have until now been constrained 
to model only independent conditions. Furthermore, in spite of the increased 
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informational demands made by a four-state system, the modelled functional 
dependency between X-related hazards conditional on C status, and vice versa, 
reduces the number of exogenous hazards that need to be directly observed. 
This is of substantial practical importance, since, while direct observation of 
conditional hazards usually requires a cohort study, it will often be possible to 
obtain estimates of the required rate ratios from more common case-control 
studies[21]. 
Related models
In addition to the multi-state life table family,[3,4] two additional families of 
mathematical models have some similarity to PopMod. One family comprises 
the class of models sometimes called incidence, prevalence and mortality 
(IPM) models.[12-14] Another family (with until now one member) is that of 
published population models, in particular Prevent.[15-18] 
IPM models per se have no population or age structure; they can be conceived 
of as stationary population models (i.e. models of a population in equilibrium, 
where the numbers of births and deaths in an age group are equal). However, 
DisMod, probably the IPM model in most common use,[12] has gone through 
several versions, and the current version allows for hazard trend analysis that 
relies on modelling a full population structure based on one-year age groups. 
Notwithstanding, IPM models analyse only a single disease condition in 
isolation, and, while Prevent was explicitly designed to analyse a full population 
cohort structure, it also analyses only a single disease condition. 
Multi-state life tables analyse multiple disease states but published versions 
have invariably required the assumption of independence across diseases. 
In addition, multi-state life tables implicitly impose a stationary population 
assumption by not independently modelling population time and age. 
Averaging and its implications
In all compartmental models, of which differential equations models are 
one type, it is assumed that health and mortality risk are conditional on 
disease state. In light of the seemingly infinite diversity of real phenomena, 
this assumption invariably results in “compression”, that is, the imposition 
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of artificial homogeneity. In many cases, compression can be considered a 
necessary simplifying assumption for the modelling exercise, but in other 
cases, heterogeneity must be explicitly modelled to avoid the phenomenon of 
confounding. In a differential equations system, modelling heterogeneity of 
disease and mortality risk amounts to introducing additional disease states. 
Thus, PopMod, with four disease states, respresents a substantial increase in 
complexity over population models modelling only two disease states (e.g. 
diseased and healthy). PopMod of course includes the two-disease-state model 
as a special case.
There is also heterogeneity other than of disease and mortality risk. In 
particular, although real populations change in integer steps at discrete 
moments in time, a differential equation system represents this process in 
continuous time. However, this approximation is in general acceptably good 
when a large number of individuals comprise the population of interest. 
Moreover, an implication of representing age in a discrete number of statistical 
bins is modelling a birth-year cohort as though it had a single average age. 
If births are distributed uniformly throughout the year, the average birthday 
of the cohort is the mid-year point, and there is no serious objection to this 
procedure. However, if the cohort average birthday is not be the mid-year 
point, PopMod’s modelled age will differ from the true average age. 
It is assumed that conditional hazards are constant within a single reporting 
interval (e.g. one year), which will in principle be problematic for conditions 
with high initial case-fatality, for example heart attack (or stroke). This sort of 
problem can be addressed by defining condition C as “acutely fatal cases” and 
condition X as “long-term survivors”. Similarly, for conditions of determinate 
duration (e.g. pregnancy), use of a constant hazard rate for “remission” will 
result in an exponential distribution of waiting time for transition out of 
the state, whereas a uniform distribution of waiting time is what would be 
wanted. 
All compartmental population models are fundamentally simplifications of 
reality by means of a system of reduced dimensionality. The mathematical 
concept of  “projection” is useful: the simplified system can be thought of as a 
“least-squares approximation” to the higher-order real system.[19] The validity 
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of input parameter values and the accuracy of the solution method determine 
the actual goodness of fit realized in a particular model. Nevertheless, 
compression applies to every modelled variable in a differential equations 
model. Other modelling approaches, such as microsimulation, require much 
less compression, so the user who wishes to avoid compression systematically 
should consider adopting the microsimulation approach. 
Types of error in PopMod
Sources of error in PopMod can be divided into three types: 
Model (or “projection”) error due to analysing a simplified system instead (1) 
of the full one. Model error includes the characterization of scenarios for 
disease interaction.
Numerical error due to obtaining approximate solution values with (2) 
numerical techniques.
Parameter error due to uncertainty about observed or derived parameter (3) 
values.
The 5th-order Runge-Kutta method provides an estimate of the local truncation 
error inherent in the 4th-order numerical technique. Monte-Carlo analysis 
of distributions around transition rates can be used to examine parameter 
uncertainty. However, comparison with a more complex model would be 
necessary for quantification of model error. A way of investigating the impact 
of model error would be to construct progressively more realistic and complex 
models. A spectrum of models, from least to most complex, can thus be 
imagined, where the “most complex” and necessarily imaginary model has 
a one-to-one relation to real system it represents. The difference between the 
results of two adjacent models in such a series would be an expression of 
model error analogous to the estimate of numerical truncation error afforded 
by the next-higher-order numerical method. 
Although intuitively natural and mathematically valid, in most situations 
it would be impractical to quantify model error in this laborious way. 
Nevertheless, model error may, in certain data-rich cases, be estimated by 
“predicting” outcomes for which numerical data are available for comparison 
but which are not used as inputs. 
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Limiting assumptions
Although any state transitions are in principle possible, PopMod assumes that 
transitions S→XC and X→C do not occur. This is because such transitions can 
be thought of as the simultaneous occurrence of two transitions (for example, 
S→XC equals S→X plus X→XC). Note that this does not imply events 
S→XC and X→C cannot occur within a single reporting interval; rather, it 
just means the mathematics of PopMod do not represent simultaneous events. 
A similar feature is the absence of a modelled cause of death “XC”.
However, the non-modelled transition S→XC can be imagined if someone in 
state S simultaneously acquires X and C as a result of, say, very high levels of 
common risk factors (i.e. someone who suffers a simultaneous heart attack and 
stroke because of high blood pressure and cholesterol). If such a “simultaneous 
event” results in mortality, one could potentially speak of a cause of death 
“XC”. Similarly, the non-modelled transition X→C could occur if there were 
“perfect interference” between two diseases such that acquiring C caused 
immediate remission from X . If either of these cases is important, PopMod 
can miss important dynamics. 
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Chapter 3 Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: 
 a global and regional analysis on reduction of cardiovascular-disease risk
Introduction
Cardiovascular disease (CVD) is a major cause of global disease burden. It 
accounts for 20.3% of DALYs lost in developed countries, and already causes 
8.1% of DALYs lost in developing countries. The World Health Report 2002 
quantified the major contribution of tobacco, alcohol, high blood pressure, 
high cholesterol, low fruit and vegetable intake, physical inactivity and high 
body mass index to the global burden of disease and the burden of CVD in 
particular [1,2]. 
Improved data on the levels of exposure and reassessments of the magnitude 
of the hazards has led to the recognition that high blood pressure and high 
cholesterol have much higher impacts on population health than previously 
thought [3]. Approximately two thirds of stroke and almost half of IHD can 
be attributed to blood pressure levels above 115 mm Hg. Total cholesterol 
over 3.8mmol/l accounted for approximately 18% of stroke and 55% of IHD. 
The joint effects of blood pressure and cholesterol would, of course, be less 
than additive because of the multi-causality of cardiovascular disease and the 
joint action of these two risk factors [1]. This regional analysis has also shown 
that high blood pressure and high cholesterol are major risks to health in all 
regions of the world, not just high-income countries. 
Given the burden of disease caused by high blood pressure and high cholesterol, 
it is important to evaluate the costs and effects of the available intervention 
strategies to reduce these risks. These strategies should, however, be seen in the 
context of more comprehensive approaches to the control of CVD that focus 
on a number of inter-related risks to health including levels of blood pressure 
and cholesterol, tobacco consumption, body mass index, physical activity, diet 
and diabetes [4,5]. In this chapter, we take advantage of the development of 
standardized methods and companion tools for the evaluation of costs, effects 
and cost-effectiveness of different interventions within and across regions 
[6-13]. These methods and tools mean that results of intervention analyses can 
be compared more meaningfully across interventions and across locations. 
Evaluation of the costs and effects of the major intervention strategies for 
reducing the burden attributable to blood pressure and cholesterol must 
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address two key debates. First, what are the relative roles of non-personal 
health services such as mass media messages to change diet or legislation 
to reduce the salt content of processed foods, and personal health services 
such as the pharmacological management of cholesterol and hypertension 
[4,5,14]? Second, should management of blood pressure and cholesterol be 
based on thresholds for each risk factor seen in isolation, such as treating for a 
systolic blood pressure over 160 mm Hg, or should management be based on 
the absolute risk of cardiovascular disease for a given individual taking into 
account all their known determinants of risk [15]? In this chapter we analyse 
the population health effects and costs of non-personal health measures, 
treatment of individual risk factors and treatment based on various levels of 
absolute risk [16-18]. 
Methods
Interventions
Seventeen non-personal and personal health service interventions or 
combinations have been included in this analysis – summary details are 
provided in Table 1. Non-personal health interventions included health 
education through the mass media focusing on blood pressure, cholesterol 
and body mass, and either legislation or voluntary agreements on salt content 
to ensure appropriate labelling and stepwise reductions of the salt content 
of processed foods. Personal health service interventions included detecting 
and treating people with elevated levels of cholesterol for two thresholds; 
treating individuals with elevated systolic blood pressure again using two 
thresholds; treating individuals for both elevated cholesterol and elevated 
systolic blood pressure; and treating individuals based on their absolute risk of 
a cardiovascular event in the next 10 years (called the “absolute risk” approach 
[20]) using four different absolute risk thresholds. Risk levels are defined by 
fitting mean risk factor values to observed baseline risk levels. Estimates of 
the relative risk of modelled risk factors on cardiovascular events are used 
to predict the absolute risk of individuals with elevated levels of risk factors. 
Individuals with an absolute risk of cardiovascular disease greater than the 
threshold all receive a beta-blocker, diuretic, statin, and aspirin. 
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Table 1. Interventions evaluated
Regions
It would be desirable to evaluate all possible combinations of interventions in 
every country of the world – and for some of the larger countries, to evaluate 
these combinations at a sub-national level. No country has yet been able to 
do this, and many countries do not have the technical capacity to evaluate 
even a few of them. At the other extreme, global estimates are of little use to 
any specific country. The World Health Organization, through its CHOICE 
project, provides information on costs and health effects at a subregional level, 
with the different parts of the world divided by geographic proximity and 
epidemiology. This allows interventions to be placed into broad categories, such 
as very cost-effective, cost-effective and cost-ineffective, revealing the extent to 
which strategies to reduce risks to health should differ across different settings.
In addition, CHOICE provides results in such a way that analysts from 
countries within a region can adapt them to their settings if they wish. The 
costs, effects and cost-effectiveness of each of the 17 interventions have been 
evaluated for 14 epidemiological subregions of the world. These subregions 
are defined and described in Annex 1. The results from three of them are 
discussed in detail - SearD (in south-east Asia with high rates of adult and 
child mortality); AmrB (in Latin America with low adult and child mortality); 
and EurA (in Europe with very low adult and child mortality).
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based on the absolute risk of cardiovascular disease for a
given individual taking into account all his or her known
determinants of risk?15 We analyse the population health
effects and costs of non-personal health measures,
treatment of individual risk factors, and treatment based
on various values of absolute risk.16–18
Methods
Interventions
17 non-personal and personal health-service interventions
or combinations have been included in this analysis 
(table 1). Non-personal health interventions included
health education through the mass media (focusing on
blood pressure, cholesterol concentration, and body
mass), and either legislation or voluntary agreements on
salt content to ensure appropriate labelling and stepwise
decreases in the salt content of processed foods. Personal
health-service interventions included detection and
treatment of people with high concentrations of
cholesterol for two thresholds; treatment of individuals
with high systolic blood pressure with two thresholds;
treatment of individuals for both these risk factors; and
treatment of individuals based on their absolute risk of a
cardiovascular event in the next 10 years (the absolute-
risk approach20) with four thresholds. Risk values are
defined by fitting mean risk-factor values to observed
baseline-risk values. Estimates of the relative risk of
modelled risk factors on cardiovascular events are used to
predict the absolute risk of individuals with high values for
risk factors. Individuals with an absolute risk of
cardiovascular disease greater than the threshold all
receive a β blocker, diuretic, statin, and aspirin.
Regions
A desirable approach would be to evaluate all possible
combinations of interventions in every country of th
world, and for some of the larger countries, at a
subnational level. No country has yet been able to do this,
and many countries do not have the technical capacity to
evaluate even a few of them. At the other extreme, global
estimates are of little use to any individual country. WHO,
through its CHOICE project, provides information on
costs and health effects at a subregional level, with the
different parts of the world divided by geographical
proximity and epidemiology. This approach allows
interventions to be put into broad categories, such as very
cost effective, cost effective, and cost ineffective, revealing
the extent to which strategies to reduce risks to health
should differ across different settings.
In addition, CHOICE provides results in such a way
that analysts from countries within a region can adapt
them to their own setting if they wish. The costs, effects,
and cost-effectiveness of each of the 17 interventions have
been evaluated for 14 epidemiological subregions of the
world (webtable 1). The results from three of them are
discussed in detail—SearD (in southeast Asia with high
rates of adult and child mortality); AmrB (in Latin
America with low adult and child mortality); and EurA (in
Europe with very low adult and child mortality)—
although the costs and effectiveness estimates for all 
14 subregions are given in webtable 2.
Intervention effects
Effect sizes used in the analysis are based on systematic
reviews of randomised trials where possible, or meta-
analyses (webtables 3, 4, 5, 6). The joint effects of
interventions were assumed to be multiplicative, drawing
from the evidence of large cohort studies in diverse
populations.21–23
Population health effects due to the interventions are
modelled by stochastically simulating populations specific
for age, sex, and subregion with the observed baseline
values of cardiovascular risk and the observed distribution
of risk factors (systolic blood pressure, cholesterol
concentration, body-mass index, and prevalence of long-
term smokers) in those regions.24,25 Interventions cover
either the entire population (non-personal interventions) or
subpopulations meeting specific characteristics (personal
interventions), such as having a 10-year risk of a cardio-
vascular event, or systolic blood pressure, over a certain
threshold. Population-level cardiovascular risk (incidence)
is recalculated after applying the effectiveness of the inter-
vention and the effect size of the implied change in risk-
factor values to the population receiving the intervention.
To translate changes in the risk of cardiovascular-
disease events specific for age and sex into changes in
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Intervention Description
Non-personal interventions
N1 Salt reduction through voluntary agreements with industry Cooperation between government and the food industry for stepwise 
decrease in salt content of processed foods and for labelling
N2 Population-wide reduction in salt intake legislation Legislation to decrease salt content in processed foods and appropriate 
labelling
N3 Health education through mass media Health education through broadcast and print media focusing on body-
mass index and cholesterol concentrations
N4 Combined intervention of N2 and N3 Combination of N2 and N3
Personal interventions
P1 and P2 Individual-based hypertension treatment and education Treatment of SBP above 160 mm Hg (P1) or above 140 mm Hg (P2) with a
standard regimen of -blocker and diuretic
P3 and P4 Individual treatment for high cholesterol concentrations and Treatment with statins for total cholesterol concentrations above
education 6·2 mmol/L (P3) and above 5·7 mmol/L (P4)
P5 Individual treatment and health education for SBP and Combination of P2 and P3, with treatment thresholds of 140 mm Hg SBP 
cholesterol concentration and 6·2 mmol/L for total cholesterol concentration
P6 to P9 Absolute risk approach People with an estimated combined risk of a cardiovascular event* over 
the next decade above a given threshold treated for multiple risk factors 
(with statin, diuretic,  blocker, and aspirin) whatever the values for 
individual risk actors; four different thresholds were evaluated: 35% (P6), 
25% (P7), 15%  (P8), and 5% (P9)
Combined personal and non-personal interventions
(C1 to C4) Addition of the absolute risk approach at the four thresholds to the Combination of N4 with P6 to P9
combined non-personal health intervention
SBP=systolic blood pressure. *Acute myocardial infarction; angina pectoris; congestive heart failure; first-ever fatal stroke; long-term stroke survivors. The definition of
a cardiovascular event differs across studies, so the results reported here may not be strictly comparable with those of similar studies.19
Table 1: Interventions evaluated
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Intervention effects 
Effect sizes used in the analysis are based on systematic reviews of randomized 
trials where possible, or meta-analysis as shown in Annexes 2-5. From the 
evidence of large cohort studies in diverse populations the joint effects between 
interventions were assumed to be multiplicative, drawing from the evidence 
of large cohort studies in diverse populations [21-23].
Population health effects due to the interventions are modelled by stochastically 
simulating age-, sex-, and sub region-specific populations with the observed 
baseline levels of cardiovascular risk and the observed distribution of risk 
factors (systolic blood pressure, cholesterol, body mass index, and prevalence 
of long-term smokers) in those regions [24-25]. Interventions cover either the 
entire population (non-personal interventions) or sub populations meeting 
specific characteristics (personal interventions), such as having 10-year risk 
of a cardiovascular event, or having systolic blood pressure, over a certain 
threshold. Population level cardiovascular risk (incidence) is recalculated after 
applying the effectiveness of the intervention and the effect size of the implied 
change in risk factor levels to the population receiving the intervention. 
To translate age and sex specific changes in the risk of cardiovascular disease 
events into changes in population health quantified using DALYs, a standard 
multi-state modelling tool, PopMod, was used [8]. In this model, health effects 
are estimated by tracing what would happen to each age/sex cohort of a given 
population over 100 years, with and without each intervention. PopMod 
is a four-state population model simulating the evolution of a population 
partitioned into four distinct health states – people who have the condition 
under study, have some other comorbid condition, have both conditions, 
and have none of the above (but are susceptible). Births and deaths are also 
included. The states can be considered either as simple states or as aggregates of 
other substates. Transition rates, such as incidence, remission, and mortality, 
govern movements between states. 
The model is described by a system of ordinary differential equations with each 
population age and sex group modelled individually as a separate differential 
system [26]. The model shows the time evolution of the size of the population 
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age and sex groups, through the four health states and death, in yearly steps. 
With the appropriate health state valuations, standard life-table measures as 
well as a variety of summary measures of population health can be derived. 
Monte-Carlo analysis of uncertainty in transition rates is possible. The side 
effect relating to the consequences of bleeding associated with the use of aspirin 
was included. The entire population is subjected to background mortality and 
morbidity, which is assumed to be independent of the cardiovascular disease 
states explicitly modelled. 
In some cases, mostly in more developed countries, information on 
intervention effects was available for only one or two settings. The association 
of blood pressure and cholesterol, however, are remarkably similar in size 
and shape across Asia, Europe and North America [22,27,28]. We could not 
obtain evidence about how adherence vary across settings, so no variation was 
included. Nevertheless, policy-makers must still make decisions about how 
to use their scarce resources. One approach would be to simply to say that 
there is no evidence. The approach taken here is to provide the best available 
evidence, even if this means extrapolating from one setting to another. This 
approach carries additional uncertainty, especially in the case of behavioural 
interventions, and this should be considered when interpreting the subsequent 
results. 
Costs
Costs include programme-level costs associated with running the intervention 
(such as administration, training and media), and patient-level costs (such 
as primary care visits, diagnostic tests and medicines). For this analysis, 
potential cost-savings related to the prevention of CVD events have not 
been incorporated because the major interest is in identifying the costs of 
improving population health by preventing CVD events. Costs have been 
based on a standardized ingredients approach that has been developed by 
the World Health Organization to facilitate costing of interventions [6-9]. 
The units of physical inputs required were assessed and multiplied by the 
unit price for each input. For programme costs the quantities of the required 
inputs (such as labour, vehicles, office space) were identified from the literature 
with additional details provided by programme staff in various parts of the 
world. The quantity of patient-level resource inputs required for a given 
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health intervention e.g. hospital inpatient days, outpatient visits, medications, 
laboratory tests etc., were identified in a similar manner. Reporting costs 
using the ingredients approach is an important part of making the results 
transparent to policy-makers as well as providing a way for analysts to adapt 
the results to their own settings if they wish.
Unit costs of programme-level and patient-level resource inputs, such as the 
salaries of central administrators, the capital costs of vehicles, offices and 
furniture, or the cost per outpatient visit, were obtained from a review of the 
literature and supplemented by primary data from programme staff in several 
countries. Costs of drugs were based on the price of off-patent drugs from the 
lowest cost vendor of high-quality drugs. 
Information on the costs and effectiveness of interventions that are undertaken 
inefficiently is of little value to decision makers. For that reason we assume 
capacity utilization of 80% in most settings – e.g. that health personnel are 
fully occupied for 80% of their time. The results identify, therefore, the set of 
interventions that, if done relatively efficiently, would be cost-effective in the 
different settings.
Costs are reported in International Dollars to facilitate more meaningful 
comparisons across regions. An international dollar has the same purchasing 
power as the U.S. dollar has in the United States. Costs in local currency units 
are converted to international dollars using purchasing power parity (PPP) 
exchange rates rather than official exchange rates. A PPP exchange rate is the 
number of units of a country’s currency required to buy the same amounts of 
goods and services in the domestic market as a U.S. dollar would buy in the 
United States. An international dollar is, therefore, a hypothetical currency 
that is used as a means of translating and comparing costs from one country 
taking into account differences in purchasing power. The base year is 2000. 
Details of the assumptions are found in Annex 2.
Cost-effectiveness
Average cost-effectiveness ratios are calculated for each intervention by 
combining the information on the total costs with information on the total 
health effects in terms of DALYs averted. All costs and effects are discounted 
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at 3% consistent with the Disease Control Priority Review [29], the first large 
scale attempt to compare the cost-effectiveness of interventions across diseases, 
and the recommendations of the US Panel on Cost-Effectiveness in Health 
and Medicine [30]. 
Using a standard approach, we have identified the set of interventions a region 
should purchase to maximize health gain for different budget levels. The order 
in which interventions would be purchased is called an expansion path and is 
based on the incremental costs and benefits of each intervention compared to 
the last intervention purchased. 
The Commission on Macroeconomics and Health recently defined 
interventions that have a cost-effectiveness ratio of less than three times Gross 
Domestic Product (GDP) per capita as cost-effective [31]. Based on this, three 
broad categories are defined here. Interventions that gain each year of healthy 
life (e.g. DALY averted) at a cost less than GDP per capita are defined as very 
cost-effective. Those averting each DALY at a cost between one and three times 
GDP per capita are cost-effective, and the remainder are not cost-effective. 
The results of cost-effectiveness analysis should not be used formulaically – 
starting with the intervention with the lowest cost-effectiveness ratio, choosing 
the next most attractive intervention, and continuing until all resources have 
been used [10]. The uncertainty surrounding estimates is generally too great 
to support this approach and, moreover, there are other goals of health policy 
in addition to improving population health. The tool is most powerful when 
it is used to classify interventions into broad categories such as those used 
in this paper. This provides decision-makers with information on which 
interventions are low cost ways of improving population health, and which 
improve health at a much higher cost. This information enters the policy 
debate to be weighed against the impact of the interventions on other goals 
of health policy. 
Sensitivity analysis
Multivariate sensitivity analysis was undertaken to assess the effect of uncertainty 
in the assumptions on the baseline levels of risks and effect sizes on the 
costeffectiveness ratios. The first step was to take several samples of hypothetical 
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individuals from correlated distributions of four risk factors: total cholesterol 
concentration, systolic blood pressure, smoking, and body-mass index. Then 
samples were taken from distributions around the population means and standard 
deviations of the risk factors, as well as around the relative risks and effectiveness 
estimates from limits developed from the review of relevant publications (Annex 
2 and 3), producing upper and lower confidence limits on mean incidence. This 
procedure also includes the effects on costs because different numbers of people 
will be covered by an intervention under the different scenarios. At the same 
time, the price of medicines—the most important driver of costs—was allowed 
to vary from half to double the base estimate. 
Results 
Table 2 provides the total annualized costs, total annual health effect in 
terms of DALYs averted and the average cost-effectiveness ratio for each of 
the 17 interventions in three subregions with differing levels of adult and 
child mortality and different patterns of risks to health, EurA, AmrB, and 
SearD. The health benefits of all interventions follow an approximately bell-
shaped curve when plotted against age. Depending on the intervention and 
the region, the curve reaches its maximum at around 60 years of age, with 
about half of the total intervention benefit occurring at younger ages, and 
about half at older ages. This is shown for AmrB in Figure 1. 
All 17 interventions in all three regions are cost-effective according to the 
Commission on Macroeconomics and Health criterion. In all regions, the 
four non-personal interventions have cost-effectiveness ratios that are lower 
than personal health service interventions. 
When considered individually, non-personal health interventions to reduce 
blood pressure and cholesterol are very cost-effective. Measures to reduce salt 
intake are potentially very cost-effective, with legislation being more cost-
effective than voluntary agreements under the assumption that it would lead 
to the larger reduction in dietary salt intake. The impact of non-personal 
health service strategies to reduce cholesterol compared to salt reduction 
strategies depends on the distribution of risk factors in the region – it has a 
slightly lower impact on population health than legislation to reduce salt in 
EurA and AmrB, and a substantially higher impact in SearD.
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Perhaps surprisingly, personal health service strategies have a much greater 
potential to reduce the burden of disease even though they are slightly less 
cost-effective than the population-wide strategies. Treatment of systolic blood 
pressure above 160 mm Hg falls into the very cost-effective category in all 
regions. Statins are now available off-patent at very low cost and their use for 
people with total cholesterol levels above 240 mg/dl (6.2 mmol/L) is also very 
cost-effective in all regions. 
Table 2.  Annual costs, effects, and cost-effectiveness  
of interventions
*See Table 1 for descriptions of interventions 
Figure 1. Total intervention benefit by age, AmrB
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addition to improving population health. The tool is most
powerful when it is used to classify interventions into
broad categories such as those we used. This approach
provides decision-makers with information on which
interventions are low-cost ways of improving population
health and which improve health at a much higher cost.
This information enters the policy debate to be weighed
against the effect of the interventions on other goals of
health policy.
Sensitivity analysis
Multivariate sensitivity analysis was undertaken to assess
the effect of uncertainty in the assumptions on the
baseline levels of risks and effect sizes on the cost-
effectiveness ratios. The first step was to take several
samples of hypothetical individuals from correlated
distributions of four risk factors: total cholesterol
concentration, systolic blood pressure, smoking, and
body-mass index. Then samples were taken from
distributions around the population means and SDs of the
risk factors, as well as around the relative risks and
effectiveness estimates from limits developed from the
review of relevant publications (webtables 3 and 4),
producing upper and lower confidence limits on mean
incidence. This procedure also includes the effects on
costs because different numbers of people will be covered
by an intervention under the different scenarios. At the
same time, the price of medicines—the most important
driver of costs—was allowed to vary from half to double
the base estimate.
Role of the funding source
The sponsor of the study had no role in the study design,
collection, analysis, or interpretation of data, or the
writing of the report.
Results
Table 2 gives the total annualised costs, total annual
health effect in terms of DALYs averted, and the average
cost-effectiveness ratio for each of the 17 interventions in
three subregions with differing levels of adult and child
mortality and different patterns of risks to health (EurA,
AmrB, and SearD; the full set of results for all 
14 subregions is given in webtable 2). The health benefits
of all interventions follow a roughly bell-shaped curve
when plotted against age. Depending on the intervention
and the region, the curve reaches its maximum at around
60 years of age, with about half of the total intervention
benefit occurring at younger ages, and about half at older
ages. This relation is shown for AmrB in figure 1.
All 17 interventions in all three regions are cost effective
according to the Commission on Macroeconomics and
Health criterion. In all regions, the four non-personal
interventions have cost-effectiveness ratios that are lower
than personal health-service interventions.
When considered individually, non-personal health
interventions to reduce blood pressure and cholesterol are
very cost effective. Measures to decrease salt intake are
potentially very cost effective, with legislation being more
cost effective than voluntary agreements under the
assumption that it would lead to the larger reduction in
dietary salt intake. The effect of non-personal health
service strategies to lower cholesterol concentrations
depends on the distribution of risk factors in the region; it
has a slightly lower effect on population health than
legislation to lower salt intake in EurA and AmrB, but a
substantially higher effect in SearD.
Perhaps surprisingly, personal health-service strategies
have a much greater potential to reduce the burden of
disease–even though they are slightly less cost effective
than the population-wide strategies. Treatment of systolic
blood pressure above 160 mm Hg is very cost effective in
all regions. Statins are now available off-patent at very low
cost, and their use for people with total cholesterol
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AmrB EurA SearD
Costs DALYs Cost/DALY Costs DALYs Cost/DALY Costs DALYs Cost/
($106) (105) ($) ($106) (105) ($) ($106) (105) DALY ($)
Non-personal
N1 82 3 24 297 7 44 199 5 37
N2 82 6 13 297 13 23 199 10 19
N3 81 6 14 202 12 16 204 14 14
N4 163 12 14 499 24 21 403 24 17
Personal
P1 3122 38 81 14777 73 203 1570 44 36
P2 8806 47 186 37385 82 454 6399 71 90
P3 2426 28 87 19187 65 297 2537 54 47
P4 4397 33 133 27142 69 393 4835 69 71
P5 11232 61 183 56572 110 516 8936 107 84
P6 1335 51
P7 2059 56 37 16015 95 168 2888 88 33
P8 3352 62 54 22226 104 215 5078 106 48
P9 6456 69 93 35750 114 314 10183 133 77
Combined
C1 1365 54 25 11045 91 121 1829 82 22
C2 2056 58 35 15474 99 157 2994 95 31
C3 3332 64 52 21612 106 203 5149 112 46
C4 6394 71 90 35095 116 302 10173 137 74
Table 2: Annual costs, effects, and cost-effectiveness of interventions
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Figure 1: Total intervention benefit by age (AmrB)
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addition to improving population health. The tool is most
powerful when it is used to classify interventions into
broad categories such as those we used. This approach
provides decision-makers with information on which
interventions are low-cost ways of improving population
health and which improve health at a much higher cost.
This information enters the policy debate to be weighed
against the effect of the interventions on other goals of
health policy.
Sensitivity analysis
Multivariate sensitivity analysis was undertaken to assess
the effect of uncertainty in the assumptions on the
baseline levels of risks and effect sizes on the cost-
effectiveness ratios. The first step was to take several
samples of hypothetical individuals from correlated
distributions of four risk factors: total cholesterol
concentration, systolic blood pressure, smoking, and
body-mass index. Then samples were taken from
distributions around the population means and SDs of the
risk factors, as well as around the relative ri ks a d
effectiveness estimates from limits developed from the
review of relevant publications (webtables 3 and 4),
producing upper and lower confidence limits on mean
incidence. This procedure also includes the effects on
costs because different numbers of people will be covered
by an intervention under the different scenarios. At the
same time, the price of medicines—the most important
driver of costs—was allowed to vary from h lf to double
the base estimate.
Role of the funding source
The sponsor of the study had no role in the study design,
collection, analysis, or interpretation of data, or the
writing of the report.
R sults
Table 2 gives the total annualised costs, total annual
health effect in terms of DALYs averted, and the average
cost-effectiveness ratio for each of the 17 interventions in
three subregions with differing levels of adult and child
mortality and different patterns of risks to health (EurA,
AmrB, and SearD; the full set of results for all 
14 subregions is given in webtable 2). The health benefits
of all interventions follow a roughly bell-shaped curve
when plotted against age. Depending on the intervention
and the region, the curve reaches its maximum at around
60 years of age, with about half of the total intervention
be efit occurring at younger ages, and about half at older
ages. This relation is shown for AmrB in figure 1.
All 17 interventions in all three regions are cost effective
according to the Commission on Macroeconomics and
Health criterion. In all regions, the four non-personal
interventions have cost-effectiveness ratios that are lower
than personal health-service interventions.
When considered individually, non-personal health
interventions to reduce blood pressure and cholesterol are
very cost effective. Measures to decrease salt intake are
potentially very cost effec ive, with legislat on being more
cost effective than voluntary agreements under the
assumption that it would lead t  the larger reducti n in
dietary salt intake. The effect of non-personal health
service strategie  to lower cholesterol concentrations
depends on the distribution of risk factors in the region; it
has a slightly lower effect on population health than
legislation to lower salt intake in EurA and AmrB, but a
substantially higher effect in SearD.
Perhaps surprisingly, personal health-service strategies
have a much greater potential to reduce the burden of
disease–even though they are slightly less cost effective
than the population-wide strategies. Treatment of systolic
blood pressure above 160 mm Hg is very cost effective in
all regions. Statins are now available off-patent at very low
cost, and their use for people with total cholesterol
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AmrB EurA SearD
Costs DALYs Cost/DALY Costs DALYs Cost/DALY Costs DALYs Cost/
($106) (105) ($) ($106) (105) ($) ($106) (105) DALY ($)
Non-personal
N1 82 3 24 297 7 44 199 5 37
N2 82 6 13 297 13 23 199 10 19
N3 81 6 14 202 12 16 204 14 14
N4 163 12 14 499 24 21 403 24 17
Personal
P1 3122 38 81 14777 73 203 1570 44 36
P2 8806 47 186 37385 82 454 6399 71 90
P3 2426 28 87 19187 65 297 2537 54 47
P4 4397 33 133 27142 69 393 4835 69 71
P5 11232 61 183 56572 110 516 8936 107 84
P6 1335 51
P7 2059 56 37 16015 95 168 2888 88 33
P8 3352 62 54 22226 104 215 5078 106 48
P9 6456 69 93 35750 114 314 10183 133 77
Combined
C1 1365 54 25 11045 91 121 1829 82 22
C2 2056 58 35 15474 99 157 2994 95 31
C3 3332 64 52 21612 106 203 5149 112 46
C4 6394 71 90 35095 116 302 10173 137 74
Table 2: Annual costs, effects, and cost-effectiveness of interventions
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300000
250000
200000
150000
100000
0
0 10 19 28 37 46 55 64 73 82 91 100
50000
H
ea
lth
y 
lif
e 
ye
ar
s 
ga
in
ed
D
AL
Ys
 a
ve
rt
ed
Figure 1: Total intervention benefit by age (AmrB)
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However, a comparison of their cost-effectiveness ratios with those of the 
absolute risk approach shows that treatment based on measured levels of 
blood pressure or cholesterol alone would not be the preferred option on cost-
effectiveness grounds. 
The absolute risk approach at a threshold of 35% is always more cost-effective 
than treatment based on the measured level of either systolic blood pressure 
or cholesterol. It would avert an additional 65 million DALYs on top of the 
21 million DALYs averted by the two non-personal interventions evaluated 
here. 
As the absolute risk threshold is lowered, the health benefits increase but so 
do the costs – it gets more and more expensive to obtain each additional 
unit of health benefit. The exact point at which policy makers might choose 
to set the threshold will vary by setting and will take into account many 
factors in addition to cost-effectiveness, but it is very cost-effective to reduce 
the threshold even below 15% in the three regions under consideration, 
even taking into account the consequences of bleeding associated with the 
additional use of aspirin.
The cost-effectiveness ratios of the individual interventions do not tell the 
whole story. Figures 2(a-c) plot the annual cost and DALYs averted for each of 
the 17 interventions in the three regions. The slope of the line connecting the 
origin to each point is the cost-effectiveness ratio. The steeper the slope the 
more expensive the intervention is per DALY averted. These figures can also 
help visualize the incremental cost and incremental health gain of moving 
from one intervention strategy to another.
From the perspective of how best to maximize population health for the 
available resources, the optimal overall strategy is a combination of the 
population-wide and individual-based interventions. The solid lines joining 
the most cost-effective points in Figures 2(a-c) show the optimal choice from a 
cost-effectiveness perspective. These “expansion paths” join the interventions 
that would be selected for increasing levels of resource availability. The slopes 
between them represent the “incremental cost-effectiveness ratio” – or the 
additional costs required to avert each additional DALY by moving from the 
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lower to the higher cost intervention. The incremental costs, effects and cost-
effectiveness ratios of points on the expansion path are reported in Table 3. 
If resources are extremely scarce, the non-personal interventions would be 
chosen first. 
In all three regions, the expansion path is similar. In settings of extreme 
resource constraints, one of the non-personal interventions to reduce salt 
and/or cholesterol would be purchased first. Decision-makers who want to 
maximize health gain for available resources would next move to a combined 
strategy of legislated salt reductions in processed foods with mass media 
campaigns, and then add the absolute risk approach to managing blood 
pressure and cholesterol. Depending on the resources available, the absolute 
risk threshold for a cardiovascular event that would trigger intervention with 
beta blockers, diuretics, statins and aspirin would be lowered. While the total 
costs, total effects and cost-effectiveness ratios vary considerably across regions, 
the sequence of intervention strategies that would be purchased is similar. 
Table 3. Annual incremental costs, effects, and cost-
effectiveness of interventions
*See Table 7.1 for descriptions of interventions
Figures 2(a-c) also show that the total effect on the burden of disease through 
the management of absolute risk is substantial. Population-level reduction in 
cardiovascular disease events of more than 50% is possible. Even in the less 
developed regions of AmrB and SearD, the absolute magnitude of the changes 
in the burden of CVD are impressive. 
The multivariate uncertainty analysis illustrates that the cost-effectiveness 
ratios vary – depending on the region, they can be up to 83% higher on 
average or 53% lower. This variation, though apparently substantial, does 
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
options or the combined interventions. However,
certainty that population reduction of salt intake at 30%
will always be more cost effective than the mass-media
intervention targeting cholesterol is not possible.
The treatment interventions are highly correlated with
each other a  are the combination interventions. If a
particular sampling for the Monte Carlo simulations
shows a low effectiveness for statins, for ex mple, it must
be the same for all interventions involving statins (ie, for
all the absolute-risk ptions and the option to treat
individuals only on the basis of measured blood
cholesterol concentration). A point at the extreme left of
any intervention’s uncertainty region would be at the
extreme left for the other uncertainty regions involving
that treatment.
Therefore, the combined non-personal and personal
interventions must also be more costly and more effective
than the single personal option in any given situation,
even if the uncertainty regions overlap—for example, the
combination of the non-personal interventions with
treatment at the threshold of 25% must always be more
effective and more costly than the option of treatment at
the 25% threshold, even though the uncertainty regions
overlap. Similarly, the options to treat only blood pressure
or only cholesterol concentration must always be inside
the expansion path, even though the uncertainty regions
overlap slightly.
The essential features of the expansion paths in the
three regions do not, therefore, change with the changes
in assumptions even if the slopes of the segments change
somewhat. The order in which the two non-personal
health interventions (reduction of salt content of
processed foods and the mass-media approach to lowering
cholesterol concentrations) would be introduced might
not be certain, but in all cases one would be chosen as the
most desirable option, then the second would be added,
before the first personal intervention would be considered.
In addition, the absolute-risk approach is more cost
effective than r atment based on either blood pressure or
cholesterol concentration alone in all cases.
Discussion
In all regions, these selected non-personal and personal
health interventions to lower blood pressure and
cholesterol concentration are very cost effective. This
finding is at odds with the perception that strategies to
prevent cardiovascular disease should strictly be the
concern of the very wealthy. Implied in these results is a
further frameshift in thinking about priorities and public-
health strategies for less developed regions. Even though
the benefits documented here are large, the potential of
the non-personal interventions may be even larger. The
effect of these interventions observed in North Karelia,
Finland, was substantially larger than that in the North
American demonstration/cluster trials such as the
Stanford five-city study,32–34 and the assumptions used
here reflect both experiences. With greater understanding
of the factors that influence the effectiveness of these non-
personal interventions, development of strategies that
increase the population health benefits even further could
well be possible.
The beneficial effects of reduction in salt intake have
been subject to debate, with one
review suggesting that the effect on
blood pressure was negligible.35 That
review focused on interventions
involving individual dietary advice to
lower salt intake rather than the
option to decrease the salt content of
processed food as assessed here.
Indeed, the review concluded that a
population-wide decrease in salt
intake through decreasing salt
concentrations in processed foods
might achieve small reductions in
blood pressure across the whole
population for sustained periods,
which would then have substantial
health effects at the population level.
This was the motivation for the
intervention analysed here. In
addition, there is evidence that small
and repeated decreases in salt intake
are not discernible on grounds of taste
(eg, less salt does not necessarily
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AmrB EurA SearD
Costs DALYs Cost/DALY Costs DALYs Cost/DALY Costs DALYs Cost/DALY
($106) (105) ($) ($106) (105) ($) ($106) (105) ($)
Non-personal
N2 82 7 13 .. .. .. .. .. ..
N3 .. .. .. 202 12 16 204 14 14
N2 to N4 81 6 14 .. .. .. .. .. ..
N3 to N4 .. .. .. 297 12 25 199 10 20
Combined
N4 to C1 1201 42 29 10546 67 157 1426 58 24
C1 to C2 692 4 160 4428 7 616 1166 13 90
C2 to C3 1276 5 239 6138 8 781 2155 17 129
C3 to C4 7899 7 432 13484 3 1392 5023 6 206
Table 3: Annual incremental costs, effects, and cost-effectiveness of interventions
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not put any of the interventions classified as very cost-effective into a less 
desirable category. In addition, the essential features of the expansion paths in 
the three regions do not change with the changes in assumptions even if the 
slopes of the segments change somewhat. The order in which the two non-
personal health interventions (salt reduction in processed foods and the mass 
media approach to reducing cholesterol) would be introduced might change, 
but in all cases one would be chosen as the most desirable option, then the 
second would be added, before the first personal intervention is considered. In 
addition, the absolute risk approach is more cost-effective than treating people 
based on either blood pressure or cholesterol alone in all cases. 
Figure 2. Annual Costs and Effectiveness of CVD risk factor 
interventions
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
concentrations above 6·2 mmol/L is also very cost
effective in all regions. However, a comparison of their
cost-effectiveness ratios with those of the absolute-risk
approach shows that treatment based on measured blood
pressure or cholesterol concentrations alone would not be
the preferred option on grounds of cost-effectiveness. The
absolute-risk approach at a theshold of 35% is always
more cost effective than treatment based on either the
measured systolic blood pressure or the measured
cholesterol concentration. It would avert an additional 65
million DALYs on top of the 21 million DALYs averted
by the two non-personal interventions evaluated here.
As the absolute risk threshold is lowered, the health
benefits increase, but so do the costs; to obtain each
additional unit of health benefit becomes more and more
expensive. The exact point at which policy-makers might
choose to set the threshold will vary by setting and will
take into account many factors in addition to cost-
effectiveness, but reduction of the threshold even below
15% in the three regions under consideration is very cost
effective, even when consequences of bleeding associated
with the additional use of aspirin are taken into account.
The cost-effectiveness ratios of the individual
interventions do not tell the whole story. Figures 2, 3, and
4 plot the annual cost and DALYs averted for each of the 
17 interventions in the three regions. The slope of the line
connecting the origin to each point is the cost-effectiveness
ratio. The steeper the slope the more expensive the
intervention is per DALY averted. This figure also helps to
show the incremental cost and incremental health gain of
moving from one intervention strategy to another.
From the perspective of how best to achieve the best
population health for the available resources, the
optimum overall strategy is a combination of the
population-wide and individual-based interventions. 
The solid lines joining the most cost-effective points in
figures 2, 3, and 4 show the best choice in terms of 
cost-effectiveness. These expansion paths join the
interventions that would be selected for increasing
availability of resources. The slopes between them
represent the incremental cost-effectiveness ratio (the
additional costs required to avert each additional DALY
by moving from the lower-cost to the higher-cost
intervention). The incremental costs, effects, and cost-
effectiveness ratios of points on the expansion path are
reported in table 3. If resources are extremely scarce, the
non-personal interventions will be chosen first.
In all three regions, the expansion path is similar. In
settings of extreme resource constraints, one of the non-
personal interventions to lower salt intake, cholesterol
concentration, or both would be purchased first.
Decision-makers who wanted to achieve the greatest
health gain for available resources would next move to a
combined strategy of legislated reductions in salt content
of processed foods with mass-media campaigns, and then
add the absolute-risk approach to management of blood
pressure and cholesterol concentration. Depending on the
resources available, the absolute-risk threshold for a
cardiovascular-disease event that would trigger
intervention with β blockers, diuretics, statins, and aspirin
would be lowered. Although the total costs, total effects,
and cost-effectiveness ratios vary across regions, the
sequence of intervention strategies that would be
purchased is similar.
Figures 2, 3, and 4 also show that the total effect on the
burden of disease through the management of absolute
risk is substantial. A population-level reduction in
cardiovascular-disease events of more than 50% is
possible. Even in the less developed regions of AmrB and
SearD, the absolute magnitude of the changes in the
burden of cardiovascular disease is impressive.
The multivariate uncertainty analysis shows that the
cost-effectiveness ratios can be up to 83% higher on
average or 53% lower depending on the region. This
variation is illustrated for SearB in figure 5. The “clouds”
or uncertainty regions show the range of possible point
estimates emerging from the uncertainty analysis for any
given intervention. Despite the uncertainty, the individual
and combined non-personal interventions are always
chosen first—the uncertainty regions for them are close to
the origin and do not overlap with any of the treatment
ARTICLES
THE LANCET • Vol 361 • March 1, 2003 • www.thelancet.com 721
1500
1000
500
0
0
N1N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·2 0·4
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
0·6 0·8
Figure 2: Yearly costs and effectiveness of AmrA
6000
4000
2000
0
0
N1 N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 3: Yearly costs and effectiveness of EurA
1000
500
0
0
N1
N3
N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 4: Yearly costs and effectiveness of SearD
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
concentrations above 6·2 mmol/L is also very cost
effective in all regions. However, a comparison of their
cost-effectiveness ratios with those of the absolute-risk
approach shows that treatment based on measured blood
pressure or cholesterol concentrations alone would not be
the preferred option on grounds of cost-effectiveness. The
absolute-risk approach at a theshold of 35% is always
more cost effective than treatment based on either the
measured systolic blood pressure or the measured
cholesterol concentration. It would avert an additional 65
million DALYs on top of the 21 million DALYs averted
by the two non-personal interventions evaluated here.
As the absolute risk threshold is lowered, the health
benefits increase, but so do the costs; to obtain each
additional unit of health benefit becomes more and more
expensive. The exact point at which policy-makers might
choose to set the threshold will vary by setting and will
take into account many factors in addition to cost-
effectiveness, but reduction of the threshold even below
15% in the three regions under consideration is very cost
effective, even when consequences of bleeding associated
with the additional use of aspirin are taken into account.
The cost-effectiveness ratios of the individual
interventions do not tell the whole story. Figures 2, 3, and
4 plot the annual cost and DALYs averted for each of the 
17 interventions in the three regions. The slope of the line
connecting the origin to each point is the cost-effectiveness
ratio. The steeper the slope the more expensive the
intervention is per DALY averted. This figure also helps to
show the incremental cost and incremental health gain of
moving from one intervention strategy to another.
From the perspective of how best to chieve the be
population health f r the available resources, he
op imum overall strategy s a combinati n f he
population-wide and individual-based intervent ons. 
Th  solid lines joining most cost-effectiv  points in
figures 2, 3, and 4 show the best choice in terms of
cost-effectivene s. These expansion paths join th
interventions that w uld be selected for increasing
availability of r sources. The slopes b tw en them
repres t the incremental cost-effectiveness ratio (the
additional costs required to avert each additional DALY
by moving from the lower-cost to the higher-cost
intervention). The incremental costs, effects, and cost-
effectiveness ratios of points on the expansion path are
reported in table 3. If resources are extremely scarce, the
non-personal interventions will be chosen first.
In all three regions, the expansion path is similar. In
settings of extreme resource constraints, one of the non-
personal interventions to lower salt intake, cholesterol
concentration, or both would be purchased first.
Decision-makers who wanted to achieve the greatest
health gain for available resources would next move to a
combined strategy of legislated reductions in salt content
of processed foods with mass-media campaigns, and then
add the absolute-risk approach to management of blood
pressure and cholesterol concentration. Depending on the
resources available, the absolute-risk threshold for a
cardiovascular-disease event that would trigger
intervention with β blockers, diuretics, statins, and aspirin
would be lowered. Although the total costs, total effects,
and cost-effectiveness ratios vary across regions, the
sequ nce of intervention strategies that would be
purchased is similar.
Figures 2, 3, and 4 also show that the total effect on the
burden of disease throug  the manageme t of absolute
risk is substantial. A population-level reduction in
cardiovascular-disease events of more than 50% is
possible. Even in the less developed regions of AmrB and
SearD, the absolute magnitude of the changes in the
burden of cardiovascular disease is impressive.
The multivariate uncertainty analysis shows that the
cost-effectiveness ratios can be up to 83% higher on
average or 53% lower depending on the region. This
variation is illustrated for SearB in figure 5. The “clouds”
or uncertainty regions show the range of possible point
estimates emerging from the uncertainty analysis for any
given intervention. Despite the uncertainty, the individual
and combined non-personal interventions are always
chosen first—the uncertainty regions for them are close to
the origin and do not overlap with any of the treatment
ARTICLES
THE LANCET • Vol 361 • March 1, 2003 • www.thelancet.com 721
1500
1000
500
0
0
N1N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·2 0·4
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
0·6 0·8
Figure 2: Yearly costs and effectiveness of AmrA
6000
4000
2000
0
0
N1 N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 3: Yearly costs and effectiveness of EurA
1000
500
0
0
N1
N3
N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 4: Yearly costs and effectiveness of SearD
For person l use.  Only reproduce with permission from The Lancet Publishing Group.
concentrations above 6·2 mmol/L is also very cost
effective in all regions. However, a comparison of their
cost-effectiveness ratios with those of the absolute-risk
approach shows that treatment based on measured blood
pressure or cholesterol conce trations alone would not be
the preferred option n grounds of cost-effectiveness. The
absolute-risk a proach at a theshold of 35% is always
more cost effective t an treatment based on either the
easured systolic blood pressure or the measured
cholesterol concentrati n. It would avert an additional 65
million DALYs o  top of the 21 million DALYs averted
by the two non-personal interventions evaluated here.
As the absolute risk threshold is lowered, the health
benefits increase, but so do the costs; to obtain eac
additional unit of health benefit becomes more and more
expensive. The exact point at which policy-makers might
choose to set the threshold will vary by setting and will
take int  account many factors in additio  to cost-
effectiveness, but reduction of the threshold even below
15% in the three regions u der consideration is very c st
effective, even when consequences of bleedi g associated
with the additional use of aspirin are taken into acc unt.
The cost-effectiveness ratios of the individual
interventions do not tell the whole story. Figures 2, 3, and
4 plot the annual cost and DALYs averted for each of the 
17 interventions in the three regions. The slope of the line
con ecting the origin to each point is the cost-effectiveness
ratio. The steeper the slope the more expensive the
intervention is per DALY averted. This figure also helps to
show the i cremental cost and incremental health gain of
m ving from one i terventio  strategy to another.
From the perspective of how best to achieve the best
population health for the available resources, the
optimum overall strategy is a combination of t e
population-wide and individual-based interventions. 
The solid lines joining the most cost-effective points in
figures 2, 3, and 4 show the best choice in terms of 
cost-effectiveness. These expansion paths join the
interventions that would be selected for increasing
availability of resources. The slopes between them
represent the incremental cost-effectiveness ratio (the
additio al costs required to avert each additional DALY
by moving from the lower-cost to the higher-cost
intervention). The incremental costs, effects, and cost-
effectiveness ratios of points on the expansion path are
reported in table 3. If resources are extremely scarce, the
non-perso al interventions will be chosen first.
In all three regions, the expansion path is similar. In
settings of extreme resource constrai ts, one of the non-
personal interventions to lower salt intake, cholesterol
conce tration, or both would be purchased first.
Decision-makers who wanted to achieve the greatest
health gain for available resources would next move to a
combined strategy of legislated reductions in salt content
of processed foods with mass-media campaigns, and then
add the absolute-risk approach to management of blood
pressure and cholesterol concentration. Depending on the
resources available, the absolute-risk threshold for a
cardiovascular-disease event that would trigger
intervention with β blockers, diuretics, statins, and aspirin
would be lowered. Although the total costs, total effects,
and cost-effectiveness ratios vary acr ss regions, the
sequence of intervention strategies that w uld be
purchased is similar.
Figures 2, 3, and 4 also show that the total effect on the
burden of disease through the management of absolute
risk is substantial. A populatio -level reduction in
cardiovasc lar-disease events of more than 50% is
possible. Even in the less developed regions of AmrB and
SearD, the absolute magnitude of the changes in the
burden of cardiovascular disease is impressive.
The multivariate ncertainty analysis shows that the
cost-effectiveness ratios can be up to 83% hig er on
average or 53% lower depending on the region. This
variation is illustrated for SearB i  figure 5. The “clouds”
or uncertainty regions show the range of possible point
estimates emerging from the uncertainty analysis for any
given interventio . Despite the uncertainty, the individual
and combined on-personal i terventions are always
chosen first—the uncertainty regions for them are close to
t e origin and do ot overlap with any of the treatment
ARTICLES
THE LANCET • Vol 361 • March 1, 2003 • www.thelancet.com 721
1500
1000
500
0
0
N1N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·2 0·4
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
0·6 0·8
Figure 2: Yearly costs and effectiveness of AmrA
6000
4000
2000
0
0
N1 N3 N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 3: Yearly costs and effectiveness of EurA
1000
500
0
0
N1
N3
N4
P3
P4
P1
P2
P5
P6
P7
P8
P9
C2
C3
C4
C1
N2
0·5 1
DALYs (millions)
C
os
ts
, 
2
0
0
0
 In
t$
 (
m
ill
io
ns
)
1·5
Figure 4: Yearly costs and effectiveness of SearD
c. SearD
b. EurAa. AmrB
Personal Interventions (P)
P1 – t eatment f ypert nti n at 160 mmHg
P2 – treatment at 140 mmHg 
P3 – treatment of cholesterol at 6.2 mmol/L
P4– treatment of c lesterol at 5.7 mmol/L
P5 – combination of I1 and I3
P6 – absolute risk approach, 35% threshold
P7 – absol t  risk approach, 25% threshold
P8 – absolute risk approach, 15% threshold
P9 – absolute risk approach, 5% threshold
Non-personal Interventions (N)
N1 – voluntary salt reduction
N2 – l islated salt reduction
N3 – mass media targeting cholesterol
N4 – combination of P2 and P3
Combined Personal and Non-Personal 
Interventions (C)
C1 – P6 & N4 C3 – P8 & N4
C2 – P7 & N4 C4 – P9 & N4
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Figure 3a. Probability of inclusion at ‘low’ levels of resources 
availability in EurA
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Figure 3b. Probability of inclusion in optimal mix at ‘high’ levels 
of resources availability in EurA
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Figure 3 shows the stochastic league diagram for the cardiovascular cluster of 
interventions for the subregion EurA only as an example when low (Figure 3a) 
and high (Figure 3b) levels of resources are available. The vertical axis shows 
The time dimension in measurements of population health
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the probability that an intervention will be included in the optimal package 
for the level of the resource constraint on the horizontal axis. Estimates of 
cost and effect are allowed to vary in terms of defined distributions, and, with 
a Monte Carlo approach, the league table is calculated many times for each 
postulated level of resource availability. This procedure effectively takes into 
account uncertainty around the input parameters. The figure shows that the 
optimal mix will differ depending on the resources available. At relatively 
low resource levels, population wide interventions are likely the most efficient 
choice; at higher resource levels, the most efficient choice are combined 
population wide interventions with the absolute risk interventions. It remains, 
of course, to be seen if these preventive CVD interventions are cost-effective 
compared to other ways of using scarce health resources.
Discussion
In all regions, these selected non-personal and personal health interventions 
to reduce blood pressure and cholesterol are very cost-effective. This result is 
at odds with the perception that CVD prevention strategies should strictly be 
the concern of the very wealthy. Implied in these results is a further frameshift 
in thinking about priorities and public health strategies for developing regions. 
Even though the benefits documented here are already large, the potential of 
the non-personal interventions may be even larger. The effect size of these 
interventions observed in North Karelia, Finland was substantially larger than 
in the North American demonstration/cluster trials like the Stanford 5-city 
study [32-34] and the assumptions used here reflect both experiences. With 
greater understanding of the factors that influence the effectiveness of these 
non-personal interventions, it could well be possible to develop strategies that 
increase the population health benefits even further. 
The beneficial effects of salt reduction have been subject to debate in the 
recent literature with one review suggesting that the impact of salt reduction 
on blood pressure was minimal [35]. That review focused on interventions 
involving individual dietary advice to reduce salt intake rather than the 
option to reduce the salt content of processed food as assessed here. Indeed, it 
concluded that reduction in salt intake population-wide through cutting salt 
concentrations in processed foods might achieve small reductions in blood 
pressure across the whole population for sustained periods of time, which 
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would then have substantial health effects at the populaton level. This was the 
motivation for the intervention analysed here. In additon, there is evidence 
that small and repeated reductions in salt intake are not discernable on taste, 
(eg less salt does not necessarily mean less taste [36]) so that people are not 
likely to resist the new foods for that reason.
The absolute risk approach to managing blood pressure and cholesterol is 
very cost-effective in all regions, and has the potential to lead to dramatic 
reductions in ischaemic heart disease and stroke. Many other combinations 
of medicines are likely to be as cost-effective as those evaluated here. A 
meta-analysis of 354 trials, involving 56,000 participants, showed the blood 
pressure reductions produced by the major classes of drug at standard dose are 
similar, independent and additive, and that using half standard dose reduces 
efficacy only by 20% while more than halving side-effects [27,37,38]. There 
are also probable or proven benefits of these interventions on other important 
outcomes not measured here, such as dementia, renal failure, peripheral 
vascular disease, congestive heart failure and the need for coronary artery 
bypass grafting [39-43]. Additionally, while the effects of blood pressure and 
cholesterol lowering drugs appear to be due largely to the amount of risk 
factor reduction achieved [24,25], there may be some additional benefits due 
to specific agents, such as coronary disease risk reduction with ACE inhibitors 
[43]. Implementation of risk screening can and should be tailored to the 
resource levels of national health systems. In high-income countries, risk 
assessment on the basis of age, sex, measured blood pressure, cholesterol, body 
mass index, diabetes, tobacco use and clinical history of previous CVD events 
is practical. In low-resource settings, however, adequate risk screening could 
be based solely on age, sex, measured blood pressure, body mass index, tobacco 
use and past CVD events. This would require no sophisticated technology or 
blood sampling. A ‘risk pill’ of anti-hypertensives, statin and aspirin could 
also be packaged as a single compound facilitating compliance. 
As the absolute risk threshold used to trigger treatment is lowered, larger and 
larger fractions of the adult population would be on long-term drug treatment 
and the number of adverse events would increase. The consequences of this 
medicalization of potentially the majority of the adult population should 
be carefully considered. Issues of long-term compliance may also limit the 
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applicability of the approach in certain populations, including younger people. 
The potential huge benefits and the apparent cost-effectiveness of the absolute 
risk approach do seem to justify some large-scale population effectiveness 
studies. States or provinces in countries facing major CVD challenges could 
be enrolled to see if the expected population benefits can be achieved in the 
short-time frame implied by the analysis. 
It is well established that in developed countries, levels of blood pressure and 
cholesterol tend to be worse in the poor than in the rich [44]. Unfortunately, 
knowledge on how to manage these risks is used more effectively by the higher 
income, more educated population groups. Consequently, the coverage of 
interventions to reduce blood pressure and cholesterol is probably lower in the poor. 
Because of the distribution of these risks, there is a potential for both non-personal 
and the absolute risk approaches to substantially contribute to the reduction in 
adult health inqualities. It is a challenge for public health to develop innovative 
strategies to encourage the uptake of the latter in the poor and disadvantaged [45]. 
‘Out of the box” thinking may be needed. Studies show that intervention uptake 
can be affected by financial incentives. Perhaps, lottery tickets should be given to 
those that reduce their absolute risk by a certain amount in a year.
Why is this analysis apparently suggesting a much bigger impact at lower 
cost for personal health service interventions to manage blood pressure and 
cholesterol than many have been expected? First, as part of the Comparative 
Risk Analysis module of the Global Burden of Disease 2000 project, a clearer 
picture of the burden of these risk factors worldwide has emerged [2]. Second, 
new ways of using existing drugs such as the absolute risk method have been 
developed. Third, lovastain is now off-patent and other statins will follow 
soon, substantially reducing the cost of these regimens. Fourth, developments 
in the analysis of hazard data to deal with the effect of measurement error 
and regression dilution bias [21,46-48] have led to a nearly doubling of the 
estimated impact of reductions in blood pressure and cholesterol on outcomes. 
These changes remind us why it will always be important to update and 
reevaluate strategies that address major public health problems. 
The non-personal interventions considered here were even more cost-effective 
than the personal interventions in the three regions despite having a lower overall 
impact on population health. Care should be taken in interpreting these results 
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because the estimates of changes resulting from the mass media intervention 
were based on changes in behaviour observed in a developed country setting, 
but even with a halving of the assumed effectiveness, this conclusion is not 
altered. Based on this assumption, non-personal interventions would be be 
the first to be introduced. Moreover, the non-personal interventions assessed 
here are only a selection of those that are possible, and their very nature makes 
reliable assessment of effects challenging. But this challenge must be accepted. 
For example, assessing strategies to achieve moderate but widespread changes 
in manufactured food (e.g. in overall fat content) would be very worthwhile, 
since sub-optimal cholesterol and blood pressure levels have major dietary 
components to their aetiology.
Three final considerations are pertinent to the policy debate to which this 
paper contributes. First, the combination of medicines that prevent people 
at high risk of cardiovascular disease from having an event would cost just 
less than $14 per person per year if the lowest cost medicines were purchased 
internationally. This is simply the costs of the medicines and does not include 
distribution mark-ups. The ability of poor countries to finance this, and all 
the other possible cost-effective interventions, from their own resources is 
limited – some countries spend less than $10 per capita on health each year. 
The availability of low cost, effective ways to improve health in all settings, 
many of which are not affordable at current levels of health expenditure, is 
why WHO has argued strongly for massive injections of resources for health 
from richer countries that could be used to reduce the burden of disease 
among the poor. 
Second, this paper has focused on reducing the health consequences associated 
with cholesterol and blood pressure. It shows which interventions should be given 
priority when developing a strategy for the control of cardiovascular disease. 
This is important information for policy-makers responsible for cardiovascular 
disease control or health promotion. It does not, however, indicate whether 
controlling cardiovascular disease should receive priority over reducing the 
risks associated with unsafe sex, for example. This requires consideration of 
the costs and effects of all possible alternatives. WHO seeks to provide this 
information through its CHOICE project, and initial results covering several 
major risks to health can be found in the World Health Report 2002 [1].
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Third, cost-effectiveness is only one of the key inputs to final decision about 
how to allocate scarce resources. Policy-makers have other concerns as well, 
such as reducing poverty and inequalities, and questions of human rights 
and community acceptance also influence policy. Another key concern 
is how different types of interventions can be incorporated into the health 
infrastructure of the country, or how the infrastructure could be adapted to 
accommodate the desired strategies. The information presented here is one, 
but only one, of the critical inputs required to inform the decision making 
process about efficient ways to reduce risks to health. 
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Annex
Annex Table 1.  Epidemiologic subregions 
Region*
Mortality 
stratum**
Countries
Afr D Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, 
Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, 
Seychelles, Sierra Leone, Togo
Afr E Botswana, Burundi, Central African Republic, Congo, Côte d’Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopia, 
Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, 
Zimbabwe
Amr A Canada, United States of America, Cuba
Amr B Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, 
El Salvador, Grenada, Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts And Nevis, Saint Lucia, Saint Vincent 
and the Grenadines, Suriname, Trinidad And Tobago, Uruguay, Venezuela
Amr D Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru
Emr B Bahrain, Cyprus, Iran (Islamic Republic of), Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Oman, Qatar, Saudi Arabia, Syrian 
Arab Republic, Tunisia, United Arab Emirates
Emr D Afghanistan, Djibouti, Egypt, Iraq, Morocco, Pakistan, Somalia, Sudan, Yemen
Eur A Andorra, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, 
Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland, United 
Kingdom
Eur B Albania, Armenia, Azerbaijan, Bosnia and Herzegovina, Bulgaria, Georgia, Kyrgyzstan,Poland, Romania, Slovakia, Tajikistan, The 
Former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Uzbekistan, Yugoslavia
Eur C Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania,  
Republic of Moldova, Russian Federation, Ukraine
Sear B Indonesia, Sri Lanka, Thailand
Sear D Bangladesh, Bhutan, Democratic People’s Republic of Korea, India, Maldives, Myanmar, Nepal
Wpr A Australia, Japan, Brunei Darussalam, New Zealand, Singapore
Wpr B Cambodia, China, Lao People’s Democratic Republic, Malaysia, Mongolia, Philippines, Republic of Korea, Viet Nam, Cook 
Islands, Fiji, Kiribati, Marshall Islands, Micronesia (Federated States of), Nauru, Niue, Palau, Papua New Guinea, Samoa, 
Solomon Islands, Tonga, Tuvalu, Vanuatu
* Afr = African Region; Amr = Region of the Americas; Emr = Eastern Mediterranean Region; Eur = European Region; Sear = South East Asian Region; Wpr = 
Western Pacific Region
** A subregions have very low rates of adult and child mortality; B = low adult, low child; C = high adult, low child; D = high adult, high child; E = very high adult, 
high child mortality
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Annex Table 2.  Assumptions on effectiveness and costs for 
non-personal interventions 
Model variables Assumptions Sources
Basic epidemiology Ischaemic heart 
disease
Cerebovascular 
disease
Acute myocardial infarction; angina pectoris; congestive heart failure.
 
First-ever fatal stroke cases; long-term stroke survivors.
Murray and Lopez, 1996 [1] 
Murray and Lopez, 1996 [1]
Risk factor and 
epidemiology
Blood pressure 
 
 
Cholesterol
Body mass index
Smoking
Region-, age- , and sex-specific systolic blood pressure levels; age-specific 
relative risks of CVD event for 1mm Hg change in systolic blood pressure 
(see Annex 4).
Region-, age- , and sex-specific cholesterol levels; age-specific relative 
risks of CVD event for 1mmol/l change in total blood cholesterol (see 
Annex 4).
Region-, age- , and sex-specific body mass index levels age-specific 
relative risks of CVD event for 1 unit change in body mass index (see 
Annex 4).
Region-, age- , and sex-specific prevalence of long-term smokers; age-
specific relative risks of CVD event for unit change in prevalence of 
long-term smokers (see Annex 4). 
World Health Organization, 2002 [2]
Programme level 
costs
Intervention N1
Intervention N2
Intervention N3
Central administration and planning costs at 95% coverage.
Central administration, planning and enforcement costs at 95% coverage.
Central administration costs, planning, media costs and printed materials 
at 80% coverage.
Johns,2002 [3]; Adam et al., 2002 [4] 
Effectiveness Intervention N1
Intervention N2
Intervention N3
Intervention N4
Region- age- and sex-specific blood pressure changes associated with a 
15% reduction in total dietary salt intake (see Annex 5).
Region- age- and sex-specific blood pressure changes associated with a 
30% reduction in total dietary salt intake (see Annex 5).
2% reduction in total blood cholesterol levels.
Combined effect of interventions N2 and N3.
Law et al., 1991 [5] 
Frost et al., 1991 [6] Law et al., 1991 [7]  
Lawes et al., 2002 [8]
Tosteson et al., 1997 [9] 
Murray CJL, Lopez AD. 1. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and 
projected to 2020, 1st edn. Cambridge, MA: Harvard University Press, 1996.
World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002.2. 
Johns B, Baltussen R, Hutubessy RCW. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003; 1(1): 13. 
Adam T, Evans DB, Murray CJL. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003; 1(1): 3.4. 
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I Analysis of observational data among populations. BMJ 1991; 5. 
302: 811–15. 
Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II Analysis of observational data within populations. BMJ 1991; 6. 
302: 815–18.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III Analysis of data from trials of salt reduction. BMJ 1991; 302: 7. 
819–24.
Lawes C, Feigin V, Rodgers A. Estimating reductions in blood pressure following reductions in salt intake by age, sex and WHO region. Auckland: Clinical Trials 8. 
Research Unit, University of Auckland, 2002.
Tosteson AN, Weinstein MC, Hunink MG, et al. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 9. 
1997; 95: 24–30.
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Annex Table 3.  Assumption for personal and combined 
interventions
Model variables Assumption Sources
Basic epidemiology Ischaemic heart 
disease
Cerebrovascular 
disease 
 
Upper 
gastrointestinal 
bleeding
Acute myocardial infarction; angina pectoris; congestive heart failure.
First-ever fatal stroke cases; long-term stroke survivors.
Adverse effect of anti-platelet therapy with low dose aspirin.
Murray, Lopez, 1996 [1] 
Hernandez-Diaz, Rodriguez, 2002 [2] 
Risk factor and 
epidemiology
Blood pressure  
 
Cholesterol 
Body mass index 
Smoking 
 
Intervention 
coverage 
Region-, age- , and sex-specific systolic blood pressure levels; global age-
specific relative risks of CVD event for 1mm Hg change in systolic blood 
pressure (Annex 7.3).
Region-, age- , and sex-specific cholesterol levels; global age-specific relative 
risks of CVD event for 1mmol/l change in total blood cholesterol (Annex 4).
Region-, age- , and sex-specific body mass index levels; global age-specific 
relative risks of CVD event for 1 unit change in body mass index (Annex 4).
Region-, age- , and sex-specific prevalence of long-term smokers; global 
age-specific relative risks of CVD event for unit change in prevalence of 
long-term smokers (Annex 4). 
Coverage of antihypertensive drug treatment among respondents aware of 
high blood pressure.
Coverage of cholesterol-lowering drug treatment among respondents 
aware of high cholesterol.
World Health Organization, 2002 [3] 
 
 
 
 
 
Molarius, Tuomilehto, et al, 1998; Tolonen, 
Kullasmaa et al, 1999; Tolonen, Ferrario et al, 
1999 [4-6] 
Patient level costs Intervention P1 
& P2
 
Intervention P3 
& P4
Intervention P5 
 
 
Intervention P6-P9 
 
 
 
Upper 
gastrointestinal 
bleeding
Drug treatment: 50mg/day atenolol (beta-blocker) ; 25mg/day 
hydrochlorothiazide (diuretic).
Provider visits: 4 health-care provider visits/year ; 1.5 outpatient visits/year 
for health education.
Laboratory tests: annual renal function, lipid profile and blood sugar tests.∗
Drug treatment: 30mg/day lovastatin.
Provider visits: 4 health-care provider visits/year ; 1.5 outpatient visits/year 
for health education.
Laboratory tests: total cholesterol and hepatic function.∗ 
Drug treatment: 50mg/day atenolol (beta-blocker) ; 25mg/day 
hydrochlorothiazide (diuretic) and 30mg/day lovastatin.
Provider visits: 4 health-care provider visits/year ; 1.5 outpatient visits/year 
for health education.
Laboratory tests: annual renal function, lipid profile and blood sugar tests; 
total cholesterol and hepatic function.∗ 
Drug treatment: 50mg/day atenolol (beta-blocker) ; 25mg/day 
hydrochlorothiazide (diuretic), 30mg/day lovastatin and 100 mg/day 
acetylsalicylic acid (aspirin).
Provider visits: 4 health-care provider visits/year ; 1.5 outpatient visits/year 
for health education.
Laboratory tests: annual renal function, lipid profile and blood sugar tests; 
total cholesterol and hepatic function.∗ 
Secondary level hospital stay of 2.7 days for GBD non-A sub regions and 
tertiary level hospital stay of 4.8 days for GBD A sub regions.
Unit prices of health facilities are based on 
Adam et al. [7] 
 
Unit price drugs are based on the 
International Drug Price indicator by 
Management Science for Health (www.erc.
msh.org)
 
 
Unit prices laboratory tests are based on 
Arizona Health Care Cost Containment 
System (AHCCCS) Fee Schedule 
(www.state.me.us/wcb/departments/
omrs/1999%20MFS/radiology.htm)
 
Hay, Lyubashevsky, et al, 1996 [8] 
Effectiveness Intervention P1 
& P2
Intervention P3 
& P4
ntervention P5
Intervention P6-P9
 
Intervention C1-C4
33% reduction of the difference between actual systolic blood pressure 
and 115 mm Hg.
20% reduction in total blood cholesterol.
Combined effect of P2 and P3.
Combined effect of P2 and P3 with additional 20% reduction of absolute 
risk for antiplatelet therapy. 
Effects of N4 evaluated first. Then the reduced number of people at risk 
of a 
Cardiovascular event are subject to the same costs and effects as with P6-9 
References [9-24]
 
Collins, Armitage et al, 2002 [25] 
Anon [26] 
∗ Only for GBD A sub regions
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Annex Table 4.  Relative risks of CVD events for unit 
changes in systolic blood pressure, total 
blood cholesterol, body mass index levels 
and prevalence of long-term smokers.
Relative risks for ischaemic heart disease
Age groups
 30-44 45-59 60-69 70-79 80+
Systolic blood pressure (mm Hg) 1.07 1.05 1.03 1.02 1.01
Total blood cholesterol (mmol/l) 3.65 2.08 1.55 1.42 1.42
Body mass index (kg/m2) 1.11 1.09 1.05 1.04 1.03
Relative risks for stroke 
Age groups
30-44 45-59 60-69 70-79 80+
Systolic blood pressure(mm Hg) 1.09 1.07 1.05 1.03 1.02
Total blood cholesterol(mmol/l) 1.48 1.35 1.25 1.17 1.09
Body mass index (kg/m2) 1.19 1.09 1.06 1.06 1.02
Relative risks for smoking and cardiovascular death
Age groups
30-44 45-59 60-69 70-79 80+
Male 2.43 2.43 1.84 1.70 1.38
Female 2.18 2.18 2.12 1.70 1.31
Annex Table 5.  Percentage reduction in systolic blood 
pressure for 15% and 30% salt reduction 
intake in three regions.
AmrB EurA SearD
15% reduction 30% reduction 15% reduction 30% reduction 15% reduction 30% reduction
Male female male Female male Female Male female male female male female
30-44 -1.1% -0.8% -2.2% -1.6% -1.3% -0.9% -2.6% -1.9% -1.1% -1.0% -2.1% -1.9%
45-59 -1.3% -1.1% -2.7% -2.2% -1.6% -1.3% -3.1% -2.6% -1.4% -1.2% -2.8% -2.5%
60-69 -1.7% -1.5% -3.4% -2.9% -1.9% -1.6% -3.8% -3.3% -1.9% -1.6% -3.7% -3.3%
70-79 -2.0% -1.7% -4.0% -3.4% -2.2% -1.9% -4.4% -3.7% -2.2% -2.0% -4.5% -3.9%
80+ -2.4% -2.0% -4.8% -3.9% -2.6% -2.1% -5.2% -4.3% -2.7% -2.4% -5.4% -4.8%
These estimates were made by applying the relationship between sodium intake and blood pressure as estimated by Law et al [1-3] to the WHO age, sex 
and region subgroups [4] , there have been no re-analyses of the strength of this association in this paper.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I Analysis of observational data among populations. 1. BMJ 
1991; 302: 811–15.
Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II Analysis of observational data within populations. 2. BMJ 
1991; 302: 815–18.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III Analysis of data from trials of salt reduction. 3. BMJ 1991; 
302: 819–24.
Lawes C, Feigin V, Rodgers A. Estimating reductions in blood pressure following reductions in salt intake by age, sex and WHO region. Auckland: 4. 
Clinical Trials Research Unit, University of Auckland, 2002.
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Abstract
Objective To determine the cost effectiveness of selected malaria control 
interventions in the context of reaching the millennium development goals 
for malaria.
Design Generalised cost effectiveness analysis.
Data sources Efficacy data came from the literature and authors’ calculations 
supported by expert opinion. Quantities for resource inputs came from the 
literature and from expert opinion; prices came from the WHO-CHOICE 
database.
Methods Costs were assessed in year 2000 international dollars and effects were 
assessed as disability adjusted life years averted by a 10 year implementation 
programme. Analysis was restricted to sub-Saharan regions where the most 
deadly form of malaria, due to resistant Plasmodium falciparum, is most 
prevalent. The impact on population health for various interventions and their 
combinations was evaluated at various coverage levels by using a state-transition 
model. Sensitivity analysis was done for age weights and discounting.
Results High coverage with artemisinin based combination treatments was 
found to be the most cost effective strategy for control of malaria in most 
countries in sub-Saharan Africa.
Conclusions A much larger infusion of resources than those currently 
available is needed to make headway in the fight to roll back malaria. On cost 
effectiveness grounds, in most areas in sub-Saharan Africa greater coverage 
with highly effective combination treatments should be the cornerstone of 
malaria control. However, treatment alone can achieve less than half the total 
benefit obtainable through a combination of interventions, and scaling up the 
use of impregnated mosquito nets or indoor spraying with insecticides is also 
critical. Intermittent presumptive treatment of pregnant women can bring a 
small but important additional health gain at relatively low cost.
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Introduction
Each year, more than one million people, mostly children and pregnant 
women, die from malaria. The human toll is tragic, and the economic cost is 
enormous.[1] [2] Most of these deaths could be avoided, however, as effective 
and affordable ways to prevent and treat malaria exist. In recognition of the 
scope of the problem, malaria control is embedded in one of the millennium 
development goals of the United Nations: to “combat HIV/AIDS, malaria 
and other diseases.”[3]
Although insufficient data are available to fully assess global experience since 
2000, malaria related mortality seems to have increased since 1990, probably 
owing to a combination of factors, including increasing exposure to the 
disease,[4] increasing resistance to antimalarial drugs,[5] and stagnant levels 
of coverage with interventions (R W Snow, personal communication, 2005). 
Complex emergencies and resistance to insecticides have also contributed.
[6] Achieving the millennium development goals clearly requires a massive 
scaling up of interventions against malaria.
However, it is important to ask whether current interventions are used 
appropriately and what is the most cost effective way to scale up activities 
to the levels needed. In particular, which prevention or treatment strategies, 
and what combination, are most effective and where? We use a generalised 
cost effectiveness analysis (See reference 10, Chapter 3) to examine the costs 
and effects of scaling up seven interventions against malaria and their most 
promising combinations. This paper deviates from others in this series[7] by 
focusing only on sub-Saharan Africa, where 90% of deaths from malaria 
occur.[8]
Whereas most economic studies have compared the relative cost effectiveness 
of implementing interventions for prevention or treatment individually—that 
is, considering the best use of small amounts of additional resources—this 
study used a generalised framework allowing for interactions, as well as for 
consideration of whether current practice is optimal and what the implications 
are of massively scaling up.
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Methods
Geographical focus
We focused on two sub-Saharan African regions: Afr-E (predominantly 
Southern and Eastern Africa), defined as African countries with high child 
mortality (all causes) and very high adult mortality (all causes), and Afr-D 
(predominantly Western Africa), African countries with high child mortality 
and high adult mortality. Annex table A gives a list of the countries by 
region.
Both regions are predominantly areas with endemic high transmission of 
malaria due to Plasmodium falciparum, although burden of disease differs 
somewhat. According to the World Health Report 2000, incidence of 
symptomatic malaria in children aged under 5 years was 1436 per thousand 
in Afr-D, whereas in Afr-E it was 1184 per thousand; these differences are 
due to patterns of urbanisation and the elevation of populated sites. In Afr-E, 
cause specific child mortality is slightly higher at 8 per thousand as opposed 
to 7 per thousand in Afr-D.
Interventions
A limited number of means are available to fight malaria. Preventive 
interventions, based on vector control, include insecticide treated nets and 
indoor residual spraying. For treatment of malaria, several drugs exist and a 
few are relatively inexpensive. However, resistance to most drugs is growing 
rapidly. Recently, combination treatments with and without artemisinin 
derivatives have been tested and found not only to be effective but also to slow 
the growth of resistance.[9] Intermittent treatment of pregnant women—
aimed largely at reducing neonatal mortality—is also an option. We evaluated 
seven individual interventions and combinations thereof (box 1). 
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Box 1: Interventions evaluated
•	 Insecticide	treated	bed	nets	(ITN)
•	 Indoor	residual	spraying	(IRS)
•	 Case	management	with	chloroquine	(CQ)
•	 Case	management	with	sulfadoxine-pyrimethamine	(SP)
•	 Case	management	with	non-artemisinin	based	(CQ-SP)	
combination treatment (Comb)
•	 Case	management	with	artemisinin	based	combination	treatment	
(ACT)
•	 Intermittent	presumptive	treatment	with	SP	in	pregnancy	(IPTp)
 (See Annex for details)
Some countries in sub-Saharan Africa still officially recommend chloroquine 
as first line treatment for malaria despite increasing resistance and declining 
cure rates. Although others have moved to sulfadoxine-pyrimethamine, 
resistance has also compromised its effectiveness. As a result, awareness is 
growing of the need to increase the use of artemisinin derivatives (especially 
in combination treatment) as resistance to these compounds is still extremely 
low (even non-existent) in sub-Saharan Africa.[10] In this study, we evaluated 
the cost effectiveness of chloroquine, sulfadoxine-pyrimethamine, non-
artemisinin based combinations, and artemisinin based combinations as first 
line treatment (we did not consider complicated malaria needing admission 
to hospital).
Population at risk and coverage
We evaluated interventions at 50%, 80%, and 95% target coverage to allow 
for unit costs and effectiveness that may vary with coverage. We estimated 
effective coverage as target coverage multiplied by population at risk.[8] We 
based region-wide estimates of population at risk (the proportion living in a 
malaria endemic area: 98% for Afr-D and 69% for Afr-E) on country specific 
figures published in 2003.[8] Table 1 shows estimates of current coverage,[8] 
used for calculating the null scenario.[7]
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Estimating the net effectiveness of interventions
We expressed the efficacy of nets and indoor spraying as a reduction in incidence 
and, thereby, a reduction in mortality, modelled here through case fatality 
(table 2). We estimated the net effectiveness of treatment, taking into account 
patients’ behaviour (adherence to the regimen), pharmacokinetics (probability 
of success when the regimen is not followed), and biogenetics (resistance of the 
parasite to the drug). These factors (table 3) determine the number of expected 
treatment failures,[11] which we subtracted from a common baseline of 98% 
efficacy. We reduced the net effectiveness of bed nets, but not spraying, to 
account for imperfect adherence. Table 4 shows estimates of net effectiveness. 
Annex table B reports the detailed assumptions on effectiveness.
Table 1  Current coverage* with selected malaria control 
interventions
Intervention Afr-D (%) Afr-E (%)
Case management with chloroquine 23 27
Case management with sulfadoxine-pyrimethamine (SP) 3 3
Case management with non-artemisinin based combination treatment 0 0
Case management with artemisinin based combination treatment 0 0
Insecticide treated bed nets 2 2
Indoor residual spraying 0 3
Intermittent presumptive treatment with SP in pregnancy 0 0
*Percentage of people at risk who are given the drug at outpatient clinic or antenatal clinic, sleep under an insecticide treated net, or live in a house that has 
been sprayed.
Table 2 Baseline efficacy (both Afr-D and Afr-E)
Intervention
Baseline reduction in 
incidence (%)
Baseline reduction in case 
fatality* (%)
Insecticide treated bed nets 50 20
Indoor residual spraying 50 20
Case management with chloroquine 0 98
Case management with sulfadoxine-pyrimethamine (SP) 0 98
Case management with non-artemisinin based combination treatment 0 98
Case management with artemisinin based combination treatment 0 98
Intermittent presumptive treatment with SP in pregnancy 0 5
*Before patients’ adherence and parasites’ drug resistance are taken into account.
Table 3 Parameters used for the calculation of net 
effectiveness
Intervention
Resistance Behavioural/drug characteristics
R0 r Adherence (%)
Probability of 
success when not 
fully compliant (%)
Insecticide treated bed nets – – 65 0
Indoor residual spraying – – 100 0
Case management with chloroquine 0.35 0.1 40 20
Case management with sulfadoxine-pyrimethamine (SP) 0.1 0.4 90 0
Case management with non-artemisinin based combination treatment 0.1 0.1 35 35
Case management with artemisinin based combination treatment 0.001 0.05 35 45
Intermittent presumptive treatment with SP in pregnancy 0.1 0.1 80 0
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Table 4 Net effectiveness of the interventions
Intervention
Reduction in  
incidence (%)
Reduction in  
case fatality (%)
Insecticide treated bed nets 50 20
Indoor residual spraying 50 20
Case management with chloroquine – 27
Case management with sulfadoxine-pyrimethamine (SP) – 44
Case management with non-artemisinin based combination treatment – 47
Case management with artemisinin based combination treatment – 63
Intermittent presumptive treatment with SP in pregnancy – 3.3
Table 5  WHO estimates of the burden of malaria
Incidence Deaths DALYs
Afr-D 176 547 940 515 528 19 088 877
Afr-E 163 442 874 470 845 17 680 061
Worldwide 381 987 866 1 120 697 41 998 576
DALY=disability adjusted life year.
Source: WHO programme on global burden of disease.
A population model[12] combined estimates of incidence, prevalence, and 
mortality (table 5)[13] with estimates of prevalence and severity from the burden 
of disease study to project the population impact of intervention scenarios in 
terms of healthy years of life lived.[7] Differences in total population healthy 
years under the intervention and baseline scenarios are expressed as disability 
adjusted life years (DALYs) averted.
Costs
Estimated costs measure the value of resources needed to provide the 
intervention[7] and are expressed in international dollars ($int, a  hypothetical 
unit of currency that has the same purchasing power that the US$ has in the 
United States at a given point in time, thus showing the average value of local 
currency units within each region’s borders). We calculated costs in light of 
experience from effectiveness trials, using data from the WHO-CHOICE 
database, existing literature, and expert opinion.[7] As we explicitly assumed 
training of human resources to be a substantial part of malaria interventions, 
training costs are reported separately. We used the CostIt model (WHO, 2002) 
to aggregate cost components and total costs for the 10 year implementation 
horizon. Details of the approach are discussed by Baltussen et al.[14]
Unit costs—We obtained unit costs of inputs, such as salaries, capital 
equipment, drugs, storage, buildings, office supplies, and furniture from a 
review of the literature supplemented by primary data from several countries 
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(a full list of estimated unit costs is available at www.who.int/evidence/cea). 
Additional details can be found in Johns et al, Johns and Baltussen, and 
Adam et al.[15][16][17]
Distribution costs—We assumed distribution costs to be most sensitive to 
changes in coverage levels and calculated them with a standard mark-up based 
on the average of free on board; cost, insurance, and freight; and additional 
trade related distributional costs.[15] [16]
Media costs—A substantial component of malaria control is creating public 
awareness of and demand for health services. We accordingly included 
media costs for all interventions and estimated them according to whether 
they consisted of a centrally determined policy change (for example, case 
management guidelines) or were intended to change population behaviour 
(for example, insecticide treated bed nets). We included both public campaigns 
(all interventions) and targeted social marketing (bed nets only, through an 
extensive level of outreach). We obtained benchmarks from cost analyses of 
existing malaria control programmes in sub-Saharan Africa.[18]
Labour costs—We estimated labour costs according to the educational level 
of the worker—for example, administrative staff or medical staff—and the 
number of full time equivalents needed for administration, training, or 
delivery of the intervention.
Cost profiles— Figures 1 and 2 summarise cost profiles for 95% coverage 
(generally the most efficient coverage level) by patient, programme, and 
training costs. Note that for some interventions patient costs are the smallest 
proportion of total costs.
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Figure 1  Cost profile of interventions at 95% coverage, Afr-D. 
See box 1 for abbreviations(labels show I$ million, size of bar indicates proportion of total)
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Figure 2 Cost profile of interventions at 95% coverage, Afr-E. 
See box 1 for abbreviations(labels show I$ million, size of bar indicates proportion of total)
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Results
Population level cost effectiveness estimates for individual and combined 
interventions are shown in table 6 (dominant interventions only) and in 
figures 3 and 4 (all interventions).
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Table 6  Costs, effectiveness, and cost effectiveness of the 
health maximising set of interventions (see Web 
Table 3 for detailed results for all interventions)
Region and intervention
Average yearly 
costs ($int)
Average yearly 
effectiveness 
(DALYs averted)
Average cost 
effectiveness ($int/
DALY averted)
Incremental cost 
effectiveness ($int/
DALY averted)
Afr-D
Insecticide treated bed nets (95% coverage) 178,216,076 8,872,378 29 29
Insecticide treated bed nets plus indoor residual spraying 
plus case management with artemisinin based combination 
therapy plus intermittent presumptive treatment in 
pregnancy (95% coverage)
434,229,098 14,561,792 36 48
Afr-E
Case management with artemisinin based combination 
therapy (80% coverage)
194,055,200 5,055,437 38 38
Case management with artemisinin based combination 
therapy plus insecticide treated bed nets (80% coverage)
343,906,545 8,136,888 42 49
Case management with artemisinin based combination 
therapy plus insecticide treated bed nets (95% coverage)
412,334,271 9,338,292 44 57
Case management with artemisinin based combination 
therapy plus insecticide treated bed nets plus indoor residual 
spraying (95% coverage)
509,794,378 10,956,811 46.5 60
Case management with artemisinin based combination 
therapy plus insecticide treated bed nets plus indoor 
residual spraying plus intermittent presumptive treatment in 
pregnancy (95% coverage)
510,921,742 10,964,451 46.6 148
DALY=disability adjusted life year; $int=international dollar.
Figure 3  Cost effectiveness plane showing 60 analysed 
interventions (20 individual and combination 
interventions at three assumed coverage levels) and 
expansion path (see text), Afr-D. DALY=disability 
adjusted life year; see box 1 for other abbreviations
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Expansion Path ITN -- 95% cov. IPTP -- 95% cov. IRS -- 95% cov.
CQ -- 95% cov. SP -- 95% cov. Comb -- 95% cov. ACT -- 95% cov.
ITN & CQ -- 95% cov. ITN & SP -- 95% cov. ITN & Combo -- 95% cov. ITN & ACT -- 95% cov.
IRS & CQ -- 95% cov. IRS & SP -- 95% cov. IRS & Combo -- 95% cov. IRS & ACT -- 95% cov.
IRS & ACT & IPTP -- 95% cov. ITN & ACT & IPTP -- 95% cov. IRS & ITN -- 95% cov. IRS & ITN & ACT -- 95% cov.
IRS & ITN & ACT & IPTP -- 95% cov. ITN -- 80% cov. IPTP -- 80% cov. IRS -- 80% cov.
CQ -- 80% cov. SP -- 80% cov. Comb -- 80% cov. ACT -- 80% cov.
ITN & CQ -- 80% cov. ITN & SP -- 80% cov. ITN & Combo -- 80% cov. ITN & ACT -- 80% cov.
IRS & CQ -- 80% cov. IRS & SP -- 80% cov. IRS & Combo -- 80% cov. IRS & ACT -- 80% cov.
IRS & ACT & IPTP -- 80% cov. ITN & ACT & IPTP -- 80% cov. IRS & ITN -- 80% cov. IRS & ITN & ACT -- 80% cov.
IRS & ITN & ACT & IPTP -- 80% cov. ITN -- 50% cov. IPTP -- 50% cov. CQ -- 50% cov.
Comb -- 50% cov. ACT -- 50% cov. ITN & CQ -- 50% cov. ITN & SP -- 50% cov.
ITN & Combo -- 50% cov. ITN & ACT -- 50% cov. IRS & CQ -- 50% cov. IRS & SP -- 50% cov.
IRS & Combo -- 50% cov. IRS & ACT -- 50% cov. IRS & ACT & IPTP -- 50% cov. ITN & ACT & IPTP -- 50% cov.
IRS & ITN -- 50% cov. IRS & ITN & ACT -- 50% cov. IRS & ITN & ACT & IPTP -- 50% cov. IRS -- 50% cov.
SP -- 50% cov.
The time dimension in measurements of population health
98
Figure 4  Cost effectiveness plane showing 60 interventions 
(20 individual and combination interventions at 
three assumed coverage levels) and expansion path 
(see text), Afr-E. DALY=disability adjusted life year; 
see box 1 for other abbreviations
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ITN & Combo -- 50% cov. ITN & ACT -- 50% cov. IRS & CQ -- 50% cov. IRS & SP -- 50% cov.
IRS & Combo -- 50% cov. IRS & ACT -- 50% cov. IRS & ACT & IPTP -- 50% cov. ITN & ACT & IPTP -- 50% cov.
IRS & ITN -- 50% cov. IRS & ITN & ACT -- 50% cov. IRS & ITN & ACT & IPTP -- 50% cov. IRS -- 50% cov.
SP -- 50% cov.
The “expansion paths” in figures 3 and 4, described in the methods paper 
for this series,[7] show the order in which interventions would be selected at 
different levels of resource availability. Notable differences exist between the 
regions. In the Afr-D region, insecticide treated bed nets at 95% target coverage 
are the most cost effective intervention overall, and would be the first chosen 
where resources are very limited, whereas in Afr-E, case management with 
artemisinin based combination treatments at 80% target coverage is the most 
cost effective intervention overall. In Afr-D, the second intervention on the 
path represents the combination of insecticide treated bed nets, indoor residual 
spraying, case management with artemisinin based combination therapy, 
and intermittent presumptive treatment with sulfadoxine-pyrimethamine in 
pregnancy, also at 95% target coverage. 
In Afr-E, case management with artemisinin based combination treatments at 
80% target coverage is followed by the combination of case management with 
artemisinin based combination therapy and insecticide treated bed nets (80% 
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coverage); then the combination of case management with artemisinin based 
combination therapy and insecticide treated bed nets (95% coverage); then the 
combination of case management with artemisinin based combination therapy, 
insecticide treated bed nets, and indoor residual spraying (95% coverage); 
and, finally, the combination of case management with artemisinin based 
combination therapy, insecticide treated bed nets, indoor residual spraying, 
and intermittent presumptive treatment with sulfadoxine-pyrimethamine 
in pregnancy (95% coverage). In both regions, the ultimate stage involves 
the use of case management with artemisinin based combination treatment, 
insecticide treated bed nets as well as indoor residual spraying, and intermittent 
presumptive treatment in pregnancy, all at 95% coverage.
All malaria interventions are highly cost effective, with average cost 
effectiveness ratios (except intermittent presumptive treatment with sulfadoxine-
pyrimethamine in pregnancy) in the order of 10-100 $int /DALY averted. 
Nevertheless, the size of potential health gains, as well as incremental cost 
effectiveness ratios, are more favourable in Afr-D than in Afr-E, as a higher 
proportion of the population is at risk in Afr-D. That allows more people to be 
covered, thereby reducing the costs per person covered (fig 5, fig 6, table 6).
Figure 5 Incremental and average cost effectiveness ratios for the 
health maximising interventions, Afr-D. DALY=disability 
adjusted life year; see box 1 for other abbreviationsIncremental and average cost effectiveness of health-maximizing intervention set, AfrD
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Figure 6  Incremental and average cost effectiveness ratios for the 
health maximising interventions, Afr-E. DALY=disability 
adjusted life year; see box 1 for other abbreviations
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set, AfrE
38
49
57 60
148
38.4
42.3 44.2
46.5 46.6
0
20
40
60
80
100
120
140
160
ACT -- 80% cov. ITN & ACT -- 80% cov. ITN & ACT -- 95% cov. IRS & ITN & ACT --
95% cov.
IRS & ITN & ACT &
IPTP -- 95% cov.
Incremental CE
Average CE
Discussion
Principal findings
Progress towards the millennium development goals has been disappointing 
and major action is needed if sub-Saharan Africa is to achieve the malaria 
specific target. Although external assistance is critical, countries also need 
to re-evaluate current strategies (box 2). A distinguishing characteristic of 
this analysis is the health system focus, integrating evidence about costs and 
effectiveness at a level relevant for policy makers.
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Recent developments such as the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, and the interest of various foundations, promise increased funding 
for malaria control. To date, however, attention has been focused on the drugs, 
other expendables, and, to a limited degree, additional staffing needed to 
scale up health interventions. This narrow focus ignores the additional system 
resources needed to implement and sustain a massive scale up of activity, as well 
as the relatively fixed constraints on existing staff time and health facilities. Our 
results suggest that the costs of reaching agreed targets are considerably greater 
than those costs that receive most current attention.
Artemisinin based combination treatments are more expensive than 
other drugs and, in the short term, non-artemisinin based combinations 
such as amodiaquine-sulfadoxine-pyrimethamine might be used as an 
interim measure.[19] However, as resistance to these drugs is increasing, 
recommendations should be guided by local resistance patterns,[20] and a 
full switch to artemisinin based combinations should be seriously considered 
in all areas with  high transmission of drug resistant P falciparum malaria.
Box 2:  Main messages—malaria and the millennium 
development goals
•	 Five	years	on	from	the	declaration	of	the	millennium	development	
goals, progress in controlling malaria remains uncertain, 
particularly in sub-Saharan Africa
•	 Health	system	decision	makers	in	most	countries	in	sub-Saharan	
Africa (see text for details) should consider switching treatment 
strategies to artemisinin based combinations as the foundation of 
effective malaria control
•	 Reinvigorating	efforts	to	scale	up	use	of	impregnated	mosquito	nets	
and indoor spraying with insecticides is critical
•	 Where	these	interventions	are	being	successfully	implemented,	
intermittent presumptive treatment of pregnant women can bring a 
small but important additional health gain
•	 A	much	larger	infusion	of	resources	than	those	currently	available	is	
needed to make headway in the fight to roll back malaria
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Differences from other studies
This analysis differs from previous studies for malaria in that we have specifically 
assessed combinations of interventions, rather than assuming that costs and 
effects sum up when interventions are used concurrently. Such studies can be 
misleading at worst, and, at best, decision makers lack necessary information 
about relevant combinations.
In the only previous study analysing sub-Saharan Africa, Goodman et al 
found the cost/DALY averted of insecticide treated bed nets to be $19-85 
(US$1995) compared with $16-29 for indoor residual spraying.[21] The 
estimates presented here (~30 $int /DALY for either intervention at 95% 
coverage in Afr-D and ~40 $int/DALY at 95% coverage in Afr-E) are roughly 
comparable. However, what does not emerge from typical cost effectiveness 
trials is the conclusion that implementing spraying and nets together has a cost 
effectiveness ratio roughly similar to that of either one alone (~35 $int/DALY 
at 95% coverage in Afr-D and ~47 $int/DALY at 95% coverage in Afr-E), 
from the realisation of substantial efficiencies due to shared costs (reducing the 
unit costs of both) counterbalanced by the reduced health benefits resulting 
from adding spraying to widespread use of bed nets.
Limitations of the analysis
The relative effectiveness of spraying and impregnated bed nets has been 
debated.[22] [23] Although we have assumed that they are equally effective 
in reducing morbidity and mortality, their respective advantages in a given 
setting will depend on whether mosquitoes are endophilic, the length of time 
they rest indoors,[24] and the time children go to bed.
People’s willingness to use bed nets effectively is often reduced by user charges 
and the need to reimpregnate nets if they are not long lasting. Moreover, nets 
must be kept in good condition and used consistently despite their at times 
uncomfortable insulating properties.[25]
Indoor residual spraying, on the other hand, is generally paid for and carried 
out by public authorities once or twice a year, which in theory makes adherence 
less burdensome; however, house owners may replaster or paint over recently 
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sprayed walls because of the smell of insecticide or visible deposits,[23] and 
residents must be willing to let sprayers into their homes. Furthermore, the 
relative effectiveness of these interventions will depend on local transmission 
patterns. For example, in epidemic-prone areas, spraying is likely to be an 
effective emergency measure as it can be implemented relatively quickly and 
needs less logistic effort than a bed net campaign.[25]
Our assumptions about the effectiveness of intermittent presumptive treatment 
with sulfadoxine-pyrimethamine in pregnancy were very conservative. We 
did not include health benefits for the mother and the effect on the infant 
was limited to a reduction in case fatality due to malaria in the first year of 
life. Costing of intermittent presumptive treatment was as part of a routine 
antenatal package of care with only the incremental costs of dedicated 
activities considered.
Owing to lack of data on reductions in all cause mortality, we assumed 
that when drugs are taken under ideal conditions they are 98% effective in 
preventing cause specific mortality. While this study does try to account 
for parasite resistance, imperfect patient compliance, and pharmacokinetic 
properties, actual effectiveness is likely to include factors omitted in the 
analysis. Modelling implementation over a 10 year period, moreover, may not 
fully capture the contrast between drugs with high versus low growth rates 
of resistance (for example, sulfadoxine-pyrimethamine v artemisinin based 
combination treatment). Consequently, our estimate of the cost effectiveness 
of artemisinin based combination treatments may be conservative compared 
with when a longer term perspective is taken.[26] Finally, the study allows no 
conclusions to be drawn about financing methods, which can be of utmost 
importance.[27]
Implications of the study
In conclusion, with the availability of increased international funding, a re-
evaluation of existing and potential strategies is appropriate. As an excessive 
disease specific focus is undesirable, an adequate portion of new funds should 
be allocated to strengthening the health system, which determines the long 
term viability of disease control activities.
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On purely cost effectiveness grounds, this study suggests that countries in 
sub-Saharan Africa should be moving to combination therapy with new 
drugs as rapidly as possible or that efforts should be regenerated to ensure 
that the use of nets is scaled up appropriately. Even where the health system is 
weak, prevention will never be a stand alone strategy, as informal distribution 
mechanisms ensure the availability of antimalarials—both effective and 
highly ineffective—even in the most isolated areas. All attempts should be 
made to ensure that the antimalarials that are accessed are indeed those that 
work. These are relatively simple messages, but ones that remain robust even 
when underlying assumptions are varied significantly.
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Annex
Individual and combination interventions
In addition to the seven individual interventions discussed in the main text 
(reproduced here for convenience):
Insecticide-treated bed nets (ITN);1) 
Indoor residual spraying (IRS);2) 
Case management with chloroquine (CQ);3) 
Case management with sulfadoxine-pyrimethamine (SP);4) 
Case management with non-artemisinin-based (CQ-SP) combination 5) 
therapy (Comb);
Case management with artemisinin-based combination therapy 6) 
(ACT);
Intermittent presumptive treatment with SP in pregnancy (IPTp);7) 
  the following combinations were analysed:
ITN & CQ;8) 
ITN & SP;9) 
ITN & Comb;10) 
ITN & ACT;11) 
IRS & CQ;12) 
IRS & SP;13) 
IRS & Comb;14) 
IRS & ACT;15) 
IRS & ACT & IPTp;16) 
ITN & ACT & IPTp;17) 
IRS & ITN;18) 
IRS & ITN & ACT;19) 
IRS & ITN & ACT & IPTp.20) 
Each of these 20 interventions was analysed at each of the three coverage 
levels (50%, 80% and 95%) and in each of the two regions (Afr-D and 
Afr-E).
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Intervention-specific assumptions
Drugs
The current subregional coverage of each case-management intervention 
was estimated as a population-weighted average on the basis of the country 
population and country-level estimates of the proportion of children who receive 
CQ or other antimalarials.1 If no data were available on the proportion of sick 
children receiving drugs, rather than assume zero coverage for the country, 
the country was excluded from both the numerator and denominator of the 
coverage calculation. Estimates for the use of ‘any antimalarial’ that were greater 
than those estimates quoted specifically for CQ were assumed to refer to that 
country’s first-line drug (if other than CQ, otherwise that country’s second-line 
drug). If specific coverage estimates for CQ were not available, it was assumed 
that 80% of ‘any antimalarial’ consisted of that country’s first-line drug, with 
the remaining 20% consisting of the second-line drug. 
Estimating drug resistance
Resistance was estimated by means of a standard logistic growth function 
(eq. 1). Projected effectiveness estimates for case management interventions 
and IPTp were thus adjusted for changing resistance profiles with increasing 
duration of use. Projected drug resistance was estimated as a function of the 
initial level of resistance prior to intervention implementation, the growth rate 
of resistance, and the maximum level of resistance (carrying capacity). As the 
estimated growth in resistance over the 10-year implementation horizon was 
in all cases approximately linear, annual numbers of treatment failures were 
averaged over the 10-year implementation period to obtain an average failure 
rate.
Resistance was measured as:1 
( ) 





−−+
=
)exp(0,0,
0,
, trRkR
R
kR
iiii
i
iti ,
where Ri, t is the proportion of parasites that resistant to drug i at time t, 
R0 is the initial level of resistance, r is the growth rate in resistance, k is the 
maximum level of resistance and t is time (see Table 1, main text). The growth 
rate of resistance was estimated in conjunction with biogeneticists on the basis 
of drug-specific pharmacokinetic properties and experience in the field.2
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Drug treatment failure 
Treatment failure was calculated as:1
( ) ( ) ( ){ }iitiititi pmRmRF ⋅−⋅−+⋅−−= 1111 ,,, ,
where F is treatment failure, m is the probability of full adherence, and p is the 
probability of treatment success without full compliance (see Table 2, main 
text).
Net drug effectiveness
Net effectiveness, E, was calculated as: 
tiFB ,E −= ,
where B is baseline efficacy, and Fi,t is treatment failure.
Preventive interventions
No vector resistance to insecticide was accounted for. Potential benefits of 
prevention on unborn children (i.e. in terms of higher birth weight) were not 
included. 
IRS and ITN were assumed to benefit from a 9% “knock-on” effect (i.e. 
transmission externality) at modelled coverage levels: that is, the costs of a 
given level of effective coverage were reduced by about 8% (= 1 − 1/1.09), 
while keeping the effects unchanged. This is likely a conservative estimate.3 
For ITNs, coverage estimates refer to individuals, while, for IRS, coverage 
estimates refer to the household (e.g. a 50% coverage level for IRS indicates 
that 91% of houses within 50% of transmission areas are assumed to be 
effectively sprayed.
ITN
ITNs were assumed to be long lasting and thus not requiring reimpregnation. 
ITNs were assumed to last on average 5 years.4 One ITN was attributed to 
each 1.5 persons.5 Estimates of ITN effectiveness assumed 65% adherence, 
defined as sleeping under an untorn net. 
IRS
Each spray team was assumed to cover 1170 houses per year. 
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Case Management
Case management refers to the first-line antimalarial drug administered to 
symptomatic patients presenting at outpatient clinics. One health center visit 
per case was assumed, as well as that a patient given an antimalarial drug does 
indeed have malaria (and therefore receives the drug benefit).
IPTp
Women of childbearing age were assumed to be those aged 15 to 49. Sixty 
percent of first-time mothers (estimated to account for 30% of births) were 
assumed to receive two doses of IPTp within the context of routine antenatal 
care (ANC) services. Sixty percent of pregnancies considered “at risk” due to 
HIV (estimated to account for an additional 20% of births) were assumed to 
receive three doses. A total of 15% of pregnant mothers (split evenly between 
first and multiparous high-risk pregnancies) treated with IPTp were assumed to 
have babies that would not survive the neonatal period. A potential reduction 
in incidence of placental malaria from IPTp was excluded from consideration, 
as its associated morbidity is difficult to quantify due to the asymptomatic 
nature of the disease in endemic areas.6 
Resistance to SP within the IPTp context was based on estimates of resistance 
to SP when used as a first-line treatment.7 However, it was assumed that when 
SP is used for IPTp it is no longer used in standard case management, since if 
SP is concurrently used as the first line treatment for malaria, it’s usefulness 
as a preventive treatment will be diminished. Resistance to SP was assumed 
to grow more slowly when used only for IPTp.
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Annex table A:  
Countries analysed in each African region 
Afr-D Afr-E
Algeria Botswana
Angola Burundi
Benin Central African Republic
Burkina Faso Congo
Cameroon Cote d’Ivoire
Cape Verde Democratic Republic of the Congo
Chad Eritrea
Comoros Ethiopia
Equatorial Guinea Kenya
Gabon Lesotho
Gambia Malawi
Ghana Mozambique
Guinea Namibia
Guinea Bissau Rwanda
Liberia South Africa
Madagascar Swaziland
Mali Uganda
Mauritania United Republic of Tanzania
Mauritius Zambia
Niger Zimbabwe
Nigeria
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Togo
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Annex table B: Estimation of effectiveness
Intervention/Parameter Value Source/Notes
ITN
Adherence 65% Estimate within range 
suggested to achieve impact8
Probability of success when 
not fully compliant
0% Estimate based on binary 
response of whether or not an 
individual has slept under the 
net
— resulting reduction in 
incidence
50% 8
— resulting reduction in case 
fatality
20% 9
IRS
Adherence 100% Estimate based on household 
level to achieve impact
Probability of success when 
not fully compliant
0% Estimate based on dosing 
schedule and pharmacokinetic 
properties
— resulting reduction in 
incidence
50% Assumed to be similar to 
ITNs3,10,11
— resulting reduction in case 
fatality
20% Assumed to be similar to 
ITNs3,10,11
CQ
Adherence 40% Estimate based on relative 
length and complexity of the 
regimen
Probability of success when 
not fully compliant
20% Estimate based on dosing 
schedule and pharmacokinetic 
properties
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Initial resistance 0.35 2
Growth rate of resistance 0.1 2
— resulting reduction in case 
fatality
27% See Drugs for details of 
calculation
SP
Adherence 90% Estimate based on relative length 
and complexity of the regimen
Probability of success when 
not fully compliant
0% Estimate based on dosing 
schedule and pharmacokinetic 
properties
Initial resistance 0.1 2
Growth rate of resistance 0.4 2
— resulting reduction in case 
fatality
44% See Drugs for details of 
calculation
CQ-SP Assumed to be co-administered, 
not co-formulated
Adherence 35% Estimate based on relative length 
and complexity of the regimen
Probability of success when 
not fully compliant
35% Estimate based on dosing 
schedule and pharmacokinetic 
properties
Initial resistance 0.1 2
Growth rate of resistance 0.1 2
— resulting reduction in case 
fatality
47%
ACT Assumed to be blister-packed 
and/or co-formulated
Adherence 35% Estimate based on relative 
length and complexity of the 
regimen
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Probability of success when 
not fully compliant
45% Estimate based on dosing 
schedule and pharmacokinetic 
properties
Initial resistance 0.001 2
Growth rate of resistance 0.05 2
— reduction in case fatality 63% See Drugs for details of 
calculation
IPTp (SP)
Adherence 80% Estimate based on relative 
length and complexity of the 
regimen
Probability of success when 
not fully compliant
10% Estimate based on dosing 
schedule and pharmacokinetic 
properties
Initial resistance 0.1 2
Growth rate of resistance 0.1 2
— reduction in case fatality 3.3% Assumes baseline reduction of 
5% based on model developed 
by Goodman et al 200012; See 
methods section for details of 
calculation of net effect
Deriving logistic distributions 
from basic processes
Based on: Lauer JA, Greenland S. Deriving logistic distributions from basic 
processes (in submission).
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Summary
The logistic distribution is one of the most widely used models in statistics. 
While its popularity may be attributed to its simplicity, it can often be derived 
from more basic contextual considerations, for example by subtracting a 
quadratic term from a linear differential equation and integrating. The 
quadratic term is a convenient choice when approximating some unknown 
density dependence in the outcome. We show that the logistic form is the 
limiting distribution of a particular Markov process on a lattice, and that 
the apparent density dependence emerges as a consequence of the lattice 
embedding. For applications in which time or age is a conditioning variable, 
the underlying discrete process lends substantive meaning to the use of its 
limiting description in modeling or estimation. We describe these properties 
for a logistic analysis of classical models of infection. We also derive a “square-
logistic” model from basic considerations. 
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Introduction
The logistic transform from the real line to the unit interval is defined by
expit(Eq. (1) x) ≡ ex/(1 + ex) = 1/(1 + e−x). 
This function is common in statistical and biological research, and is ubiquitous 
in some fields, such as epidemiology. In most statistical applications it is 
merely a range-limiting function for regressions confined to the unit interval. 
Specifically, the logistic regression model corresponds to use of its inverse, 
logit(Eq. (2) u) = ln[u/(1 − u)],
as the link function in a generalized-linear model (McCullagh and Nelder, 
1989). In this usage it provides easily interpreted coefficients and a closed 
form, unlike the probit (inverse-normal) transform (Hosmer and Lemeshow, 
2000). 
Our primary concern here is with the also-common usage of the logistic 
transform as a model for the distribution of a random variable (e.g., Greenland 
and Lash, 2008). We begin by describing the distribution and its history. 
We will describe how this distribution (like the Gaussian) arises as the limit 
of a natural diffusion process, providing a deeper rationale for the logistic 
distribution as a starting model in several applications. Along the way we 
note some natural connections between logistic regression and the logistic 
distribution, that is, between the logistic transform used as a link function 
versus used as a distribution.
The logistic distribution
Let P(y) ≡ Pr(Y≤y) and Q(y) ≡ Pr(Y >y) be the cumulative (“risk”) and survival 
distributions for a random variable Y. The standard logistic distribution then 
has P(y) = expit(y) and 
Q(Eq. (3) y) = expit(−y) = 1/(1 + ey),
with density 
p(Eq. (4) y) = P(y)Q(y) = expit(y)expit(−y) = ey/(1 + ey)2
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and hazard p(y)/Q(y) = P(y); in fact the standard logistic is definable as the 
distribution with hazard equal to risk (much as the standard exponential is 
definable as the distribution with density equal to survival). Like the normal 
distribution, the logistic is symmetric, unimodal, and unbounded, and 
generalizes to include location and scale parameters m and s by substituting 
z = (y−m)/s for y in the above formulas. The logistic is heavier-tailed than the 
normal however, with standard deviation σ = s(π/3½) ≈ 1.81s, whereas the 
normal has scale s equal to its standard deviation σ.
Like the normal, the logistic has several simple mathematical derivations. 
Suppose U is uniform on the unit interval; then F = U/(1−U) is an F-variate with 
2-numerator and 2-denominator degrees of freedom, and Y = ln(F) = logit(U) 
is logistic. The logistic distribution is thus a special case of the log-F distribution 
(Jones, 2004). There is a related Bayesian derivation. Because a uniform variate 
is also a beta variate, the logistic is also a logit-beta distribution, and is thus 
a conjugate prior for logistic regression (Greenland, 2003). In particular, the 
logistic distribution generalizes Laplace’s law of succession for a binomial 
parameter (Good, 1983) to logistic-regression coefficients: The coefficient β of 
a regressor X can be given a logistic prior by adding two records to the data, 
one with 1 success and one with 1 failure, with all regressors (including the 
constant) set to zero except X, which is set to 1 in each added record. Ordinary 
maximum likelihood applied to the resulting augmented data then gives the 
corresponding posterior mode, and location and scale parameters can be added 
by slight modification of the added record (Greenland, 2007). 
Historical origins
Cramer (2005) recounts that Verhulst (1838) developed the logistic distribution 
as a result of questions put to him by his teacher, the “astronomer turned 
statistician”, Alphonse Quetelet. Verhulst apparently arrived at the logistic 
model as one of several modifications to exponential growth, modifications 
undertaken to avoid “impossible values” of unbounded growth. The 
exponential growth model is
)(
d
)(d tP
t
tP α=Eq. (5) ,
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where α is a constant. With the boundary condition P(0) = P0 the solution is
)exp()( 0 tPtP α=Eq. (6) .
For positive α, P(t) increases faster than any power of t (Rudin, 1976).
Cramer states the logistic form was but one alternative explored by Verhulst. 
Let the exponential term of the differential equation for growth be denoted by 
the function f(P(t)) ≡ αP(t); Verhulst investigated various forms for a second 
term, g(P(t))
))(())((
d
)(d tPgtPf
t
tP −=Eq. (7) .
The logistic distribution results when g is quadratic. The form usually seen in 
the demographic and ecologic literature is 
)()(1
d
)(d tP
K
tPr
t
tP 



 −=Eq. (8) , 
where r represents the “intrinsic growth rate” and K the “carrying capacity”. 
We call this form the “Verhulst equation”. By letting p = P/K and τ = rt, the 
Verhulst equation can be written 
)()())(1)((
d
)(d 2 ττττ
τ
τ ppppp −=−=Eq. (9) 
(Cantrell and Cosner, 2003). In the following we typically assume this 
rescaling has been done. Although the other forms investigated by Verhulst are 
not mentioned in Cramer, non-quadratic forms for g were later proposed by 
Gompertz and Bertalanffy in the eponymous growth models (Fletcher, 1974). 
The choice of g quadratic might appear arbitrary. For example, Cardy (1996) 
writes:
Consider a population of individuals whose local density is 
described by the fluctuating variable n(r, t). When n is small, there 
is a birth rate, λ, but, when the local population gets too large, it is 
limited by a shortage of food. In the absence of fluctuations, such a 
system may be modelled by a rate equation of the form
.2nnn µλ −='  (10.53)
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In this approximation, there is a dynamic phase transition at λ 
= 0. For λ < 0, the population always eventually dies out, while, 
for λ >0, it achieves a steady state with density λ/µ. 
Cardy does not explain why “shortage of food” should be quadratic in 
population size, and the squared term appears to be only a convenient choice. 
By “approximation”, Cardy evidently means that the differential equation 
(10.53) is local and non-stochastic. He continues:
To describe the system more completely, the effects of diffusion 
and noise must be added. Thus (10.53) gets replaced by
,22 ζµλ +−+∇= nnnDn'   (10.54)
where D is the diffusion coefficient.
Other than the added “noise” term ς, Cardy's (10.54) is equivalent to Fisher's 
equation for gene diffusion (Fisher, 1937). 
Cantrell and Cosner (2003), citing Enright (1976), derive logistic growth by 
expressing the birth (respectively mortality) rate as the sum of a constant, 
density-independent, term and a negative (resp. positive) term that varies 
linearly with population 
[ ] )())(())((
d
)(d tptdpctbpa
t
tp +−−=Eq. (10) .
Collecting density-independent (a − c ≡ r) and density-dependent terms (b + 
d ≡ q), the resulting expression 
[ ] )()(
d
)(d tptqpr
t
tp −=Eq. (11) 
is equivalent to the Verhulst equation when K is set equal to r/q. Thus, 
quadratic density dependence in net reproduction can be derived from a linear 
dependence of the birth (resp. mortality) rate on density.
Other standard presentations introduce the logistic distribution as a statistical 
convenience, for example, in non-linear models for censored response (Aldrich 
and Nelson, 1984), or as a variance-reduction device (Armitage, Berry and 
Matthews, 2002). In the following, we describe contexts where the logistic 
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distribution is neither arbitrary nor approximate, and thus its rationale need 
not rely solely on statistical convenience or mathematical simplicity. In those 
contexts, the logistic equation does not enforce damping by means of vague 
constraints such as “shortage of food,” “resistance to further growth,” or 
alternative heuristics. Instead, the logistic equation is the limiting form of a 
particular random walk on a lattice subject to local interaction. Furthermore, 
the logistic form is a “hydrodynamic limit” in the sense that smooth 
macroscopic dynamics are deduced from random microscopic interactions 
(Kipnis and Landim, 1999).
We show, moreover, that the growth (“reaction”) term of reaction-diffusion 
equations such as Fisher’s law for gene advance is, under this derivation 
at least, itself a diffusion (i.e., a Markov process with a continuous time 
path), and thus non-local in the sense of Cardy. In other words, we develop 
a context in which most of the motivating claims for logistic growth and 
logistic reaction-diffusion equations do not apply: we show that logistic 
growth yields the logistic distribution and a lattice embedding imposes an 
intrinsic constraint. The derivation is relevant, at least as an idealization, to a 
variety of estimation and modeling situations found in population dynamics, 
epidemiology, ecology and related disciplines. Finally, we develop a logistic 
analysis of classical infection models. 
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Contact process on the lattice
To begin our development, we show how the logistic distribution arises from 
a Markov process subject to local interaction (Spitzer, 1970). Related fields in 
probability and statistical physics such as contact processes (Harris, 1974), 
percolation theory (Grimmet, 1999) and interacting particle systems (Liggett, 
2005), provide background. 
A contact process is a type of Markov process whose domain is a lattice of 
points (Harris, 1974). It is commonly understood as an idealization of the 
spread of infection or of a population. Interaction between sites is local: the 
state of a site depends only on the state of sites in its immediate neighborhood 
(i.e., those “in contact”). In a typical specification, sites take the value of 
0 (uninfected, unoccupied) or 1 (infected, occupied) according to a rule 
specifying a non-zero probability of occupation only when a neighboring site 
is occupied. 
If adjacent sites are joined by a bond (edge) when occupied, contact processes 
form a branch of percolation theory on graphs. Originally, percolation refers to 
the movement or filtering of fluids through porous materials. The mathematical 
study of percolation was presumably motivated by questions like “What is the 
probability that the centre of a large porous stone, when immersed in water, 
is wetted?” (Grimmet, 1999), or, more formally, “What is the probability of a 
long connected path on a lattice where sites are connected with probability p 
and unconnected with probability 1 − p?”. An object is said to be percolated 
if traversed by a connected path; “infinite” paths arise when the scale of the 
object’s structure is negligible compared with its size (Grimmet, 1999). If 
the “object” is a population of individuals (e.g., represented by a lattice of 
points) and the contact process is an infection, percolation is equivalent to the 
emergence of an epidemic.
Our contact process derives from directed (oriented) percolation, in other 
words where edges form in only a given direction (Durrett, 1984). Directed 
percolation is frequently a model for dynamic, non-equilibrium, processes 
(Cardy, 1996; Dickman, 1997). We restrict attention to a simple directed 
process on the square lattice. 
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Figure 1 Small subset of the square lattice
Figure 2 The contact process as an example of directed percolation
 t
p(t) = p
 t + 1
            p(t+1) = p2?
Formally, a lattice is a set whose elements correspond one-to-one with the set 
of integers Z; a square lattice has two-dimensional elements and can thus be 
mapped onto Z2. A small subset of the square lattice is shown in Figure 1.
In Figure 2, a lattice site is shown to be “occupied” by means of a heavy black 
dot (upwards and to the left); it is shown as “unoccupied” with a lighter grey 
dot (downwards and to the right). 
Occupied sites may propagate to adjacent unoccupied sites in the positive time 
direction. Whether an occupied site will successfully propagate is determined 
according to a probability model. In Figure 2, the uncertain outcome is 
represented by a question mark. When two adjacent sites are occupied, they 
are joined by an arrow (directed edge), indicating the connection (an open 
directed path). Sites are occupied with probability p. 
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Let a random site transected by the line t be occupied. The adjacent site at 
time t + 1 can be occupied, independently with probability p. If the site at 
time t is not occupied, the probability of occupation for the site at time t + 1 
is zero. Thus, unconditionally, the probability of a site at t + 1 being occupied 
is p2, the probability that the parent site is occupied times the conditional 
probability that the offspring site is occupied given the parent is occupied (see 
Figure 2). 
The change in the probability of site occupation with respect to time is equal 
to the probability of site occupation at time t + 1 minus the probability of site 
occupation at time t: 
∆Eq. (12) p = p(t+1) − p(t) = p2 − p.
If the change in time ∆t is 1, the ratio of changes ∆P/∆t is also p2 − p. Since 
the time interval in the lattice is of unit size, the difference ratio ∆P/∆t can be 
written as the discrete-time derivative
pp
t
p −= 2
d
dEq. (13) ,
which is a differential equation defining the logistic cumulative distribution 
as the distance between adjacent sites (∆t) goes to zero.
The cumulative logistic distribution is usually defined as the function with 
derivative p(1 − p) = p − p2, in other words, the negative integral of our 
expression (cf. Lloyd, 1967 for a review of standard derivations). However, the 
two forms are complementary and define the same distribution. First, with the 
addition of arbitrary constants (α, β), the solution of the differential equation 
p2 − p (for positive values of the constants) is a monotonically decreasing 
logistic function
)exp(
)(
Ct
tp
ααβ
α
++
=Eq. (14) .
(C is a constant of integration.) See Figure 3.
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Figure 3 The solution of p2 − p
Figure 4 The solution of p2 − p
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For the same constants the equation
2
d
d pp
t
p −=Eq. (15) ,
defines a monotonically increasing logistic function (Figure 4) that is the 
complement (in the sense that the abscissas for a given ordinate sum to 1) of 
the function shown in Figure 3. 
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Figure 5 Vertical propagation cannot fill the square lattice
t + 1 
t + 2 
t 
Indeed, this follows from the fact that P = expit(y) and Q = expit(−y) for the 
logistic distribution. Thus, the complement of the change in the probability of 
site occupation is the change in the probability that a site is not occupied. 
We now extend the description for a single pair of sites so that the contact process 
constitutes a percolation model. First, we consider the necessary conditions 
for the process to be logistic in form; then we ask under what conditions the 
process can percolate the lattice. Suppose at time t there are N sites, of which 
a proportion p = n/N are occupied (Figure 5; for convenience occupied sites 
are shown as adjacent). Each site at time t connects to two sites in the positive-
time direction (diagonally downwards to the right). Suppose further for the 
moment that site occupation can proceed only vertically downwards, in the 
direction of the solid-black arrows (see Figure 5). Then induction on t shows 
that the probability of site occupation evolves according to 
pp
t
p −= 2
d
dEq. (16) ,
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Figure 6 Square lattice and superimposed epidemic lattice. 
Without bidirectional (orthogonal) propagation only the 
part of the lattice shown in grey can be occupied.
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as previously. Restricting propagation to the vertical (resp. horizontal) 
direction, at any point in time each of the sites occupied with probability p 
can propagate to one other site only, which is unconditionally occupied with 
probability p2. Thus, the logistic form arises by constraining propagation from 
an occupied site to one other site only. 
However, this process can percolate the lattice only in a single direction. 
Although occupied adjacent sites are connected (in Figure 5, horizontal dashed 
lines are used for these passive connections), propagation in the vertical (resp. 
horizontal) direction only does not percolate the lattice in both directions. 
Since the restriction is necessary to preserve the logistic form, it would appear 
that a logistic contact process cannot percolate the lattice bidirectionally. To 
emphasize this point, suppose the process initiates at a single site at location r 
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Figure 7 Epidemic lattice with cyclic boundary condition
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chosen at random at time t (Figure 6). For concreteness, suppose it represents 
an infectious disease with a high probability of transmission (1 − p << 1). 
Unless infection can proceed both horizontally and vertically, the potential 
epidemic will be restricted to the single grey vertical (resp. horizontal) line 
defined by the points (r − n, t + n). On the other hand, if each site can infect 
both downstream sites, that is (r, t) → (r − 1, t +1) and (r, t) → (r + 1, t + 1), 
the probability of infection is no longer logistic (cf. Cardy, Table 10.1, p. 203). 
Notice, with reference to Figure 6, that an epidemic defines a superimposed 
square lattice, rotated by 90 degrees with respect to the original one.
Thus, while a logistic differential equation is a valid representation of the 
epidemic when each site potentially infects only one other, a modification is 
required if infection probability is to evolve logistically and the epidemic is to 
be capable of percolating in both directions. If the points connected by the 
grey dashed arcs in Figure 7 are superimposed, bidirectional transmission can 
proceed freely. This modification is equivalent to applying a cyclic boundary 
condition. In other words, the lattice is folded upon itself on the line defined 
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by the points (r + n, t + n) and (r − n, t + n) (Figure 8). With the folding, 
logistic evolution is maintained; moreover, although each site can infect only 
one other, the entire lattice can now be percolated. Finally, only space is 
made cyclical by the boundary condition, so the folding respects temporal 
irreversibility (Figure 9). 
With the exception of three points whose connectivity is changed by the 
folding, the epidemic domain (i.e., the conical part of the lattice) remains 
a square lattice, albeit non-planar. The affected points, whose post-folding 
connectivity is 1, 3 and 3, respectively, are (r, t), (r, t + 2) and (r ± 1, t + 1). 
Thus, with the exception of these points, another planar square lattice can be 
obtained by projecting the epidemic domain from the apex of the cone onto 
a flat surface. In the projected lattice, the positive time direction is radially 
outwards from the image of the apex. The projection shows that, despite the 
changes imposed by the folding, the epidemic lattice can cover the plane 
(Figure 10). It also suggests that the logistic contact process can serve as a 
model for spatial diffusion from a point source. 
Figure 8 Epidemic lattice after folding
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Figure 10 Projection of the intial part of the epidemic lattice 
onto a plane
Figure 9 Silhouettes of the r−t lattice following the folding (top 
view and side view; time shown in light gray dashed 
lines, location in dark gray)
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The logistic equation as a hyperbolic 
conservation law
An important class of random-walk processes with zero-mean flux on the 
lattice converges to the Gaussian probability distribution (Kipnis and Landim, 
1999). Brownian motion in Rn is another such class (Gardiner, 2004). Unlike 
Gaussian processes, since the particles flow in a characteristic direction, 
logistic diffusion is not zero-mean flux and is therefore described in the limit 
by a first-order hyperbolic conservation law rather than by variants of the 
second-order heat equation (Kipnis and Landim, 1999).
Although folding the lattice changes the geometry of the epidemic domain 
it leaves lattice connectivity largely unchanged. On the folded lattice, at any 
point in time the change in the probability of site occupation is 
pp
t
p −= 2
d
dEq. (17) ,
as before. Similarly, the change in the probability of a site not being occupied 
is
2
d
d pp
t
p −=Eq. (18) ,
as before. Site occupation can percolate the entire lattice. The standard logistic 
distribution is thus the limiting distribution of the contact process as the 
number of points goes to infinity and as the distance between points (∆t) 
goes to zero. It follows that the “damping” imposed by logistic growth can be 
explained solely as a consequence of the lattice embedding, without the need 
to invoke density-dependent arguments.
The logistic description of the contact process is hydrodynamic in the sense 
that, in the above limits, the parameter p evolves smoothly according to a 
differential equation (Kipnis and Landim, 1999). The hydrodynamic limit 
provides the justification for associating the discrete random walk with the 
continuous distribution. As previously suggested, moreover, with the lattice 
embedding, the Verhulst ordinary differential equation (expressing change 
with respect to time only) defines a partial differential equation (expressing 
change with respect to time and position). That is, on the lattice, the logistic 
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equation is a model of spatial as well as temporal dynamics. Specifically, the 
Verhulst equation can now be characterized as a first-order partial differential 
equation of the form
0)( =∂+∂ pfp rtEq. (19) 
(Kipnis and Landim, 1999), where f(p) is the (mean) flux of the quantity p 
across sites, and r is location. Applying the chain rule, the equation can be 
rewritten in “quasilinear” form
0)( =∂+∂ ppap rtEq. (20) 
(Bressan, 2000), where a(p) = f´(p) is the derivative of flux. A system of such 
equations where A(p) ≡ Df(p) has all real eigenvalues defines a “hyperbolic 
system of conservation laws” for p, and the eigenvalues of A are called the 
wave speeds of p (LeFloch, 2002).
In general, solutions to first-order quasilinear hyperbolic equations are not 
well behaved, and develop discontinuities with the characteristics of “shock 
waves” (Bressan, 2000). Nevertheless, if a(p) is a constant a, the relation is an 
example of a linear advection equation
0=∂+∂ pap rtEq. (21) 
(LeFloch, 2002), a subclass of hyperbolic conservation laws with explicit 
solutions. The logistic differential equation is a hyperbolic conservation law 
of this type since, in the lattice embedding, ∂rp is equal in the limit to p2 − p. 
As noted previously, the intrinsic growth rate (here called the wave speed, a) 
can be set to 1 by a change of units, now seen to be the natural coordinate 
system defined by the eigenvalues of A. Thus, the Verhulst equation is a linear 
advection equation with an explicit analytical solution in terms of the logistic 
distribution. 
To summarize: Constant flux implies the possibility of a “natural” description 
of flows or transmission in terms of the logistic rather than the Gaussian 
distribution. Thus formal analogies between the distributions (Cramer, 
2004; Banks, 1994; Cox DR and Snell, 1989) are complemented by parallel 
derivations as limiting behaviors in particle systems.
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Logistic distributions in practice
Banks (1994) cites numerous applications of the logistic distribution to growth 
problems that might be more naturally modeled as diffusions according to the 
contact process described here. We mention two additional examples relevant 
to epidemiology.
National data on HIV prevalence have been collected by the South African 
Department of Health, Pretoria, at antenatal clinics in South Africa since 
1990. The pooled data, fitted model and hazard are shown in Figure 11. 
Overall coherence of the data with the logistic distribution suggests that 
the basic features of logistic diffusion may be relevant to understanding the 
infection process. For example, HIV infection in women of childbearing age 
appears to proceed according to a simple random walk. 
Figure 11 Time series of HIV prevalence and infection hazard in 
South African antenatal clinics
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Some non-transmissible outcomes are also well modeled by logistic diffusion. 
For example, suppose in a time period t an individual has a probability p of 
not experiencing transition to an absorbing state. The state of the individual 
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in each period is represented by a lattice site adjacent to his or her site in the 
previous period. Not experiencing the transition by t means the lattice sites 
representing that individual’s state are occupied in that and in all previous 
periods. 
Now suppose that, for an individual not having experienced the event, the 
probability of not experiencing the event is p in every period. If the event 
does not occur by t, the probability of not experiencing the event by the 
subsequent period is p2. Conversely, if transition to the absorbing state has 
already occurred by t, the probability of not experiencing the event by t + 1 is 
then zero. In this model, the individual can be said to “interact” only with his 
or her state and only “locally” (i.e., across adjacent time periods). Under these 
assumptions the probability of an individual’s experiencing the event follows 
a logistic diffusion in the limit of a small time interval. 
Provided each individual shares the common parameter p, the model can be 
extended to a population by adjoining the corresponding number of sites in 
the lattice. Such a model comprises a series of collections of Bernoulli trials 
with parameter p, which is the standard rationale for logistic regression. In the 
limit of many individuals, not only the evolution of the cumulative probability 
but also the series of realized outcomes will follow a logistic distribution. An 
example is time-to-failure data for breastfeeding by month of age, where non-
breastfeeding is the absorbing state, and the prevalence of non-breastfeeding 
by month of age is well approximated by a logistic survival distribution (Lauer 
et al., 2004; see the reference for a detailed set of figures).
The logistic distribution in models of infection
SI model
The logistic form arises from the standard susceptible−infective (SI) model of 
disease transmission, called by Daley and Gani (1999) "the simple epidemic 
in continuous time." We show that it is also the limiting form of a related 
discrete process. In the SI model, the equation of transmission (i.e., for the 
number of infectives, y, in a population of size N) is given by
)(
d
d yNyxy
t
y −== ββEq. (22) ,
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where x is the number of susceptibles. The solution can be written
)exp()(
)(
00
0
NtyNy
Nyty
β−−+
=Eq. (23) ,
which is equivalent to logistic survival. The relation giving rise to this form is 
the “law of mass action”, i.e., that the rate of change in infectives is proportional 
to the product of infectives and susceptibles (where β is per-capita probability 
of infection). 
The classical SI model thus relies on an assumption that susceptible and 
infective populations are "well mixed". As opposed to logistic diffusion, the 
law of mass action proceeds from a macroscopic law about the ensemble of 
particles (in particular, their equiprobability of interaction) and "averages 
down" to the level of the individual particle. This is conceptually very different 
than an individual-level microscopic law that is aggregated up to obtain the 
law for the ensemble. Nevertheless, the law of mass-action is also an exact 
derivation of the logistic distribution.
SIR model
The SIR model (Kermack and McKendrick, 1927) also has a fundamental 
relationship to the logistic distribution. 
Although the SIR model does not have an exact solution, an approximate 
solution is obtained by means of a series expansion, yielding the result (Daley 
and Gani, 1999)
)
2
1tanh()1()(
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0
0
2
ϕγααρ
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ρ −+−≈ t
x
x
x
tzEq. (24) ,
where z(t) is the number of removals at time t, βγρ =  is the relative removal 
rate, x0 is the initial number of susceptibles and α and ϕ are combinations of 
other constants. 
This result can be written in logistic form by means of the identity
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The lower asymptote of the logistic curve is set by c1 − c2, the upper asymptote 
by c1 + c2, and the rate and the level (i.e. the z(t) = 0 intercept) of logistic 
growth by c3 and c4, respectively (Figure 12). As shown by Kendall (1956), 
this approximate solution is exact if per-capita force of infection obeys the 
following density dependence
1
0
)1()1(
2)(
−−+−
=
ρρ
ββ zzzEq. (27) ,
where β0 is the original (constant) per-capita force of infection (Daley and 
Gani, 1999). 
The approximate solution from series expansion is a description of the SIR 
epidemic even when there is no density dependence in the force of infection.
Figure 12 Removals are a logistic function of time in the 
approximate solution to the SIR model
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In that solution, the evolution of susceptibles x(t) is a quadratic polynomial (a 
+ bu + cu2) in terms of the logistic argument u
)(tanh
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)( 43
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0 ctccctcc
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xtx +++++= αρEq. (28) ,
and infectives also evolve according to a quadratic polynomial (a´  + c´ u2) in 
the logistic term
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Thus, up to constant terms, the infective series is the square of a simple logistic 
series. Furthermore, the quadratic logistic a´  + c´ u2 has a valid interpretation 
as an independent differential equation model, that is, the solution of the 
evolution equation
23)()1(
d
d ppppppp
t
p −=−=−=Eq. (30) .
It follows that model parameters corresponding to a “square-logistic” process 
(such as an infectives time series in an SIR epidemic) can be estimated by 
transforming the time series in terms of a “logit-square-root” model:
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where a is the upper asymptote of the series. In microscopic terms, square-
logistic diffusion requires that the probability of site occupation at t + 1 be 
inflated by a factor p1  in comparison with simple logistic diffusion. In 
continuous time, this is a hyperbolic conservation law with non-constant wave 
speed a(p) = exp[log(p)⋅2−t]. The approximate SIR equations for removals and 
infectives therefore constitute a system of hyperbolic conservation laws. 
While it would be natural to extend that system to include the logistic form for 
susceptibles (a + bu + cu2), there appears to be no obvious way to write the wave-
speed equation for this quantity, at least in terms of a contact process on a lattice. 
Nonetheless, since susceptibles are merely the complement of infectives and removals, 
we conjecture that there exists a lattice or other graph for which the general logistic 
quadratic form can be represented as a diffusion with non-constant wave speed. 
In any case, the approximate SIR model can be factored as five separate logistic 
curves, where each population element z(t), x(t) and y(t) is expressed as either a 
simple logistic term or as the product of two logistic terms (Figure 13). 
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Figure 13 Kendall’s SIR model can be factored into five simple 
logistic curves: z(t), cyan line, x(t), the product of the red 
and light-orange lines plus a constant, y(t), the product 
of the bright-green and lime-green lines plus a constant
Figure 14 Per-capita infectiousness in Kendall’s exact SIR model is 
the ratio of a logistic curve (red line) over the product of 
two logistic curves (blue and lavender lines)
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Finally, in Kendall’s exact model, the function β(z) can be written as the ratio 
of a linear and a quadratic logistic (Figure 14). 
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Generalized linear modeling
In a generalized linear framework with a quadratic loss function (McCullagh 
and Nelder, 1989), estimation minimizes the quantity:
),()( 1 myVmy −′− −Eq. (32) 
where V is the covariance matrix of the data y and m is the vector of sample 
means. The normal equations for least-squares estimation are thus
.0)(1 =−
∂
′∂ − myVm
βEq. (33) 
For the exponential family of distributions, the normal equations are the same 
as the score equations from the loglikelihood (Cox C, 1996). Thus, within 
this family, in either a least-squares or a likelihood framework, estimation 
employs an identical set of differential equations for the regression. 
The generalized-linear framework requires specification of a link function, h, 
such that:
)(µη h=Eq. (34) ,
where µ is the conditional mean and η = x´  β is the linear predictor; x may 
include a constant (McCullagh and Nelder, 1989). For various distributions, 
there is a “canonical” link for which there is a sufficient statistic of dimension 
equal to that of the model manifold (i.e., the span of the linear predictor in 
the regression space). For Bernoulli outcomes with probability parameter p, μ 
= p and the canonical link is the logit (McCullagh and Nelder, 1989), so that 
the inverse link is logistic. Taking the derivative of the mean yields
2µµ
η
µ −=
∂
∂Eq. (35) = p(1 − p)
Thus, for the set of applications described here, the canonical link for Bernoulli 
regression can be viewed as arising from the dynamics of logistic diffusion. 
In a quasi-likelihood framework, the distribution of the data is not characterized 
beyond a variance relation (Wedderburn, 1974), and the canonical link is 
defined as the function satisfying 
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where ν(µ) specifies the dependence of the variance on the mean (McCullagh 
and Nelder, 1989; Cox C, 1996). Although the logistic distribution is not a 
member of the exponential family (Cox DR and Snell, 1989), because the 
Bernoulli variance is defined by the logistic link it still has identical quasi-
likelihood, likelihood and least-squares estimators. 
Even without a restriction on distributional family, the variance function 
imposes strong restrictions on the data. In a generalized-linear framework these 
restrictions enter either implicitly (through specification of the dependence of 
µ on x) or explicitly (through specification of the dependence of the variance 
of y on µ). In either case, the estimation procedure produces a differential 
equation for the regression. When η is a linear function of time, choice of the 
link/variance function is equivalent to selection of a dynamic model for the 
data-generating process. 
The logistic regression model states that regression is linear after the logit 
transformation. For transmissible outcomes (such as infection, drug addiction, 
product preferences, and some forms of time-to-failure data), the results we 
have described suggest that, as a consequence of underlying diffusion-like 
phenomena, the individual Bernoulli outcomes may sometimes follow a 
logistic regression on time (or, in birth-cohort models, age). When considering 
additional covariates, logit-additive approximations to varying temporal 
effects may sometimes be expected based on mechanical considerations. 
Furthermore, if the covariate levels define separate diffusion compartments 
within which we have logit-linearity in time (i.e., if the covariates define a 
system of hyperbolic conservation laws), the overall model will be logit linear 
with time-covariate product terms (“interactions”).
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Conclusion
We have described how the logistic distribution can be derived from a 
description of the microscopic dynamics of diffusion on the square lattice, and 
that with this embedding it has both a temporal and a spatial interpretation. 
Its appearance in various applications to population dynamics, epidemiology 
and ecology could thus be predicted from its status as the limiting 
distribution of a stochastic process that is a plausible model for generating 
the data. In particular, a family of polynomial representations of the logistic 
distribution plays a fundamental role in classical models of infection, at least 
as an approximation. In special cases of importance these relations induce a 
correspondence between dynamics of the data-generating process and classical 
estimation processes. 
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Abstract 
Background: Suboptimal breastfeeding is associated with higher mortality 
among infants and young children in the developing world. We describe 
patterns in ‘exclusive breastfeeding’ and ‘any breastfeeding’ rates and quantify 
exposure to suboptimal breastfeeding among children aged two years or 
younger in developing countries.
Methods: We reviewed nationally representative surveys that collected data 
on breastfeeding rates in 94 developing countries. Surveys were categorized by 
completeness and comprehensiveness of data. Complete and comprehensive 
data were analysed with minimum chi-square regression. With a fitting 
procedure, estimated parameters were used to impute missing observations 
for incomplete or non-comprehensive surveys. Breastfeeding indicators were 
calculated and are reported for 135 developing countries by UN region.
Results: Amongst infants aged six months or younger in the developing 
world, the prevalence of exclusive breastfeeding is 39% and the prevalence of 
no breastfeeding is 5.6%. The prevalence of continued breastfeeding is 86% 
and 68% for infants and children aged 6-11 and 12-23 months, respectively, in 
the developing world. Imputation expands population coverage of indicators, 
especially for infants. Breastfeeding trends are highly linear and estimated 
parameters defining the age-specific attrition hazard are robust. Survey-reported 
rates, particularly for exclusive breastfeeding, appear to have systematic upward 
bias, and exposure estimates must be considered conservative.
Conclusions: Compliance with breastfeeding recommendations in developing 
countries is low, and more attention should be given to increasing breastfeeding 
- especially exclusive breastfeeding - and to monitoring trends. Although the 
introduction of more standardized and better validated survey instruments is 
desirable, since data coverage, completeness and comprehensiveness are extensive, 
global exposure assessment is relatively robust. Moreover, the regularity of 
breastfeeding patterns show existing survey data capture real biological and 
social phenomena. Our method for the analysis of breastfeeding rates provides 
a potent tool for summarizing trends, validating observations, translating and 
extrapolating indicators (as well as projecting and imputing estimates when 
necessary) and should support more effective child health monitoring.
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Background
Objectives
For almost all infants, breastfeeding remains the simplest, healthiest and 
least expensive feeding method that fulfils the infant’s nutritional needs. 
The prevalence and duration of breastfeeding are therefore recognized as 
important health indicators, and their impact on infant and child health has 
been frequently studied [1-3]. The aim of this study is to describe patterns in 
‘exclusive breastfeeding’ and ‘any breastfeeding’ rates reported in complete, 
comprehensive and nationally representative surveys and to quantify exposure 
to suboptimal breastfeeding in 135 developing countries among children aged 
two years or younger. ‘Suboptimal breastfeeding’ is used as a generic term to 
denote exposure to any increased risk relative to age-specific minimum risk.
Policy background
Recent policy debate has focused on the optimal duration of exclusive 
breastfeeding in infancy, and WHO commissioned a systematic review [1] to 
elucidate the issue. In 2001, the World Health Assembly passed a resolution 
recommending exclusive breastfeeding for the first six months of life as a global 
public health recommendation [1,2]. International consensus is that optimal 
breastfeeding practice for infants and young children consists of exclusive 
breastfeeding for the first six months of life, with continued breastfeeding up 
to two years of age and beyond [2,3].
Exposure categories
The term ‘category’ as used here refers primarily to individual status. For 
infants ≤6 months of age, exclusive breastfeeding represents ‘theoretical 
minimum’ [4] exposure. ‘Exclusive breastfeeding’ means the infant receives 
only breast milk from the breast, or expressed breast milk, and receives no 
other liquids or solids with the exception of drops or syrups consisting of 
vitamins, mineral supplements or medicines [5].
Ideally, exposure to suboptimal breastfeeding for infants ≤6 months of age 
would be measured as a continuous variable. Such a variable might express, 
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for example, the proportion of energy, water and nutrients in the diet derived 
from breast milk. However, since all survey-reported data on breastfeeding 
are categorical, and in view of the fact that there is heterogeneity in the 
categories employed, we define two categories: ‘partial breastfeeding’ and ‘no 
breastfeeding’ for the purpose of measuring exposure to increased risk among 
infants ≤6 months of age. The defining characteristic of partial breastfeeding 
is that the infant ≤6 months of age receives some breast milk, but not 
exclusively. 
For infants >6 months and children ≤2 years of age, theoretical minimum 
exposure is defined as ‘continued breastfeeding’, and ‘no breastfeeding’ is 
the sole exposure category of increased risk. The defining characteristic of 
continued breastfeeding is that the infant >6 months or child ≤2 years of age 
receives at least some breast milk regardless of the quantity or the presence 
of other foods or liquids in the diet. For all infant and child age groups, the 
defining characteristic of ‘no breastfeeding’ is that the infant or child receives 
no breast milk.
For analysis purposes we further define the category ‘any breastfeeding’, 
which refers to infants or children receiving breast milk regardless of quantity 
or the presence of other foods or liquids in the diet. For infants ≤6 months 
of age, ‘any breastfeeding’ is equivalent to the category ‘exclusive or partial 
breastfeeding’, and for infants >6 months and children ≤2 years of age is 
identical to the category ‘continued breastfeeding’. For children >2 years of 
age analysed in subregional estimation models, ‘any breastfeeding’ is used 
merely as a descriptive category without regard to risk status.
For infants >6 months of age, the failure to provide safe and appropriate 
complementary foods has been identified as a risk factor. We do not investigate 
this exposure in the present study. 
Breastfeeding indicators
For population-level assessment, exposure categories are aggregated across 
individuals and expressed as indicators. Therefore, breastfeeding indicators, 
in the sense used here, are primarily summary measures of population-level 
exposure with direct relevance for health outcomes. Although many types 
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of indicator are in common use, the breastfeeding indicators reported here 
are measures of cross-sectional prevalence for the defined exposure categories 
and age ranges. Cross-sectional prevalence is also called ‘point prevalence’ or 
‘period prevalence’.
Since surveys include prevalence estimates for states that may only indirectly 
be a measure of exposure according to our definitions, some of our indicators 
(complex indicators) represent sums of other indicators. For example, partial 
breastfeeding represents an aggregation of survey feeding categories such 
as ‘breast milk plus formula’, ‘breast milk plus solid foods’, ‘predominant 
breastfeeding’, and so on. Continued breastfeeding likewise represents an 
aggregation of various indicators. However, exclusive breastfeeding and no 
breastfeeding are simple, not complex, indicators.
Breastfeeding and HIV
Breastfeeding for more than one year has been estimated to pose a 10-20% 
risk of HIV transmission in children of infected mothers [6]. The risk of 
HIV transmission needs to be balanced, however, against competing risks 
for infant mortality and morbidity. WHO states that ‘when replacement 
feeding is acceptable, feasible, affordable, sustainable and safe, avoidance 
of all breastfeeding by HIV-positive women is recommended; otherwise, 
exclusive breastfeeding is recommended during the first months of life; and 
that those who choose other options should be encouraged to use them free 
from commercial influences’ [6,7]. 
Since recommended practice depends on mothers’ HIV status and other 
individual factors, only an individual-level assessment can explicitly account 
for the offsetting risks posed by mother-to-child transmission of HIV through 
breastfeeding. The population-level indicators reported here cannot measure 
this risk in a manner consistent with current international infant-and-child-
feeding recommendations. In a related study, we use an outcomes-based 
assessment to estimate the potential magnitude of the risks of mother-to-child 
transmission of HIV through breastfeeding (results not shown).
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Methods
Data sources
Data sources are nationally representative surveys - published and unpublished 
- that we identified as of June 2002 with data on breastfeeding in 94 
developing countries. Most surveys were undertaken by the Demographic 
and Health Surveys (DHS) programme of Macro International, Calverton, 
MD, USA [8], or by UNICEF under its initiative on Multiple Indicators 
Cluster Surveys (MICS) [9]. About a dozen surveys were undertaken by 
national institutions.
For developing countries with more than one survey, the most recent was 
used for calculating breastfeeding indicators, but all available complete, 
comprehensive and nationally representative surveys that we identified were 
used for estimating patterns in exclusive and any breastfeeding rates. The 
Annex to this article presents a list of the developing countries for which data 
were identified, the data source used for the indicators we report, and the 
corresponding survey year and data category (see below).
DHS surveys report prevalence estimates for various breastfeeding indicators 
for children in 18 two-month age groups through the end of the third year 
of life (0-1, …, 34-35 months of age). DHS estimates are based on 24-hour 
recall, in which mothers or caregivers are asked about the infant or child’s food 
and fluid intake during the 24-hour period preceding the interview. Because 
of the wide age range (comprehensiveness, or coverage in breadth), fine age 
stratification (completeness, or coverage in depth) and use of comparable 
feeding categories, DHS survey data on breastfeeding are the most complete 
and comprehensive, and we consider them the most reliable. They are also 
nationally representative. Data from DHS surveys are termed ‘category A’. 
About 78% of the surveys used for calculating breastfeeding indicators are 
category A.
MICS surveys report prevalence estimates only for selected indicators, such 
as ‘exclusive breastfeeding, 0-3 months of age’, and are not as consistent as 
DHS surveys in covering either a given set of age groups or a given age range. 
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Consequently, MICS data required imputation or extrapolation (see below) of 
missing observations of two-month prevalence for analysis on a comparable 
basis with those of DHS. Like DHS, MICS surveys employ 24-hour recall, 
but use a questionnaire superior in some respects to those of DHS surveys (see 
Discussion, 24-hour recall). However, we found some evidence of low internal 
validity in MICS surveys, although this impression could be due merely to 
otherwise benign typographical errors in reports. Data from MICS surveys 
are considered ‘category B’.
Other, non-standard, surveys report various breastfeeding indicators estimated 
with diverse methods for a variety of age groups. When such data were 
nationally representative they were included, but required imputation of missing 
observations of two-month prevalence for analysis on a comparable basis with 
those of DHS. A few surveys with data reported as cohort rather than period 
measures additionally required translation (see below) prior to imputation. 
Although it is possible that non-standard surveys are less reliable than MICS, 
since there was no obvious reason to conclude this, and since the sort of analysis 
they required for comparability with DHS surveys was similar to that required 
for MICS, non-standard surveys are also considered ‘category B’.
Table 1.  Prevalence estimates for breastfeeding indicators, 
by subregion and age group
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category C for infants; for children 12–23 months of age,
51 countries were category C.
Reporting regions
The 135 developing countries were grouped according to
the UN regional and subregional classification (see Table
1) [10]. Japan was excluded from regional and subre-
gional estimates for Asia. The region Oceania (including
developing countries Guam, Fiji, French Polynesia, New
Caledonia, Papua New Guinea, Samoa, Solomon Islands
and Vanuatu) was excluded, as no nationally representa-
tive breastfeeding data were obtained for any developing
countries in Oceania.
Analysis regions
Although UN regions are geographical designations only,
WHO has developed a subregional classification on the
basis of both geographical and epidemiologic criteria. The
14 subregions represent a classification of countries in the
six WHO regions according to four possible patterns of
child and adult mortality [11]. Since no WHO region
presents more than three of the defined patterns, there are
substantially fewer than the theoretically possible 24
subregions.
The mortality patterns used in the classification are
defined so as to locate a country with regard to the epide-
miologic transition, and therefore represent a macro-level
classification of conditions affecting demography, devel-
opment and proportional causes of death [12,13]. For
estimating age trends in exclusive and any breastfeeding
rates, we used a stratification defined by the nine WHO
subregions found in the developing world.
Basic calculation of indicators
Basic calculation methods described in this section were
used to calculate indicators for category-A countries.
Other countries first required either imputation of miss-
ing observations or extrapolation or, occasionally, transla-
tion of observations prior to calculation of indicators.
Country indicators for no breastfeeding were calculated as
weighted averages of reported estimates of the cross-sec-
tional prevalence of no breastfeeding for two-month age
groups by summing over the relevant age ranges (0–5, 6–
11 and 12–23 months of age) with population weights.
Population weights for aggregation across age ranges
(aggregation within category-A countries) were calculated
using the numbers of infants or children surveyed in each
two-month age group. The country indicator for exclusive
breastfeeding for infants d6 months of age was similarly
calculated as a weighted average of the cross-sectional
country prevalence of exclusive breastfeeding for two-
month age groups over the range 0–5 months of age.
Table 1: Prevalence estimates for breastfeeding indicators, by subregion and age group
Region Breastfeeding indicator estimates (%)
Subregion Infants <6 months of age Infants 6–11 months of age Children 12–23 months of age
Exclusive Partial No Continued No Continued No
Africa 24.9 71.2 3.9 91.8 8.2 69.9 30.1
Eastern 41.4 56.1 2.4 95.1 4.9 75.6 24.4
Middle 19.4 79.6 1.0 96.6 3.4 76.8 23.2
Northern 36.5 53.9 9.6 77.7 22.3 49.6 50.4
Southern 8.2 75.7 16.0 70.4 29.6 46.7 53.3
Western 6.1 92.1 1.8 96.8 3.2 74.9 25.1
Asia (excluding Japan) 44.9 50.7 4.5 87.5 12.5 72.4 27.6
Eastern 58.6 36.3 5.1 85.7 14.3 NDa ND
South-Central 42.1 55.3 2.6 93.3 6.7 78.8 21.2
South-Eastern 37.5 55.0 7.5 76.7 23.3 61.7 38.3
Western 17.7 72.0 10.3 71.3 28.7 37.3 62.7
Latin America and the Caribbean 30.8 51.2 18.0 59.9 40.1 36.5 63.5
Caribbean 25.8 63.8 10.4 64.6 35.4 34.2 65.8
Central America 23.4 55.0 21.6 60.2 39.8 37.0 63.0
South America 35.1 48.0 16.9 59.3 40.7 36.4 63.6
Developing countriesb 38.7 55.7 5.6 85.8 14.2 68.3 31.7
a ND = no data. b The region Oceania (including developing countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea, Samoa, 
Solomon Islands and Vanuatu) was excluded, as nationally representative breastfeeding data were not available for any developing countries in 
Oceania.
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Surveys with potential category-B data were not included unless they 
contained at least one observation of either exclusive, any or no breastfeeding. 
About 22% of the surveys used for calculating breastfeeding indicators are 
category B, with about half non-standard, and half MICS. The term for the 
implicit data category for countries with no nationally representative data 
on breastfeeding is ‘category C’. As shorthand, we refer to countries with 
category-A, B or C data as category-A, B or C countries, respectively.
Available data for infants were category A in 75 countries; for children 12-23 
months of age, data were category A in 73 countries. Available data for infants 
were category B in 19 countries; for children 12-23 months of age, data were 
category B in 11 countries. A total of 41 countries were category C for infants; 
for children 12-23 months of age, 51 countries were category C.
Reporting regions
The 135 developing countries were grouped according to the UN regional 
and subregional classification (see Table 1) [10]. Japan was excluded from 
regional and subregional estimates for Asia. The region Oceania (including 
developing countries Guam, Fiji, French Polynesia, New Caledonia, Papua 
New Guinea, Samoa, Solomon Islands and Vanuatu) was excluded, as no 
nationally representative breastfeeding data were obtained for any developing 
countries in Oceania.
Analysis regions
Although UN regions are geographical designations only, WHO has 
developed a subregional classification on the basis of both geographical and 
epidemiologic criteria. The 14 subregions represent a classification of countries 
in the six WHO regions according to four possible patterns of child and 
adult mortality [11]. Since no WHO region presents more than three of the 
defined patterns, there are substantially fewer than the theoretically possible 
24 subregions.
The mortality patterns used in the classification are defined so as to locate a 
country with regard to the epidemiologic transition, and therefore represent 
a macro-level classification of conditions affecting demography, development 
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and proportional causes of death [12,13]. For estimating age trends in exclusive 
and any breastfeeding rates, we used a stratification defined by the nine WHO 
subregions found in the developing world.
Basic calculation of indicators
Basic calculation methods described in this section were used to calculate 
indicators for category-A countries. Other countries first required either 
imputation of missing observations or extrapolation or, occasionally, 
translation of observations prior to calculation of indicators.
Country indicators for no breastfeeding were calculated as weighted averages 
of reported estimates of the cross-sectional prevalence of no breastfeeding 
for two-month age groups by summing over the relevant age ranges (0-5, 
6-11 and 12-23 months of age) with population weights. Population weights 
for aggregation across age ranges (aggregation within category-A countries) 
were calculated using the numbers of infants or children surveyed in each 
two-month age group. The country indicator for exclusive breastfeeding for 
infants ≤6 months of age was similarly calculated as a weighted average of the 
cross-sectional country prevalence of exclusive breastfeeding for two-month 
age groups over the range 0-5 months of age.
The country indicator for partial breastfeeding for infants ≤6 months of age 
was calculated as 100% – (%Exclusive breastfeeding + %No breastfeeding), 
where ‘%Exclusive breastfeeding’ and ‘%No breastfeeding’ are the country 
indicators (expressed as percentages) for exclusive and no breastfeeding, 
respectively, for the age range 0-5 months. For infants >6 months and ≤2 years 
of age, the country indicator for continued breastfeeding for each age range 
(6-11 and 12-23 months of age) was calculated as 100% – %No breastfeeding, 
where ‘%No breastfeeding’ is the country indicator for no breastfeeding for 
the relevant age range.
Regional breastfeeding indicators were calculated as infant-population weighted 
averages of country indicators (aggregation between category-A countries). 
Estimates of infant population are based on figures published by the United 
Nations [13]. Weights calculated with country infant populations were also 
used to calculate regional indicators for children 12-23 months of age.
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Subregional estimation models
We used subregional regression models to estimate age trends in exclusive 
and any breastfeeding rates for category-A countries. The models are stratified 
by the nine WHO subregions found in the developing world. Subregion-
specific results were used to impute missing observations of breastfeeding rates 
for category-B countries in the corresponding subregions. We refer to any 
estimation, imputation, extrapolation, translation or projection as ‘analysis’.
Breastfeeding rates were transformed with the logit function prior to analysis 
[14]. The logit of breastfeeding rate p is Log(p/1–p), where p is a proportion 
(that is, p = %Rate/100). For data where, as here, country-specific observations 
of p are available only for defined age groups, and where the dependent 
variable represents a dichotomous response, minimum chi-square regression, 
also called Berkson-Theil weighted least squares, yields unbiased, minimum-
variance estimates of regression betas [14].
The regression equation is: 
Log(p/1 – p) = a + bx + ε,              Equation 1
where p is the breastfeeding rate, x is month of age, a and b are the parameters 
to estimate (regression betas) and ε is the error term. Regressions were run 
separately for exclusive and any breastfeeding rates in each of the nine 
subregions. Parameter estimates were used to predict breastfeeding rates by 
solving the regression equation for p: 
)ˆˆ(Exp1
)ˆˆ(Expˆ
xab
xabp
++
+= .                   Equation 2
The regression equation implies p is a logistic function of age.
A linear model for the logit of prevalence is equivalent to a log-linear model 
for prevalence odds. The log-linear odds model is one of the most common in 
epidemiology [15], but its use is often justified on merely pragmatic grounds 
[16]. However, on the assumption that breastfeeding attrition rates continually 
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decrease (that is, become more negative) with age, the logarithm of breastfeeding 
prevalence odds is constrained to be linear, implying the logit model is correctly 
specified for estimation of regression betas (results not shown).
Imputation
The parameters (a, b) estimated for category-A countries were the starting 
point for imputing missing observations of two-month prevalence for 
category-B countries in the same subregion. The first step was to calibrate (by 
changing the intercept, b, or by changing the slope, a, and the intercept, b) 
the subregional category-A trend line so as to fit available observations of the 
breastfeeding rate in the desired category-B country in a least-squares sense. 
Secondly, missing observations of breastfeeding prevalence in the desired 
category-B country were predicted with the calibrated trend line. Finally, 
indicators were calculated for the desired category-B country using the basic 
calculation methods described above, with the difference that population 
weights were calculated on the basis of the country’s infant mortality rate.
For example, suppose country X in subregion Y has category-B data consisting 
of an observation of cross-sectional prevalence of exclusive breastfeeding 
of 16% for infants 0-3 months of age. The observed prevalence can be 
considered as a weighted average of two unobserved prevalences, for infants 
0-1 and 2-3 months of age, respectively. Now suppose the subregional trend 
for category-A countries in subregion Y predicts (after back-transformation 
with the logistic function) a cross-sectional prevalence of 44% exclusive 
breastfeeding for infants 0-1 months of age and 34% for infants 2-3 months 
of age. Applying population weights calculated with country X’s infant 
mortality rate (aggregation within category-B countries), the two predictions 
imply a predicted cross-sectional prevalence of exclusive breastfeeding of 40% 
for infants 0-3 months of age.
Keeping the slope of the estimated trend constant, the intercept is changed 
until the predicted prevalence of exclusive breastfeeding for infants 0-3 months 
of age in country X is 16%, as observed. Following calibration of the trend 
line to country X’s observation, it was possible to predict the prevalence of 
exclusive breastfeeding for infants 4-5 months of age using the new intercept, 
b’. Again applying population weights calculated with country X’s infant 
161
Chapter 6 Breastfeeding patterns and exposure to suboptimal 
 breastfeeding among children in developing countries: 
 review and analysis of nationally representative surveys
mortality rate, the three predicted prevalences of exclusive breastfeeding 
are summed, yielding an imputed estimate for the exclusive breastfeeding 
indicator for country X.
Now suppose country X has additional category-B data consisting, for example, 
of an observation of the cross-sectional prevalence of no breastfeeding of 18% 
for infants ≤6 months of age. Taking 100% – 18% yields an estimate of any 
breastfeeding of 82% for infants ≤6 months of age. Now suppose the trend 
for category-A countries in subregion Y predicts a cross-sectional prevalence of 
76% any breastfeeding for infants 0-1, 70% for infants 2-3, and 64% for infants 
4-5 months of age. Applying population weights calculated with country X’s 
infant mortality rate, the three predictions imply a cross-sectional prevalence 
of 70% any breastfeeding for infants ≤6 months of age, which is the same as an 
estimated prevalence of 30% no breastfeeding for the age group.
Keeping the slope of the estimated trend constant, the intercept is changed 
until the predicted prevalence of any breastfeeding for infants ≤6 months 
of age in country X is 82% (corresponding to a predicted prevalence of no 
breastfeeding of 18%, as observed). With the new intercept, b’, and population 
weights calculated for the corresponding two-month age groups, it is possible 
to impute the prevalence of no breastfeeding for infants 6-11 months of age, 
as well as for children 12-23 months of age.
When, as in the above example, available data for country X contain only 
one observation of exclusive and no breastfeeding, it is possible to fit the 
observed prevalence exactly by changing the intercept of the estimated 
subregional trend. However, if country X has two or more observations of 
prevalence for a breastfeeding category, in general it will not be possible to fit 
all observations exactly. In such a case, it was necessary to change both the 
slope and the intercept to fit available observations. Here, again, although 
with two observations it is possible to fit them exactly by changing two 
parameters, if more observations are available, generally it will not be possible 
to fit them all exactly. When such cases arose, a least-squares approach was 
used, whereby the parameter values that best fit, in the least-squares sense, all 
available observations were chosen.
The time dimension in measurements of population health
162
Note that the slope parameter estimates the rate of change of the logit of 
prevalence, while the intercept estimates the logit of prevalence at 0 months 
of age. We made the arbitrary decision that it was preferable to change the 
intercept. Therefore, as a rule of thumb, when it was necessary to change both 
parameters, the intercept was changed first to fit the observations as nearly as 
possible before changing the slope. If necessary, this two-step (intercept then 
slope) fitting procedure was repeated until a defined tolerance level (that is, 
sum of squared deviations less than a given threshold) was satisfied.
Once all available observations for country X were fit - either exactly or in 
the least squares sense - with the trend line thus calibrated it was possible to 
predict a complete and comprehensive series of cross-sectional prevalence for 
exclusive and any breastfeeding. However, if, in a given country, observations 
were available for only one rate (exclusive or any), the estimated subregional 
trend was used without adjustment to predict the other. In any case, once 
predictions were available for both exclusive and any breastfeeding, it was 
possible to predict rates of partial and continued breastfeeding by relying 
on the fact that, for infants ≤6 months of age, the percentages of exclusive, 
partial and no breastfeeding must add to 100%, and, for infants 6-11 and 
children 12-23 months of age, percentages of continued and no breastfeeding 
must add to 100%.
Country estimates of indicators calculated with predictions deriving from 
subregional estimation, whether or not a subsequent fitting procedure was 
performed, are called imputed indicators. To impute indicator estimates for 
category-C countries, the subregional averages calculated on the basis of both 
category-A and category-B countries were used without adjustment. 
Extrapolation
If enough observations were available for a category-B country, it was possible 
to estimate a country-specific trend line. In such cases, observed rates were 
extrapolated by means of a regression on age for that country alone, and the 
resulting series of predicted rates was averaged with population weights to 
obtain estimates of indicators. Because it relies on a country’s own data, this 
procedure is called extrapolation in order to distinguish it from imputation 
(applying estimates based on other countries’ data). Depending on available 
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data, a country might have extrapolated estimates for one rate (exclusive or 
any) and imputed estimates for the other.
Translation between cohort and period indicators
DHS and similar surveys report estimates of cross-sectional (period) 
prevalence for two-month age groups. However, in a few countries, estimates 
were reported in longitudinal (cohort) terms, that is, as the proportion of 
a birth cohort remaining in a category at a specific age. Prior to analysis, 
longitudinal estimates were translated into cross-sectional ones by assuming 
the implicit cohort attrition rate applied to the other infant and child cohorts 
in the population, and averaging the resulting series with population weights 
calculated on the basis of the country’s infant mortality rate. Since translation 
yields a complete but not comprehensive series of predictions, extrapolation 
or imputation was performed to obtain the series of predictions required for 
calculation of indicators.
Uncertainty
A random-effects model (that is, with country-specific random effects) can 
be used to obtain estimates for the standard error of regional estimates of 
breastfeeding indicators based on category-A country data. However, the kind 
of error analysed with a random-effects (or similar) model is that arising from 
observing only part of the entire population, and is termed statistical error. 
Depending on the validity of the survey methods and responses, category-A 
data may also involve systematic measurement error.
Indicators based on category-B or C data involve a further source of uncertainty 
deriving from use of the subregional estimation model, and also, in the case 
of category B, the validity and statistical error of available data. Reported 
indicators therefore potentially involve statistical, model and measurement 
error, which interact non-linearly. Model error and measurement error are 
not captured by random-effects estimates, and there is no general analytical 
method capable of taking account of these sources of error. 
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Results
Indicator estimates
Table 1 shows cross-sectional prevalence estimates for breastfeeding indicators 
by UN region. Exclusive breastfeeding rates are low, at about 25% in Africa, 
45% in Asia and 31% in Latin America and the Caribbean, or 39% of infants ≤6 
months of age in developing countries. However, most of the infant population 
in developing countries is receiving some breast milk, as the prevalence of 
no breastfeeding is only 5.6% for infants, ranging from about 4% in Africa 
to 18% in Latin America and the Caribbean. The prevalence of continued 
breastfeeding is about 86% for infants 6-11 months of age in the developing 
world, and ranges from 92% and 88% in Africa and Asia, respectively, to 60% 
in Latin America and the Caribbean. For children 12-23 months of age, the 
prevalence of continued breastfeeding drops to about 70% and 72% in Africa 
and Asia, respectively, and to 37% in Latin America and the Caribbean.
Uncertainty analysis performed with the random-effects model yielded 
confidence intervals on the order of 1-2 percentage points for each indicator 
(results not shown).
Population coverage of indicators
The distribution of age-specific population by data category in each UN region 
is shown in Table 2. In Africa and Latin America/the Caribbean, about 80% 
and 91% of the infant population, respectively, was covered with category-A 
data. In Asia 64% of the infant population was covered with category-A data.
For children 12-23 months of age, 86% of the population in Latin America 
and the Caribbean was covered with category-A data, as was 79% in Africa 
and 59% in Asia. For developing countries, 70% of infants and 67% of 
children 12-23 months of age were covered with category-A data.
When category-B data are considered, population coverage in developing 
countries increases to 95% for infants (representing about 106 million 
infants worldwide) and 73% for children 12-23 months of age. Inclusion of 
category-B data increases population coverage most in Africa (for both infants 
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and children 12-23 months of age) and Asia (for infants only). Lack of data 
for China on children 12-23 months of age substantially limits population 
coverage in Asia for that age group.
Subregional estimation models
Selected results for the subregional estimation models are presented in Tables 
3 and 4 and Figures 1-9. These figures show estimated age trends for exclusive 
breastfeeding for the age groups 0-1 to 8-9 months of age (upper panels; 
reference line, 1% prevalence), and for any breastfeeding for the age groups 
0-1 to 22-23 months of age (lower panels; reference line, 15% prevalence). 
Regressions use minimum chi-square estimation with dependent variable the 
logarithm of prevalence odds (that is, Log(p/1 − p), where p is prevalence of 
the breastfeeding indicator), and independent variable the oldest month of 
age by two-month age group; exclusive breastfeeding was estimated for five 
age groups 0-1 to 8-9 months of age, any breastfeeding for 18 age groups 0-1 
to 34-35 months of age (shown only for children ≤2 years of age); n is the 
number of pooled observations; inverse-variance weights used in estimation 
are shown by the relative size of data markers; regressions for category-A 
countries are stratified by geographical and epidemiologic criteria as noted in 
the figure legends. Data sources are listed in the Annex.
For almost all countries, the logit transformation reduced a markedly non-
linear age trend to one well described by the estimated slope and constant 
(Figure 10). Some countries are systematically over- or under-predicted by the 
subregional trend, but still show highly linear patterns (Figure 11). Although 
for a small group of countries systematic non-linearity remained (Figure 12), 
at the subregional level the linear component, as measured by the F statistic 
(results not shown), was always strongly significant.
Some countries showed highly variable observations month by month, which 
is suggestive of the limitations of 24-hour recall or the presence of systematic 
measurement error (Figure 13). These anomalies were particularly evident in 
observations of exclusive breastfeeding at older ages (Figures 14-17).
Analysis of Equation 2, the logistic expression for prevalence, shows that the 
regression betas (a, b) fully define the attrition hazard for the corresponding 
The time dimension in measurements of population health
166
BMC Medicine 2004, 2:26 http://www.biomedcentral.com/1741-7015/2/26
Page 8 of 29
(page number not for citation purposes)
Table 2: Population coverage by subregion, age group and data category
Region Infants aged 0–11 months Children aged 12–23 months
Subregion Population with data (%)a Category Population with data (%)a Category
A B C A B C
Africa 99.1 79.5 19.6 0.9 97.6 79.2 18.4 2.4
Eastern 99.4 91.8 7.6 0.6 99.4 91.8 7.6 0.6
Middle 96.5 25.9 70.6 3.5 96.5 25.9 70.6 3.5
Northern 99.8 52.3 47.5 0.2 95.1 57.2 37.9 4.9
Southern 95.1 91.5 3.6 4.9 95.1 91.5 3.6 4.9
Western 100 100 0 0 97.9 96.7 1.2 2.1
Asia (excluding Japan) 93.5 63.5 30.0 6.5 62.0 59.4 2.5 38.0
Eastern 94.1 0 94.1 5.9 0 0 0 100
South-Central 97.3 97.3 0 2.7 90.9 90.9 0 9.1
South-Eastern 84.6 74.5 10.1 15.4 84.7 74.5 10.1 15.4
Western 83.6 65.1 18.5 16.4 65.2 50.3 14.9 34.8
Latin America and the Caribbean 92.6 91.2 1.4 7.4 86.2 86.2 0 13.8
Caribbean 84.9 77.3 7.6 15.1 84.9 84.9 0 15.1
Central America 98.2 95.6 2.6 1.8 98.2 98.2 0 1.8
South America 90.8 90.6 0.2 9.2 80.6 80.6 0 19.4
Developing countriesb 94.8 70.1 24.7 5.2 72.9 66.8 6.1 27.1
Percentage of infant and child population in each region for which there were complete and comprehensive (category A), incomplete or non-
comprehensive (category B) or no (category C) data on breastfeeding. a Includes categories A and B. b The region Oceania (including developing 
countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea, Samoa, Solomon Islands and Vanuatu) was excluded, as nationally 
representative breastfeeding data were not available for any developing countries in Oceania.
Table 3: Summary regression results for age trends for exclusive breastfeeding
Stratum 
name
Stratum characteristics Intercept (95% 
confidence interval)
Slope (95% confidence 
interval)
Standard error of the 
residual
AfrD Africa: high adult, high child mortality -0.98 (-1.33, -0.63) -0.21 (-0.29, -0.14) 1.66
AfrE Africa: very high adult, high child mortality 0.68 (0.29, 1.07) -0.38 (-0.47, -0.29) 1.79
AmrB Americas: low child, low adult mortality 0.23 (-0.20, 0.66) -0.39 (-0.50, -0.29) 1.14
AmrD Americas: high adult, high child mortality 0.91 (0.47, 1.34) -0.39 (-0.49, -0.28) 1.10
EmrB Eastern Mediterranean: low child, low adult 
mortality
-0.84 (-1.75, 0.06) -0.47 (-0.80, -0.14) 0.57
EmrD Eastern Mediterranean: high adult, high child 
mortality
0.26 (-0.25, 0.76) -0.29 (-0.39, -0.18) 0.90
SearB South-east Asia: low child, low adult 
mortality
1.01 (0.55, 1.48) -0.47 (-0.58, -0.35) 0.92
SearD South-east Asia: high adult, high child 
mortality
1.03 (0.83, 1.23) -0.38 (-0.42, -0.33) 0.63
WprB Western Pacific: low child, low adult 
mortality
0.58 (-0.15, 1.31) -0.45 (-0.68, -0.22) 1.49
Regressions use minimum chi-square estimation with dependent variable logarithm of prevalence odds (that is, Log(p/1 - p), where p is prevalence 
of exclusive breastfeeding), and independent variable oldest month of age by two-month age groups; regressions for category-A countries stratified 
by geographical and epidemiologic criteria as noted in the table; exclusive breastfeeding estimated for five age groups 0–1 to 8–9 months of age. 
Data sources listed in the Annex (Additional file 1).
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breastfeeding rate as a function of age (results not shown). The average hazards 
for exclusive (upper panel) and any (lower panel) breastfeeding are displayed 
in Figure 18 versus month of age.
Discussion
24-hour recall
An assessment based on 24-hour recall will not always represent true exposure 
status, since infants may change feeding practices when ill or during the absence 
of the mother. In particular, 24-hour recall will generate a large number of 
false positives for exclusive breastfeeding [17]. This conclusion is supported by 
results from community-based studies [18,19]. Other studies have found that 
infants classified as exclusively breastfeeding with 24-hour recall receive other 
liquids and even solid foods on a less-than-daily basis [17,20].
In a prospective analysis published in 2000, the difference between data from 
24-hour recall and those from mothers’ daily records was compared, and it 
was found that 24-hour recall overestimated exclusive breastfeeding rates by 
an absolute magnitude of about 40% percentage points at both two and four 
months of age (92% versus 51% at two months, and 73% versus 30% at four 
months of age) [21]. The most common reason for misclassification was the 
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subregional trend, but still show highly linear patterns
(Figure 11). Although for a small group of countries sys-
tematic non-linearity remained (Figure 12), at the subre-
gional level the linear component, as measured by the F
statistic (results not shown), was always strongly
significant.
Some countries showed highly variable observations
month by month, which is suggestive of the limitations of
24-hour recall or the presence of systematic measurement
error (Figure 13). These anomalies were particularly evi-
dent in observations of exclusive breastfeeding at older
ages (Figures 14, 15, 16, 17).
Analysis of Equation 2, the logistic expression for preva-
lence, shows that the regres ion betas (a, b) fully define
the attrition hazard for the corresponding breastfeeding
rate as a function of age (results not shown). The average
hazards for exclusive (upper panel) and any (lower panel)
breastfeeding are displayed in Figure 18 versus month of
age.
Discussion
24-hour recall
An assessment based on 24-hour recall will not always
represent true exposure status, since infants may change
feeding practices when ill or during the absence of the
mother. In particular, 24-hour recall will generate a large
number of false positives for exclusive breastfeeding [17].
This conclusion is supporte  by results from com unity-
based studies [18,19]. Other studies have found that
infants classified as exclusively breastfeeding with 24-
hour recall receive other liquids and even solid foods on a
less-than-daily basis [17,20].
In a prospective analysis published in 2000, the difference
between data from 24-hour recall and those from moth-
ers' daily records was compared, and it was found that 24-
hour recall overestimated exclusive breastfeeding rates by
an absolute magnitude of about 40% percentage points at
both two and four months of age (92% versus 51% at two
months, and 73% versus 30% at four months of age) [21].
The most common reason for misclassification was the
consumption of water or water-based drinks. Infants
receiving water or water-based drinks in addition to breast
milk are referred to as 'predominantly breastfed'.
The study hows i fants whose true status is 'predomi-
nant' are frequently classified as 'exclusive' with 24-hour
recall. Consistent with international recom endations,
only infants not receiving water or water-based drinks
should be classified as exclusive, and studies have shown
that the introduction of any fluids other than breast milk
is associated with increased risk of morbidity and mortal-
ity [22-24]. Since data from the same study sh w that
about 30% of infants classified as 'exclusive' or 'predomi-
nant' receive some solid-food supplements, it appears
there is a significant tendency to under-report small-quan-
tity items administered in addition to breast milk.
An additional cause of overestimation is the use of filter
questions. In many surveys, including DHS, the mother is
asked 'For how long have you given your child only the
breast?'. Although instructions following the question
Table 4: Summary regression results for age trends for any breastfeeding
Stratum 
name
Stratum characteristics Intercept (95% 
confidence interval)
Slope (95% confidence 
interval)
Standard error of the 
residual
AfrD Africa: high adult, high child mortality 4.28 (4.05, 4.51) -0.20 (-0.21, -0.19) 1.30
AfrE Africa: very high adult, high child mortality 4.71 (4.43, 5.00) -0.20 (-0.21, -0.18) 1.12
AmrB Americas: low child, low adult mortality 1.34 (1.16, 1.52) -0.12 (-0.13, -0.11) 0.79
AmrD Americas: high adult, high child mortality 3.57 (3.29, 3.86) -0.18 (-0.20, -0.17) 0.83
EmrB Eastern Mediterranean: low child, low adult 
mortality
2.85 (2.58, 3.12) -0.22 (-0.23, -0.20) 0.36
EmrD Eastern Mediterranean: high adult, high child 
mortality
3.40 (3.16, 3.64) -0.17 (-0.18, -0.16) 0.80
SearB South-east Asia: low child, low adult 
mortality
3.58 (3.36, 3.79) -0.14 (-0.15, -0.13) 0.49
SearD South-east Asia: high adult, high child 
mortality
4.03 (3.72, 4.34) -0.14 (-0.15, -0.12) 0.89
WprB Western Pacific: low child, low adult 
mortality
2.18 (1.77, 2.60) -0.14 (-0.16, -0.12) 2.77
Regressions use minimum chi-square estimation with dependent variable logarithm of prevalence odds (that is, Log(p/1 - p), where p is prevalence 
of any breastfeeding), and independent variable oldest month of age by two-month age groups; regressions for category-A countries stratified by 
geographical and epidemiologic criteria as noted in the table; any breastfeeding estimated for 18 age groups 0–1 to 34–35 months of age. Data 
sources listed in the Annex (Additional file 1).
Table 4.  Summary regression results for age trends for any 
breastfeeding
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consumption of water or water-based drinks. Infants receiving water or water-
based drinks in addition to breast milk are referred to as ‘predominantly 
breastfed’.
The study shows infants whose true status is ‘predominant’ are frequently 
classified as ‘exclusive’ with 24-hour recall. Consistent with international 
recommendations, only infants not receiving water or water-based drinks 
should be classified as exclusive, and studies have shown that the introduction 
of any fluids other than breast milk is associated with increased risk of 
morbidity and mortality [22-24]. Since data from the same study show that 
about 30% of infants classified as ‘exclusive’ or ‘predominant’ receive some 
solid-food supplements, it appears there is a significant tendency to under-
report small-quantity items administered in addition to breast milk.
An additional cause of overestimation is the use of filter questions. In many 
surveys, including DHS, the mother is asked ‘For how long have you given 
your child only the breast?’. Although instructions following the question 
specify ‘(not even water)’, since the instructions are not part of the question 
itself, information on the consumption of water may not be systematically 
elicited. Moreover, since the 24-hour-recall module is implemented only for 
infants who are not reported to be given ‘breast only’, there is no mechanism 
for the identification of false positives. A more valid approach is used in 
UNICEF’s MICS surveys, in which 24-hour recall is performed for all infants, 
regardless of whether or not they are reported to be given ‘breast only’. Our 
own experience is that unless mothers are specifically asked about water and 
herbal teas, they will report that they gave only breast milk because water and 
teas are not perceived as foods (CGV, personal communication).
Systematic measurement error
We highlight the presence of anomalous observations of exclusive breastfeeding 
among older children in category-A data (see Figures 14-17), and interpret these 
results as providing evidence of measurement error resulting in systematic 
over-reporting in DHS surveys for exclusive and possibly other breastfeeding 
categories. In our view, while these findings have clear implications for the 
validity of observations of exclusive breastfeeding in DHS data at all age 
groups, the interpretation must take account of differences between regions 
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and countries (see Figures 14-17), perhaps due to differing perceptions about 
infant-and-child feeding practices. However, the anomalies detected become 
obvious only at older ages, and there are valid reasons why a small percentage 
of older children may be exclusively breastfed on a given day (for example, 
illness of child or no food in the house). However, exclusive breastfeeding 
rates in some countries (particularly in the regions AfrD, EmrD and WprB) 
display patterns that probably could not be completely explained in this 
manner. While the true explanation may remain unknown in the absence 
of further validation studies, it seems plausible that misunderstanding on 
the part of survey respondents or interviewers, or validity problems with the 
survey instrument beyond the limitations of 24-hour recall, are important 
contributing factors.
Implications for exposure assessment
Validity problems in DHS surveys have implications for the measurement of 
the whole distribution of exposure to suboptimal breastfeeding, especially for 
infants ≤6 months of age. If the exposure baseline (that is, the group at no 
increased risk) is not validly measured, it is likely that classifications of low 
or intermediate risk (for example, the category predominant breastfeeding) 
are similarly underestimates of true risk. Conversely, it is unlikely that 
infants classified as at low, intermediate or high-risk are in fact at no, low or 
intermediate risk.
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in AfrD (Africa: high-adult, high-child-mortality stratum)Figure 1
Estimated age trends for exclusive breastfeeding and for any breastfeeding in AfrD (Africa: high-adult, high-child-mortality stra-
tum). Exclusive breastfeeding (upper panel, n = 81), any breastfeeding (lower panel, n = 301).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in AfrE (Africa: very-high-adult, high-child-mortality stratum)Figure 2
Estimated age trends for exclusive breastfeeding and for any breastfeeding in AfrE (Africa: very-high-adult, high-child-mortality 
stratum). Exclusive breastfeeding (upper panel, n = 66), any breastfeeding (lower panel, n = 304).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in AmrB (Americas: low-adult, low-child mortality-stratum)Figure 3
Estimated age trends for exclusive breastfeeding and for any breastfeeding in AmrB (Americas: low-adult, low-child mortality-
stratum). Exclusive breastfeeding (upper panel, n = 22), any breastfeeding (lower panel, n = 117).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in AmrD (Americas: high-adult, high-child mortality stratum)Figure 4
Estimated age trends for exclusive breastfeeding and for any breastfeeding in AmrD (Americas: high-adult, high-child mortality 
stratum). Exclusive breastfeeding (upper panel, n = 24), any breastfeeding (lower panel, n = 89).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in EmrB (Eastern Mediterranean: low-adult, low-child-mort lity stratum)Figure 5
Estimated age trends for exclusive breastfeeding and for any breastfeeding in EmrB (Eastern Mediterranean: low-adult, low-
child-mortality stratum). Exclusive breastfeeding (upper panel, n = 4), any breastfeeding (lower panel, n = 18).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in EmrD (Eastern Mediterranean: high-adult, high-child-mort lity stratum)Figure 6
Estimated age trends for exclusive breastfeeding and for any breastfeeding in EmrD (Eastern Mediterranean: high-adult, high-
child-mortality stratum). Exclusive breastfeeding (upper panel, n = 30), any breastfeeding (lower panel, n = 125).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in SearB (South-east Asia: low-adult, low-child-mor-tality s ratum)Figure 7
Estimated age trends for exclusive breastfeeding and for any breastfeeding in SearB (South-east Asia: low-adult, low-child-mor-
tality stratum). Exclusive breastfeeding (upper panel, n = 9), any breastfeeding (lower panel, n = 36).
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Estimated age trends for exclusive breastfeeding and for any breastfeeding in SearD (South-east Asia: high-adult, high-child-mortality stratum)Figure 8
Estimated age trends for exclusive breastfeeding and for any breastfeeding in SearD (South-east Asia: high-adult, high-child-
mortality stratum). Exclusive breastfeeding (upper panel, n = 20), any breastfeeding (lower panel, n = 69).
lo
g
 p
re
v
a
le
n
c
e
 o
d
d
s
SearD - exclusive breastfeeding
oldest month of age in age group
 observed log prevalence odds  predicted log prevalence odds
 reference line, 1% prevalence
1 3 5 7 9
-7
-6
-5
-4
-3
-2
-1
0
1
2
lo
g
 p
re
v
a
le
n
c
e
 o
d
d
s
SearD - any breastfeeding
oldest month of age in age group
 observed log prevalence odds  predicted log prevalence odds
 reference line, 15% prevalence
1 3 5 7 9 11 13 15 17 19 21 23
-3
-2
-1
0
1
2
3
4
5
6
7
The time dimension in measurements of population health
178
BMC Medicine 2004, 2:26 http://www.biomedcentral.com/1741-7015/2/26
Page 18 of 29
(page number not for citation purposes)
Estimated age trends for exclusive breastfeeding and for any breastfeeding in WprB (Western Pacific: low-adult, low-child-mor-tality s ratum)Figure 9
Estimated age trends for exclusive breastfeeding and for any breastfeeding in WprB (Western Pacific: low-adult, low-child-mor-
tality stratum). Exclusive breastfeeding (upper panel, n = 16), any breastfeeding (lower panel, n = 70).
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Examples of good predictive performance for India (upper panel) and Burundi (lower panel)Figure 10
Examples of good predictive performance for India (upper panel) and Burundi (lower panel). Data markers show oldest month 
of age for the observation. The patterns are typical for many developing countries.
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Examples of systematic over- (Morocco, upper panel) and under- (El Salvador, lower panel) predictionFigure 11
Examples of systematic over- (Morocco, upper panel) and under- (El Salvador, lower panel) prediction. Data markers show 
oldest month of age for the observation. The patterns are typical for many developing countries.
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Examples of systematic non-linearity: concave (Gabon, upper panel); convex (Colombia, younger age groups, lower panel)Figure 12
Examples of systematic non-linearity: concave (Gabon, upper panel); convex (Colombia, younger age groups, lower panel). 
Data markers show oldest month of age for the observation. Only a few developing countries display these patterns.
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Examples of probable measurement error: especially months of age five and 11 (Niger, upper panel) and 11, 13 and 15 (Ghana, lower panel)Figu e 13
Examples of probable measurement error: especially months of age five and 11 (Niger, upper panel) and 11, 13 and 15 (Ghana, 
lower panel). Data markers show oldest month of age for the observation. High variability could be due to limitations of 24-
hour recall, but consistently high age-specific values suggest systematic measurement error.
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specify '(not even water)', since the instructions are not
part of the question itself, information on the
consumption of water may not be systematically elicited.
Moreover, since the 24-hour-recall module is
implemented only for infants who are not reported to be
given 'breast only', there is no mechanism for the identifi-
cation of false positives. A more valid approach is used in
UNICEF's MICS surveys, in which 24-hour recall is
performed for all infants, regardless of whether or not
they are reported to be given 'breast only'. Our own expe-
rience is that unless mothers are specifically asked about
water and herbal teas, they will report that they gave only
breast milk because water and teas are not perceived as
foods (CGV, personal communication).
Systematic measurement error
We highlight the presence of anomalous observations of
exclusive breastfeeding among older children in category-
A data (see Figures 14, 15, 16, 17), and interpret these
results as providing evidence of measurement error
resulting in systematic over-reporting in DHS surveys for
exclusive and possibly other breastfeeding categories. In
our view, while these findings have clear implications for
the validity of observations of exclusive breastfeeding in
DHS data at all age groups, the interpretation must take
account of differences between regions and countries (see
Figures 14, 15, 16, 17), perhaps due to differing percep-
tions about infant-and-child feeding practices. However,
the anomalies detected become obvious only at older
ages, and there are valid reasons why a small percentage of
Projected and observed exclusive breastfeeding for age groups 12–13 to 34–35 months of age, with reference lines of 10% (short dashes) and 1% (long dashes) prevalence in AfrEFigure 14
Projected and observed exclusive breastfeeding for age groups 12–13 to 34–35 months of age, with reference lines of 10% 
(short dashes) and 1% (long dashes) prevalence in AfrE. Low but non-zero observed rates of exclusive breastfeeding through-
out second and third year of childhood in AfrE, with persistent rates of about 1%, show limitations of 24-hour recall. This pat-
tern is also typical for AmrB, AmrD, SearB and SearD (EmrB had no observations of exclusive breastfeeding during the second 
and third year of childhood). Data markers show country identifiers.
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Conclusions
The size of the gap between breastfeeding practice and recommendations in 
developing countries is striking. More attention should be given to increasing 
breastfeeding, especially exclusive breastfeeding, and to monitoring trends. 
The introduction of more standardized and better validated survey instruments 
would be a valuable addition to child health monitoring. However, while 
existing data on breastfeeding are not perfect, in view of their extensive 
coverage, completeness and comprehensiveness, global exposure assessment 
is relatively robust. Although most data used here are category A, inclusion 
of category-B data allows for a more complete assessment in developing 
countries, especially among infants and in Africa. 
Category-A data present anomalies suggesting the limitations of current survey 
methods and the presence of systematic measurement error. Nevertheless, the 
regularity and consistency of observed patterns of breastfeeding (see Figures 
1-11) support the view that existing data capture the effects of real biological 
and social processes. More studies of the sort done by Aarts and colleagues 
[21] are probably necessary for a full understanding to emerge of measurement 
error and validity problems in breastfeeding surveys.
While the random-effects model yields a valid expression of statistical error, 
measurement and model error - essentially unquantifiable here - are larger by 
probably an order of magnitude or more. On balance, we believe our estimates 
must be interpreted as conservative (that is, lower-bound) estimates of 
exposure to suboptimal breastfeeding, especially non-exclusive breastfeeding, 
among children in developing countries. To our knowledge, these are the 
first published global estimates reporting exclusive breastfeeding rates for the 
infant population ≤6 months of age [25-27].
Our method for the analysis of breastfeeding rates provides a potent tool for 
summarizing trends, validating observations, translating and extrapolating 
indicators (as well as projecting and imputing estimates when necessary) and 
should support more effective child health monitoring.
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suboptimal breastfeeding among 
children in the developing world: 
a global ecological risk assessment
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Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
Abstract
Objective
We estimate attributable fractions, deaths and years of life lost among infants 
and children ≤ 2 years of age due to suboptimal breastfeeding in developing 
countries.
Design
We compare actual practices to a minimum-exposure pattern consisting 
of exclusive breastfeeding for infants ≤ 6 months of age and continued 
breastfeeding for older infants and children ≤ 2 years of age. For infants, we 
consider deaths due to diarrhoeal disease and lower respiratory infections, and 
deaths due to all causes are considered in the second year of life. Outcome 
measures are attributable fractions, deaths, years of life lost and offsetting 
deaths potentially caused by mother-to-child transmission of HIV through 
breastfeeding.
Setting
Developing countries.
Subjects
Infants and children ≤ 2 years of age.
Results
Attributable fractions for deaths due to diarrhoeal disease and lower respiratory 
infections, respectively, are 55% and 53% for the first six months of infancy, 
20% and 18% for the second six months, and are 20% for all-cause deaths in 
the second year of life. Globally, as many as 1.45 m lives (117 m years of life) 
are lost due to suboptimal breastfeeding in developing countries. Offsetting 
deaths caused by mother-to-child transmission of HIV through breastfeeding 
could be as high as 242,000 (18.8 m years of life lost) if relevant WHO 
recommendations are not followed.
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Conclusions
The size of the gap between current practice and recommendations is striking 
when one considers breastfeeding involves no out-of-pocket costs, that there exists 
universal consensus on best practices, and that implementing current international 
recommendations could potentially save 1.45 m children’s lives each year.
Introduction
Recent work on major global risk factors
In 2002, the World Health Organization (WHO) highlighted the public 
health importance of major global risk factors for burden of disease.1 Modifiable 
childhood nutritional risk factors such as underweight (3.75 m deaths) and 
zinc (789,000 deaths), vitamin A (778,000 deaths) and iron (841,000 deaths) 
deficiency were estimated to be responsible for over 6 m childhood deaths 
per year. Environmental risk factors such as unsafe water, sanitation and 
hygiene, whose effects fall overwhelmingly on children, were estimated to be 
responsible for an additional 1.73 m deaths per year. 
Although WHO did not analyse suboptimal breastfeeding, other recent 
analyses of causes of childhood death have qualified it as one of “the most 
powerful shared risk factors”2 and estimated that 1.3 m deaths could be 
prevented in 42 high-mortality countries by increased levels of breastfeeding 
among infants.3 That work, by the Bellagio Child Survival Group, suggests 
that suboptimal breastfeeding is a childhood risk factor of the same magnitude 
as the other major nutritional and environmental risk factors studied by the 
WHO Collaborating Group. 1;4;5
On a number of technical grounds, the present work extends that published 
by the Bellagio Group: we use published estimates of exposure for the entire 
developing world (135 countries),6 we apply estimates of risk consistent with 
current international infant-feeding recommendations and, consistent with 
best available evidence,7 we assess the effect of suboptimal breastfeeding 
throughout the second year of life. Finally, we present a detailed account of 
methods, assumptions and data sources.
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Policy background
Excluding neonatal disorders, the most important causes of childhood deaths 
in developing countries are lower respiratory infections and diarrhoea.2 It has 
been long understood that breastfeeding reduces not only the incidence of 
these diseases but also their severity and duration.8-11 
Recent debate has focused on the optimal duration of exclusive breastfeeding 
in infancy, and, in 1999, WHO commissioned a systematic review of 
evidence,12 following which the World Health Assembly voted in 2001 to 
recommend exclusive breastfeeding for the first six months of life as a global 
public health recommendation.13 On the basis of the best available evidence, 
therefore, current international consensus holds that optimal breastfeeding 
practice for infants and young children consists of exclusive breastfeeding for 
the first six months of life with continued breastfeeding up to two years of 
age and beyond.14 
Nevertheless, breastfeeding for more than one year has been estimated to pose 
a 10−20% risk of HIV transmission in children of infected mothers.15 Since 
the risk of HIV transmission clearly needs to be balanced against other risks 
faced by infants and children, WHO currently states that “when replacement 
feeding is acceptable, feasible, affordable, sustainable and safe, avoidance 
of all breastfeeding by HIV-positive women is recommended; otherwise, 
exclusive breastfeeding is recommended during the first months of life”; 
WHO emphasizes, however, “that those who choose other options should be 
encouraged to use them free from commercial influences”.15;16
Methods
Design
Using the method of population attributable risk,17 we report estimates 
of attributable fractions, deaths and years of life lost due to suboptimal 
breastfeeding among children in the developing world. Population attributable 
risk measures the proportion of an outcome potentially avertable through 
reduced exposure to a risk factor. The outcomes considered here are childhood 
The time dimension in measurements of population health
200
deaths due to diarrhoeal disease and lower respiratory infections in 12 global 
subregions; the corresponding risk factor is suboptimal breastfeeding.
Reduced exposure is defined here as a counterfactual distribution of 
childhood breastfeeding defined with reference to current international 
recommendations.13 As recommendations distinguish children 0−5, 6−11 
and 12−23 months of age, all our analyses are stratified for these age 
groups. The counterfactual distribution constitutes the minimum level of 
exposure that is in principle possible; such a reference distribution has been 
termed “theoretical minimum exposure”17. We use the term “suboptimal 
breastfeeding” throughout to refer to practices inconsistent with this defined 
minimum exposure distribution. 
Estimates of population attributable risk require information on current 
exposure status and the relative risk of the studied outcomes in the exposed 
group. Our exposure estimates were derived from a comprehensive review of 
breastfeeding patterns obtained from nationally representative data sources in 
the developing world. Calculation methods and validation procedures have 
been described elsewhere.6 Our estimates of relative risk were derived from 
a re-analysis of data identified through a review of suitable epidemiological 
studies; the studies, as well as the analysis methods used to derive and validate 
our risk estimates, are described more fully below. 
All outcome estimates refer to 2000, the year of the most recent comprehensive 
review of the global burden of disease, our source for data on deaths and years 
of life lost. Estimates of population attributable risk are mutiplied by total 
numbers of deaths and years of life lost due to diarrhoeal disease and lower 
respiratory infections to yield estimates of attributable deaths and attributable 
years of life lost. 
Risk of suboptimal breastfeeding
Current knowledge
In 2000, the WHO Collaborative Study Team published a systematic 
review of the risk of death attributable to suboptimal breastfeeding.7 For the 
purposes of an assessment such as the one presented here, a major limitation 
201
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
of that study was that pooled analysis was possible only in terms of aggregate 
causes of death (e.g. all infections), and only for the dichotomous categories 
“any” vs “no” breastfeeding. Moreover, no pooled estimate was published for 
suboptimal breastfeeding in the second year of life. 
Risk categories
For infants ≤ 6 months of age, theoretical minimum risk is defined as 
“exclusive breastfeeding”. In conformity with available exposure data,6 
we define two increased risk categories, “partial breastfeeding” and “no 
breastfeeding,” resulting in a polytomous minimum risk distribution for this 
age group. For infants >6 months of age and for children ≤ 2 years of age, 
theoretical minimum risk is defined as “continued breastfeeding”, with “no 
breastfeeding” the sole increased risk category.6 
Risk data
When the WHO Collaborative meta-analysis was published,7 only one study 
with data for young infants in terms of polytomous exposure categories had 
been identified, a case-control study performed a number of years ago in 
Brazil.9 A recent cohort study in Bangladesh11 has since been published, also 
with polytomous exposure data. Each study presents certain limitations for the 
present purposes. While the Brazilian study characterized its reference group 
in terms of “predominant breastfeeding” rather than exclusive breastfeeding, 
the study performed in Bangladesh enrolled virtually no infants in the no-
breastfeeding category. Furthermore, the small number of deaths recorded in 
the Bangladesh study severely limited its power to estimate mortality risk for 
infants >6 months of age. 
Risk model
For use in the present study, risk data, consisting of observations of exposure 
and outcomes in infant and child populations, require aggregation in terms of 
the age groups and outcomes defined here as well as transformation, by means 
of a mathematical structure representing the relationships in this information, 
into summary estimates of risk. 
For the two infant age groups, re-analysis of the Brazilian data affected the age 
distribution in the sample and it was necessary to analyse cases and controls 
irrespective of matching. Although ignoring matching can bias the association 
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only towards the hypothesis of no effect,18 exploratory comparisons showed 
that estimates of risk were reduced only slightly.
We used maximum-likelihood estimation of a logistic regression model 
implemented with the Stata procedure logit. Selection of covariates was 
facilitated with a hierarchical model embodying a particular realization of a 
distal−proximal causal web. A model with all variables at the top (most distal) 
level was fit, and variables with P-values greater than 0.20 were removed, one 
at a time, starting with the highest P-value, until all remaining variables had 
P-values less than 0.20. The procedure was repeated for subsequent (more 
proximal) levels, keeping variables retained in previous levels irrespective of 
their P-values in subsequent regressions.
For the second year of life, five previous studies contained sufficient information 
to compute the risk of no breastfeeding on all cause mortality,7 and we used 
those data to compute a variance-weighted pooled mean of all-cause-mortality 
risk for children >1 and ≤2 years of age using the Stata procedure metan.19
External validation
Risk estimates were compared where possible with those from other studies 
and settings to ensure that they were reasonably consistent with other data 
and could therefore be applied across the diverse settings studied here. We 
made detailed comparisons, in polytomous terms, to appropriately re-analysed 
data from the study in Bangladesh, and in dichotomous terms, to the two 
other data sets20;21 with information on suboptimal breastfeeding and fatal 
outcomes in infants identified by the WHO Collaborative meta-analysis. 
Outcomes
For infants, only deaths due to diarrhoeal disease and lower respiratory 
infections are considered, but for children ≤2 years of age, deaths due to all 
causes are included. The corresponding outcomes we derive are attributable 
fractions, attributable deaths and attributable years of life lost. An upper 
bound on deaths potentially caused by mother-to-child transmission of HIV 
through breastfeeding is estimated for 32 high-prevalence countries in the 
developing world. All estimates are reported for developing countries by UN 
subregion.22
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We use WHO figures for cause-specific deaths and years of life lost in 2000, 
which are estimated subject to a variety of internal and external validity 
constraints23;24 for the world and a set of defined epidemiological subregions.25 
WHO cause-specific death estimates are reported, by sex, for infants (≤ 1 year 
of age) and other children (>1 and ≤  5 years of age) and six other age groups of 
varying width; estimates of all-cause deaths are reported, by sex, for infants, 
other children and successive five-year age groups.26
Age distribution of infant outcomes
As breastfeeding recommendations distinguish children 0−5, 6−11 and 12−23 
months of age,13 it was necessary to estimate the proportion of cause-specific or 
all-cause deaths occurring in various age subgroups. We used published data 
Figure 1. Linear relation between the logarithm of cumulative 
childhood mortality odds and age for selected 
causes. Circles (diarrhoeal disease) and squares (lower 
respiratory infections) show pooled data points;27 solid and 
dashed lines show the estimated relation. Estimated parameter 
values reported in the figure.
Lo
ga
rit
hm
 c
um
ul
at
iv
e 
ch
ild
ho
od
 m
or
ta
lit
y 
od
ds
Age (years)
 Diarrhoeal disease  Lower respiratory infections
 slope 1.19, constant -1.18  slope 1.34, constant -0.31
.5 1 1.5
-1
0
1
2
The time dimension in measurements of population health
204
on the age distribution of deaths due to diarrhoeal disease and lower respiratory 
infections among children27 to estimate a linear relation between the logarithm 
of childhood mortality odds and age for the relevant cause categories (Figure 
1). The estimated slope determines the age distribution of cause-specific deaths 
and the constant, the overall level of risk in the published data. 
To apply this relation to the subregions defined here, we assumed that the age 
distribution of deaths remains the same across regions but that the level of risk is 
context specific. Accordingly, the estimated relations were calibrated, by changing 
the constant, to fit WHO estimates of cause-and-sex-specific deaths occurring by 
1 year of age for each subregion. The calibrated relation was then used to predict 
subregion-specific deaths by 6 months of age. The resulting estimates (predicted) 
are shown in Figure 2 by cause and sex, along with the reported WHO estimates 
(observed) for comparison. We assumed that the subregional age distributions of 
years of life lost by 6 months of age were the same as those we estimated for deaths.
A similar procedure was used to obtain estimates of the proportion of 
childhood mortality occurring by the end of the second year of life. Here, 
though, we used estimated all-cause mortality risk at one and five years of age 
obtained from each country’s life table26 and simply interpolated, on the odds 
scale, values for the second year of life. 
Offsetting outcomes
Since, for HIV-positive mothers, breastfeeding can result in transmission of HIV 
infection to the infant, international recommendations take into account the need 
to assess competing risks. As a shorthand locution, we use the term “offsetting 
outcomes” throughout to denote the expected number of childhood deaths or 
years of life lost that would be caused by HIV-positive mothers were they to 
breastfeed their children at the same counterfactual rate as non-HIV-positive 
mothers. It is important to distinguish this artificial concept of “offsetting deaths” 
(based on an assumption of breastfeeding without regard to HIV status and, 
therefore, in a manner inconsistent with international recommendations) from 
deaths that might potentially be caused as a result of the vertical transmission 
of HIV infection through full compliance with international breastfeeding 
recommendations, which specifically require a judgement concerning the 
balance of risk. “Offsetting deaths” as used here thus refers to theoretical deaths 
205
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
that would attributable to breastfeeding by HIV-positive mothers were they to 
breastfeed fully but without regard to individual- and setting-specific factors. 
With such “indiscriminate” breastfeeding (i.e. without considering individual- 
and setting-specific factors), “offsetting outcomes” would reduce the population 
benefit achievable by breastfeeding because some of the breastfed children will 
die from AIDS. While a number of offsetting deaths of children of HIV-positive 
mothers might be unavoidable even taking into account individual- and setting-
specific factors, logically, such deaths must always be fewer than those attributable 
to so-called indiscriminate breastfeeding by HIV-positive mothers. We estimate 
here the offsetting outcomes of indiscriminate breastfeeding as an upper bound 
on the potential harms of breastfeeding by HIV-positive mothers. 
We analysed offsetting deaths in 32 high-prevalence countries (Footnote, 
Table 5). The population at risk for mother-to-child transmission through 
breastfeeding was assumed to be the subregion’s infant population, and we 
assumed independence in the probabilities of a mother’s being HIV positive,28 
having a live-born child survive the neonatal period and breastfeeding her 
child for at least one year. The probability of HIV transmission for children of 
infected mothers who breastfeed for at least one year was assumed to be 15%,15 
and homogeneous across breastfeeding categories. The probability of mothers’ 
breastfeeding for at least one year was calculated as the complement of the 
no breastfeeding rate among infants.6 We assumed that all infants becoming 
HIV positive through breastfeeding die at exact age 5 years.29
Figure 2. Share of childhood deaths (diarrhoeal disease, upper 
panel; lower respiratory infections, lower panel). 
Observed (circles, 1 year) and predicted (squares, 6 month) 
cause-and-sex-specific shares by subregion, by rank. 
determines the age distribution of cause-specific deaths
and the constant, the overall level of risk in the published
data.
To apply this relationship to the sub-regions defined
here, we assumed that the age distribution of deaths
remains the same across regions but that the level of risk is
context-specific. Accordingly, the estimated relationships
were calibrated, by changing the constant, to fit WHO
estimates of cause- and sex-specific deaths occurring by
1 year of age for each sub-region. The calibrated
relationship was then used to predict sub-region-specific
deaths by 6 months of age. The resulting estimates
(predicted) are shown in Fig. 2 by cause and sex, along
with the reported WHO estimates (observed) for
comparison. We assumed that the sub-regional age
distributions of years of life lost by 6 months of age were
the same as those we estimated for deaths.
A similar procedure was used to obtain estimates of the
proportion of childhood mortality oc urring by the en of
the second year of life. Here, though, we used estimated
all-cause mortality risk at 1 and 5 years of age obtained
from each country’s life table26 and simply interpolated,
on the odds scale, values for the second year of life.
Offsetting outcomes
Since, for HIV-positive mothers, breast-feeding can result
in transmission of HIV infection to the infant, international
recommendations take into account the need to assess
competing risks. As a shorthand locution, we use the term
‘offsetting outcomes’ throughout to denote the expected
number of childhood deaths or years of life lost that would
be caused by HIV-positive mothers were they to breast-
feed their children at the same counterfactual rate as non-
HIV-positive mothers. It is important to distinguish this
artificial concept of ‘offsetting deaths’ (based on an
assumption of breast-feeding witho t regard to HIV tatus
and, th refore, in a manner inconsistent with international
recommendations) from deaths that might potentially be
caused as a result of the vertical transmission of HIV
infection through full compliance with international
breast-feeding recommendations, which specifically
require a judgement concerning the balance of risk.
‘Offsetting eaths’ as used here thu refer to theoretical
deaths that would be attributable to breast-feeding by HIV-
positive mothers were they to breast-feed fully but without
regard to individual- and setting-specific factors. With such
‘indiscriminate’ breast-feeding (i.e. without considering
individual- and setting-specific factors), ‘offsetting out-
comes’ would reduce the population benefit achievable
by breast-feeding because some of the breast-fed children
will die from AIDS. While a number of offsetting deaths of
children of HIV-positive mothers might be unavoidable
even taking into account individual- and setting-specific
factors, logically, such deaths must always be fewer than
those attributable to so-called indiscriminate breast-
feeding by HIV-positive mothers. We estimate here the
offsetting outcomes of indiscriminate breast-feeding as an
upper bound on the potential harms of breast-feeding by
HIV-positive mothers.
We analysed offsetting deaths in 32 high-prevalence
countries (footnote, Table 6). The population at risk for
mother-to-child transmission through breast-feeding was
assumed to be the sub-region’s infant population, and we
assumed independence in the probabilities of a mother
being HIV-positive28, having a live-born child survive the
neonatal period and breast-feeding her child for at least
1 year. The probability of HIV transmission for children of
infected mothers who breast-feed for at least 1 year was
assumed to be 15%15 and homogeneous across breast-
feeding categories. The probability of mothers breast-
feeding for at least 1 year was calculated as the
complement of the no breast-feeding rate among infants6.
We assumed that all infants becoming HIV-positive
through breast-feeding die at exactly 5 years of age29.
Results
Risk of suboptimal breast-feeding
Table 1 shows a comparison, by exposure status and cause
of death, of adjusted and crude estimates of risk for infants
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determines the age distribution of cause-specific deaths
and the constant, the overall level of risk in the published
data.
To apply this relationship to the sub-regions defined
here, we assumed that the age distribution of deaths
remains the same across regions but that the level of risk is
context-specific. Accordingly, the estimated relationships
were calibrated, by changing the constant, to fit WHO
estimates of cause- and sex-specific deaths occurring by
1 year of age for each sub-region. The calibrated
relationship was then used to predict sub-region-specific
deaths by 6 months of age. The resulting estimates
(predicted) are shown in Fig. 2 by cause and sex, along
with the reported WHO estimates (observed) for
comparison. We assu ed that the sub-regional age
distributions of years of life lost by 6 months of age were
the sa e as those we estimated for deaths.
A similar procedure was used to obtain estimates of the
proportion of childhood mortality occurring by the end of
the second year of life. Here, though, we used estimated
all-cause mortality risk at 1 and 5 years of age obtained
from each country’s life table26 and simply interpolated,
on the odds scale, values for the second year of life.
Offsetting outcomes
Since, for HIV-positive mothers, breast-feeding can result
in transmission of HIV infection to the infant, international
recommendations take into account the need to assess
competing risks. As a shorthand locution, we use the term
‘offsetting outcomes’ throughout to denote the expected
number of childhood deaths or years of life lost that would
be caused by HIV-positive mothers were they to breast-
feed their children at the same counterfactual rate as non-
HIV-positive mothers. It is important to distinguish this
artificial concept of ‘offsetting deaths’ (based on an
assumption of breast-feeding without regard to HIV status
and, therefore, in a manner inconsistent with international
recommendations) from deaths that might potentially be
caused as a result of the vertical transmission of HIV
infection through full compliance with international
breast-feeding recommendations, which specifically
require a judgement concerning the balance of risk.
‘Offsetting deaths’ as used here thus refers to theoretical
deaths that would be attributable to breast-feeding by HIV-
positive mothers were they to breast-feed fully but without
regard to individual- and setting-specific factors. With such
‘indiscriminate’ breast-feeding (i.e. without considering
individual- and setting-specific factors), ‘offsetting out-
comes’ would reduce the population benefit achievable
by breast-feeding because some of the breast-fed children
will die from AIDS. While a number of offsetting deaths of
children of HIV-positive mothers might be unavoidable
even taking into account individual- and setting-specific
factors, logically, such deaths must always be fewer than
those attributable to so-called indiscriminate breast-
feeding by HIV-positive mothers. We estimate here the
offsetting outcomes of indiscriminate breast-feeding as an
upper bound on the potential harms of breast-feeding by
HIV-positive mothers.
We analysed offsetting deaths in 32 high-prevalence
countries (footnote, Table 6). The population at risk for
mother-to-child transmission through breast-feeding was
assumed to be the sub-region’s infant population, and we
assumed independence in the probabilities of a mother
being HIV-positive28, having a live-born child survive the
neonatal period and breast-feeding her child for at least
1 year. The probability of HIV transmission for children of
infected mothers who breast-feed for at least 1 year was
assumed to be 15%15 and homogeneous across breast-
feeding categories. The probability of mothers breast-
feeding for at least 1 year was calculated as the
complement of the no breast-feeding rate among infants6.
We assumed that all infants becoming HIV-positive
through breast-feeding die at exactly 5 years of age29.
Results
Risk of suboptimal breast-feeding
Table 1 shows a comparison, by exposure status and cause
of death, of adjusted and crude estimates of risk for infants
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Results
Risk of suboptimal breastfeeding
Table 1 shows a comparison, by exposure status and cause of death, of adjusted 
and crude estimates of risk for infants from the re-analysed Brazilian data. 
Pooled and individual estimates of the risk of no breastfeeding for deaths due 
to all causes during the second year of life are shown in the “forest plot”19 
depicted in Figure 3.
External validation
To validate the polytomous estimates for infants, data from the studies in 
Brazil and Bangladesh were tabulated on a comparable basis and re-analysed; 
re-analysis for Bangladesh was possible only for infants ≤6 months of age 
(personal communication, Shams Arifeen). After adjusting for a similar set of 
covariates (Footnote, Table 1), levels of risk in the two studies are similar and 
show overlapping confidence intervals (Table 2). 
from the reanalysed Brazilian data. Pooled and individual
estimates of the risk of no breast-feeding for deaths due to
all causes during the second year of life are shown in the
‘forest plot’19 depicted in Fig. 3.
External validation
To validate the polytomous estimates for infants, data from
the studies in Brazil and Bangladesh were tabulated on a
comparable basis and reanalysed; reanalysis for Bangla-
desh was possible only for infants aged #6 months
(S Arifeen, personal communication). After adjusting for a
similar set of covariates (footnote, Table 1), levels of risk in
the two studies are similar and show overlapping
confidence intervals (Table 2).
Figure 4 compares age-specific levels of risk for deaths
due to infectious diseases found in Brazil with those in
each of the other two studies (Philippines20 and
Pakistan21) where dichotomous (i.e. ‘any’ vs. ‘no’ breast-
feeding) comparisons were possible. The plot suggests
decreasing age-specific risk, linear in the logarithm of the
odds ratio. The estimates from Brazil are consistent with
those from the other settings and are generally intermedi-
ate in risk.
Attributable fractions
Attributable fractions denote the proportion of an
outcome attributable to the exposure and are reported
by cause in Table 3. For infants aged #6 months,
attributable fractions are highest in Latin America and the
Caribbean, followed by Africa and Asia. Globally,
attributable fractions for younger infants account for
more than half of fatal outcomes due to the selected causes
in developing countries. For older infants, attributable
fractions are highest in Latin America and the Caribbean,
followed by Asia and Africa. Globally, attributable
fractions for older infants account for nearly one-fifth of
fatal outcomes due to selected causes in developing
countries. For children in the second year of life,
attributable fractions are highest in Latin America and the
Caribbean, followed by Africa and Asia, and globally
account for one-fifth of all fatal outcomes in developing
countries.
Attributable deaths
Attributable deaths are calculated by multiplying attribu-
table fractions by total deaths and are reported by cause in
Table 4. Globally, we estimate that 1.45 million childhood
deaths are attributable to suboptimal breast-feeding in
developing countries. A total of 96% of all attributable
infant deaths (i.e. 1.24 million deaths) occur during the
first six months of life, with 168 000 attributable deaths
occurring during the second year of life (12% of all
Table 1 Crude and adjusted* odds ratios (OR) and 95% confidence intervals (CI) of infant
mortality due to suboptimal breast-feeding, by cause of death and exposure category. Esti-
mates obtained from reanalysis of data from the study reported in reference 9
Age group/cause of death
Suboptimal
breast-feeding
category
OR, crude estimate
(95% CI)
OR, adjusted
estimate
(95% CI)
0–5 months
Diarrhoeal disease Partial 3.9 (2.0–7.7) 2.4 (1.1–5.2)
Diarrhoeal disease No 8.1 (4.6–14.5) 7.3 (3.7–14.4)
Lower respiratory tract infections Partial 3.2 (1.6–6.4) 2.8 (1.4–5.8)
Lower respiratory tract infections No 5.6 (3.1–10.0) 4.7 (2.4–9.1)
6–11 months
Diarrhoeal disease No 2.2 (1.0–4.5) 2.5 (1.1–5.7)
Lower respiratory tract infections No 2.3 (0.9–5.7) 2.8 (1.0–7.7)
*Covariates controlled for were father living in the same household, income per capita, infant’s age in
months, number of previous pregnancies, mother’s age in years, birth weight in grams (lower respiratory
tract infections, 0–5 months); mother’s education in years, mother’s ethnicity, infant’s age in months,
household has flush toilet, birth interval in months, mother’s age in years, birth weight in grams, hospital
birth, delivery by Caesarian section, number of antenatal visits (diarrhoeal disease, 0–5 months); mother’s
education in years, household head employed, infant’s age in months, birth weight in grams, low Apgar
score at birth (lower respiratory infections, 6–11 months); and income per capita by quartile, male infant,
infant’s age in months, household has piped water, number of persons per sleeping room, number of pre-
vious pregnancies, mother’s age in years (diarrhoeal disease, 6–11 months).
Odds ratio
0.1 1 10 100
Study % WeightOdds ratio(95% CI)
2.15 (1.50–3.08)Senegal 66.2
2.05 (0.34–12.28)Pakistan 3.5
1.99 (0.11–35.72)Ghana 1.4
1.26 (0.59–2.72)Philippines 18.2
0.80 (0.29–2.21)Gambia 10.7
1.75 (1.25–2.46)Overall (95% CI)
Fig. 3 Risk estimates for no breast-feeding versus continued
breast-feeding during the second year of childhood (all causes of
death) in five different settings. Relative size of the squares indi-
cates relative sample size (% weight) and the diamond shows the
variance-weighted mean of the squares (overall); CI – confidence
interval
Global risk assessment of suboptimal breast-feeding 677
Table 1  Crude and adjusted* odds ratios (OR) and 95% 
confidence intervals (CI) of infant mortality due to 
suboptimal breast-feeding, by cause of death and 
xposure category. Estim tes obtaine  from r analysis  data 
from the study reported in reference 9
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Figure 4 compares age-specific levels of risk for deaths due to infectious diseases 
found in Brazil with those in each of the other two studies (Philippines20 and 
Pakistan21) where dichotomous (i.e. “any” vs “no” breastfeeding) comparisons 
were possible. The plot suggests decreasing age-specific risk, linear in the 
logarithm of the odds ratio. The estimates from Brazil are consistent with 
those from the other settings and are generally intermediate in risk. 
Attributable fractions
Attributable fractions denote the proportion of an outcome attributable to the 
avoided exposure and are reported by cause in Table 3. For infants ≤ 6 months 
of age, attributable fractions are highest in Latin America and the Caribbean, 
followed by Africa and Asia. Globally, attributable fractions for younger 
infants account for more than half of fatal outcomes due to the selected causes 
in developing countries. For older infants, attributable fractions are highest 
Figure 3.  Risk estimates for non-breastfeeding vs continued 
breastfeeding during the second year of childhood (all 
causes of death) in five different settings. Relative size of 
squares indicates relative sample size (% weight) and the diamond 
shows the variance-weighted mean of the squares (overall).
  
Odds ratio
.1 1 10 100
Study  % Weight
 Odds ratio
 (95% CI)
 2.15 (1.50,3.08) Senegal  66.2
 2.05 (0.34,12.28) Pakistan   3.5
 1.99 (0.11,35.72) Ghana   1.4
 1.26 (0.59,2.72) Philippines  18.2
 0.80 (0.29,2.21) Gambia  10.7
 1.75 (1.25,2.46) Overall (95% CI)
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in Latin America and the Caribbean, followed by Asia and Africa. Globally, 
attributable fractions for older infants account for nearly one-fifth of fatal 
outcomes due to selected causes in developing countries. For children in the 
second year of life, attributable fractions are highest in Latin America and the 
Caribbean, followed by Africa and Asia, and globally account for one-fifth of 
all fatal outcomes in developing countries.
Attributable deaths
Attributable deaths are calculated by multiplying attributable fractions by total 
deaths and are reported by cause in Table 4. Globally, we estimate that 1.45 m 
childhood deaths are attributable to suboptimal breastfeeding in developing 
countries. A total of 96% of all attributable infant deaths (i.e. 1.24 m deaths) 
occur during the first 6 months of life, with 168,000 attributable deaths 
occurring during the second year of life (12% of all attributable childhood 
deaths). Attributable childhood deaths are much higher in Asia (830,000) 
and Africa (572,000) than in Latin America and the Caribbean (50,000), 
due to the effects of larger population (Asia) and higher underlying death 
rates (Africa and parts of Asia). Globally, attributable infant deaths due to 
lower respiratory infections are higher (685,000) than those due to diarrhoeal 
disease (600,000), although the pattern is reversed in Latin America and the 
Caribbean (20,000 and 23,000 deaths, respectively).
attributable childhood deaths). Attributable childhood
deaths are much higher in Asia (830 000) and Africa
(572 000) than in Latin America and the Caribbean
(50 000), due to the effects of larger population (Asia)
and higher underlying death rates (Africa and parts of
Asia). Globally, attributable infant deaths due to lower
respiratory tract infections are higher (685 000) than those
due to diarrhoeal disease (600 000), although the pattern is
reversed in Latin America and the Caribbean (20 000 and
23 000 deaths, respectively).
Attributable years of life lost
Attributable years of life lost are calculated by multiplying
attributable fractions by total years of life lost and
are reported by cause and age group in Table 5.
Globally, 117 million years of life lost are attributable to
suboptimal breast-feeding among children in developing
countries.
Offsetting outcomes
Offsetting deaths and offsetting years of life lost potentially
caused by mother-to-child transmission of HIV through
indiscriminate breast-feeding are reported in Table 6.
Globally, offsetting deaths (242 000) potentially amount to
17% of those attributable to suboptimal breast-feeding in
the developing world, but are as high as 36% in Africa as a
whole and 48% in Eastern Africa. In Southern Africa,
however, deaths potentially caused by mother-to-child
transmission of HIV through breast-feeding are three times
as high as those attributable to suboptimal breast-feeding.
Discussion
Comparisons
Compared with other childhood risk factors, our estimate
of childhood deaths attributable to suboptimal breast-
feeding (1.45 million) is substantially lower than estimates
of deaths attributable to unsafe water, sanitation
Table 2 Comparison of polytomous risk estimates (odds ratios and 95% confidence intervals) for infant mortality due to selected causes,
by exposure category and age group. Estimates obtained from reanalysis of data from the studies reported in references 9 (Victora et al.)
and 11 (Arifeen et al.)
Cause of death, age group Study No breast-feeding
Partial
breast-feeding
Predominant/exclusive
breast-feeding*
Diarrhoeal disease, 0–5 months† Arifeen et al. 4.2 (0.5–34.3) 3.6 (1.6–8.1) 1.0
Diarrhoeal disease, 0–5 months Victora et al. 7.3 (3.7–14.4) 2.4 (1.1–5.2) 1.0
Lower respiratory tract infections, 0–5 months† Arifeen et al. 5.7 (1.2–26.5) 2.7 (1.4–5.4) 1.0
Lower respiratory tract infections, 0–5 months Victora et al. 4.7 (2.4–9.1) 2.8 (1.4–5.8) 1.0
Diarrhoeal disease, 6–11 months‡ Victora et al. 2.5 (1.1–5.7) 1.0 –
Lower respiratory tract infections, 6–11 months‡ Victora et al. 2.8 (1.0–7.7) 1.0 –
*Reference category with predominant and exclusive breast-feeding groups pooled.
†Reanalysed hazard ratios for infants aged 0–5 months, adjusted for selected confounding variables (S Arifeen, personal communication). Confounding
variables included child’s age and sex; mother’s age, education, height, place of birth, parity and history of previous child death; father’s education; and
household religion, monthly income and economic status.
‡ Estimates for this age group could not be calculated (S Arifeen, personal communication).
Odds ratio
0.1 1 10 100
Study % WeightOdds ratio(95% CI)
21.27 (7.58–59.67)0–1 months (Pakistan) 6.7
7.25 (3.26–16.10)0–1 months (Brazil) 8.2
2.53 (0.98–6.54)0–1 months (Philippines) 7.2
11.79 (2.78–50.03)2–3 months (Pakistan) 4.6
3.75 (2.29–6.15)2–3 months (Brazil) 10.3
5.07 (1.80–14.27)2–3 months (Philippines) 6.7
1.64 (0.20–13.45)4–5 months (Pakistan) 2.7
2.50 (1.39–4.47)4–5 months (Brazil) 9.7
2.56 (1.11–5.90)4–5 months (Philippines) 7.9
3.54 (0.32–39.22)6–8 months (Pakistan) 2.2
2.39 (1.20–4.74)6–8 months (Brazil) 9.0
1.46 (0.82–2.61)6–8 months (Philippines) 9.8
1.92 (0.67–5.47)9–11 months (Brazil) 6.6
1.21 (0.57–2.59)9–11 months (Philippines) 8.5
3.23 (2.18,4.78)Overall (95% CI)
Fig. 4 Comparison of age-specific crude risk estimates for no breast-feeding versus any breast-feeding in infants (all infectious causes of
death). Relative size of the squares indicates relative sample size (% weight) and the diamond shows the variance-weighted mean of the
squares (overall); CI – confidence interval
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Table 2.  Comparison of polytomous risk estimates (odds 
ratios and 95% confidence intervals) for infant 
mortality due to selected causes, by exposure 
category and age group. Estimates obtained from 
reanalysis of data from the studies reported in references 9 
Victora et al.) and 11 (Arifeen et al.) 
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Attributable years of life lost
Attributable years of life lost are calculated by multiplying attributable 
fractions by total years of life lost and are reported by cause and age group 
in Table 5. Globally, 117 m years of life lost are attributable to suboptimal 
breastfeeding  among children in developing countries.
Offsetting outcomes
Offsetting deaths and offsetting years of life lost potentially caused by mother-
to-child transmission of HIV through indiscriminate breastfeeding are 
reported in Table 6. Globally, offsetting deaths (242,000) potentially amount 
to 17% of those attributable to suboptimal breastfeeding in the developing 
world, but are as high as 36% in Africa as a whole and 48% in Eastern Africa. 
In Southern Africa, however, deaths potentially caused by mother-to-child 
transmission of HIV through breastfeeding are 3 times as high as those 
attributable to suboptimal breastfeeding. 
Discussion
Comparisons
Compared with estimates for other childhood risk factors, our estimate of 
childhood deaths attributable suboptimal breastfeeding (1.45 m) is substantially 
lower than estimates of deaths attributable to unsafe water, sanitation and hygiene 
(1.73 m) and less than half (39%) as high as childhood deaths attributable to 
underweight (3.75 m).1 Fatal adult risk factors are responsible for many more 
deaths: for example, high blood pressure (7.14 m) and cholesterol (4.42 m) 
jointly account for 11.6 m cardiovascular deaths worldwide.1
However, when outcomes are measured in terms of attributable years of life 
lost, suboptimal breastfeeding (117 m years) ranks second only to underweight 
(127 m years) and well ahead of the next largest childhood or adult risk factor 
studied by the WHO Collaborating Group (unsafe sex, 77 m years).1 High 
blood pressure (56 m years) and cholesterol (35 m years) jointly account for 91 m 
years of life lost.1 The change in the ranking of risk factors when compared with 
different outcome measures is due to the fact that deaths caused by suboptimal 
breastfeeding occur at earlier ages than those attributable to other risk factors. 
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Previously, we estimated that 52,000 infant deaths due to diarrhoeal disease 
and lower respiratory infections in Latin America and the Caribbean were 
attributable to suboptimal breastfeeding.30 Our present estimate for the 
same region, ages and causes is 43,000 deaths, lower by 18% but within the 
uncertainty interval of the former estimate (31,000−73,000). The difference 
can be explained by the fact that the relative risks used here are lower. 
Our estimate of childhood attributable deaths (1.45 m) appears to be higher 
than that published by the Bellagio Child Survival Group (1.3 m). However, 
as we include deaths during the second year of life and do not restrict the 
analysis to 42 countries,3 our total should be higher. Comparing only 
attributable infant deaths, our estimate (1.28 m), which does not account for 
deaths potentially caused by mother-to-child transmission of HIV, is lower 
Figure 4.  Comparison of age specific crude risk estimates for 
non-breastfeeding vs any breastfeeding in infants 
(all infectious causes of death). Relative size of squares 
indicates relative sample size (% weight) and the diamond 
shows the variance-weighted mean of the squares (overall).
Odds ratio
.1 1 10 100
Study  % Weight
 Odds ratio
 (95% CI)
 21.27 (7.58,59.67) 0-1 mos (Pakistan)   6.7
 7.25 (3.26,16.10) 0-1 mos (Brazil)   8.2
 2.53 (0.98,6.54) 0-1 mos (Philippines)   7.2
 11.79 (2.78,50.03) 2-3 mos (Pakistan)   4.6
 3.75 (2.29,6.15) 2-3 mos (Brazil)  10.3
 5.07 (1.80,14.27) 2-3 mos (Philippines)   6.7
 1.64 (0.20,13.45) 4-5 mos (Pakistan)   2.7
 2.50 (1.39,4.47) 4-5 mos (Brazil)   9.7
 2.56 (1.11,5.90) 4-5 mos (Philippines)   7.9
 3.54 (0.32,39.22) 6-8 mos (Pakistan)   2.2
 2.39 (1.20,4.74) 6-8 mos (Brazil)   9.0
 1.46 (0.82,2.61) 6-8 mos (Philippines)   9.8
 1.92 (0.67,5.47) 9-11 mos (Brazil)   6.6
 1.21 (0.57,2.59) 9-11 mos (Philippines)   8.5
 3.23 (2.18,4.78) Overall (95% CI)
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by 20,000 deaths than the figure published by the Bellagio Group. However, 
before accounting for the offsetting effects of HIV/AIDS, their figure is 1.5 
m deaths (i.e. 17% higher than our corresponding estimate). It is difficult to 
identify the reasons for this difference since the data sources and methods 
used by the Bellagio Group are not publicly available.3, Ref. 53 
and hygiene (1.73 million) and less than half (39%) the
childhood deaths attributable to underweight (3.75
million)1. Fatal adult risk factors are responsible for
many more deaths: for example, high blood pressure (7.14
million) and cholesterol (4.42 million) jointly account for
11.6 million cardiovascular deaths worldwide1.
However, when outcomes are measured in terms of
attributable years of life lost, suboptimal breast-feeding
(117 million years) ranks second only to underweight (127
million years) and is well ahead of the next largest
childhood or adult risk factor studie by the WHO
Collaborating Group (unsafe sex, 77 million years)1. High
Table 3 The fraction of mortality attributable to suboptimal breast-feeding by sub-region, age group and cause of death
Attributable fraction (%)
Infants , 6 months
of age
Infants 6–11 months
of age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 59 55 13 11 19
Eastern 52 48 8 7 16
Middle 59 54 6 5 16
Northern 57 58 29 25 29
Southern 66 67 35 31 30
Western 63 58 5 5 17
Asia (excluding Japan) 52 50 18 16 18
Eastern 46 45 21 18 18*
South-Central 52 48 11 9 14
South-Eastern 56 55 30 26 23
Western 63 62 34 30 33
Latin America and the Caribbean 61 65 42 38 34
Caribbean 61 65 42 38 34
Central America 64 68 42 37 33
South America 60 63 42 38 34
Developing countries 55 53 20 18 20
DD – diarrhoeal disease; LRTI – lower respiratory tract infection.
* Since exposure data for Eastern Asia were not available for the second year of life, the attributable fraction is the regional average attributable fraction for
the age group.
Table 4 Numbers of deaths attributable to suboptimal breast-feeding, by sub-region, age group and cause of death
Attributable deaths (000 s)
Infants , 6 months
of age
Infants 6–11 months
of age
Children 12–23
months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 197.0 255.7 7.4 7.1 104.5
Eastern* 68.2 113.0 2.7 2.3 32.6
Middle 30.1 35.8 1.1 0.6 18.0
Northern* 17.8 19.6 1.2 1.7 6.3
Southern 7.4 2.4 0.6 0.3 3.9
Western 73.6 84.9 1.8 2.2 43.6
Asia (excluding Japan) 359.3 385.5 12.8 16.4 56.4
Eastern* 35.8 35.2 2.2 2.4 7.7‡
South-Central 265.6 304.3 6.2 8.8 33.7
South-Eastern 38.2 23.1 3.2 3.0 9.0
Western* 19.6 22.9 1.2 2.2 5.9
Latin America and the Caribbean 20.9 18.1 2.1 2.3 7.0
Caribbean* 2.9 2.2 0.2 0.3 1.3
Central America 4.5 5.7 0.5 0.6 2.0
South America 13.4 10.2 1.4 1.3 3.6
Developing countries† 577.2 659.3 22.3 25.8 167.8
DD – diarrhoeal disease; LRI – lower respiratory tract infection.
* A small number of developing countries were omitted as they are not member countries of the World Health Organization and basic demographic and epi-
demiological data were not available: Reunion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Administrative Region and Macau
(Eastern Asia); Gaza Strip (Western Asia); Guadeloupe, Martinique, Netherlands Antilles and Puerto Rico (Caribbean).
† The United Nations region Oceania (including developing countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea, Samoa, Solomon
Islands and Vanuatu) was omitted as exposure data were not available for these countries.
‡ Since exposure data for Eastern Asia were not available for the second year of life, the estimate of deaths is based on the regional average attributable
fraction for the age group.
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and hygiene (1.73 million) and less than half (39%) the
childhood deaths attributable to underweight (3.75
million)1. Fatal adult risk factors are responsible for
many more deaths: for example, high blood pressure (7.14
million) and cholesterol (4.42 million) jointly account for
11.6 million cardiovascular deaths worldwide1.
However, when outcomes are measured in terms of
attributable years of life lost, suboptimal breast-feeding
(117 million years) ranks second only to underweight (127
million years) and is well ahead of the next largest
childhood or adult risk factor studied by the WHO
Collaborating Group (unsafe sex, 77 million years)1. High
Table 3 The fraction of mortality attributable to suboptim l breast-feeding by sub-region, age group and cause of death
Attributable fraction (%)
Infants , 6 months
of age
Infants 6–11 months
of age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 59 55 13 11 19
Eastern 52 48 8 7 16
Middle 59 54 6 5 16
Northern 57 58 29 25 29
outhern 66 67 35 31 30
estern 63 58 5 5 17
Asia (excluding Japan) 52 50 18 16 18
Eastern 46 45 21 18 18*
South-Central 52 48 11 9 14
outh-Eastern 56 55 30 26 23
Western 63 62 34 30 33
Latin America and the Caribbean 61 65 42 38 34
Caribbean 61 65 42 38 34
Central Am rica 64 68 42 37 33
South America 60 63 42 38 34
Developing countries 55 53 20 18 20
DD – diarrhoeal disease; LRTI – lower respiratory tract infection.
* Since exposure data for Eastern Asia were not available for the second year of life, the attributable fraction is the regional average attributable fraction for
the age group.
Table 4 Numbers of deaths attributable to suboptimal bre st-feeding, by sub-region, age group nd cause of death
Attributable deaths (000 s)
Infants , 6 months
of age
Infants 6–11 months
of age
Children 12–23
months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 197.0 255.7 7.4 7.1 104.5
Eastern* 68.2 113.0 2.7 2.3 32.6
Middle 30.1 35.8 1.1 0.6 18.0
Northern* 17.8 19.6 1.2 1.7 6.3
outhern 7.4 2.4 0.6 0.3 3.9
estern 73.6 84.9 1.8 2.2 43.6
Asia (excluding Japan) 359.3 385.5 12.8 16.4 56.4
Eastern* 35.8 35.2 2.2 2.4 7.7‡
South-Central 265.6 304.3 6.2 8.8 33.7
outh-Eastern 38.2 23.1 3.2 3.0 9.0
Western* 19.6 22.9 1.2 2.2 5.9
Latin America and the Caribbean 20.9 18.1 2.1 2.3 7.0
Caribbean* 2.9 2.2 0.2 0.3 1.3
Central Am rica 4.5 5.7 0.5 0.6 2.0
South America 13.4 10.2 1.4 1.3 3.6
Developing countries† 577.2 659.3 22.3 25.8 167.8
DD – diarrhoeal disease; LRI – lower respiratory tract infection.
* A small number of developing countries were omitted as they are not member countries of the World Health Organization and basic demographic and epi-
demiological data were not available: Reunion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Administrative Region and Macau
(Eastern Asia); Gaza Strip (Western Asia); Guadeloupe, Martinique, Netherlands Antilles and Puerto Rico (Caribbean).
† The United Nations region Oceania (including developing countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea, Samoa, Solomon
Islands and Vanuatu) was omitted as exposure data were not available for these countries.
‡ Since exposure data for Eastern Asia were not available for the second year of life, the estimate of deaths is based on the regional average attributable
fraction for the age group.
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Table 3.  The fraction of mortality attributable to suboptimal 
bre st-feeding by sub-region, ag  group and cause of 
death 
Table 4.  Numbers of deaths attributa le to subopti al breast-
feeding, by sub-regi n, age group and cause of death 
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blood pressure (56 million years) and cholesterol (35
million years) jointly account for 91 million years of life
lost1. The change in the ranking of risk factors when
compared with different outcome measures is due to the
fact that deaths caused by suboptimal breast-feeding occur
at earlier ages than those attributable to other risk factors.
Previously, we estimated that 52 000 infant deaths due to
diarrhoeal disease and lower respiratory tract infections in
Latin America and the Caribbean were attributable to
suboptimal breast-feeding30. Our present estimate for the
same region, ages and causes is 43 000 deaths, lower by
18% but within the uncertainty interval of the former
estimate (31 000–73 000). The difference can be explained
by the fact that the relative risks used here are lower.
Our estimate of childhood attributable deaths (1.45
million) appears to be higher than that published by the
Bellagio Child Survival Group (1.3 million). However, as
we include deaths during the second year of life and do
not restrict the analysis to 42 countries3, our total should
be higher. Comparing only attributable infant deaths, our
estimate (1.28 million), which does not account for deaths
potentially caused by mother-to-child transmission of HIV,
is lower by 20 000 deaths than the figure published by the
Bellagio group. However, before accounting for the
offsetting effects of HIV/AIDS, their figure is 1.5 million
deaths (i.e. 17% higher than our corresponding estimate).
It is difficult to identify the reasons for this difference since
Table 5 Years of life lost attributable to suboptimal breast-feeding, by sub-region, age group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 15834 20541 617 587 8477
Eastern* 5478 9107 223 190 2644
Middle 2403 2871 90 51 1462
Northern* 1433 1582 100 142 513
Southern 597 189 51 22 320
Western 5923 6792 153 182 3539
Asia (excluding Japan) 28 980 31098 1070 1371 4576
Eastern* 2893 2866 188 200 626‡
South-Central 21 416 24533 520 733 2736
South-Eastern 3085 1853 265 254 730
Western* 1586 1845 97 184 483
Latin America and the Caribbean 1682 1459 179 190 569
Caribbean* 232 178 20 27 108
Central America 366 461 42 52 165
South America 1084 819 117 110 296
Developing countries† 46496 53097 1866 2148 13622
DD – diarrhoeal disease; LRTI – lower respiratory tract infection.
* A small number of developing countries were omitted as they are not member countries of the World Health Organization and basic demo-
graphic and epidemiological data were not available: Reunion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Adminis-
trative Region and Macau (Eastern Asia); Gaza Strip (Western Asia); Guadeloupe, Martinique, Netherlands Antilles and Puerto Rico
(Caribbean).
† The United Nations region Oceania (including the developing countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea,
Samoa, Solomon Islands and Vanuatu) was omitted as exposure data were not available for these countries.
‡Since exposure data for Eastern Asia were not available for the second year of life, the estimate of years of life lost is based on the regional
average attributable fraction for the age group.
Table 6 Offsetting deaths and years of life lost potentially
caused by mother-to-child transmission of HIV through indiscrimi-
nate breast-feeding, by sub-region. These estimates provide
an upper bound on the offsetting outcomes potentially caused
by full compliance with international infant feeding recomm-
endations
Region/sub-region
Offsetting
deaths (000 s)*
Offsetting years of
life lost (000 s)*
Africa 208.6 16240
Eastern 106.1 8255
Middle 17.6 1373
Northern 2.8 218
Southern 43.7 3401
Western 38.5 2994
Asia (excluding Japan) 31.7 2465
Eastern 3.1 239
South-Central 24.4 1898
South-Eastern 4.2 329
Western – –
Latin America
and the Caribbean
1.8 138
Caribbean – –
Central America – –
South America 1.8 138
Developing countries 242.1 18842
*Analysed for 32 selected high-prevalence countries in the developing
world: Burundi, Ethiopia, Kenya, Malawi, Mozambique, Rwanda, Uganda,
United Republic of Tanzania, Zambia, Zimbabwe (Eastern Africa); Angola,
Cameroon, Central African Republic, Democratic Republic of the Congo
(Middle Africa); Sudan (Northern Africa); Botswana, Lesotho, Namibia,
South Africa, Swaziland (Southern Africa); Burkina Faso, Coˆte d’Ivoire,
Ghana, Guinea, Nigeria (Western Africa); China (Eastern Asia); India
(South-Central Asia); Indonesia, Myanmar, Thailand, Vietnam (South-East-
ern Asia); Haiti (Caribbean).
JA Lauer et al.680
blood pressure (56 million years) and cholesterol (35
million years) jointly account for 91 million years of life
lost1. The change in the ranking of risk factors when
compared with different outcome measures is due to the
fact that deaths caused by suboptimal breast-feeding occur
at earlier ages than those attributable to other risk factors.
Previously, we estimated that 52 000 infant deaths due to
diarrhoeal disease and lower respiratory tract infections in
Latin America and the Caribbean were attributable to
suboptimal breast-feeding30. Our present estimate for the
same region, ages and causes is 43 000 deaths, lower by
18% but within the uncertainty interval of the former
estimate (31 000–73 000). The difference can be explained
by the fact that the relative risks used here are lower.
Our estimate of childhood attributable deaths (1.45
million) appears to be higher than that published by the
Bellagio Child Survival Group (1.3 million). However, as
we include deaths during the second year of life and do
not restrict the analysis to 42 countries3, our total should
be higher. Comparing only attributable infant deaths, our
estimate (1.28 million), which does not account for deaths
potentially caused by mother-to-child transmission of HIV,
is lower by 20 000 deaths than the figure published by the
Bellagio group. However, before accounting for the
offsetting effects of HIV/AIDS, their figure is 1.5 million
deaths (i.e. 17% higher than our corresponding estimate).
It is difficult to identify the reasons for this difference since
Table 5 Years of life lost attributable to suboptimal breast-feeding, by sub-region, age group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 15834 20541 617 587 8477
Eastern* 5478 9107 223 190 2644
Middle 2403 2871 90 51 1462
Northern* 1433 1582 100 142 513
Southern 597 189 51 22 320
Western 5923 6792 153 182 3539
Asia (excluding Japan) 28 980 31098 1070 1371 4576
Eastern* 2893 2866 188 200 626‡
South-Central 21 416 24533 520 733 2736
South-Eastern 3085 1853 265 254 730
Western* 1586 1845 97 184 483
Latin America and the Caribbean 1682 1459 179 190 569
Caribbean* 232 178 20 27 108
Central America 366 461 42 52 165
South America 1084 819 117 110 296
Developing countries† 46496 53097 1866 2148 13622
DD – diarrhoeal disease; LRTI – lower respiratory tract infection.
* A small number of developing countries were omitted as they are not member countries of the World Health Organization and basic demo-
graphic and epidemiological data were not available: Reu ion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Adminis-
tr tive Region and Macau (Eastern Asia); Gaza Strip (Western Asia); G adeloupe, Martinique, Netherl ds A tilles and Puert Rico
(C ribb an).
† The U ited Nations region Oceania (including the dev lopi g countries Guam, Fiji, French Polynesia, New Caledoni , Pap a New Guinea,
Samoa, Solomon Islands and Vanuatu) was omitted as exposure data were not available for these countries.
‡Since exposure data for E stern Asia were not available for the second year of lif , t e estimate of years of life lost is b sed on the regional
verage attributable fraction for the ge group.
Table 6 Offsetting deaths and years of life lost potentially
caused by mother-to-child transmission of HIV through indiscrimi-
nate breast-feeding, by sub-region. These estimates provide
an upper bound on the offsetting outcomes potentially caused
by full compliance with international infant feeding recomm-
endations
Region/sub-region
Offsetting
deaths (000 s)*
Offsetting years of
life lost (000 s)*
Africa 208.6 16240
Eastern 106.1 8255
Middle 17.6 1373
Northern 2.8 218
Southern 43.7 3401
Western 38.5 2994
Asia (excluding Japan) 31.7 2465
Eastern 3.1 239
South-Central 24.4 1898
South-Eastern 4.2 329
Western – –
Latin America
and the Caribbean
1.8 138
Caribbean – –
Central America – –
South America 1.8 138
Developing countries 242.1 18842
*Analysed for 32 selected high-prevalence countries in the developing
world: Burundi, Ethiopia, Kenya, Malawi, Mozambique, Rwanda, Uganda,
United Republic of Tanzania, Zambia, Zimbabwe (Eastern Africa); Angola,
Cameroon, Centr l African Republic, De ocratic epublic of the Congo
(Middle Africa); Sudan (Northern Africa); Botswa a, Lesotho, N mibia,
S uth Africa, Swaziland (Southern Afric ); Burkina Faso, Coˆte d’Ivoire,
Ghana, Guinea, Nigeria (Western Africa); China (Eastern Asia); India
(South-Central Asia); Indon sia, My nmar, Th iland, Vietnam (South-East-
ern Asia); Haiti (Caribbean).
JA Lauer et al.680
blood pressure (56 million years) and cholesterol (35
million years) jointly accou t for 91 million years of life
lost1. The change in the ranking of risk factors when
compared with differ nt outcome measures is due to the
fact that deaths caused by suboptimal breast-feeding occur
at earlier ages than those attributable to other risk factors.
Previously, we estimated that 52 000 infant deaths due to
diarrhoeal disea e and lower respirat ry tract infections in
Latin America and the Caribbean were attributable to
suboptimal breast-feeding30. Our present estimate for the
same region, ages and causes is 43 000 deaths, lower by
18% b t wi h the uncertain y interval of the former
estimate (31 000–73 000). The difference can be explained
by th fact that the relative risks used here are lower.
Our estimate of childhoo tributable deaths (1.45
million) app ars to be higher t an that published by the
Bellagio Child Survival Group (1.3 million). However, as
we include d aths during the second year of life and do
not restrict the analysis to 42 c untries3, our total should
be higher. Comparing only at ributable infant deaths, our
est mate (1.28 millio ), which does not account for deaths
potentially caused by mother-to-child transmission of HIV,
is lower by 20 000 deaths than the figure published by the
Bellagio group. However, before accounting for the
offsetting effects of HIV/AIDS, their figure is 1.5 million
deat s (i.e. 17% higher tha our corresponding estimate).
It is difficult to identify e reasons for this difference since
Tab e 5 Years of life lost attributa le to suboptimal breast-feeding, by sub-region, ag group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 15834 20541 617 587 8477
Eastern* 54 8 9107 223 190 2644
Middle 2403 2871 90 51 1462
Northern* 1433 1582 100 142 513
Southern 5 7 89 51 22 320
Western 5 3 6792 153 182 3539
Asia (excluding Japan) 28 0 31 98 1070 1371 4576
Eastern* 2893 2 66 188 200 626‡
South-Central 21 416 24533 520 733 2736
South-Eastern 3085 1853 265 254 730
Western* 1586 1845 97 184 483
Latin America and the Caribbean 1682 1459 179 190 569
Caribbean* 232 178 20 27 108
Central America 366 461 42 52 165
South America 1084 819 117 110 296
D veloping countries† 46496 53097 1 66 2148 13622
DD – diarrhoeal disea e; LRTI – lower respiratory tract infection.
* A small umber of dev loping countries were omi ted as they are not member countries of the World Health Organization and basic demo-
graphic and epidemiol gic l data w re not available: Reunion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Adminis-
trative Region a d M cau (E ste n Asia); Gaza Strip (Western Asia); Guad loupe, Martinique, Netherlands Antilles and Puerto Rico
(Caribbean).
† The United Nations reg on Oceania (including the developing countries Guam, Fiji, French Poly esia, New Caled nia, Papua New Guinea,
Samo , Solomon Islands and Vanuatu) was omi ted as exposure data were not available for these countries.
‡Since exposure data for Eastern Asia were not available f r the second y ar of lif , the estimate of years f life lost s based on the regional
average attributabl fraction for the ag group.
Table 6 Offsetting deaths and years of life lost potentially
caused by mother-t -child transmission of HIV through indiscrimi-
nate breast-feeding, by sub-region. These stimates provide
an upper bound on he offsetting outcome potentially caus d
by full compli nce with i ternational infant feeding recomm-
endations
Region/sub-region deaths (000 s)*
Offsetting years of
life lost (000 s)*
Africa 208.6 16240
Eastern 106.1 8255
Middle 17.6 1373
Northern 2.8 218
Southern 43.7 3401
Western 38.5 2994
Asia (excluding Japan) 31.7 2465
Eastern 3.1 239
South-Central 24.4 1898
South-Eastern 4.2 329
Western – –
Latin America
and the Caribbean
1.8 138
Caribbean – –
Central America – –
South America 1.8 138
D veloping countries 242.1 18842
*Analysed for 32 s lected high-prevalence countries in the developing
world: Burundi, Ethiopia, Kenya, Mala i, Mozambique, Rwanda, Uganda,
United Republic of Tanz nia, Zambia, Zimb bwe (Eastern Africa); Angola,
Cameroon, Central African Republic, Democratic Republic of the Congo
(Middle Africa); Sudan (Northern Africa); B tswana, Lesotho, Namibia,
South Africa, Swaz land (Southern Africa); Burkina Faso, Coˆte d’Ivoire,
Ghana, Guine , Nigeria (West rn Africa); China (Eastern Asia); India
(South-Central Asia); Indonesi , Myanmar, Thailand, Vietnam (South-East-
ern Asia); Haiti (Caribbean).
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blo d pressure (56 milli n years) and cholesterol (35
million years) joi tl ccount for 91 million years of life
lost1. The change in the ranking of risk factors when
compared wit different outcome measures is due to the
fact that deaths caused by suboptimal breast-feeding occur
arl er ages than those t ributable to other risk factors.
Pr viously, we estimate that 52 000 infant deaths due to
diarrho al disease and lower respiratory tract infections in
L t n America and the Caribbean were attributable to
suboptimal breast-feeding30. Our present estimate for the
same region, ag s and causes is 43 000 deaths, lower by
18% but within the uncertainty interval of the former
estimat (31 000–73 000). The difference can be explained
by the fact that the re ative risks used here are lower.
Our estimate of childhood attributable deaths (1.45
million) appears to be higher than that published by the
Bellagio Child Survival Group (1.3 million). However, as
we include eaths during the second year of life and do
not restrict the analysis to 42 countries3, our total should
be higher. Comp ring only attributable infant deaths, our
estimat (1.28 million), which does not account for deaths
potentially caused by mother-to-child transmission of HIV,
is lower by 20 000 deaths than the figure published by the
Bellagi g oup. Howeve , b fore accounting for the
offsetting effects of HIV/AIDS, their figure is 1.5 million
deaths (i.e. 17% higher than our corresponding estimate).
It is difficult o identify th reasons for this difference since
Table 5 Years of life lo t at ributable to suboptimal breast- eeding, by sub-region, age group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 15834 20 41 617 587 8477
Eastern* 5478 9 07 223 190 2644
Middle 2403 287 90 51 1462
Northern* 1433 158 100 142 513
Southern 597 189 51 22 320
Western 5923 679 153 182 3539
Asia (excluding Japan) 28 980 31098 1070 1371 4576
Eastern* 2893 2866 188 200 626‡
South-Central 21 416 245 520 733 2736
South-Eastern 3085 18 3 265 254 730
Western* 1586 1845 97 184 483
L tin America and the Caribbean 1682 1459 179 190 569
Caribbean* 232 178 20 27 108
Central America 366 461 42 52 165
South America 1084 8 9 117 110 296
Developing countries† 46496 53097 1866 2148 13622
DD – diarrhoeal disease; LRTI – lower respiratory tract infection.
* A small number of veloping countries w r mitted as they are n t mem er ountries of the Worl Health Organization and basic demo-
graph c and epidemiological da were not available: Reunion (Eastern Africa); Wester Sahara (Northern Africa); Hong Kong Special Adminis-
trat ve R gi n and Macau (East rn Asia); Gaza Strip (Western Asi ); Guadeloupe, Martiniq , Netherlands Antilles and Puerto Rico
(Caribbean).
† The United Na ions r gi n O ea ia (including the d veloping cou tries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea,
S moa, Solomon Islands and Vanu tu) wa omitted a exposur data w re not available for these countries.
‡Since xposure d t fo East rn Asia w re n t av il bl or th econd year of life, the estimate of years of life lost is based on the regional
average attributable fraction for the ag group.
Tab e 6 Offsetting deaths a d ears of life lost potentially
caused by mother to-child transmission of HIV through indiscrimi-
nate br ast-fe ding, by ub-region. These estimates provide
an upper bound on the offs tting outcom s potentially caused
by full compliance w th international infant feeding recomm-
endations
Region/ ub-region
Offsetting
deaths (000 s)*
Off tting ye rs of
life lost (000 s)*
Africa 208.6 16240
Eastern 106.1 8255
Middle 17.6 1373
Northern 2.8 218
Southern 43.7 3401
Western 38.5 2994
Asia (excluding Japan) 31.7 2465
Eastern 3.1 239
South-Central 24.4 1898
South-Eastern 4.2 329
Western – –
Latin America
and the Caribbean
1.8 138
Caribbean – –
Central America – –
South America 1.8 138
Developing countries 242.1 18842
*Analysed for 32 selected high-prevalence countries in the developing
world: Burundi, Ethiopia, Kenya, M lawi Mozambique, Rwanda, Uganda,
Unite R public of Tanzania, Zambia, Zimbabwe (Eastern Africa); Angola,
C mero n, Central African Republic, Democratic Republic of the Congo
(Middle frica); Sudan (Northern Africa); Botswana, Lesotho, Namibia,
South Africa, Swaziland (South rn Africa); Burkina Faso, Coˆte d’Ivoire,
Ghana, Guine , Nigeria (We tern Africa); China (Eastern Asia); India
(South-Centr l Asi ); Indonesia, Myanmar, Thailand, Vietnam (South-East-
ern si ); Haiti (Caribbean).
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blood pressure (56 million years) and cholesterol (35
million years) jointly account for 91 million years of life
lost1. The change in the ranking of risk factors when
compared with different outcome measures is due to the
fact that deaths caused by suboptimal breast-feeding occur
at earlier ages than those attributable to other risk factors.
Previously, we estimated that 52 000 infant deaths due to
diarrhoeal disease and lower respiratory tract infections in
Latin America and the Caribbean were attributable to
subopti al breast-feeding30. Our present estimate for the
same region, ages and causes is 43 000 deaths, lower by
18% but within the uncertainty interval of the former
estimate (31 000–73 000). The difference can be explained
by the fact that the relative risks used here are lower.
Our estimate of childhood attributable deaths (1.45
million) appears to be higher than that published by the
Bellagio Child Survival Group (1.3 million). However, as
we include deaths during the second year of life and do
not restrict the analysis to 42 countries3, our total should
be higher. Comparing only attributable infant deaths, our
estimate (1.28 million), which does not account for deaths
potentially caused by mother-to-child transmission of HIV,
is lower by 20 000 deaths than the figure published by the
Bellagio group. However, before accounting for the
offsetting effects of HIV/AIDS, their figure is 1.5 million
deaths (i.e. 17% higher than our corresponding estimate).
It is difficult to identify the reasons for this difference since
Table 5 Years of if s ttri utabl to suboptimal breast-feeding, by sub-region, age group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12–23 months of age
Region/sub-region DD LRTI DD LRTI All causes
Africa 1583 20541 617 587 8477
Eastern* 5478 9107 223 190 2644
Middle 2403 2871 90 51 1462
Northern* 143 1582 100 142 513
Southern 597 189 51 22 320
Western 592 6792 153 182 3539
Asia (excluding Ja a ) 28 980 31098 1070 1371 4576
Eastern* 2893 2866 188 200 626‡
South-Centr l 21 41 24533 520 733 2736
South-Easte 3085 1853 265 254 730
Western* 1586 1845 97 184 483
Latin America nd the r bbe n 1682 1459 179 190 569
Caribbean* 232 178 20 27 108
entral America 36 461 42 52 165
South America 1084 819 117 110 296
Developing co ntri s† 6 49 53097 1866 2148 13622
DD – diarrhoeal dis as ; RTI – l er respiratory tract infection.
* A small number of dev l pi g c unt ies were itted as they are not member countries of the World Health Organization and basic demo-
graphic and epide i gi l d t e t v il ble: Reunion (Eastern Africa); Western Sahara (Northern Africa); Hong Kong Special Adminis-
trative Region d M c u (E s n As ); Gaza Str p (Western Asia); Guadeloupe, Martinique, Netherlands Antilles and Puerto Rico
(Caribbean).
† The United N t n g o Oc a i (i cl i g th d veloping countries Guam, Fiji, French Polynesia, New Caledonia, Papua New Guinea,
Samoa, Solomon Isl d d V a ) w s omit d as exposure data were not available for these countries.
‡Since exposur da a fo E ste n Asi n t vailab e for the second year of life, the estimate of years of life lost is based on the regional
average attribut ble ct n f the age group.
Table 6 Offsetting d a hs ars f lif lost potentially
caused by mother-to- ild t i io f HIV thr ugh indiscrimi-
nate breast-feedi g, y s r gi n. The timates provide
an upper bound on t f tt g u comes potentially caused
by full complianc w th i er a i l i fan fe ding recomm-
endations
Region/sub-region
O fs t in
ath 00 s *
Offsetting years of
life lo t (000 s)*
Africa 2 .6 16240
Eastern 10 .1 8255
Middle .6 1373
Northern .8 218
Southern .7 3401
Western 3 .5 2994
Asia (excluding Japa ) 3 . 2465
Eastern .1 239
South-Central 2 .4 1898
South-Eastern .2 329
Western – –
Latin America
and the Caribbean
.8 138
Caribbean – –
entral Americ – –
South America .8 138
Developing countri s 2 .1 18842
*Analysed for 32 s ct hi h-p val ce u t ies in the developing
world: Burundi, Ethiopia, eny l i, Moz bique, Rwa da, Uganda,
United Republic of Tanza i Z i Zi babw (Ea tern Africa); Angola,
Cameroon, Central Afric Re ublic, De cratic R publi of the Congo
(Middle Africa); Sudan ( o th n Af ic ); B tswana, L s tho, Namibia,
South Africa, Swazila d S ut er Af ca); Burk a Faso, Coˆte d’Ivoire,
Ghana, Guinea, Nigeri (W st r Afr ca); Chi a (E st r Asia); India
(South-Central Asia); Ind e i My m r, T il d, Vietnam (South-East-
ern Asia); Haiti (Caribb .
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blood pressure (56 millio years) and cholesterol (35
million years) jointly a co t for 91 million years of life
lost1. T e change in the king of risk factors when
compared with diff rent o ome measures is due to th
fact th deaths caused by s ptimal breast-feeding occur
at e rli r ages than those at ibutable to other risk factors.
Previously, we estimated at 52 000 infa t dea hs due to
diarrhoeal dis ase and low respiratory t ac infections in
Latin America and the C i bean were attributable to
suboptimal breast-feeding3 ur pres nt estimate for he
same region, ages and cau s is 43 00 deaths, lower by
18% but within the uncer inty interval of the former
estimate (31 000–73 000). T differ nce an be explained
by the fact that the relative sks used here a lower.
Our es imate of childh d attributable deaths (1.45
million) appears to be hig r than that published by the
Bellagio Child Survival Gro (1.3 million). However, as
we include deaths during t second year of life and do
not restrict the analy is to countries3, our total shou d
b higher. Comparing only ttributable infant dea hs, our
estimate (1.28 million), whi does not account for deaths
potentially caused by moth -to-child transmis ion of HIV,
is lower by 20 000 deaths th the figure published by the
Bellagi group. However, efore accounting for the
offsetting effects of HIV/AI S, their figure is 1.5 million
deaths (i.e. 17% higher tha ur corresponding estimate).
It is difficult to identify the r sons for this differenc since
Ta l 5 Y a s of life l st attributable to suboptimal breast-feeding, by sub-region, a e group and use of death
Attributable years of life lost (0 s)
Infants
, 6 months of age
Infants
6–11 months of
age
Children
12– 3 months of age
Re ion/sub-region DD LRTI DD LRTI All causes
Af ica 15834 20541 617 587 8477
astern* 5478 9107 223 190 2644
iddle 2403 2871 90 51 1462
orthern* 1433 1582 100 142 513
outhern 597 189 51 2 320
estern 5923 6792 153 182 3539
As a (excluding Japan) 28 980 31098 1070 1371 4576
astern* 2893 2866 188 2 0 626‡
outh-Central 21 416 24533 520 7 3 2736
outh-Eastern 3085 1853 265 254 730
estern* 1586 1845 97 184 483
La in Am rica and the Caribbean 1682 1459 179 190 569
aribbean* 232 178 20 27 108
entral America 366 461 42 52 165
outh America 1084 819 117 10 296
De eloping countries† 46496 53097 1866 2148 13622
D – i rrho l dis ase; LRTI – lower respirat ry tract infection.
* A all u e f v l ping cou tri s were omitted as hey are not membe countries of the World Heal Organization and basic demo-
gr h c d pid mi logic l dat were ot available: R u ion (Eastern Africa); Western S hara (Northern Afri ); Hong Kong Special Adminis-
tr iv Regio an M cau (E t r Asia); Gaza Strip (Western Asia); Guadeloupe, Martinique, Nether nds Antilles and Puerto Rico
(C ribbea ).
† T Unit d ti n r g on Oceani ( nc uding the developing countries Guam, Fiji, French Polynesia, New aledonia, Papua New Guinea,
S , So m n I l nds and Vanu tu) was omitt d as exposure data were not available for these countries.
‡S nc xp ur d t r E stern Asia were no available for the sec nd y ar of life, the es imate of years of life lost is based on the regional
v r g t rib table fraction for the age group.
Table Off etting de t and year of life lost potentially
caused y m ther-t - hild transmissio f HIV th ough indiscrimi-
ate b a t-f ding, by sub-region. Th se estimates provide
a upp r b u d the of s ing ou comes potentially caused
by full o pli c with i ational infant feeding recomm-
ndatio
Region/ ub-region
O fsetting
at s ( 00 )*
Offsetting years of
life lost (000 s)*
Africa 208.6 16240
Eastern 106.1 8255
Middl 17.6 1373
North rn 2.8 218
Southern 4 .7 3401
West rn 38.5 2994
Asi (e cluding Jap n) 31.7 2465
Eastern 3.1 239
South-C ntr l 24.4 1898
South-Eastern 4.2 329
West rn – –
L tin A erica
nd the r bb an
1.8 138
Carib ean – –
Centr l Am ric – –
South Am rica 1.8 138
Develo ing cou tries 242.1 18842
*A aly for 32 s lecte high-prevalence countri s in the developing
world: B rundi Ethiopi , Keny , Malawi, Mozambique, Rw nda, Uganda,
U ted R publ c f T zania, Zambia, Zim abw (Eastern Africa); Angola,
ro C ntral African Rep blic, Democratic Republic f the Congo
(Middle fr ca); Suda (Northern Africa); Botswan , Lesotho, Namibia,
outh ic , Sw zil nd (S ut rn frica); Burkina Faso, Coˆte d’Ivoire,
h , uine , Ni eri (We t r Africa); China (Eastern Asia); India
(So th- tr l A i ); ndon sia, Myanmar, Thailand, Vietnam (South-East-
e n A ia ; Hait (Caribb a ).
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blood pr sure (56 million years) and cholesterol (35
mill ye s) jointly account for 91 million y ars f life
lost1. Th change in the ranking of risk factors when
co pared wit different outcome measures is due to the
fact t d aths caus d by s b ptimal breast-fee ing ccur
t earli r ges than those attributable to other risk factors.
Previously, we estimated that 52 000 infant deaths due to
d a rhoeal dis ase and lower respiratory tract infections in
L ti America and the Caribbean were attributable to
subopti al br ast-feeding30. Our present estimate for the
am r gi n, ag s an causes is 43 000 d aths, lower by
18% but within the uncertainty interval of the former
estimat (31 000–73 000). The difference can be explained
by th f ct that the relative risks us d here are lower.
O r timate of childhood attributable deaths (1.45
million) appears to be higher than that published by the
Bel agi Child Survival Group (1.3 million). However, as
w i cl d aths during the second year of life and do
n restrict t e analysis to 42 countries3, our total should
high r. Comparing only attributable infant deaths, our
stim te (1.28 million), which does not account for deaths
po ntially caused by mot er-to-child transmission of HIV,
is lower b 20 000 deaths than the figure published by the
B ll o roup. However, before acco nting for t
ffs tti g effects of HIV/AIDS, their figure is 1.5 million
deat s ( . . 17% higher than our corresponding estimate).
It is d ficult to identify the reasons for this difference since
Tab 5 Year f i l s t ib t bl to suboptimal reast-fee ing, by sub-region, age group and cause of death
Attributable years of life lost (000 s)
Infants
, 6 months f age
Infants
6–11 months of
age
Children
12–23 months of age
Reg n/sub- gio DD RTI DD LRTI All causes
Afric 5 834 20541 617 587 8477
E t rn* 4 8 07 223 190 2644
M dle 2 3 2871 90 51 1462
N th rn* 143 582 10 142 513
S t er 5 7 1 9 51 2 320
W ster 5923 6792 1 3 182 3539
Asia xclud ng J p ) 8 80 3 8 1070 1371 4 76
E ter * 8 3 866 188 200 626‡
S th-C tr l 21 16 24533 520 733 2736
t -E t n 3085 85 265 254 0
W st rn* 15 6 45 97 18 483
Lati mer c nd t Caribbe 682 59 179 90 569
C i b * 23 178 20 27 108
tr l A ic 3 6 461 42 52 65
S th A ri a 1084 19 117 110 296
Dev loping untri s† 464 6 53 97 1866 2 48 13622
D diarrh e l is ; LRTI – l r spir tor tract i f ction.
* A s ll nu f v l pin o ntri s w r itted as th y ar o member countries of the World Health Organization and basic demo-
grap ic and i l i l t w r not v il bl : R ni (E s rn Africa); We tern Sahara (Northern Africa); Ho g Kong Speci l Adminis-
trativ Regio (E t rn Asi ); G za Stri (West rn sia); Guadel pe, Martinique, Netherl nds Antilles and Puerto Rico
(C ri an).
† Th ited r g O ia (i clu ing the dev l ping co ntries Gu m, Fiji, Fre ch Polynesia, New Caledonia, Papua New Guinea,
Sam , Solo I l V u t ) was omitt d xp ur dat w r ot vailable for t ese countries.
‡ in exp s E si re n t av ila l for t e s cond year of life, th estimate f years of life lost is based on the regional
aver attri t l f cti f r t group.
Table 6 ffs tti g a s ars of life l st pot ntially
c us d b oth -t - i t i i n of HIV thr ugh i di crimi-
nate br t-f , y b-r i . Thes e timat s provide
an upper ou d ff ti g tco s tentially caused
by full c pli w t i t i l infa t feeding omm-
endation
Region/s -regi
Off e in
d ( 0 s)*
Offset in ye rs f
life lost (000 )*
Africa 208 16240
Easter 1 6 8 55
Middl 17 1373
Northe 2 218
S ut 4 3401
Wester 38 2994
Asia (exc ding J p n) 1 2465
Easter 239
South- ntra 2 1898
t - ster 329
Wester – –
Latin Am ica
and the ri b
138
C rib n – –
entral meric
South ric 1 138
Devel pi cou t i 42 18842
*Analysed for 32 l ct hi -p v l c cou tri s in he dev loping
world: Bur di, Eth K y , M l wi M z mbiqu , R anda, Ugan a,
United Re blic i , Z mbi , Zi w (E stern Afric ); Angol ,
Camero n ent l f R b c, D r tic R public of the Congo
(Middle f ica); u ( rth r Afric ); Botsw na, Lesotho, Namibia,
South Afri , w zil d (S th Afri ); Burki a Faso, Cˆ e d’Ivoire,
Ghan , G inea, N g s fri ); Chi (Ea t rn As a); India
(Sout -Ce ral Asi ; I , My ma , Th il nd, Vietnam (So th-East-
ern Asia); ti (C r b ).
JA Lauer et al.680 Table 5.  Years of life lost attributable to suboptimal breast-
feeding, by sub-region, age group and cause of death 
Tabl  5.  Ye rs of life l t t ributable to subopti al r st-
feeding, by s -regio , age gr up and caus  f death 
 l  for 32 selected hig -prevalenc  countries in th  dev loping wo ld: Burundi, Ethiopia, Kenya, Malawi, Mozambiqu , Rwa da, Uganda,United 
Republic of Tanzania, Zambia, Zimbabwe (Eastern Africa); Angola,C meroon, Central African Republic, Democratic Republic of the Congo (Middle Africa); 
Sudan (Northern Africa); Botswan , Lesoth , Namibi ,Sou h Africa, Swazil nd (Southern Africa); Burkina Faso, Côte d’Ivoire, Ghana, Guinea  Nig r a 
(Western Africa); Chin  (E stern Asia); Indi  (South-Centr l Asia); Indonesia, Myanmar, T ailand, Vietnam (South-Eastern Asia); Haiti (Caribbean).
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Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
Offsetting outcomes
Estimates of offsetting outcomes are sensitive to the estimated probability 
of HIV transmission in breastfeeding children of infected mothers, which 
could be as much as 33% higher or lower than the figure used here while 
still consistent with available evidence.15 Offsetting outcomes for individual 
subregions will also be sensitive to estimates of HIV prevalence among 
women of childbearing age.28 Furthermore, while pooled data from developed 
countries show 70% survival at 15-year follow up for seroconverters <5 years 
of age,29 corresponding values for developing countries are probably much 
lower, and we arbitrarily assumed survival to age 5. 
On the other hand, assuming an homogeneous risk of vertical transmission by 
breastfeeding status may overstate offsetting deaths.31 In addition, although 
WHO has estimated that 1.6 m babies are born each year to HIV-positive 
mothers,15 the independent-risk model we use here predicts that nearly 2 m 
babies are born annually to HIV-positive mothers in just 32 high-prevalence 
countries, in other words, possibly a substantial overestimate due to not 
accounting for the effect of seropositivity on fertility. Moreover, estimating 
vertical HIV transmission with cross-sectional breastfeeding prevalences such 
as those used here6 probably results in overestimates; nevertheless, since infants 
of infected mothers who breastfeed for less than one year are presumably 
exposed to some risk, we assumed all such infants face the same risk of HIV 
transmission as those who breastfeed for one full year. 
Substantial inter-regional heterogeneity in the relative magnitude of the benefits 
and harms of indiscriminate breastfeeding underscores that this important 
child-health intervention requires the sort of individual and setting-specific 
assessment recommended by WHO.13 Moreover, an ecological analysis like 
that reported here cannot precisely estimate the fatal outcomes that could 
be offset by HIV infection for the very reason that recommended practice 
depends on the mother’s HIV status and other individual- and setting-specific 
factors. 
Offsetting outcomes, however, establish an upper bound to fatal outcomes 
attributable to breastfeeding by HIV-positive mothers. Notably, even in the 
The time dimension in measurements of population health
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hypothetical case of breastfeeding without regard to HIV status, the offsetting 
outcomes would not alter the importance of suboptimal breastfeeding as a 
global risk factor. Without the possibility of being more precise, the estimate 
of fatal childhood outcomes attributable to non-compliance with international 
breastfeeding recommendations lies in the range 1.21−1.45 m deaths (98−117 
m years of life lost). The lower bound of this range represents a potential 
reduction in the global benefit of breastfeeding of nearly one-fifth (19%) 
compared with widely reported estimates of the number of deaths avoidable 
by improved breastfeeding prior to the explosion of the AIDS pandemic in 
Africa.32;33
Multi-causality
Recognizing the multiple causality of outcomes, double counting of deaths 
due to unsafe water, sanitation and hygiene and those due to suboptimal 
breastfeeding (both contributing to diarrhoeal disease), between suboptimal 
breastfeeding and underweight (both contributing to diarrhoeal disease 
and all-cause deaths in the second year of life), or between suboptimal 
breastfeeding and indoor air quality (both contributing to lower respiratory 
infections) cannot be excluded.17 The synergistic effect of selected childhood 
diseases and risk factors has moreover been highlighted.2 
Confounding and measurement error
As mothers in developing countries who breastfeed their babies tend to be 
poorer than those who do not, residual confounding by socio-economic 
status could result in underestimates of the risk of suboptimal breastfeeding 
due to clustering of common risk factors with poverty. However, other 
potential confounding factors could lead to overestimates: since babies born 
with higher birth weights are more likely to breastfeed, mothers’ failure to 
breastfeed underweight babies (i.e. with higher risk of mortality) may result 
in “selection bias”. 
One may further argue that, while our risk estimates are calculated relative 
to a baseline of “predominant breastfeeding”,9 we measure the prevalence 
of unexposed in terms of exclusive breastfeeding. However, we have argued 
in other work,6 on the basis of both internal and external validity criteria, 
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that infants reported in surveys as exclusively breastfed typically include a 
notably high proportion (ca. 15%) who are receiving other liquids or even 
solid foods. We believe it is consequently unlikely that the nominal exposure 
data derived from nationally representative surveys, on the one hand, and 
from epidemiological studies that form the basis of the estimates of risk of 
suboptimal breastfeeding, on the other, are inherently comparable despite 
their use of similar terms to describe breastfeeding status. On balance, 
therefore, assessment of the existence or net effect of bias due to confounding 
or measurement error is uncertain. 
Implications for developed countries
As childhood deaths due to diarrhoeal disease and lower respiratory infections 
are very rare in developed countries, and second-year childhood deaths even 
rarer,23;24;26 the present study is confined to developing countries. However, 
if outcomes were defined to include breastfeeding-attributable morbidity, 
developed and developing countries alike would have a substantial attributable 
burden of disease.34-36
Conclusions 
The age distribution of attributable outcomes reinforces the importance 
of emphasizing exclusive breastfeeding for infants ≤ 6 months of age. The 
substantial benefits of continued breastfeeding in the second year of life, 
moreover, highlight the importance of this neglected aspect of infant-and-
child feeding recommendations. 
The size of the gap between practice and recommendations is striking, 
especially considering that breastfeeding involves no out-of-pocket costs, that 
there exists universal consensus on best practices, and that implementing 
current international recommendations could save between 1.21 and 1.45 m 
lives (between 98 and 117 m years of life) among children in the developing 
world each year. Although the HIV/AIDS pandemic has substantially 
mitigated the benefits of universal (i.e. indiscriminate) breastfeeding, especially 
in parts of Africa, full compliance with current international breastfeeding 
recommendations remains one of the most important child health goals. 
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Moreover, breastfeeding is arguably cheaper and more readily implementable 
than interventions such as improvements in water, sanitation and hygiene, or 
in general nutritional status, since unlike so many interventions the principal 
barriers to improved breastfeeding are not to be found in the direct monetary 
costs of delivery. 
Nevertheless, breastfeeding, especially exclusive breastfeeding, imposes a time 
and energy cost on the mother, and may also have important indirect costs, 
such as the inability of breastfeeding mothers to participate in the wage-
earning workforce. Notwithstanding, virtually all mothers can breastfeed 
provided they have accurate information and support within their families 
and communities and from the health system. Recent findings from two 
experimental studies37;38 and one quasi-experimental one39 demonstrate that 
breastfeeding counselling given in hospitals and in the community is a cost-
effective way of increasing exclusive breastfeeding. A similar conclusion was 
reached by a systematic review of the effects of breastfeeding support.40
However, implementation of large-scale breastfeeding counselling 
programmes demands substantial resources and political commitment. 
Ideally, breastfeeding support would be provided as an integral part of routine 
health services for mothers. This implies the need to train health workers, 
lay and peer counsellors and certified lactation consultants who can help 
build mothers’ confidence, improve feeding technique and prevent or resolve 
problems. Similarly, women in paid employment require minimum enabling 
conditions to prolong the duration of exclusive breastfeeding, such as paid 
maternity leave, part-time work arrangements, on-site nurseries, facilities for 
expressing and storing breast milk and breastfeeding breaks.
A remaining challenge is to understand better the causes that determine the 
practice of exclusive breastfeeding in different settings. These include national 
breastfeeding policies; socio-economic and cultural factors such as medical 
attitudes, commercial advertising, family pressures, maternal work demands, 
women’s employment legislation and maternal beliefs; biological factors such 
as infant’s size, sex, growth rate, development, interest/desire and appetite and 
maternal lactation capacity; and the local epidemiology of HIV/AIDS. 
217
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
Acknowledgements
The views expressed are solely those of the authors and do not necessarily 
reflect the decisions or the stated policy of the World Health Organization. 
We are grateful to Shams Arifeen for re-analysing the data from Bangladesh 
and to Cesar G. Victora for guidance throughout the course of the research.
Competing interests
None declared.
Authors’ contributions
JAL and APB designed the study, analysed the data and results and drafted 
the manuscript. AJDB designed and interpreted the statistical methods used 
to re-analyse risk in the data from the Brazilian study. MdO drafted key 
manuscript sections and participated in the interpretation of data and results. 
All authors revised and approved the final manuscript.
The time dimension in measurements of population health
218
References
1.  The World Health Report 2002. Reducing risks, promoting healthy life. 
Geneva, Switzerland: World Health Organization, 2002.
2.  Black RE, Morris SS, Bryce J. Where and why are 10 million children 
dying every year? Lancet 2003;361:2226-34.
3.  Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many 
child deaths can we prevent this year? Lancet 2003;362:65-71.
4.  Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, 
Comparative Risk Assessment Collaborating Group. Selected 
major risk factors and global and regional burden of disease. Lancet 
2002;360:1347-60.
5.  Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, 
Murray CJ. Estimates of global and regional potential health gains from 
reducing multiple major risk factors. Lancet 2003;361:271-80.
6.  Lauer JA, Betrán AP, Victora CG, de Onis M, Barros AJ. Breastfeeding 
patterns and exposure to suboptimal breastfeeding among children in 
developing countries: review and analysis of nationally representative 
surveys. BMC Medicine 2004;2:26.
7.  WHO Collaborative Study Team on the Role of breastfeeding on the 
Prevention of Infant Mortality. Effect of breastfeeding on infant and 
child mortality due to infectious diseases in less developed countries: a 
pooled analysis. Lancet 2000;355:451-5.
8.  Brown KH, Black RE, Lopez de Romaña G, Creed de Kanashiro H. 
Infant feeding practices and their relationship with diarrhoeal and other 
diseases in Huascar (Lima), Peru. Pediatrics 1989;83:31-40.
9.  Victora CG, Vaughan JP, Lombardi C, Fuchs SMC, Gigante LP, Smith 
PG et al. Evidence for protection by breast-feeding against infant deaths 
from infectious diseases in Brazil. Lancet 1987;2:319-22.
10.  Hanson LA. Breast-feeding as a protection against gastroenteritis and 
other infections. Acta paediatrica scandinavica 1985;74:641-2.
219
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
11.  Arifeen SE, Black RE, Antelman G, Baqui AH, Caulfield LE, Becker S. 
Exclusive breastfeeding reduces acute respiratory infection and diarrhea 
deaths among infants in Dhaka slums. Pediatrics 2001;108:E67.
12.  Kramer, M. S. and Kakuma, R. The optimal duration of exclusive 
breastfeeding. A systematic review. WHO/NHD/01.08. 2002. Geneva, 
Switzerland, World Health Organization. 
13.  World Health Assembly. Infant and young child nutrition. Resolution 
WHA54.2 (document WHA54.2; available from: http://www.who.int/
gb/ebwha/pdf_files/WHA54/ea54r2.pdf). 2001. Geneva, Switzerland, 
World Health Organization. 
14.  The optimal duration of exclusive breastfeeding. Report of an expert 
consultation, Geneva, Switzerland, 28-30 March 2001. WHO/
NHD/01.09. 2002. Geneva, Switzerland, World Health Organization. 
15.  Global strategy for infant and young child feeding. Geneva, 
Switzerland: World Health Organization, 2003.
16.  Newell ML. Prevention of mother-to-child transmission of HIV: 
challenges for the current decade. Bulletin of the World Health 
Organization 2001;79:1138-44.
17.  Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S. 
Comparative quantification of health risks: Conceptual framework and 
methodological issues. Population Health Metrics 2003;1:1.
18.  Rothman KJ, Greenland S. Modern epidemiology. Philadelphia, USA: 
Lippincott Williams and Wilkins, 1998.
19.  Bradburn, M. J., Deeks, J. J., and Altman, D. G. Stata technical bulletin 
44 (sbe24). Internet communication of 8 January 2002 at web site 
http://www.stata.com. 2002. 
20.  Yoon PW, Black RE, Moulton LH, Becker S. Effect of not breastfeeding 
on the risk of diarrheal and respiratory mortality in children under 
2 years of age in Metro Cebu, The Philippines. American journal of 
epidemiology 1996;143:1142-8.
The time dimension in measurements of population health
220
21.  Hanson LA, Ashraf R, Karlber J, Lindbland BS, Jalil F. Breast feeding 
is a natural contraceptive and prevents disease and death in infants, 
linking infant mortality and birth rates. Acta paediatrica 1994;83:3-6.
22.  World Population Prospects. The 2000 Revision. New York: United 
Nations. Department of Economic and Social Affairs. Population 
Division, 2001.
23.  Murray, C. J., Lopez, A. D., Mathers, C. D., and Stein, S. The Global 
Burden of Disease 2000 project: aims, methods and data sources. (GPE 
Discussion paper No. 36). 2001. Geneva, Switzerland, World Health 
Organization. 
24.  Mathers, C. D., Stein, S., Ma Fat, D., Rao, C., Inoue, M., Tomijima, 
N., Lopez, A. D., and Murray, C. J. Global Burden of Disease 2000: 
Version 2 methods and results. (GPE Discussion paper No. 50). 2002. 
Geneva, Switzerland, World Health Organization. 
25.  The World Health Report 2003. Shaping the future. Geneva, 
Switzerland: World Health Organization, 2003.
26.  Lopez, A. D., Ahmad, O. B., Guillot, M., Inoue, M., Ferguson, B. 
D., and Salomon, J. A. Life tables for 191 countries for 2000: data, 
methods, results. GPE Discussion paper No. 40. 2001. Geneva, 
Switzerland, World Health Organization. 
27.  Kirkwood BR, Gove S, Rogers S, Lob-Levyt J, Arthur P, Campbell H. 
Potential interventions for the prevention of childhood pneumonia in 
developing countries: a systematic review. Bulletin of the World Health 
Organization 1995;73:793-8.
28.  UNICEF. http://www.unicef.org/infobycountry/.  2003.  Accessed 
December 4, 2003. 
29.  Collaborative Group on AIDS Incubation and HIV Survival including 
the CASCADE EU concerted Action. Time from HIV-1 seroconversion 
to AIDS and death before widespread use of highly-active antiretroviral 
therapy: a collaborative re-analysis. Lancet 2000;355:1131-7.
221
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
30.  Betrán AP, de Onis M, Lauer JA, Villar J. Ecological study of 
effects of breast feeding on infant mortality in Latin America. BMJ 
2001;323:303-6.
31.  Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence 
of infant-feeding patterns on early mother-to-child transmission of 
HIV-1 in Durban, South Africa: a prospective cohort study. Lancet 
1999;354:471-6.
32.   Infant and young child nutrition (progress and evaluation report; and 
status of implementation of the International Code of Marketing of 
Breast-milk Substitutes): Report by the Director-General. Document 
EB/9317. 2001. Geneva, Switzerland, World Health Organization. 
33.  Walker ARP, Adam FI. Breast-feeding in sub-Saharan Africa: outlook 
for 2000. Public Health Nutrition 2000;3:285-92.
34.  Silfverdal SA. Protective effect of breastfeeding on invasive 
Haemophilus influenzae infection: a case-control study in 
Swedish preschool children. International journal of epidemiology 
1997;26:443-50.
35.  Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz 
B. Risk factors for invasive pneumococcal disease in children: a 
population-based case-control study in North America. Pediatrics 
1999;103.
36.  Nafstad P. Breastfeeding, maternal smoking and lower respiratory tract 
infections. European respiratory journal 1996;9:2623-9.
37.  Morrow AL, Guerrero ML, Shults J, Calva JJ, Lutter C, Bravo J et 
al. Efficacy of home-based peer counselling to promote exclusive 
breastfeeding: a randomised controlled trial. Lancet 1999;353:1226-31.
38.  Haider R, Ashworth A, Kabir I, Huttly SR. Effect of community-
based peer counsellors on exclusive breastfeeding practices in Dhaka, 
Bangladesh: a randomised controlled trial. Lancet 2000;356:1643-7.
The time dimension in measurements of population health
222
39.  Lutter CK, Perez Escamilla R, Segall A, Sanghvi T, Teruya K, 
Wickham C. The effectiveness of a hospital based program to promote 
exclusive breastfeeding among low income women in Brazil. American 
journal of public health 1997;87:659-63.
40.  Sikorski, J., Renfrew, M. J., Pindoria, S., and Wade, A. Support for 
breastfeeding mothers (Cochrane Review). In: The Cochrane Library, 
Issue 1 . 2002.  Oxford: Update Software. 
223
Chapter 7 Deaths and years of life lost due to suboptimal breastfeeding 
 among children in the developing world: a global ecological risk assessment
Annex: Supplementary material
Table A1. Prevalence of breastfeeding indicators, by subregion 
and age groups.6
Region/subregion Breastfeeding prevalence estimates (%)
Infants <6 months of age Infants 6-11 months 
of age
Children 12-23 months 
of age
Exclusive Partial None Continued None Continued None
Africa 24.9 71.2 3.9 91.8 8.2 69.9 30.1
Eastern 41.4 56.1 2.4 95.1 4.9 75.6 24.4
Middle 19.4 79.6 1.0 96.6 3.4 76.8 23.2
Northern 36.5 53.9 9.6 77.7 22.3 49.6 50.4
Southern 8.2 75.7 16.0 70.4 29.6 46.7 53.3
Western 6.1 92.1 1.8 96.8 3.2 74.9 25.1
Asia 44.9 50.7 4.5 87.5 12.5 72.4 27.6
Eastern* 58.6 36.3 5.1 85.7 14.3 ND ND
South-Central 42.1 55.3 2.6 93.3 6.7 78.8 21.2
South-Eastern 37.5 55.0 7.5 76.7 23.3 61.7 38.3
Western 17.7 72.0 10.3 71.3 28.7 37.3 62.7
Latin America  
and the Caribbean 30.8 51.2 18.0 59.9 40.1 36.5 63.5
Caribbean 25.8 63.8 10.4 64.6 35.4 34.2 65.8
Central America 23.4 55.0 21.6 60.2 39.8 37.0 63.0
South America 35.1 48.0 16.9 59.3 40.7 36.4 63.6
Developing countries 38.7 55.7 5.6 85.8 14.2 68.3 31.7
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Table A2. Odds ratios of suboptimal breastfeeding and 
selected control variables for infant mortality  
due to lower respiratory infections among infants 
0-5 months of age.
Variable Odds ratio 95% Confidence 
interval
P-value
Le
ve
l 1
Father not living with child 2.0 1.1 - 3.6 0.03
Income per capita 0.02
1st  quartile —
2nd quartile 0.7 0.4 - 1.3
3rd quartile 0.9 0.5 - 1.6
4th quartile 0.4 0.2 - 0.7
Infant’s age (months) 0.001
0 - 1 —
2 - 3 3.2 1.7 - 6.1
4 - 5 2.4 1.2 - 4.7
Le
ve
l 3
No. previous pregnancies 0.06
0 —
1 0.7 0.3 - 1.5
2-3 1.7 0.8 - 3.5
4+ 2.2 0.9 - 5.7
Mother’s age (years) 0.13
14 - 19 —
20 - 24 0.6 0.3 - 1.1
25 - 29 0.4 0.2 - 1.0
30 - 45 0.4 0.1 - 0.9
Le
ve
l 4
Birth weight (g) 0.15
<2500 1.9 0.9 - 4.3
2500 - 2999 1.5 0.9 - 2.5
3000+ —
Breastfeeding mode <0.001
Predominant/exclusive —
Partial 2.8 1.4 - 5.8
None 4.7 2.4 - 9.1
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Table A3. Odds ratios of suboptimal breastfeeding and 
selected control variables for infant mortality  
due to lower respiratory infections among infants 
6-11 months of age.
Variable Odds ratio 95% Confidence
interval
P-value
Le
ve
l 1
Mother’s education (years) 0.13
0 3.1 1.1 - 9.1
1 - 4 1.4 0.6 - 3.3
5+ —
Household head employed 0.5 0.2 - 1.4 0.20
Infant’s age (months) 0.04
6 - 8 —
9 - 11 0.4 0.2 - 1.0
Le
ve
l 4
Birth weight (g) 0.01
<2500 5.4 1.8 - 15.8
2500 - 2999 2.7 1.1 - 6.6
3000+ —
Low Apgar score at birth 0.2 0.0 - 1.9 0.10
Non-breastfed 2.8 1.0 - 7.7 0.03
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Table A4. Odds ratios of suboptimal breastfeeding and 
selected control variables for infant mortality due to 
diarrhoeal disease among infants 0-5 months of age.
Variable Odds ratio 95% Confidence
interval
P-value
Le
ve
l 1
Mother’s education (years) 0.06
0 2.7 0.9 - 8.3
1-4 2.7 1.0 - 7.2
5-8 1.7 0.6 - 4.6
9+ —
Mother’s ethnicity 0.10
White —
Mixed race 1.4 0.8 - 2.4
Black 1.7 1.0 - 3.0
Infant’s age (months) <0.001
0 - 1 —
2 - 3 2.9 1.6 - 5.2
4 - 5 2.7 1.4 - 5.1
L 
2 Household has no flush toilet 1.7 1.1 - 2.7 0.02
Le
ve
l 3
Birth interval (months) 0.002
First child 2.8 1.5 - 5.5
9 - 20 1.6 0.9 - 3.1
21 - 50 0.8 0.3 - 2.0
51+ —
Mother’s age (years) 0.20
14 - 19 —
20 - 24 1.5 0.8 - 2.9
25 - 29 0.8 0.4 - 1.7
30 - 45 1.0 0.4 - 2.1
Le
ve
l 4
Birth weight (g) 0.03
<2500 2.7 1.3 - 5.8
2500 - 2999 1.4 0.8 - 2.5
3000+
Birth not in hospital 3.7 1.3 - 10.2 0.01
Delivery by Caesarian section 0.6 0.2 - 1.3 0.10
No. of antenatal care visits 0.02
0 —
1 - 4 0.9 0.5 - 1.8
5 - 8 0.5 0.2 - 1.0
9+ 0.4 0.2 - 0.9
Breastfeeding mode
Predominant/exclusive — <0.001
Partial 2.4 1.1 - 5.2
None 7.3 3.7 - 14.4
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Table A5. Odds ratios of suboptimal breastfeeding and 
selected control variables for infant mortality due to 
diarrhoeal disease among infants 6-11 months of age.
Variable Odds ratio 95% Confidence
interval
P-value
Le
ve
l 1
Income per capita 0.11
1st  quartile —
2nd quartile 0.7 0.3 - 1.7
3rd quartile 0.8 0.3 - 1.8
4th quartile 0.3 0.1 - 0.9
Male infant 1.5 0.8 - 2.9 0.19
Infant’s age(months) <0.001
6 - 8 —
9 - 11 0.2 0.1 - 0.5
Le
ve
l 2
Household has piped water 0.5 0.2 - 1.0 0.04
No. persons  per sleeping room 02
1 - 2 —
3 - 5 2.5 0.7 - 9.1
6+ 3.9 0.9 - 17.2
Le
ve
l 3
No. previous pregnancies 0.10
0 —
1 4.2 1.4 - 12.4
2 - 3 1.4 0.4 - 4.3
4+ 2.2 0.6 - 8.8
Mother´s age (years) 0.30
14 - 19 —
20 - 24 0.4 0.2 - 1.2
25 - 29 0.5 0.1 - 1.5
30 - 45 0.2 0.0 - 0.8
Not breastfed 2.5 1.1 - 5.7 0.02
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Abstract
Objective
To study population-level determinants of caesarean section trends in 
developed countries.
Data sources/study setting
National-level data (1980-2004) from developed countries on trends and 
potential determinants of caesarean section utilization.
Study design
The effect of maternal mortality, national income, hospital infrastructure and 
the health system financing and human resources profile on caesarean section 
rates was analysed with a dynamic econometric model. 
Data collection/extraction methods
Annual data on utilization and potential determinants of caesarean section were 
obtained from health statistical services and international organizations.
Principal findings
The capacity of the health system to deliver surgical obstetric care, its financing 
structure, and possibly also its human resources profile, have stronger 
aggregate-level effects on caesarean section rates than does income.
Conclusions
Health system factors are potentially important aggregate-level determinants 
of caesarean section utilization which have been overlooked in debates focusing 
on the impact of women’s choices and doctors’ preferences.
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Introduction
Caesarean section rates are high and continue to rise in developed countries.
[1][2][3] , However, the impact of guidelines and recommendations in curbing 
their growth has been limited: in 1985, representatives of a study group 
convened by the World Health Organization wrote, “there is no justification 
for any region to have caesarean section rates higher than 10–15%.”[4] 
Although levels of 10–15% were considered high but acceptable at the 
time, average caesarean rates in most developed regions (with the exception 
of eastern Europe) now exceed 20%; the recommendation thus appears to 
have been largely overtaken by events.[5] Neverthless, little research exists on 
determinants of caesarean section utilization, at either the aggregate[6] or the 
individual level,[7][8] and, until recently,[9] the few randomised trials that 
have been published have found no effect, for the intervention studied, on 
rates of caesarean delivery.[10][11] 
Understandably, in such a context, there is concern that apparently inexorably 
rising rates of caesarean delivery have the potential to divert human and 
financial resources from other, arguably higher priority, interventions.[12] 
Furthermore, the possibility that indiscriminate use of caesarean section can 
have a negative impact on maternal and neonatal health has been raised[13] 
and has recently received support from a number of studies.[3][14][15][16] 
On the other hand, it has been argued that reducing caesarean delivery rates 
would have a detrimental effect on mothers’ and infants’ health, and that 
patients’ choices should be considered.[17]
Against this background, we set out to study trends in caesarean delivery 
rates in developed countries with the aim of identifying potential population-
level determinants. Previous ecological research,[6] limited to cross-sectional 
analysis in Latin America, has suggested that it is primarily income that 
determines caesarean section rates at aggregate level. Here we use a cross-
country dynamic regression model to exploit the additional information 
available from data on trends to present evidence that caesarean rates in 
developed countries respond not only to economic incentives such as income 
but also, and more strongly, to important modifiable health-system factors.
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Methods
Our analysis focuses on developed countries as defined in the United Nations’ 
classification.[18] Developed countries include countries in Europe and 
Australia, Canada, Japan, New Zealand and the United States of America. 
Trend data were collected for 38 of these countries since 1980. Variables used 
in the analysis, and their interpretation, are described in the Table. 
Potential determinants of CS rates
Determinant Reason for inclusion
Medical
• Maternal mortality ratio* Indicator of medical need
Non-medical
Income
• Gross domestic product per capita (GDP per capita)* Indicator of consumer demand
Health-system infrastructure
• Number of hospitals per capita# Relatively fixed indicator of the capacity of the health system to deliver 
surgical obstetric procedures
• Number of hospital beds per capita# More flexible indicator of the capacity of the health system to deliver surgical 
obstetric procedures
Health-system financing and human resources organization
• Proportion of total health expenditure derived from 
government sources#
Indicator of the financial organization of the health system
• Number of midwives per capita# Indicator of the human resources profile of the reproductive health system
*Data available for all 38 countries (“basic” data).
# Data available for only 25 countries (“full” data).
For European countries, data were obtained from the European Health for 
All Database (www.who.dk), maintained by the WHO European Regional 
Office. For Australia, Canada, Japan, New Zealand, the United Kingdom and 
the United States, national health statistical services issue regular publications 
and maintain web pages with information on maternal health indicators. 
Previous research on international comparisons of caesarean delivery rates 
has relied on cross-sectional data from Latin America and simple bivariate 
correlation models.[6] As a preliminary analysis, and to establish a baseline 
for comparison with the results from our trend analysis, we performed a 
simple linear regression of caesarean section rate versus income per head in 
Latin America and in developed countries, using a previously published cross-
sectional data set, in order to confirm previous findings.[3] 
Subsequently, trend data on caesarean section rates and their potential 
determinants (Table) were analysed using a dynamic econometric model 
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combining a standard time-series analysis with a simple panel-data model 
for cross-country variation.[19][20] (For full details of analysis methods, see 
Annex).
A basic set of indicators (maternal mortality ratio and income per head) 
was available for 38 countries (Table), with an average of over 11 years of 
observation per country. A larger set of indicators (consisting of the basic 
indicators plus estimates of hospitals, hospital beds and midwives per head as 
well as the proportion of total expenditure on health derived from government 
sources) was available for 25 countries, with an average of over 6 years of 
observation per country. 
Results from both data sets (basic and full) using the dynamic econometric 
model are reported below. Since the 38 countries for which basic data were 
available might differ systematically from the 25 countries for which full 
data were available, a model with basic indicators only was studied for both 
sets of countries in order to establish that countries with full data were not 
qualitatively different than those with basic data only. 
Results
Cross-sectional analysis
In the same set of developed countries as those studied in the dynamic model, 
a log-log linear regression of cross-sectional caesarean section rate versus cross-
sectional income per head predicts that a doubling in income corresponds to a 
33% (95% CI, 18% − 46%) increase in caesarean delivery rate (see Annex for 
details of the log-log regression). For comparison with previous research,[6] 
the same model estimated in Latin American countries only suggests that a 
doubling in income would be associated with a 77% (67% − 87%) increase.
Basic dynamic model
At only 4% (3% − 6%), the estimate of the effect of a doubling in income 
obtained from the basic dynamic model is substantially lower than the 
estimate obtained from cross-sectional analysis (Annex, Table 3). A small 
positive coefficient was associated with calendar year, indicating an average 
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increase of 0.3% (0.2% − 0.4%) per year after controlling for other variables 
in the basic model (Annex, Table 1). There was also a negative but insignificant 
association with maternal mortality (Annex, Table 1). 
These results were qualitatively robust across all alternative model specifications 
using the basic indicators. Standard tests of model validity show that no 
estimation assumptions were unsatisfied.[21] 
Full dynamic model
When the full set of indicators was analysed, a doubling in income per head 
was found to correspond to an increase in caesarean section rates of 6% (4% − 
8%; Annex, Table 3). Notably, however, variables associated with the capacity 
of the health system to deliver surgical obstetric care were also found to have a 
significant positive effect on caesarean utilization rates: for example, a doubling 
in the stock of hospitals per head corresponded to a 15% (4% − 26%) increase 
in caesarean section rates (Annex, Table 3); a doubling in the number of 
hospital beds per head, however, was associated with approximately a 26.8% 
(12.2% − 41.4%) increase in the caesarean section rate (Annex, Table 2). 
Moreover, the financial organization of the health system appeared to have an 
even stronger effect on caesarean utilization: a doubling in the share of health 
expenditure derived from government sources was found to correspond to a 
29.8% (9.6% − 50%) decrease in caesarean rates (Annex, Table 2). Although the 
coefficient was not quite significant (Annex, Table 3), there was a suggestion that 
a doubling in the number of midwives per head would result in a 3% (−1% − 6%) 
increase in caesarean section rates, which is contrary to what might be expected. 
There was a small, although also not significant, increase in caesarean section 
rates associated with increased maternal mortality ratio (Annex, Table 2).
When the full model was analysed for long-run relationships (Annex, Table 
4), the effect of health system financing was seen to be much larger, with a 
doubling of the share of health expenditure from public sources implying a 
95% (42% − 149%) reduction in the caesarean section delivery rate in the 
long run. An effect of similar magnitude but in the opposite direction was 
observed for the number of hospital beds per head, which was associated with 
an 86% (45% − 126%) increase in the caesarean section rate in the long run. 
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Although the coefficient was not significant, the effect of doubling the number 
of hospitals per head was predicted to have only a 12% (−18% − 42%) increase 
in the caesarean section rate in the long run. Possibly because hospitals are a 
relatively fixed measure of health system infrastructure, the long-term effect 
of the hospital stock was found to be of about the same magnitude as that 
in the short run. Although still not significant, a doubling in the number 
of midwives per head was found to be associated with a 14% (−4% − 32%) 
decrease in the caesarean delivery rate in the long run; in other words, the 
effect of the number of midwives per head appeared to be different in the 
long run, and moreover consistent with expectations, as compared with the 
estimated effect in the short term. A switch in the direction of effect also 
obtained for income per head in the long run, since a doubling in income was 
found to imply a 5% (−3% − 14%) decrease in caesarean section rates in the 
long run (although the coefficient was not significant).
See Annex for further details on the estimation model, interpretation and 
results.
Discussion
The estimate of a 77% increase in the caesarean section rate for a doubling of 
income in the Latin American region that we obtained from the preliminary 
cross-sectional analysis is remarkably close to the value of the linear correlation 
reported for that region previously.[6] For developed countries, however, the 
cross-sectional relationship, estimated here at 32%, is substantially weaker. In 
any case, both previous ecological research[6] and our own preliminary cross-
sectional analysis could be claimed to support the hypothesis that, at aggregate 
level, caesarean section rates respond strongly to income, or to factors that 
are themselves strongly associated with income. Results from cross-sectional 
analyses would therefore seem to raise the possibility of dramatically increasing 
caesarean section rates with rising incomes in the future. 
Our principal new finding, however, is that the relationship of caesarean 
section rates with income is in fact substantially weaker when longitudinal 
rather than cross-sectional data are analysed. Since, in either the basic or the 
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full dynamic model, the effect of income on caesarean section rates is an 
order of magnitude weaker than that found in cross section, estimates derived 
from cross-sectional studies would appear to be biased. Such bias could be 
attributable to either the failure to control for the dynamic aspects of the 
relationship, as well as possibly also the absence of relevant control variables 
in the cross-sectional analyses. Our second important finding is that, when 
health system variables are included, a much richer picture of the population-
level determinants of caesarean section rates emerges than that available from 
previous research. 
The main strength of the study is its application of dynamic econometric 
models to health-care utilization trends in developed countries so as to explore 
competing hypotheses about aggregate-level determinants of caesarean section 
rates. Its main limitations are those inherent in the ecological nature of the 
data;[22] there are clearly individual-level factors affecting the utilization of 
caesarean section[9] which this study could only measure in the aggregate. A 
specific limitation of the econometric model is its assumption that different 
countries respond similarly to determinants of caesarean section utilization.
[23] Finally, since several of the estimates for coefficients of interest were not 
significant, we cannot be certain that their reported value was not positive or 
negative due merely to chance.
The conventional model for growth in caesarean section rates implies that 
caesarean delivery is a conventional economic good, in the sense that the 
higher one’s income the more one is inclined to “purchase” it. We call such 
a model “demand-driven”. A demand-driven model is consistent with the 
hypothesis that it is primarily women’s choices that determine caesarean 
section rates. Although a demand-driven model receives support from the 
results presented here, the size of the estimated effect is nevertheless much 
smaller than that previously reported.[6] 
The observed effect of the number of hospitals and of hospital beds per head 
suggests that, in addition to demand, supply factors are also important. A 
supply-driven model would imply that, regardless of medical need, the greater 
the capacity of the health system to deliver surgical obstetric care, the more 
will be delivered. Such a model suggests that “suppliers” of ceasarean delivery 
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(e.g. obstetricians) have substantial influence on delivery mode, and contribute 
importantly to rising caesarean section rates. A “supply-driven” model also 
receives support from the data analysed here. 
Nevertheless, health system factors such as the human-resources and financing 
profile are seen to have the largest impact on caesarean utilization rates. Health 
system financing, in both the short and the long run in fact, is the single 
factor among those studied here with the strongest impact on aggregate levels 
of caesarean delivery. This finding suggests the importance of a previously 
under-recognized model for determinants of caeasarean section, one related 
neither to supply or to demand factors but rather to the health system itself. 
Health system factors are largely institutional, in other words, related to the 
legal environment in which health-care decisions are made.
Overall, our results therefore suggest that, in the context of debates about 
whether patients’ choices or doctors’ preferences are more responsible for 
rising caesarean delivery rates,[24][25], health system factors may be an 
important overlooked population-level determinant. One obvious implication 
is that caesarean delivery rates might be amenable to control through policy 
instruments acting at the health system level. While it is acknowledged that 
such instruments would be likely to affect a broad range of other outcomes as 
well, these findings nevertheless suggest novel avenues for policy intervention 
and investigation into determinants of utilization of this important obstetrical 
procedure. 
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Annex: estimation methods, interpretation 
and detailed results 
Characteristics of the estimation model
A time-series regression model using lagged dependent variables is typically 
used to analyse complex systems whose time-dependent outcome (here, 
caesarean section rate) is held to depend on numerous intermediate outcomes, 
some of which may not be directly observed. In such an approach, the effect 
of the intermediate outcomes is controlled for by using lagged values of the 
dependent variable as instruments (i.e. variables with many of the same 
statistical properties as the variables that cannot be observed). The effect of 
other, directly observed, covariates in the regression equation can then be 
inferred from their coefficients in the standard way. 
Since we wish however to study relationships between caesarean section rates 
and their determinants across a group of countries with similar characteristics, 
a standard time-series model is inadequate.[1] We therefore use a so-called 
“dynamic panel” model, which combines the time series (i.e. “dynamic”) 
approach with a simple model for inter-country (i.e. “panel”) variation.[2][3] 
A requirement of the particular dynamic panel model used here is that inter-
country variation is measurable in terms of a single parameter; the model 
requires, in other words, the assumption that slope coefficients are homogeneous 
across countries and that inter-country differences are expressable by means of 
country-specific intercepts.[4] 
Theoretical basis of the model
On the hypothesis that caesarean delivery is a conventional economic good, 
it is expected that caesarean rates will respond positively (i.e. in direct 
relationship) to income per capita as a result of increased patient demand. 
On the alternative hypothesis that doctors’ preferences are an important 
determinant of caesarean section rates (i.e. the hypothesis that, other things 
being equal, obstetricians prefer patients to have caesarean deliveries), a direct 
relationship with caesarean rates is posited for measures of the capacity of 
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the health system to deliver surgical obstetric care (for example, the stock of 
hospitals, or of hospital beds, per capita). On the still different hypothesis that 
health system factors, such as the human resources profile of obstetric care and 
the organization of health system financing, are important determinants of 
caesarean section rates, it is expected that caesarean utilization would respond 
negatively (i.e. in inverse relationship) to the number of midwives per capita 
or to the proportion of total expenditure on health derived from government 
sources. Finally, since it has been shown to be a covariate of caesarean section 
rates in cross-sectional analysis,[5] we include the maternal mortality ratio as 
a control variable representing medical need.
With the exception of calendar year, all variables are entered as the logarithm. 
The two model specifications that we report (i.e. “basic” and “full”, described 
below) are robust in the sense that, except as noted immediately following, in any 
alternative model specification tested, the coefficients of all variables included 
in the reported model specifications were strongly significant; conversely, 
the coefficients of none of the variables not included in the reported model 
specifications were significant in any of the alternative model specifications. 
The sole exceptions were that the coefficients for maternal mortality ratio 
and for the number of midwives per capita in the current period, t, were 
not significant in most of the model specifications tested; nevertheless, these 
variables were retained in the corresponding reported model specifications on 
account of their interest as potential determinants of caesarean section rates. 
The inclusion or exclusion of these variables in any case had no important 
effect on the coefficient values of any of the other variables reported.
The basic model, ignoring error terms, can be written: 
CSt = c1⋅CSt − 1 + c2⋅CSt − 2 + c3⋅GDPt + c4⋅GDPt − 1 + c5⋅MMRt + c6⋅Yeart.
The full model, ignoring error terms, can be written:
CSt = c1⋅CSt − 1 + c2⋅CSt − 2 + c3⋅GDPt + c4⋅GDPt − 1 + c5⋅MMRt + c6⋅Yeart + c7⋅Hospt +  
c8⋅Hospt − 1 + c9⋅HospBedt  + c10⋅Midwt + c11⋅Midwt − 1 + c12⋅PubHExpt.
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A list of variables and their abbreviations follow:
Caesarean section rate in the current year (t) CSt 
Caesarean section rate in the previous year (t −1) CSt − 1
Caesarean section rate two years previoius to the current year (t −2) CSt − 2
Income per head in the current year (t) GDPt 
Income per head in the previous year (t −1) GDPt − 1
Maternal mortality ratio in the current year (t) MMR t
Number of hospitals per head in the current year (t) Hospt
Number of hospitals per head in the previous year (t−1) Hospt − 1
Number of hospital beds per head in the current year (t) HospBedt
Number of midwives per head in the current year (t) Midwt
Number of midwives per head in the previous year (t−1) Midwt − 1
Proportion of total expenditure on health from government sources in the current year (t) PubHExpt
Calendar year (t) Year.
Raw coefficient estimates for the variables are reported below in Annex Table 
1 (basic model) and Annex Table 2 (full model). 
The dynamic model is estimated using the Stata (version 9) procedure xtabond.
Model and parameter interpretation
Log-log regression
Regression with logarithmically transformed dependent (i.e. left-hand side) 
and independent (i.e. right-hand side) variables yield coefficients that can 
be interpreted as elasticities, which means that the coefficient value gives 
the proportional change in the dependent variable (i.e. caesarean section 
rate) associated with a doubling in the independent variable (i.e. potential 
determinant).
Changes rather than levels
In the Results section of the main text, it is claimed that “changes” in income 
or other variables are a potential determinant of caesarean section rates. This 
is a common interpretation applied to dynamic econometric models of the 
type used here, and it relies on the following argument. 
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Taking income as an example, the relevant part of the regression equation can 
be written as follows:
CSt = … + c3⋅GDPt + c4⋅GDPt-1 + ….
If the estimated value of the coefficient c3 is approximately equal in absolute 
value to the estimated value of the coefficient c4, and if, in addition, c4 is 
negative in sign (i.e. c3 > 0 and c3 = −c4), we can then write the regression 
equation as, with approximate equality:
CSt ≈ … + c3⋅GDPt − c3⋅GDPt-1 + ….
The following rearrangement and relabelling is then possible:
CSt ≈ … + c3⋅ (GDPt − GDPt-1) + … ⇒
CSt ≈ … + c3⋅∆GDP + …,
where ∆x is used as an abbreviation for xt − xt-1 (i.e. “changes in x”). When 
the above conditions hold, this argument gives rise to the interpretation that 
it is changes in, rather than levels of a variable (e.g. income) that determine 
caesarean section rates.[6]
This interpretation can in fact be legitimately applied whenever the confidence 
intervals of the coefficients, for example c3 and c4, are substantially overlapping 
(i.e. the coefficients are equal within statistical error). Since, in practice, the 
coefficients will rarely be exactly equal, their absolute values can be averaged 
to produce a statistically more robust estimate of the impact of changes in the 
independent variable on the dependent variable. 
Averaging the coefficients is equivalent to defining a new coefficient based on 
a combination of the original ones:
c∆ ≡ (c3 − c4)/2.
The transformed coefficient c∆ is then used to infer the effect of changes in the 
independent variable. 
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This is the procedure used to interpret the effect of income, the number of 
hospitals per capita and the number of midwives per capita on caesarean section 
rates. The transformed coefficients, and their approximate confidence intervals, 
corresponding to these variables are reported below in Annex Table 3.
Long run
In Results, so-called “long run” relationships are reported for certain variables. 
This is another standard interpretation for econometric models of this type. 
This interpretation is motivated by the argument that, in the long run, the 
values of variables at different time periods (i.e. at t, t − 1 and so forth) will 
become equal. In other words, the dynamic system estimated by the model 
is assumed to reach equilibrium in the long run in the sense that there are no 
further changes in the values of any of the variables. 
However, if the use of the term “long run” seems objectionable for any reason, 
one can alternatively think of the long run relationships as equilibrium 
relationships. They are, in other words, the relationships that would obtain if 
and when the system estimated by the model reaches a steady state. The long 
run coefficients thus show the intrinsic response (equilibrium elasticity) of the 
estimated dynamic system to exogeneous shocks in any of the variables.
If we are interested in the long-run relationship between caesarean section 
and income, for example, we suppress the corresponding subscripts for period 
(since the variables have reached steady state and are therefore equal in all 
periods). The relevant part of the regression equation can then be written:
CSt = c1⋅CSt-1 + c2⋅CSt-2 + c3⋅GDPt + c4⋅GDPt-1 + … ⇒
CS = c1⋅CS  + c2⋅CS + c3⋅GDP + c4⋅GDP + ….
The common terms for caesarean section and income are then collected 
together and their coefficients added:
(1 − c1 − c2)⋅CS =  (c3 + c4)⋅GDP + ….
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The long-run relationship of caesarean section and income can then be 
calculated by solving the above equation for CS:[6]
CS = (c3 + c4)/(1 − c1 − c2)⋅GDP + ….
This defines a new, long run (“LR”) coefficient for the independent variable 
in terms of the estimated coefficients; it expresses the proportional response 
of the caesarean section rate to exogeneous shocks in income at steady state:
cLR ≡ (c3 + c4)/(1 − c1 − c2) .
We have calculated long run elasticities of caesarean section rates for income 
per head, hospitals per head, hospital beds per head and the number of 
midwives per head. The transformed coefficients, and their approximate 
confidence intervals, for the long run elasticities for these variables are 
reported below in Annex Table 4.
Uncertainty estimates
Approximate 95% confidence intervals are reported in the annex tables for 
both raw and transformed coefficient estimates. The estimates for the raw 
coefficients are derived directly from the standard errors of the regression 
coefficients in the conventional manner. The confidence intervals reported 
for the transformed coefficients, however, are derived using a statistical 
technique called the “delta method” that relies on a linear-order series 
expansion of the equation for the transformed coefficient. The variance of 
the linear-order expansion of the coefficient equation can then be calculated 
by using standard statistical identities. This approach takes into account 
the main (i.e. first-order) effect of the variance and covariance of the raw 
coefficients (Annex Table 5). 
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Annex tables
Annex Table 1:  Raw coefficients estimates for the basic modela
Variable Coefficient P value 95% Confidence Interval
CS b (t−1)   0.646 0.000   0.557   0.735
CS (t−2)   0.178 0.000   0.091   0.265
GDP c   0.040 0.000   0.020   0.060
GDP (t−1) −0.045 0.000 −0.062 −0.029
MMR d −0.013 0.373 −0.043   0.016
Year   0.003 0.000   0.002   0.004
a Sargan test of over-identifying restrictions: χ2(479) = 404.7; Probability > χ2 = 0.994. Arellano-Bond test that average autocorrelation in residuals of order 
1 is 0 : H0: no autocorrelation; z = −14.00, Probability > z = 0.000. Arellano-Bond test that average autocorrelation in residuals of order 2 is 0 : H0: no 
autocorrelation; z = 0.580, Probability > z = 0.562.
b CS = caesarean section rate.
c GDP = gross domestic product per capita (income per head).
d MMR = maternal mortality ratio.
Annex Table 2:  Raw coefficients estimates for the full modela
Variable Coefficient P value 95% Confidence Interval
CS b (t−1)   0.430 0.000   0.318   0.542
CS (t−2)   0.257 0.000   0.150   0.363
GDP c   0.052 0.000   0.022   0.081
GDP (t−1) −0.069 0.000 −0.094 −0.049
MMR d   0.011 0.569 −0.027   0.049
Hospitals per capita   0.167 0.007   0.045   0.289
Hospitals per capita (t−1) −0.130 0.024 −0.242 −0.017
Hospital beds per capita   0.268 0.000   0.122   0.414
Midwives per capita   0.006 0.805 −0.045   0.058
Midwives per capita (t−1) −0.051 0.011 −0.091 −0.012
Share of health expenditure 
from government sources
−0.298 0.004 −0.500 −0.096
Year   0.007 0.000   0.005   0.010
a Sargan test of over-identifying restrictions: χ2(479) = 198.43; Probability > χ2 = 1.000. Arellano-Bond test that average autocorrelation in residuals of 
order 1 is 0 : H0: no autocorrelation  z = −4.72, Probability > z = 0.0000. Arellano-Bond test that average autocorrelation in residuals of order 2 is 0 : H0: no 
autocorrelation  z =  0.390, Probability > z = 0.698. 
b CS = caesarean section rate.
c GDP = gross domestic product per capita (income per head).
d MMR = maternal mortality ratio. 
Annex Table 3:  Transformed regression coefficients for 
changes in independent variables
∆Variable (model) Equation for transformed 
coefficient
Numerical value Approximate 95% Confidence Interval
∆GDP a (basic) (c3 − c4)/2 0.04 0.03 0.06
∆GDP a (full) (c3 − c4)/2 0.06 0.04 0.08
∆Hospitals per capita (full) (c7 − c8)/2 0.15 0.04 0.26
∆Midwives per capita (full) (c10 − c11)/2 0.03 −0.01 0.06
a GDP = gross domestic product per capita (income per head).
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Annex Table 4:  Transformed regression coefficients for 
the long-run elasticities of the independent 
variables
Variable (model) Equation for transformed 
coefficient
Numerical value Approximate 95% Confidence Interval
GDP a (basic) (c3 + c4)/(1 − c1 − c2) −0.02 −0.11 0.07
GDP a (full) (c3 + c4)/(1 − c1 − c2) −0.05 −0.14 0.03
Hospitals per capita (full)   (c7 + c8)/(1 − c1 − c2) 0.12 −0.18 0.42
Hospital beds per capita (full)  c9/(1 − c1 − c2) 0.86 0.45 1.26
Midwives per capita (full)   (c10 + c11)/(1 − c1 − c2) −0.14 −0.32 0.04
Share of health expenditure 
from government sources (full)
  c12/(1 − c1 − c2) −0.95 −1.49 −0.42
a GDP = gross domestic product per capita (income per head).
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Annex Table 5:  Approximate variance−covariance estimates 
for the raw coefficients in the full model
Variable CS t−1 CS t−2 GDPt GDPt−1 MMRt Hospt Hospt−1 HospBedt Midwt Midwt−1 PubHExpt Year
CSt − 1 0.003
CSt − 2 −0.002 0.003
GDPt −0.0001 0.00002 0.0002
GDPt − 1 0.00002 0.0001 0.0001 0.0002
MMR t 0.00009 0.0004 −0.00003 0.00002 0.0004
Hospt 0.001 0.001 0.0001 0.0001 0.00002 0.004
Hospt − 1 −0.001 −0.0002 0.0001 −0.00006 0.00005 −0.002 0.003
HospBedt −0.001 −0.001 0.0002 −0.00001 0.00006 −0.002 0.0003 0.006
Midwt 0.0002 0.0002 −0.00003 −0.00003 −0.0002 0.0001 −0.0003 −0.001 0.001
Midwt − 1 0.0001 0.0001 0.00001 −0.00003 −0.0006 0.0002 −0.0003 −0.0003 −0.00005 0.0004
PubHExpt 0.002 0.002 0.00008 0.00008 −0.0001 0.001 0.00003 −0.003 0.00001 0.00009 0.011
Year −0.00003 −0.00002 ~0 ~0 ~0 −0.00002 0.00002 0.0001 −0.00002 0.00001 0.00003 ~0
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Discussion
Restatement of the general research questions
The general questions developed in the Introduction are: 
— Should we care about the longitudinal (i.e. time) dimension of population 
health? In order to answer this question, we attempted to show why 
longitudinal population dynamics are an important concern for the 
measurement of population health.
— Do longitudinal measures allow us to answer questions about population 
health better than other measures? There, we focused on how we can 
apply longitudinal models to measure population health benefits and 
risks.
— Are standard models from other scientific fields relevant to questions 
of population health measurement? For the last question, we applied 
common models from epidemiology and econometrics to questions in 
population health measurement and related areas. 
We proposed to illustrate the general questions through several more specific 
questions. Based on our research, we now propose answers to those questions.
Is it possible to develop an easy-to-use, reasonably generic, 
longitudinal model that can be used for population health 
measurement with generally available epidemiologic and 
demographic data?
As shown in Chapter 2, it is possible to develop a generic longitudinal model 
that can be used for population health measurement. The model discussed is 
a multi-state dynamic population life table (“PopMod”). Although it might 
be claimed that it is easy to use, with a few exceptions, it has been used only 
by trained specialists employed by institutions with an established interest 
in longitudinal population health measurement (e.g. The World Health 
Organization, Erasmus University, Harvard University). While it is possible 
to apply the model using generally available epidemiological and demographic 
data, these data typically require transformation, and in some cases preliminary 
modelling, before the required input parameters can be estimated.
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It appears that there is a tension in generic models between generality and 
realism: it will come as no surprise to researchers in the field that the more 
realistic the model, the less generic it is. Here, we propose as a working 
definition of a realistic model one that has an acceptable face validity for a 
specialist familiar with the modelling question. Realism is a principal aim 
motivating the modelling of independent age and time dimensions. Generality 
is important for the comparability of results, as well as to promote ease of 
use by those who may not be specialists in a given subject area. We outline 
following how these divergent aims are addressed in PopMod.
Generality and realism
The model presented in Chapter 2 allows for four health states to be 
represented. Notionally these states are: (1) a healthy, or susceptible, state, (2) 
an index disease state, (3) a second disease state and (4) the state of having 
both diseases. Each state is subject to a specific profile of mortality and other 
rates (see Figure 7, Chapter 1). However, since the labels on the states are 
arbitrary, they can be interpreted in any other way consistent with this disease 
process ( including interpretations in which some transition rates are set to 
zero). The states have been used in various applications to represent either 
stages in a disease process or risk factors predisposing to disease.
However, those wishing to model a multi-stage disease, such as for some 
cancers or chronic diseases, have found that four states are occasionally 
insufficient to satisfy the criterion of realism as defined above. This problem 
arises because such diseases can involve an arbitrary number of clinically 
and epidemiologically distinct stages accessed in a progressive, usually non-
reversible, fashion. Representation of such diseases in PopMod can only be 
done by the compression of the desired number of states into four or fewer. 
Similarly, analysts interested in modelling multiple interacting risk factors 
and diseases (such as for physical activity, diet, obesity and related health 
outcomes), have found a limiting factor in the number of possible interactions 
between modelled health states. Moreover, although it has not been a typical 
complaint, the problem of modelling continuous risk-factor distributions is 
completely unaddressed by a model like PopMod. We return in more detail 
to the problem of modelling interacting disease and risk-factor states in the 
appendix Modelling complex interactions in longitudinal population models.
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On the other hand, a number of analysts have found that it was sufficient to 
represent the disease process of interest with only a single state, resulting in 
frequent use of a two-state version of the model. Examples have been road 
traffic accidents, heavy alcohol use, blindness, deafness and mental health 
conditions like schizophrenia and depression. Although this approach has 
not been based on a claim that the conditions are not complex, progressive 
or multifactorial in causality, it highlights the fact that many analysts have 
in practice been able to capture what they considered to be the essential 
features of their problem without the need for comorbidity, disease staging 
or interactions. 
Based on this experience, it appears there is no reason why a partition of 
the population into four health states should have any special claim to be 
considered the right level of complexity to adopt for a generic disease model. 
Although four states may be suited to the original conception of an index, 
comorbid and joint condition, our experience suggests that the questions 
that can be addressed with such a model may not be truly generic concerns 
but rather specific to the context of two causes of death that are strongly 
interacting, such as ischaemic heart disease and stroke.
Interest from the public
Interest in longitudinal population health modelling has come in the form 
of regular requests for download of the PopMod model. Most requests are 
generated by the WHO-CHOICE web page (www.who.int/choice), where 
the availability of the program is advertised. Since we have maintained 
continuous records, we have recorded about 75 download requests per year. 
However, we have received relatively few follow-up questions, at a rate only 
slightly higher than 1 every 4 weeks. In addition, most such requests have 
concerned administrative aspects of the download process. As only rarely 
have we received technical queries, the most likely conclusion is that potential 
users of PopMod are not becoming actual users. 
Although this is in some sense a failure, it is doubtful that it represents a 
failure for the cause of longitudinal modelling per se. Likewise, although 
life expectancy is a widely cited concept, the ordinary period life table has 
never been widely used by non-specialists. Similarly, although the concept of 
“burden of disease” has thoroughly penetrated current discourse on public 
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health, only a fraction of the community has ever been engaged in actual 
burden of disease estimation. Thus, although ease of use remains a barrier to 
the diffusion of longitudinal modelling, it would not seem to be an absolute 
one.
Data needs
On the other hand, the need to transform observed data to estimate the input 
parameters required for generic longitudinal population models may pose a 
more critical barrier. Since data come in many forms, only a few of which 
are amenable to being used directly as input parameters, statistical and other 
problem-solving skills are usually required in order to estimate the parameters 
values required. Moreover, the cumulative impact of the assumptions required 
for parameter estimation can undermine the objective of realism sought by 
use of a multi-state longitudinal population model. It can also be argued that 
the use of ad-hoc assumptions in estimating parameter values limits a generic 
model’s claim to be generic.
Is it feasible to apply a generic, longitudinal model to 
quantify real population health risks and what sort of 
insights can be obtained through its application?
As demonstrated in Chapter 3 and Chapter 4, quantifying population health 
risks and benefits with a generic population model is feasible. In Chapter 3, we 
applied the model to an analysis of interventions for cardiovascular disease, a 
major cause of non-communicable disease burden; in Chapter 4 we analysed 
interventions for malaria, a major cause of infectious disease burden. The 
corresponding research reports have been prominently published; the paper 
on interventions for cardiovascular disease has in addition been widely cited. 
This suggests that the application of generic longitudinal population models 
to real public-health problems can be interesting, plausible and of potential 
policy relevance.
Both of these research examples concern studies of cost effectiveness, rather 
than population health modelling per se. As noted earlier, our choice of 
method of population health measurement was guided in part by the need 
to find answers to questions about the impact on health of interventions. In 
other words, an important motivation for the measurement approach was to 
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quantify the impact of changes from one, usually currently observed, state 
to another, usually hypothetical, state. This is called counterfactual analysis 
(Pearl, 2000). 
Cost-effectiveness analysis
Cost-effectiveness analysis provides a rational basis for priority setting, and 
requires measuring effectiveness. The advantage of measures of effectiveness 
obtained from longitudinal population models is that the age, period and 
cohort position of health benefits are accounted for and can be tabulated 
when required. Failure to account for these classification variables can lead to 
inconsistencies in health measurement. 
One example is that statements such as “intervention A averted x-thousand 
deaths” is, without further information, imprecise. To make the statement 
somewhat more precise, an explicit time period must be specified. Often, the 
intended time horizon is one year, i.e. “intervention A, if implemented now, would 
avert x-thousand deaths in the following year”. This interpretation is reasonable 
because a one-year time period is held to be meaningful in the case of a 
stationary population. Thus, the implicit use of a one-year time period in health 
measurement (as, for example, with ordinary life-table analysis) is equivalent to 
an implicit assumption that the population is stationary (Preston, 1993). 
For a non-stationary population, a one-year time horizon is of limited relevance. 
To adequately distinguish between interventions in such a population, the 
age and the time position of the averted deaths must be precisely specified. 
Moreover, since interventions with intertemporal impact induce non-stationary 
population effects, to distinguish between such actions it can also necessary 
to identify the cohort position of the events. For these reasons, a longitudinal 
model allows for a more meaningful measure of intervention benefit than that 
obtained with ordinary life table analysis.
Prediction versus projection
The time dimension of a longitudinal population model implicitly raises the 
question of whether it should be considered to represent historical time. In 
other words, does a longitudinal population simulation represent a prediction 
about the future course of the population? While there is no logical problem 
with interpreting a population simulation as a prediction, in most cases it will 
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be better to avoid this view. The strongest reason is perhaps simply the fact 
that predictions are always wrong, and they are usually wrong even according 
to approximate criteria. Although making statements about the future of a 
population is logically possible, doing so therefore tends to make population 
modelling non-scientific. Population models nevertheless arguably display 
an interest in the future, or more properly stated, in a hypothetical (often 
counterfactual) state of population health. The hypothetical state typically 
represents either a desired or a deprecated future state of population health. 
For example, a simulation based on current parameter values could be said to 
represent the future the population would face if it continued to experience 
currently estimated parameters, all other factors being held constant. If it is 
not a prediction, a simulation based on the current scenario is still of interest 
if current parameter values represent factors relevant for the question at hand. 
Current values might be relevant because, for example, they represent the 
parameters that medical theory claims are relevant for health. They might 
also be of interest because they are the parameters that most easily modifiable 
through intervention. Although there are many reasons a given set of parameters 
can be relevant, when applied to a modelling question, these reasons take the 
form of an hypothesis: if these parameters are relevant, then the simulation is of 
interest. Notice that the hypothesis does not necessarily claim that the current 
parameters are solely those that determine the future population health. 
To distinguish simulations from predictions, they are occasionally referred to as 
projections (Keyfitz and Caswell, 2005), the usual term employed in the field of 
matrix population models (Caswell, 2001). A projection is distinguished from 
a prediction because its time dimension is mainly a mathematical construct 
used to represent the desired object of analysis. A longitudinal population 
model, in other words, uses a time dimension for purposes of measurement, 
and not for the sake of making statements about the future.
Comparability and generality
Cost-effectiveness analysis using longitudinal population models and using 
standard life tables can yield the same ordinal ranking of interventions. This is 
not surprising because measurements made using the same model have the same 
implicit time horizon. Moreover, exceptions to invariance in ordinal ranking can 
often be explained by factors unrelated to the choice of model. One might therefore 
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decide that answers to questions about cost-effectiveness analysis are insensitive to 
the choice of model. Is there then any advantage to generic longitudinal population 
modelling for the purpose of cost-effectiveness analysis? 
Although different models may yield similar rankings, comparisons across 
models nevertheless remain problematic. One advantage of cost-effectiveness 
analysis using generic longitudinal population models may therefore be 
unrelated, strictly speaking, to the longitudinal aspects of the model but 
rather to the comparability resulting from use of a generic model. This kind 
of advantage can be referred to as that of standardization: since analyses 
performed with a similar set of methods can be mutually compared, 
standardization facilitates, for example, sector-wide cost-effectiveness analysis, 
where interventions with many different kinds of effect (and costs) must be 
mutually compared. 
Relevance for policy
The more explicit are the assumptions on which they are based, and the more 
comparable the health measurements, the more relevant they are for policy 
making. Although relevance for policy making is different than use in policy 
making, discussing the reasons for this distinction goes beyond the scope 
of the questions we have investigated here. Work in the context of WHO-
CHOICE has nevertheless resulted in a few experiences where it is possible to 
trace a direct connection between cost-effectiveness analysis and subsequent 
policy making. 
Most prominent among these examples is probably our experience with the 
Estonian Ministry of Social Affairs. The ministry sought our assistance for 
the use of cost-effectiveness analysis of interventions designed to decrease 
alcohol and tobacco use. A revised policy on excise taxes was subsequently 
implemented. The ministry continues to work with WHO on applications of 
cost-effectiveness analysis to national health policy.
Does the logistic family of models offer an approach 
relevant to longitudinal population health measurement?
We have shown that models of the logistic family can be interpreted 
longitudinally in two types of case: first, when the model is an explicitly 
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longitudinal model describing exponential or logistic population growth or 
disease transmission, or when the model describes an age-dependent set of 
outcomes that can be interpreted as time dependent under the assumption of 
a stationary population.
In the context of population health measurement, the first case is mainly 
relevant to phenomena of contagion or growth. In Chapter 5, we show how 
individual-level random processes, which are an idealization of infection 
transmission or the spread of a population, are relevant to the population-level 
description of growth or of an epidemic. We also argue there that the same 
mechanism makes the second case (implicit logistic models) relevant to the 
estimation of population processes measured in cross section.
In both cases, the applications concern those where the term “logistic model” 
refers to a distribution function for a random variable with a logistic cumulative 
probability distribution. Since this distribution arises naturally as the limit of 
a discrete random process, for applications where time or age is a conditioning 
variable, the mechanics of the discrete process lend substantive meaning to 
the use of its limiting description in modelling or estimation. 
In particular, contagious outcomes (such as infection, drug addiction and 
product preferences), may follow a logistic regression on the time predictor 
as a consequence of underlying diffusion-like phenomena. When considering 
additional covariates, logit-additive approximations to varying temporal 
effects may sometimes be expected due to similar mechanisms. Furthermore, 
if the covariate levels define separate diffusion compartments within which 
there is logit-linearity in time, the overall model will be logit linear with time-
covariate product terms (“interactions”). 
Is it feasible to apply logistic models to quantify real 
population health risks and what sort of insights can be 
obtained through their application?
Application of logistic models to population health measurement
In Chapter 6 and Chapter 7, we present an application of logistic modelling 
to an important child-health risk factor, suboptimal breastfeeding. Although 
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suboptimal breastfeeding remains a significant global concern (Black RE et 
al., 2008), exposure measurement has been hampered by the poor availability 
of population-representative breastfeeding data. In the work presented in 
Chapter 6, we show that the logit-linear age structure observed in breastfeeding 
data from countries with comprehensive nationally representative surveys can 
facilitate the use of partial data from other countries. 
Logistic regression of breastfeeding prevalence on age yields a simple two-
parameter (slope and intercept) logit function for breastfeeding time-to-
failure rates. The slope is interpretable as a constant per-capita risk of stopping 
breastfeeding and the intercept as the initial breastfeeding odds at age zero. 
With this model it is possible to emply a simple fitting procedure to impute 
missing data in a target country. The procedure consists of fixing the slope 
as found in a country with similar characteristics to the target country, but 
where there is a comprehensive survey, and then selecting the intercept so 
as to fit the limited data available from the target country. Once values for 
both parameters are obtained in this way, the entire age-specific breastfeeding 
schedule can be solved for in the target country by using the inverse logit 
transformation, thereby extending the geographic range of coverage with 
breastfeeding indicators. 
In Chapter 7, we apply the exposure estimates from Chapter 6, together 
with results from a re-analysis of a previously published case-control study 
on the mortality risk of suboptimal breastfeeding, to develop estimates of 
the population attributable fraction of fatal outcomes in children. In other 
words, relying on the stationary population assumption, estimates of exposure 
and risk, respectively from two cross-sectional studies, are used to estimate 
mortality burden in a longitudinal framework.
A counter example
The application of cross-sectional methods to fundamentally longitudinal 
problems in population health measurement is nevertheless not advisable 
in the absence of supporting evidence, or when evidence in favour of the 
stationary population interpretation is weak. We describe an example of such 
a case in Chapter 8, where an econometric longitudinal model, called the 
“dynamic panel” model, was applied to the analysis of trends in caesarean 
section utilization rates at population level. 
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The study was motivated by the fact that rates of caesarean section utilization 
continue to rise amid concerns that they represent a diversion of resources 
from activities with greater health benefit, and that unnecessary caesarean 
sections can have a negative impact on mothers’ and children’s health. 
One of the principal aims was to measure the relationship between caesarean 
section rates and income, which was motivated in part by our previous work 
(Betrán et al., 2007) in which income was suggested to have a large impact 
on caesarean section rates. When the trend data were analysed dynamically, 
however, the relationship of caesarean section rates with income was found 
to be substantially weaker, implying that the estimates we had derived with 
cross-sectional methods were biased. 
Another finding was that, when health system infrastructure, human 
resources and financing profile are controlled for, a richer picture of potential 
population-level determinants of caesarean section rates emerges. Although 
debate has tended to center around either a “women’s choice” or a “doctors’ 
preference” model to explain determination of delivery method (Castro, 2001; 
Showalter and Griffin, 2001), we found that the largest effect on caesarean 
section utilization at population level was associated with aspects of the health 
system infrastructure and its human resources and financing profile. The use 
of longitudinal methods was necessary for making these distinctions.
Priorities for further research
Uncertainty analysis in longitudinal population models
The fact that indirect modelling and estimation methods are often required to 
estimate the parameters used by multi-state longitudinal population life tables 
implies that such models use estimated inputs to produce yet further estimates 
as outputs. The outputs therefore convolve input uncertainty with the effect 
of model-specific processes. Characterization of the impact of uncertainty 
in model inputs on model outputs is therefore important for understanding 
population health measurement with multi-state longitudinal models. Despite 
the long history of use of life-table methods, we have nevertheless been unable 
to find published work analysing this problem. In Appendix I, Uncertainty 
analysis in longitudinal population models, we propose an approach where we 
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focus on the uncertainty of input rates only; uncertainty in the estimates 
of the size and relative size of input populations is considered secondary, as 
is uncertainty in the estimates of the input prevalence of the diseases, risk 
factors or conditions analsyed as well as uncertainty in the estimates of input 
health state valuations. The main thrust of the approach is to analyse both 
demographic and epidemiological transition rates as random variables. The 
analysis is applied first to the case of a single population exposed to a single 
risk of transition to an absorbing state (i.e. the ordinary life-table model), 
then extended to the multi-state dynamic life-table framework. The main 
theme that emerges is that continuous-time dynamic models imply a simple 
“additive-in-the-exponent” rule for rates; this rule carries over, with minor 
modifications, to the case where rates are random variables, where additivity 
needs also to consider the statistical properties of the input rates.
Complex interactions in longitudinal population models
As noted, the goal of generality in model formulation can be illusory, since 
the need for realism according to subject matter criteria inevitably introduces 
an ad-hoc component to the model. In particular, one of the problems 
identified for the would-be user of PopMod is the need to model more 
than four population states. Since, as the number of states x increases, the 
number of possible transitions between states increases approximately as x2, 
estimating the corresponding input parameters using only generally available 
data rapidly becomes a complex problem. For example, a typical modelling 
situation might require determining the joint distribution of the prevalence of 
m × k population states when only m + k marginal distributions are observed. 
There is the related problem of partitioning a total disease rate r across the 
m × k joint population states. A formal statement of the problem is provided 
as Appendix II, Modelling complex interactions in longitudinal population 
models, where both the prevalence and the rate aspects of the problem are 
characterized in terms of a system of linear equations. Simple matrix algebra 
theory permits the development of general insights regarding the amount of 
information required for the solutions to these problems. 
The two appendices represent preliminary steps that we have taken to address 
these important areas for future research. In order to complete the theory of 
the time dimension in the measurement of population health, this preliminary 
work should be expanded upon and complemented by additional research.
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Conclusions
Longitudinal population models are superior to others because they 1. 
permit the tabulation, when required, of the age, period and cohort 
position of health events. 
Generic multi-state longitudinal population models can be developed, 2. 
but require trade offs between generality and realism. 
Generic multi-state longitudinal models promote consistent standards of 3. 
population health measurement. 
Generic multi-state longitudinal population models can be applied 4. 
to real problems using available epidemiological and demographic 
data, but they often require estimates of some epidemiological and 
demographic parameters that are not typically available. 
Cost-effectiveness analysis using generic multi-state longitudinal 5. 
population models can contribute to rational priority setting and policy 
making. 
Standard statistical and epidemiological models can be used to obtain 6. 
information about required input parameters that are not directly 
observed, but their use for multi-state longitudinal population 
modelling may require assumptions that are potential sources of bias. 
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Appendix 1 Uncertainty analysis in longitudinal population models
Introduction1 
Multi-state longitudinal life tables are used to measure population health as 
well as to study the effect of specific interventions implemented for the sake 
of improving population health (Lauer et al. 2003). How does uncertainty 
in parameter values used as inputs affect the projections of multi-state 
longitudinal life tables? It seems that the uncertainty in the results of such 
models will depend on the individual contributions of multiple uncertain 
parameters, as well as on the dynamic characteristics of the model itself. 
Despite their obvious interest, these and related questions seem to have 
been ignored in the relevant literature on demography, ecology (e.g. matrix 
population models; Caswell, 2001) and epidemiology. In fact, to identify 
methods relevant to the analysis of these questions, one has to turn to the 
mathematical, physical and statistical literature on stochastic processes and 
Markov models.
We shall discuss uncertainty in the rate parameters of the population 
model only. This restriction is partly for the sake of convenience and 
partly a reflection of the fact that rates of mortality and disease are greater 
determinants of population health than other parameters (e.g. the sizes, or 
relative sizes, of initial populations). Moreover, we shall not develop detailed 
results for the distributions of individual life table quantities but shall rather 
discuss the methods and principles that allow for a general approach to such 
calculations. 
1 Harald Wirth, Klaus Röhrich, Jan Barendregt and Dik Habbema are gratefully acknowledged 
for their helpful discussions on this appendix.
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Formal statement of the problem
For the purposes of population health measurement, we consider a 
differential equation system of the following form:
 Eq. (1) p´ (t) = C ⋅ p(0),
where p´  ≡ dp/dt denotes the derivative of p with respect to time, C is a 
matrix of non-time-varying rates and p(0) is the vector of initial populations. 
For the case of the population model, it is natural to consider p(0) as the 
population of interest partitioned in the set of defined age groups. 
It is well known that the general solution to the system of differential 
equations can be written as (see, for example, Strang, 1988):
 Eq. (2) p(t) = e C ⋅ t ⋅ p(0).
This result means that initial populations evolve exponentially with time; 
Eq. (2) is merely a concise way of representing the population model. 
In terms of Eq. (2), we are interested in the uncertainty of p(t) when there is 
uncertainty in the elements of C. We are also interested in the uncertainty 
of various life-table functions of the populations p(t), which we can write as 
f(p(t)). Important examples of such functions are the average population size 
in an interval (population residence time) and the sums of populations or of 
average populations over a given horizon (Lauer et al., 2003). 
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Scope of the analysis
Uncertainty in p(t) can in general be attributed to the following sources:
— model uncertainty,
— stochastic uncertainty (i.e. random variation) in the modelled process, and
— uncertainty in model parameters.
We briefly describe each of these sources below.
Model uncertainty. Model uncertainty refers to uncertainty in the 
populations p(t) when the specific mathematical method used to model 
the population (e.g. Eq. (2)), or its related assumptions, are incorrect or 
represent a simplification or idealization of the true underlying population 
process. For example, exponential evolution in continuous time may be 
used to approximate an underlying process that is in fact discontinuous. 
Alternatively, rates may not be constant but time varying. Typically, 
however, model uncertainty arises when the matrix C is missing elements 
that are important for the question under study. This can arise due to the 
fact only a small number of known transitions are typically represented in 
C, as well as to the fact that there are many important transitions that are 
unknown (e.g. exposure to unknown risk factors).
Stochastic uncertainty. Stochastic uncertainty arises when the population 
process is inherently stochastic. It is useful to distinguish the uncertainty 
arising from modelling a discrete process by means of a continuous one, or 
from modelling a random process by means of a deterministic one (both 
of which would be causes of model uncertainty in terms of the definition 
above), from the intrinsic variability of an inherently random process. 
Parameter uncertainty. Parameter uncertainty refers to the fact that 
parameters in the population model may be unknown or are measured 
imperfectly. Measurement uncertainty can either be statistical or systematic. 
Statistical measurement uncertainty refers to random variation in either the 
measurement tools or in the measurers (which implies that measurement is 
a random process, i.e. subject to inherent random variation). Since statistical 
parameter uncertainty can either be model error (for example, if the 
measurement tool is deterministic but the process measured is random) or 
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simple stochastic uncertainty, it is therefore best considered under one or the 
other of those respective headings. On the other hand, systematic parameter 
uncertainty can arise due to the presence in the measurement tool of non-
random dependence on important parameters whose values are unmeasured 
or unknown or to systematic bias in the measurement method (cf. Hubble 
telescope). Notice therefore that systematic parameter uncertainty can 
therefore be considered as a form of model uncertainty. 
In terms of these definitions, the analysis here applies to uncertainty in 
model outcomes due to stochastic variability in the elements of the matrix 
of rates C. However, the approach is also well suited to the characterization 
of statistical parameter uncertainty arising due to random errors in the 
measurement tool or in the measurers). Finally, inherently random processes 
modelled by deterministic processes will display model error that is 
assimilable to the sort of uncertainty characterized here. We do not address 
other forms of model uncertainty or systematic parameter uncertainty.
In the notation of (Lauer et al., 2003), the matrix of rates C can be written 
as follows:












++++−−
−+++−
−+++−
−−++
→→→→
→→→→
→→→→
→→→→
CXXXCCXCXCCXCX
CXCCSCXCCCS
XXCXSXXCXXS
SCSXCSXS
ffmhhhh
hfmhhh
hfmhhh
hhmhh
0
0
0
0
Note that, other than the stochastic component, all matrix entries are 
non-time varying. Transitions between health states are denoted by h, and 
distinguished by subscripts, and background mortality and case fatality rates 
are labelled m and f, respectively, the latter also distinguished by subscripts. 
In terms of that notation, p(0) =  (S(0) X(0) C(0) XC(0))T, where the 
population of each possible health state is defined at t = 0. 
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Analysis of specific cases
It is convenient to consider initially the case of a single population exposed 
to a single transition, in other words, the case of a standard cohort life table, 
where C = µ and p(0) = p(0). 
Cohort life table under uncertainty
We refer to a continuous-time life table comprising a single state exposed to 
constant mortality rate µy, where the subscript y indexes the rate prevailing 
during period y (notionally, one year). With subscripts now denoting time, 
within any period the population at time t is given by:
t
tt
yepp ⋅−−=
µ
1Eq. (3) .
Suppose pt−1 = p0 and p0 = 1 (the latter condition can always be enforced 
without loss of generality by dividing both pt and p0 by p0). Suppose, 
moreover, that t = 1 year and that µy has units “year−1”. Then we can write:
1
1
µ−= epEq. (4)  
for the population surviving at the end of year 1. 
Now suppose that, starting from the beginning of year 2, the population 
surviving at the end of year 1 is exposed to µ2. Substituting the value 
obtained for p1, it follows that the population surviving at the end of year 2 
can be written as: 
)(
2
2121 µµµµ +−−− =⋅= eeepEq. (5) . 
Similarly, if the population surviving at the end of year 2 is exposed to µ3 
from the beginning of year 3, the surviving population at the end of year 3 
is given by:
)()(
3
321321 µµµµµµ ++−−+− =⋅= eeepEq. (6) . 
Under these assumptions, it is clear that in year t, 
∑= − t yept
µEq. (7) . 
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Notice, however, that these assumptions are merely those of the cohort 
version of the standard life table in continuous time where age-specific 
mortality is assumed constant within an age group but differs by year of age.
Independent rates
Now suppose that µy no longer represents a constant mortality rate but 
is instead the mean value of a normally distributed random rate hy, with 
variance 2yσ , and that the hy are independent. We refer to this concept of 
random variability as the “null model”. The null model provides a useful 
reference case for comparison with more complicated types of variability. 
It follows from the definition of the log-normal random variable that P1 
is not a constant with value 1µ−e  but rather a log-normally distributed 
random variable with mean 
2
12
1
1 σµ +−e  and variance 
2
11
2
11 222 σµσµ +−+− − ee ,  
the latter equal to )1(
2
1
2
112 σσµ ee +−+−  after factoring. Notice that, when 
compared with the case of constant rates, mean mortality is reduced by 
the quantity 221 yσ . Regardless of the precise distributional form, when rates 
are random the mean population at year’s end will show correction factors 
whose values are subtracted from mean mortality. Thus, the mean number 
of survivors when rates are random is greater than the number of survivors 
when rates are constant.
The sum of t independent normal random variables with means µy 
and variances 2yσ  is itself a normally distributed random variable with 
mean ∑t yµ  and ∑t y2σ  (Gardiner, 2004). It follows that pt is a log-
normally distributed random variable with mean ∑+∑ t yt ye
2
2
1 σµ  and variance 
)
22
2
122
2
1 2)(2)(2 ∑∑∑+∑∑∑ ++−++− t yt yt yt yt yt y ee σσµσσµ , the latter expression equal to 
)1(
22 ∑+−∑− t yt y ee σµ  after cancellations and factoring. 
Since the distributional family of populations in the cohort null model 
is invariant by year, it is natural to think of the quantities ∑t yµ  as 
“pseudorates” (i.e. “cumulative rates”) with variance ∑t y2σ . Since 
pseudorates are in this respect indistinguishable from actual (annual) rates, 
uncertainty analysis of the cohort null model can be greatly simplified. 
For example, if all annual rates have mean µ and variance σ2, the mean 
population after t years is simply 
2
2
1 σµ tte + , and the corresponding expression 
for population variance is )1(
22 σµ tt ee +−− .
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Population correlations when rates are independent
Although rates are independent in the cohort null model, age-specific 
populations follow a specific correlation law. Write hy = µy + dhy, where dhy is 
a normally distributed random variable with a mean of zero and variance 2yσ .  
We know from the population model that: 
yh
tt epp
−
−= 1Eq. (8) . 
Rewriting hy in terms of deviations around its mean, we can moreover write: 
yyy hh ee d−−− = µEq. (9) . 
By both adding and subtracting the quantity 221 yσ  in the exponent and 
factoring we then write: 
2
2
12
2
1 d yyyyy hh eee σσµ −−+−− =Eq. (10) . 
It follows that the population model can be written as: 
2
2
12
2
1 d
1
yyyy h
tt eepp
σσµ −−+−
−=Eq. (11) . 
But Eq. (11) says that pt is equal to the product of pt−1, a positive constant 
2
2
1
yye σµ +−  
(whose value is less than 1), and a random variable 
2
2
1d yyhe σ−−  with a mean of 
1 (since 221d yh σ−−  is normally distributed with mean 221 yσ−  and variance 
2
yσ , its exponential is a log-normal random variable with mean 
2
2
12
2
1
yye σσ +− , 
which is equal to e 0). 
A closely related model from the time-series literature is the first-order 
autoregressive (AR-1) process (Goldberger, 1991): 
ttt pp εα += −1Eq. (12) , 
where εt is a random variable with zero mean and variance 
2σ  and α is a 
constant whose value is less than 1. In a similar notation, the cohort null 
model could be written: 
Eq. (13) , 
where αy is equal to 
2
2
1
yye σµ +−  and xt is equal to 
2
2
1d yyhe σ−− . 
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With identically distributed rates, by induction on t it can be seen that the 
covariance of two populations t years different in age is given by αtσ2; this is 
clearly the same correlation law as for the additive AR-1 process (Goldberger, 
1991), justifying the application of the term “first-order autoregressive” to 
the null cohort model. Moreover, when rates differ by year, it is not hard to 
see that the covariance of two populations separated by t years is given, by 
induction on t, by the variance of the first population σ12 times the product 
of the t coefficients αy, in other words, σ12⋅Ptαy. The error process of the 
cohort null model is thus a multiplicative analog of the standard AR-1 
process, with the additional possibility that αy is a period-specific constant.
Such a model is also closely related to geometric Brownian motion and to 
the geometric random walk (Franke et al., 2004). Taking the logarithm of 
both sides of Eq. (11), we get:
logEq. (14)  pt = log pt−1 − µy − dhy. 
But, since dhy has a mean of zero, we can also write: 
logEq. (15)  pt = −µy + log pt−1 + dhy. 
Thus, the logarithm of population in the cohort null model follows a random 
walk with a period-specific drift term −µy. This differs from the standard 
geometric random walk in that the drift term can be period specific; it differs 
from geometric Brownian motion in that dhy is not continuously random. 
In sum, the correlation law for populations in the cohort null model is well 
defined. The null model correlation law can also be related to well known 
stochastic-process and time-series models.
Distributional characteristics of residence time
So far we have focused on the uncertainty analysis of population quantities. 
The population residence time (i.e. aggregate population life years, pLY) in an 
interval is another quantity of interest. 
Population residence time is equal to the time integral of the population 
within the interval. For example, in the cohort null model for the first year, 
we have (Lauer et al., 2003):
0
1
1
0 0)1(LY
1
1
1d p
h
etepp
h
th ⋅−==
−
−∫Eq. (16) .
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For h1 random, the right-hand side of Eq. (16) defines a distribution 
for pLY(1). Although p0 is non-stochastic by assumption, in general pt−1 
is a random variable. Nevertheless, we focus first on the distributional 
characteristics of the expression (1 − e−h)/h. In a continuous-time life table, 
this expression gives the general formula for the time average of survivors of 
a population exposed to mortality rate h during a one-year interval. Since 
the time average of survivors is nothing other than the population residence 
time (life years) accumulated during the interval, the distribution defined by 
Eq. (16) is of general interest for population health measurement. 
Since the distributional characteristics of residence time cannot in general 
be given in terms of closed-form analytical expressions (exceptions are when 
h is gamma or uniform distributed), we seek approximate expressions for 
its mean and variance. For any standard distributions for h, approximations 
can be found by means of the delta method (Goldberger, 1991). For the 
mean, the delta method to linear order implies taking the function of the 
mean f(µ) as an approximation to the mean of the function E[f(h)], in other 
words we take the quantity (1 − e−µ)/µ as an approximation to the mean of 
(1 − e−h)/h. 
To obtain the delta-method approximate variance, the Taylor-series 
expansion of the function around the mean of h is truncated at linear 
order, and the theorem for variance of a linear function is used. This 
yields the expression 422 ))1(( −− +− µµµµ ee  as the linear-order delta-
method approximation to the variance of (1 − e−h)/h. Thus, linear-order 
approximations for both the mean and the variance of residence time are 
expressable in terms of the mean only of the rate h. 
If it is relevant to consider the value of pt−1 as a random variable, residence 
time in the interval is therefore the product of two random variables. 
Calculating the expectation and variance of the product of random variables 
requires the covariance of the random variables. By using the delta-method 
result for the mean (i.e. 1 − e−µ)/µ), the required covariance can be given as 
approximately 22)(
2
2
1
σµσµ −+−− yye . 
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Correlated rates
We maintain the assumption that rates hy are normally distributed with 
mean µy and variance 2yσ  but relax the assumption of independence by 
interval. Successive rates therefore have a non-zero covariance. Since the 
expected value of a sum is equal to the sum of expected values, the mean 
value of any period-specific pseudorate is still ∑t yµ . However, the variance 
of the pseudorate is no longer equal to ∑t y2σ . Moreover, the pseudorates are 
no longer normally distributed, and the distribution of year-end populations 
will not be log-normal. 
We claim that the distribution of year-end populations exposed to random 
rates in a single-state population model will be given by the distribution 
of the exponential of some function f(.), where the arguments of f(.) 
are random rates not necessarily independently, normally or identically 
distributed. However, because of the nature of the population model, f(.) 
is in fact restricted to a simple sum, i.e. f(h y) = Σhy. In the null model, 
attention was restricted to the case where arguments of f(.) are independent 
normal random variables. In the correlated case we drop the restriction 
of the independence of the hy and consider non-independent normally 
distributed random variables. The sums of such random variables are not 
normally distributed, which has implications for caculating the moments 
of )(hfe . We shall see that, without much additional complication, we can 
subsequently drop the assumption of normality. In all of these cases, our 
aim is to find expressions for the distribution of )(hfe , or at least for its mean 
and variance. In the null model, we can determine the distribution of )(hfe  
exactly; in other cases we can do so only approximately. 
A natural approach is to characterize the distribution of )(hfe  in terms of the 
mean and variance of f(.). Such an approach is attractive since f(.) is always 
additive and its mean and variance can always be easily obtained. Although 
the mean will always be given by the sum of the means of its arguments, to 
obtain the variance of f(.), the covariance between rates needs to be taken 
into account. For example, the variance of the sum of two random rates, h1 
and h2, is given by: 
),(Cov2)(Var)(Var)(Var)Var( 212121 hhhhhhf ++=+=Eq. (17) . 
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For a pseudorate in year 3, three possibly non-zero covariance terms need to 
be considered: 
).3,2(Cov2)3,1(Cov2)2,1(Cov2)3(Var)2(Var)1(Var)321(Var hhhhhhhhhhhh +++++=++Eq. (18)  
).3,2(Cov2)3,1(Cov2)2,1(Cov2)3(Var)2(Var)1(Var)321(Var hhhhhhhhhhhh +++++=++
It follows that, for the variance of the pseudorate in year t, there are 



2
t  
potentially non-zero covariance terms. 
Despite the growing number of terms in the variance of f(.), provided 
that the means, variances and covariances of the hy are known, the mean 
and variance of f(.) can be exactly determined. A simple model for non-
independent rates that satisfies this condition is one where rates follow an 
AR-1 process. Under such or similar conditions, therefore, determining the 
exact mean and variance of f(.) is feasible. 
Series expansion methods
Approximating the mean and variance of )(hfe  can be done with methods 
of series expansion. If it is sufficent to estimate the mean and variance of 
)(hfe , one approach is to express )(hfe  as a series expansion in terms of 
powers of a dummy constant and to take the required moments of the terms 
of a truncated version of the series (Weigel, 1986). If, on the other hand, 
one needs to characterize more fully the distribution of )(hfe , the methods 
of Edgeworth expansion, whereby the density of )(hfe  is approximated in 
terms of a modified normal density, are available (Kolassa, 2006). 
Taking the first approach, we write feλ  as a series expansion in the powers 
of λ and take the mean of both sides (equivalent to writing f in terms of its 
characteristic function):
 Eq. (19) 〈eλf 〉 = 1+λ〈 f 〉 + 21 λ2〈f 2〉 +….
The right-hand side can then be rewritten (Weigel, 1986): 
 Eq. (20) 〈eλf 〉 = exp{〈λf 〉 + 21 λ2(〈f 2〉 − 〈f 2〉) + O(λ3f 3)}.
Setting λ = 1, the mean of )(hfe  can be written in terms of the mean, µ, and 
variance, σ 2, of f(.) and a term that is O( f 3):
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 Eq. (21) 〈e f 〉 = exp{µ + 21 σ 2 + O( f 3)}. 
Note that when f is normally distributed, O( f 3) must be identically equal to zero. 
Truncating Eq. (21) at second order in the exponential, the mean of )(hfe  
can thus be written as approximately:
 Eq. (22) 〈e f 〉 ≈ exp{〈f 〉 − 21 (〈f 2〉 − 〈f 〉2)}. 
To obtain the variance of )(hfe , we proceed as follows. Since: 
Var(Eq. (23) X) = 〈X 2〉 − 〈X〉2, 
it follows that:
Var(Eq. (24) e f ) = 〈e2f 〉 − 〈e f 〉2.
But since, by Eq. (21):
 Eq. (25) 〈e 2 f 〉 = exp{〈2f 〉 − 21 (〈4 f 2〉 − 〈2f 〉2) + O( f 3)}, 
and:
 Eq. (26) 〈e f 〉2 = exp{2〈f 〉 + 〈f 2〉 − 〈f 〉2 + O( f 3)},
it follows that:
Var(Eq. (27) e f ) ≈ exp{2〈f 〉 − 2〈f 2〉 + 〈f 〉2} − exp{2〈f 〉 + 〈f 2〉 − 〈f 〉2},
with exact equality when f is normal. So approximate expressions for the 
mean and the variance of )(hfe  can be written in terms of the mean and 
variance of f. 
The above approach is equivalent to approximating the exponential of an 
arbitrary random variable by the exponential of a normally distributed 
random variable. This is evidently analogous to approximating an arbitrary 
distribution by a normal distribution with the same mean and variance. 
While this may seem to be a somewhat arbitrary procedure, it is equivalent 
to truncating the Edgeworth expansion of f at the first term (Kolassa, 2006); 
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an expression for the error of truncation is moreover obtained. When f is 
even approximately normal, this is a reasonable procedure and is in fact 
commonly used (Weigel, 1986). 
However, it is straightforward to obtain a better approximation if necessary 
by writing the distribution of )(hfe  directly in terms of its Edgeworth 
expansion (also referred to as the cumulant expansion):
 Eq. (28) )(hfe  ~ φ(e f ) × [1 + κ3 h3 (e f )/6 + (κ4 h4 (e f )/24 + 10κ32 h6 (e f )/720) + …],
where φ(e f ) is the normal density function with the same mean and variance 
as e f , the κi are the cumulants of e f  of order i and hi(e f ) are the Hermite 
polynomials (McCullagh, 1987). The higher-order cumulants of e f  (i > 2)  
will in general have to be estimated from a sample (possibly obtained by 
simulation) of e f . The sample-dependent nature of the estimates of the 
higher-order cumulants makes it relevant to express the error in truncation in 
terms of a measure of sample size. However, even for theoretical calculations, 
it is almost never necessary to include more than the first or second non- 
constant term in square brackets (McCullagh, 1987). Truncation error 
can be expressed in terms of the sample size, n, used for estimation of 
the cumulants. Truncating the series after the first non-constant term in 
square brackets yields error O(n-1); truncating after the second term (i.e. not 
including the dots) yields error O(n-3/2) (McCullagh, 1987).
Recall that the covariance of populations depends only on the mean value 
of year-end populations (e.g. in the independent case αy = 
2
2
1
yye σµ +− ). In the 
dependent case, therefore, αy will depend only on the mean of )(hfe . Thus 
dependence in rates affects the correlation of populations only indirectly, in 
other words, through the means of the pseudorates. In the dependent case as 
well, the pseudorates therefore remain the key to the uncertainty analysis of 
the population model.
Implications of various random models for h
It is possible to make several qualitative statements about the behaviour of 
f(.) for different random distributions h: 
— When h is uniformly distributed, Σh rapidly converges to an 
approximately normal distribution as the number of terms h increases. 
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— When h is gamma distributed with a common parameter θ, Σh will be 
gamma distributed, so when h is gamma distributed with parameters θ y 
approximately equal, Σh will be approximately gamma distributed.
— When h is log-normally distributed, Σh will be approximately log-
normally distributed (Wu et al., 2005). 
Population model under uncertainty
The conclusions of the cohort model generalize relatively easily to the full 
population model. Considering other age-group cohorts, the conclusions 
stated above remain valid: under the null model, year-end populations 
are log-normally distributed random variables whose means and variances 
follow a simple additive-in-the-exponent rule and null-model populations 
can be characterized in terms of stochastic processes whose covariance 
properties are well established. 
One additional complication is possible, however. Rates may be either 
correlated or uncorrelated across age groups. However, whatever the 
correlation pattern across age-specific rates, age-specific populations across 
the respective cohorts will be correlated through their respective population 
means. 
Multi-state life table under uncertainty
Introduction
When there is more than one possible state in the population model, as in 
the longitudinal population model described in (Lauer et al., 2003), we have 
the exponential of the matrix of transition rates (Eq. (2)) rather than the 
exponential of a single transition rate. The exponential of a matrix is defined 
in terms of the infinite series of the powers of the matrix (cf. Singer and 
Spilerman, 1976). However, for diagonalizable matrices (i.e. for square matrices 
of full rank) the matrix exponential has a closed-form expression in terms of the 
eigenvalues and eigenvectors. A diagonalizable matrix C can be written 
 Eq. (29) C = Ν⋅Λ⋅Ν −1,
where N is the matrix whose columns are the eigenvectors and Λ is a 
diagonal matrix of the eigenvalues. It is then easy to show that
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exp(Eq. (30) C) = Ν⋅exp(Λ)⋅Ν −1,
and that exp(Λ) is equal to the diagonal matrix whose elements are the 
exponentials of the individual eigenvalues (Strang, 1988). All C matrices 
for a population model will be square matrices of full rank, so these results 
apply to our case. In the population-model context, the eigenvalues are 
analogous to the rate in the scalar case; the eigenvectors represent the initial 
population values, and it is seen in the equation above, as in the equation 
for the scalar case, that they multiply the exponentiated eigenvalues in 
the matrix exponential (Caswell, 2001). Each distinct eigenvalue of C is 
associated with a unique state in the population model, and expresses the 
“long-term growth potential” of that state (Caswell, 2001).
When rates have units “year−1”, the matrix exponential gives a matrix 
of probabilities whose i,j-th element expresses the one-year probability 
of transition from state i to state j in the population model (Singer and 
Spilerman, 1976). As such, each element in the matrix exponential represents 
the sum of the probabilities of making the i→j-transition considering all 
possible paths from state i to state j, including paths requiring an infinite 
number of steps (Van Kampen, 1992). As it affords what is called a “spectral 
decomposition” of the transition matrix C, the matrix exponential provides 
a very useful formalism for the multi-state population model. The matrix 
exponential representation allows an analogous representation to that given 
for the single-cohort case in Eq. (3):
 Eq. (31) p(t) = A(C) ⋅ p(t − 1).
Here A(C) is the notation adopted for the matrix of survival probabilities 
(written as a function of the transition operator C to emphasize its 
dependence on the rates). 
When rates are random, A(C) can be partitioned, as in Eq. (11), into 
a matrix of the constant means and a matrix of multiplicative random 
deviations. The multi-state longitudinal population model can then be 
written:
 Eq. (32) p(t) = 〈A(C)〉 ⊗ d〈A(C)〉 ⋅ p(t − 1), 
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where 〈A(C)〉 refers to the matrix of means of the elements of A(C), d〈A(C)〉 
refers to the matrix of multiplicative random deviations around the means 
and "⊗" indicates the Hadamard, or element-by-element, product. 
In analogy, moreover, with the constant factors αy of Eq. (13), the elements 
of 〈A(C)〉 are expressable in terms of the series expansion of the elements 
of A(C). For example, if an element of A(C), which we can notionally 
represent as e f (the notion being that f is an eigenvalue of C), happens to 
be log-normally distributed, its mean as given by Eq. (21) will not contain 
a term of O( f 3) but will be exactly equal to 
2
2
1σµ+e , where µ and σ 2 are 
the mean and variance, respectively, of f (Gardiner, 2004). In this case, 
the corresponding element in the matrix of deviations, d〈A(C)〉, is a log-
normally distributed random variable with a mean of 1 and variance equal 
to )1(
2
1
2
112 σσµ ee +−+− .
Distribution of elements of A(C)
Since, however, each element of A(C) is in fact of the form Σigi⋅e fgi−1, where 
gi represents eigenvector i of C and f represents an eigenvalue of C, elements 
of A(C) will in general not be log-normal in distribution. However, algebraic 
expressions for the eigenvalues and eigenvectors of the matrix C can be 
calculated for any arbitrary population model with four or fewer states. In 
addition, for many reasonable population models containing five or more 
states, the eigenvectors and eigenvalues can still be calculated as algebraic 
expressions. Entries in A(C) can therefore often be expressed in terms of 
analytic functions of algebraic expressions of random variables. 
For example, for a population model with the 2 x 2 matrix C:




+−
−+
bac
bca
,
the eigenvalues are:




++ cba
a
,
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the eigenvectors are the columns of:



 −
11
1cb
,
and the corresponding matrix A(C) is:












+
+
+
+−−
+
+−−
+
+
++
++
cb
bece
cb
ece
cb
ebe
cb
cebe
cbacba
cbacba
)()1(
)1()(
.
What can we say in this case about the distribution of the elements of A(C) 
when the elements of C are random? If one assumes that rates are normally 
distributed and independent, their sums and differences will also be 
normally distributed. In addition, the exponentials of normally distributed 
random variables are log-normally distributed. So the numerators of the 
individual elements can be reduced to a sum of the products of normal and 
log-normal distributions. Since the denominators in this case are  themselves 
normal distributions, it is reasonable to expect that the ratio distribution will 
be approximately log-normally distributed (as an heuristic, one can imagine 
that the normal densities “cancel” in both the numerator and denominator). 
However, for a population model such as that in (Lauer et al., 2003), with 
a 4 x 4 matrix C, these expressions contain hundreds of terms, including 
polynomial combinations of elements of C and roots of polynomial 
combinations of elements of C. In such a case, no obvious intuition seems 
available concerning the distribution of the elements of A(C); calculating the 
distributional form analytically is moreover a virtual impossibility. 
We suggest the following conjecture. Since, when many random terms 
combine additively a normal distribution is the result, and when many such 
terms combine multiplicatively a log-normal distribution results, when many 
random terms combine both additively and multiplicatively, depending on 
the predominance of one or the other operation, as well as on the relative 
magnitudes of the terms, one can expect either the normal or the log-normal 
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form to dominate, at least as an approximation. We support this conjecture 
below with results from simulations.
Cumulant expansion of elements of A(C)
As both the eigenvalues ( f ) and eigenvector elements (g) of C are functions 
of random variables, the cumulant expansion of the elements will depend 
on the distributions of g and of f, as well as on their correlations. Moreover, 
as there is no guarantee that elements of A(C) are normal in distribution, 
their cumulant expansion will in general have a potentially infinite number 
of terms. Consequently explicit expressions for their means and variances 
will necessarily be approximate, and the elements of d〈A(C)〉 can likewise 
be written as only approximately equal to 1 in expectation. Although this 
implies that we are limited to writing Eq. (26) as an approximate equality 
only, any arbitrary level of precision can be obtained by means of additional 
terms in the cumulant expansion if necessary. 
Simulation approach
This difficulty of calculating an explicit distributional form for the elements 
of A(C) when its elements are not normally distributed suggests an efficient 
use of the simulation method for purposes of studying the uncertainty of a 
given multi-state longitudinal population model: 
One defines distributions for the random rates that make up the 1. 
elements of C.
Multiple random draws are made from each of these distributions, so as 2. 
to produce a distribution of random matrices C. 
For each draw of 3. C, the matrix of one-year probabilities Ay(Cy) , which 
is in general understood to be period specific, is computed numerically. 
The resulting distribution of random matrices 4. Ay(Cy) is used to compile 
distributions for each of its elements. 
The distributions of each of the elements of 5. Ay(Cy) is used to calculate 
numerically the desired number of cumulants for each of the element 
distributions.
Using the results from step (5), the matrices 6. 〈A(C)〉 and d〈A(C)〉 are 
constructed. 
The population model is then approximately represented in the form of 7. 
Eq. (26).
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When the uncertainty of multiple-year life-table quantities are required, 8. 
the matrix products Pt〈Ay(Cy)〉 and Ptd〈Ay(Cy)〉 are calculated.
The product 9. Pt〈Ay(Cy)〉 gives the correlation constant for the population 
model and the product Ptd〈Ay(Cy)〉 gives the random component.
The delta method can be used to calculate the mean and variance of 10. 
derived life-table quantities like population residence time. 
It can thus be seen that the distribution of the elements of the matrix Ay(Cy) 
is sufficient for defining the uncertainty characteristics of any life-table 
quantity in the multi-state population model. Just as for the pseudorates, 
the exponential component of elements of PtAy(Cy) will show additivity in 
the eigenvalues, so it may be possible to achieve some simplifications in the 
above methods (e.g. calculating only the distributions of the eigenvalues 
of C). However, for the purposes of simulation it will usually be just as 
convenient to calculate the full expression for the components of PtAy(Cy). 
Simulation results
Regarding our conjecture concerning the distributional form of the elements 
of Ay(Cy), we stated above that it should be either approximately normal or 
approximately log-normal. This is indeed what is found in simulations based 
on population models such as the one presented in (Lauer et al., 2003). In 
fact, these simulations suggest that elements of A(C) show a strong tendency 
overall to converge towards an approximately normal distribution (Figure). 
The histograms of the elements of Ay(Cy) display a bell-shaped curve well fit 
by the normal density, that shows either negligible skewness or a slight log-
normal skewness).
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Figure: Histograms of elements of A(C) for the population model in [Lauer et al., 2003], showing 
the corresponding line of normal density. The distributions were obtained from 10,000 simulations 
where the elements of C are independent and normally distributed.
Notice, however, that the distribution of anti-diagonal elements {(i, j): (1, 
4), (2, 3), (3, 2), (4, 1)} in the array are noticeably more skew (i.e. more log-
normal) than the distribution of other elements, which are only negligibly 
if at all skew. This pattern has a meaning in terms of the population model 
in (Lauer et al., 2003), since the anti-diagonal elements represent transitions 
that cannot be made in a single step, that is {( j → i): (4 → 1), (3 → 2), (2 → 
3), (1 → 4)}, but only as a result of a series of two or more steps. 
Thus, the shortest path that implements the transition {(4 → 1) = (XC → 
S)} is either the path {(XC → C)} ∪ {(C → S)} or the path {(XC → X)} ∪ 
{(X → S)}. Similarly, the shortest path implementing the transition {(3 → 
2) = (X → C)} is either the path {(X → XC)} ∪ {(XC → C)} or the path {(X 
→ S)} ∪ {(S → C)}. Since the probabilities of making a double or higher-
order transistion always involve the product of at least two probabilities, 
it is reasonable to expect that the distributions of the probabilities of these 
transitions should be more log-normal.
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The same is true of the diagonal probabilities, which represent the 
probability of starting in a state and ending in that same state in the 
same interval. The relevant paths also contain at least two steps. Taking 
the logarithm of the distributions from the simulations shows that, for 
all distributions other than the diagonal and anti-diagonal distributions, 
the logarithmically transformed distributions are distorted whereas the 
transformed diagonal and anti-diagonal distributions appear symmetric. 
This suggests that the diagonal and anti-diagonal distributions have a more 
pronounced tendency to converge to log-normal distributions than the other 
distributions.
These findings suggest the possibility of making the following emendation 
to the simulation procedure, above. After step (4), insert:
If the distributions of any of the elements of 4a. Ay(Cy) are noticeably skew, 
take the logarithm of the values and calculate the cumulants of this 
transformed distribution (where a low-order truncation of the cumulant 
expansion will be more justified). Exponentiate to recover the original 
distribution.
Conclusions
The problem of determining the distributional features of p(t) in a multi-
state longitudinal population model can be seen to reduce to the problem 
of determining the distribution of elements of A(C) when C is a random 
matrix. The demographic or statistical literature on Markov models does not 
appear to address the question of random elements in the operator matrix 
C. The indicative results we present here are nevertheless a straightforward 
extension of the linear algebra theory that underlies most multi-state 
modelling theory. 
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Appendix 1I Modelling complex interactions in longitudinal population models
Introduction1
Generic population health models [1] offer the possibility of easy-to-use 
longitudinal models that can be used for population health measurement. 
In many cases, generic models can be implemented with generally available 
epidemiologic and demographic data and can be used to quantify real 
population health risks. In spite of these possibilities, analysts who are 
faced with the need to model complex disease processes, such as those 
presented by many chronic diseases, for example, may find that four health 
states are not sufficient for a decent level of realism. Typically chronic 
disease processes can involve an arbitrary number of disease stages accessed 
in a progressive, non-reversible fashion. Or, if an analyst is interested in 
modelling multiple risk factors and disease states, the factor limiting the 
realism of the model may not be the number of states available in the model 
but rather the number of interactions between risk factors, in other words, 
the need to model combinations of risk factors requiring the definition of 
many more than four states. For such situations, four different health states 
is far too few and the use of generic models [1] will therefore ultimately 
be unsatisfying for some population health problems and a greater level of 
heterogeneity will be sought. Although different approaches are possible, 
and many of them will share a similar set methods for addressing the 
problem we describe, microsimulation is one natural approach. With 
microsimulation methods, one can readily investigate questions of multiple 
interacting risk factors and causes of disease (i.e. “causal web”). However, 
the technology of microsimulation does not change the fundamental need 
to characterize a joing distribution from a set of observations of marginal 
distributionsw. Moreover, the question of characterizing in quantitative 
terms the interactions in the causal web becomes important. Thus, the kinds 
of data transformation that are required to define the initial state of the 
population simulation can be more complex. Several generic insights are 
nevertheless possible.
When one wishes to model several population states in a longitudinal 
1 I am grateful to Claude Charette and Steve Gribble of Statistics Canada for their assistance 
in helping me to start thinking about the problem discussed in this appendix and for their 
having worked through a complete example.
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population model, lack of information about the joint distribution of 
risk (either longitudinal, in terms of rates, or cross sectional, in terms of 
prevalences) is a common problem. Even for the simple case of estimating 
the effect of a risk factor within a given strata of the population, in the 
absence of knowledge about the joint distribution of risk factors within the 
stratum, the estimation of effects is − in most cases − hopelessly confounded 
[2]. Of course, if risk distributions were statistically independent, the 
problem would be trivial since the joint distribution would merely be 
calculated as the product of the marginal distributions. Yet departures from 
independence are often precisely what make the joint distribution of risk of 
interest [2]. So determining the joint distributions of non-independent risk 
factors is not only an ubiquitous but also an important problem.
These questions can be related more generally to concepts of "interaction" 
as discussed in the epidemiological literature [3-22]. However, in the 
mainstream literature, interaction is typically defined with respect to rates, 
relative rates or incidence proportions [3]. In any case, since rates, relative 
rates and relative incidence proportions are measured longitudinally, 
one can conclude that the kind of interaction typically discussed in the 
epidemiological literature is what could be called "longitudinal interaction" 
(i.e. related to interaction in rates). Despite its similar importance, the 
problem of determining the joint distribution of risk factors and stratification 
variables in cross section typically goes underrecognized, although it has been 
mentioned as a source of unavoidable estimation bias [19,21]. 
In either the longitudinal or the cross-sectional case, however, it is important 
to be modest in trying to relate statistical concepts of dependence and 
independence to biological processes of interaction [6]. It is important to 
keep in mind that, among other problems in moving from a statistical to 
a biological concept, that a variety of different biological interactions can 
produce the same statistically observed outcomes[13]. Recognizing the 
inherent gulf between biological and statistical concepts, we develop here a 
pragmatic approach to "interaction" that is defined primarily in statistical 
terms. Our concept will therefore be mostly agnostic about the true 
underlying biological mechanisms, although it will occasionally be possible to 
rule out certain biological mechanisms as inconsistent with the observed data.
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Moreover, in the approach presented here, headway can be made on both 
the problem of longitudinal and cross-sectional interaction through the 
application of a single conceptual framework and approach. Indeed, since 
the current cross-sectional distribution of exposure is merely the cumulative 
result of past events, it should in principle be possible to approach the 
problem of the joint prevalence of risk factors (i.e. static, or cross-sectional, 
interaction) as well as the decomposition of aggregate rates (i.e. dynamic, or 
longitudinal, interaction) with a common set of methods. 
For both conceptual clarity and measurement purposes, however, it is useful 
to distinguish dynamic and static concepts of interaction in the following 
exposition, where we define a minimal set of necessary and sufficient 
information to determine the joint distribution in the static case as well 
as solve the decomposition of aggregate  rates. We specify that the "joint 
distribution" can be understood to refer either to the joint distribution of 
persons or of person time and that the methods employed do not depend on 
one or the other distributional concept, although it is of course always useful 
to use a consistent set of definitions in the course of a particular problem. 
It is also useful to recognize, at least as an approximation, that the concepts 
of prevalence, rates and odds can be referred to together, as necessary, by 
means of the common term "risk" [3] without damage to either common 
sense or the main conclusions of the argument. 
Static problem
To fix ideas, we refer to a case of stratification variables and risk factors, 
although the actual boundaries between the two concepts are fluid. Typical 
stratification variables might be age, sex, income or educational status, 
whereas typical risk factors are usually the exposures of primary interest 
in the question at hand. However, these designations are mainly arbitrary 
since risk factors will typically become stratification variables once they are 
well known. In any case, suppose there are K strata for the stratification 
variable M = {Mk}, k = 1, …, K, and J levels of risk factor X ={Xj}, j = 1, …, J. 
It should be clear that we refer here to the partition of the population into a 
2-way discrete classification.
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We may start by noticing that, in such a case, it will always be possible to 
define the joint distribution of risk within strata as the solution of a system 
of K x J independent equations. For the problem to be well posed, these 
equations, whatever their actual positive content, must be written in terms of 
a vector of the unknown joint prevalences p, a matrix of known coefficients 
A and a vector of observable constants b. The observable constants b will 
typically be either the marginal prevalences or zeros (discussed below), and 
the coefficients A will typically be either known relative risks or other known 
constants (discussed below). We return to this in more detail subsequently. 
In any case, based on a suitable identification of the different elements of the 
system, we then write A⋅p = b. It is well known that whenever the matrix A is 
of full rank, the system has a unique solution for p.
To define solution conditions that are consistent with the empirical problem, 
it is reasonable to assume that the marginal distributions b of both X and 
M are known. The marginal distributions can be thought of here as the 
population-level risk of (i.e. the probability of finding) the members of 
the different risk-factor and stratification-variable levels based on uniform 
random sampling from the entire population. Actual observations of b will 
typically not strictly fulfill these conditions but rather approximate them. 
These marginal prevalences, which we assume are observed, define J + K − 1 
independent summing-up equations. That is, for each marginal prevalence, 
we can always write K equations of the form ∑
=
=
J
j
jii pm
1
, , as well as for each 
risk factor J equations ∑
=
=
K
i
jij px
1
, . Note that pi,j are unknown in both cases 
When written in matrix form, these J + K − 1 equations define a submatrix 
of A whose coefficients are all ones (1s). Note however that although we 
could in principle write J + K equations, only J + K − 1 of the equations are 
actually independent, since one of the equations can always be expressed in 
terms of a linear combination of the others (i.e. by summing across either 
risk-factor or stratification-variable levels, the total population is recovered: 
∑∑
==
==
K
i
ji
J
j
ji pp
1
,
1
,1 ). 
Since the observed marginal prevalences yield only K + J − 1 independent 
equations in terms of the joint prevalences, (K x J) − (K + J − 1) = (J −1) × ( 
K−1) additional equations are required in order for the system to be solvable. 
This number (J −1) × ( K−1) is evidently equal to zero only when K or J = 1. 
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We propose that, in general, it will be reasonable to characterize these ( J 
−1) × ( K−1) additional equations in terms of relative risk relations. The 
advantage of relative risk measures for this purpose are several. First, and 
most importantly, relative risk provides a concise way to define interaction 
in statistically observable terms. Second, estimates of relative risk as 
defined below are typically available from case-control studies. Third, it 
will often be possible to make reasonable guesses about the magnitude of 
a given relative risk even in the absence of data. Finally, using relative risk 
measures such as those defined below to construct the required additional 
equations to complete the system A⋅p = b does not for the moment require 
any assumption about the functional form of relative risk (e.g. additive, 
multiplicative etc.). We return to this topic when we discuss dynamic 
interaction, below.
As is typical, we define relative risk as a ratio of conditional risk
)(
)(
1
1,
j
jk
k xXp
xXp
=
=
≡℘Eq. (1) ,
where pk represents the probability of finding an exposure unit (person or 
person-time) in stratum level k conditional upon a specific exposure status 
(e.g. X = xj). We say that when there is interaction between levels of the risk-
factor and the stratification-variables ℘k ≠ 1. Subsequently, we define more 
precisely what kind of conditional risk measures are required to solve A⋅p = b. 
Suppose, for example, that, for each risk-factor level j, an equation of the form
)(
)(
1 j
jk
k xXp
xXp
=
=
=℘Eq. (2)  
can be written, where X = xj signifies that there is exposure to risk factor level 
j. This represents the typical sort of measure that is available from case-control 
studies. Suppose for the moment that there are two stratification-variable levels 
(k = 1, 2), one risk factor level, one baseline, or non-exposed, level, and that the 
interaction of risk-factor level j with stratum 2 is written ℘2, j
1,1
2,2
,2 mp
mp
j
j
j =℘Eq. (3) ,
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where the marginal prevalence of measurement units in stratum 1 is given 
by m1, the marginal prevalence of measurement units in stratum 2 is given 
by m2 and we write p2,j and p1,j for the unknown joint prevalence of risk-
factor level j in stratum-level 1 and 2, respectively. Rearranging the latter 
equation for the relative risk, we can then evidently write
01,2,22,1 =−℘ mpmp jjjEq. (4) ,
which is a linear equation in terms of the unknown joint prevalences p2,j and 
p1,j. On the basis of the observation of the value ℘2,j, such an equation can 
be added to the (K + J − 1) equations that were previously written in terms 
of the summing-up constraints for the marginal prevalences.
Since, when the marginal prevalences are known (which is our assumption), 
it is always possible to write the summing-up constraints, and since each 
relative risk ℘i,j that we know defines one additional equation in terms of a 
subset of the joint prevalences pi,j and some of the marginal prevalences mi 
and xi, it will always be possible to solve for the full set of joint prevalences 
whenever we know the value of a set of (J −1) × ( K−1) complete and 
independent relative risks. The equations are shown in matrix form for the 
J = K = 3 case in the Figure. The solution can be obtained by matrix algebra 
or by Gaussian elimination (i.e. repeat substitution). 
Figure: The matrix equations for the J = K = 3 case.
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What is an “independent” or “complete”relative risk in this context? Each 
relative risk relates the conditional prevalence of a single stratum-risk 
pair with that of another stratum-risk pair. Independence simply requires 
that there are no redundant stratum-risk pairs among the available set of 
observed relative risks. Completeness, which is in fact satisfied whenever 
there are (J −1) × ( K−1) independent relative risks, requires that all existing 
strata and risk levels can be mutually related, for example, for four strata, 
three stratum-risk pairs are required to mutually relate all four strata. 
For example, if the strata are labeled i, j, k, and l, any of the sets of strata 
pairs {i→ j,  j→ k, k→ l}, {i→ j,  j→ k, j→ l}  and {i→ j,  j→ k, i→ l} are 
complete. A complete set of strata pairs is required for each risk level except 
for “baseline” risk since the relative risk of the “last” risk factor level can 
always be expressed as in terms of the other relative risks.
So far we have discussed the case of a single risk factor with J levels X ={Xj}, 
j = 1, …, J and a single stratification variable with K levels M = {Mk}, i = 
1, …, K. However, when there are additional risk factors or stratification 
variables that are also of interest, provided there are enough additional 
relative risks estimates available, the approach described above can be 
iteratively applied to find the solution to the joint prevalence. To begin, we 
notice first that additional risk factors (or stratification variables) must be 
either interacting or non-interacting with the initial pair of risk factor and 
stratification variable. If the additional variables are non-interacting, a new 
joint distribution can easily be obtained by multiplying each element of the 
joint distribution solved for in the first step by each element of the marginal 
distribution of the new risk factor (or stratification variable). 
However, if the new risk factor or stratification variable is interacting, 
it must interact either with the existing risk factor, with the existing 
stratification variable or with both. If it interacts with only one of them, 
the process of writing summing-up constraints and relative-risk equations 
can be repeated with that one. If, on the other hand, it interacts with both 
of them, then one of the interactions can be chosen first. The new variable 
must interact either with levels, or with aggregates of levels, of the marginal 
distribution of the chosen variable. On the basis of that interaction (i.e. 
using the relative risk observations that are available), one then write a 
The time dimension in measurements of population health
302
new system of the form A⋅p = b, which will again be solvable whenever the 
matrix A can be written so as to be of full rank. The same process can then 
be repeated for the other interaction. 
Provided the conditions for the existence and uniqueness of a solution are 
satisfied for each step (i.e. the matrix A is of full rank), this process can be 
repeated an arbitrary number of times. This is true even when none of the 
joint prevalences that are sought are actually known to start with. Moreover, 
because of considerations of symmetry, regardless of which risk-factor/
stratification-variable pair is chosen as the starting point (assuming there are 
several alternatives), the end-point of the iterated solution process must be 
the same (i.e. in practice, the solution is constrained by the available data on 
marginal distributions and relative risk). 
One may futher observe that, due to measurement error or bias in 
measurement, the supposedly known quantities can in fact be uncertain. 
As a result, the mapping from the space of the known quantities (marginal 
prevalences) to the space of the joint prevalences may be subject to 
uncertainty. In this case, a notional uncertainty analysis can proceed as 
follows. Suppose error in the known quantities is normally distributed. 
Since the solution vector of joint prevalence is, according to matrix theory, 
a linear combination of the known quantities, its elements will also tend to 
have normal distributions. This tendency will be more pronounced the more 
independent known quantities are represented in the solution expressions.
Dynamic problem
As noted earlier, the epidemiological literature has typically been concerned 
what we have termed dynamic interaction (interaction in rates). 
Interaction hypotheses
In the static case, we have discussed interaction without regard to its 
functional form (cf. Eq. 3, which depends on the magnitude of interaction 
but not on its specification). This sort of measure is non-parametric in the 
sense that whatever kind of interaction is present, it is captured in the data 
that are observed. This type of assumption is consistent moreover with 
the sort of observations of static interaction that are typically available 
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from case-control studies. In the case of dynamic interaction, however, 
considerable attention has been devoted to a number of different canonical 
forms of interaction and their implications [3,11,14-16]. 
Additive models
For example, a simple additive model for rates has been defined as follows [3]
βα xxr kk +=)(Eq. (5) ,
where x is the vector of exposures, k indexes the stratum and β is a vector 
of effect measures expressing the change in risk per unit increase in the 
exposure x. Since rk(0) ≡ αk, the additive model implies (or can be derived 
from) additivity of the rate difference
βxrxrxD kkk =−= )0()()(Eq. (6) .
Since the model of additive rate-different is synonymous with the hypothesis 
of “no causal interaction” under Rothman’s sufficient-component cause 
model [3], the lack of causal interaction can be taken as a definition of 
the simple model of additive rate difference, and a finding of additive 
rate difference can be taken as evidence if favour of the absence of causal 
interaction.
Another model typically referred to as “additive” is the additive relative rate 
model. The rate model that corresponds to the additive relative-rate model 
can be written as follows [14,16]
)1()( *βα xxr kk +=Eq. (7) ,
where β* is a vector of constant effect measures expressing the change in 
relative risk per unit increase in x (note that this is a different measure of 
effect than that which is relevant to the model of addtive rate difference, 
above). The additive relative rate model implies that excess relative risk, 
defined as
*1
)0(
)(
)( βx
r
xr
xE
k
k
k =−≡Eq. (8) 
is also additive. The additive relative rate model is also a proportional risk 
model [3], since, as can be seen from the definition of the model, stratum-
specific exposure effects differ only by a constant of proportionality αk. The 
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additive relative rate model is therefore is not a model of non-interaction 
(as has sometimes been claimed) but rather a restriction on interaction to a 
particular multiplicative form (i.e. constant of proportionality αk).
A less restricted additive model is the following [3]
kkk xxr βα +=)(Eq. (9) .
Here, the effect of exposure is stratum specific, and interaction is not limited 
to a particular mathematical specification. Such stratum-specific interaction 
would therefore need to be observed. This less restricted additive model can 
also be written in terms of an additive relative (or excess) risk model
)ˆ1()1()( kk
k
kkkk x
xxxr βα
α
βαβα +≡+=+=Eq. (10) .
Here, each element βk is divided by the corresponding αk and renamed , 
yielding an additive relative risk model with stratum specific coefficients. 
This is in fact the specification in which additivity of risk is usually tested 
for in studies [3].
In every additive model but the simple additive model risk-difference model 
of no interaction, therefore, the assumed additivity relation in underlying 
rates, risk or odds can be represented in terms of a corresponding additivity 
relation in relative risk, relative rates or relative odds. Moreover, the 
different additive models represent a spectrum of (additive) specifications for 
interaction: the least restricted model of Eq. 9 allows stratification variables 
to interact with risk factors in a non-specified manner; the model of additive 
relative risk allows risk factors to interact with stratification variables but 
limits the interaction to constant factors αk; finally, the additive risk model 
implies no interaction between stratification variables and exposures [3].
Equivalence between additive models
The simple additive model for rates (Eq. 5) is equivalent to an additive 
model for relative rates (Eq. 7) only if [3]: 
— there is only one stratum, or 
— the baseline rate rk(0) is constant across strata (i.e. rk(0) = r(0)). 
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However, we have shown that is always possible to solve for unique values 
for rk(x) when J + K marginal prevalences are known and there are ( J −1) 
× ( K−1) independent known relative risks. We now show that, in general, 
the existence of such a solution will almost always require baseline risk to 
differ across strata, implying that the additive model for rates is almost never 
equivalent to the additive model for relative rates. 
The stratum-specific (i.e. joint) risk, rate or odds that are the solution of 
the matrix equation correspond to a basis vector in the space of the joint 
prevalences. Moreover, precisely because the solution vector for the joint 
prevalences is a basis in the space of joint prevalence, each solution element 
is necessarily algebraically different (since if they were the same, one element 
would be redundant and, contrary to the construction of the problem, the 
basis would then not span the space of joint prevalence). We can nevertheless 
ask under what conditions these algebraically different solution elements 
may be numerically equal.
The conditions for this can be determined by setting the different solution 
expressions for baseline risk equal, 0,0, ji rr =  for all possible i,j pairs, where i 
and j index the stratum levels. For K levels, the number of possible i,j  
pairs where i ≠ j can be written compactly as the binomial coefficient 



2
K
. 
When the relative risks are independent and complete, solutions for baseline 
risk will moreover necessarily be expressed in terms of all J × K  known 
quantities for marginal risks and relative risks. The baseline risks cannot be 
expressed in terms of fewer than J × K known quantities because solvability 
of the system requires each of the known quantities and no fewer. Each of 
the 



2
K  equalities that need to be written to enforce equality of baseline 
risk across strata is therefore an expression written in terms of each of the 
J × K known quantities. Since each equality can be solved in terms of one 
of the J × K known quantities, each of the 



2
K  equality constraints induces 
a corresponding equality constraint on each of the J × K other known 
quantities it contains. 
Since there are 



2
K
 equalities that can be solved for a given known quantity, 
these in turn induce 










2
2
K  pairwise equalities in terms of the remaining J × 
K − 1 known quantities. From this group of pairwise constraints, another 
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one of the J × K − 2 remaining known quantities can then be solved 
for. However, this solved-for quantity now has to satisfy 


























2
2
2
K
 constraints 
expressed in terms of the remaining J × K − 3 known quantities. Proceeding 
in this fashion, it can be seen that the binomial coefficient 



2
K  must be 
nested J × K times, in other words, until all the known quantities except 
for the last one have been expressed in terms of all the others. For the case 
of 4 strata and 4 known quantities, the first known quantity therefore has 
to satisfy 6 constraints, the second 15, the third 105 and the last 5460. 
However, since the order of choosing the known quantities is arbitrary, 
symmetry requires that each of the known quantities should satisfy 5460 
additional constraints.
However, since each such additional constraint represents a linear 
combination of the solution values for the joint risk, rate or odds, even one 
such additional constraint is too many for the known quantities to satisfy. 
This is because the only combinations of the solution values for joint risk, 
rate or odds that also are combinations of the known quantities are those 
specified in the system of equations A⋅p = b, which was solved to obtain 
the joint prevalences. In fact, the matrix A from that system of equations 
is guaranteed by construction (i.e. by the full rank condition) to represent 
a unique transformation that maps elements from the space of the joint 
prevalences to the space of the known quantities. 
If any single additional linear combination was in fact possible, it would 
be equivalent to adding an extra row to the original matrix equation. 
However, since the original matrix equation is the unique transformation 
that maps the joint prevalences into the known quantities, two possibilities 
arise: either the additional row is linearly dependent on the other, original, 
rows, in which case the matrix is singular (and the “additional” constraint 
is therefore implicit in the original system and is consequently not an 
additional constraint), or the additional row is independent (and the 
matrix is therefore inconsistent). In either case, the full rank condition is 
violated and a solution to the matrix equation is impossible. Therefore, any 
additional constraints on the known quantities in terms of the joint solved-
for prevalences are not possible.
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There is nevertheless one case where the condition of equality of baseline risk 
does not impose any additional constraints on the known quantities. That is 
the case of two strata only (regardless of the number of risk levels). Since 



2
2  
= 1, equality of baseline risk across the two strata can induce only a single 
equality constraint on the joint solution quantities, but, since 














2
2
2  = 0, no 
equality constraints are in turn induced on the marginal prevalences). 
It has already been noted in [3] that the additive relative risk model is 
equivalent to the additive risk model only when there is only one stratum 
or when baseline risk is equal across strata. The arguments presented here 
provide an important restriction on the second possibility, namely, that it 
is only possible in principle for baseline risk to be equal across strata when 
there are only two strata. 
The additive relative risk model can therefore only be equivalent to the 
simple additive risk model of no interaction when there are at most two 
strata (and it is by no means guaranteed to hold in the two-strata case). In 
any other case, the additive risk model cannot be equivalent to the additive 
relative risk model.
Multiplicative model
A multiplicative model for risk is typically written [21]:
)0()(exp)( kk rxxr ⋅= βEq. (11) ,
from which it can be seen that relative risk can be written:
)0(exp
)(exp
)0()0(exp
)0()(exp
)0(
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β
β
β
β x
r
rx
r
xr
xR
k
k
k
k
k =⋅
⋅=≡Eq. (12) .
Since by Eq. 11, expβ(0) must be equal to 1, it follows that
)(exp)( xxRk β=Eq. (13) ,
which is a multiplicative model for relative risk. The multiplicative relative 
risk model is of considerable interest in practical work since estimates of 
relative risk obtained using such a model are interpretable as standardized 
parameters, i.e. parameters standardized to the risk distribution in the study 
population from which they were obtained [21]. 
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Multiplicative versus additive models of interaction
While it has been claimed that additivity of risk, rate and odds remains the 
“most basic manifestation of independent action” [6], empirical additivity of 
rates does not by itself imply the absence of interaction [3] and it is therefore 
a necessary but not sufficient condition for a definite claim about the 
absence of interaction. Interaction, moreover, as we have discussed above, 
can have different specifications, including additive and multiplicative 
relative rate specifications. 
In any case, for certain simple biological models of interaction, it is in 
general possible to say whether an additive or multiplicative model is 
preferred. For example, in simple multi-stage models model derived from 
studies of carcinogenesis, it can be shown that two risk factors acting on 
the same stage of pathogenesis interact in an additive fashion, whereas risk 
factors that act on different stages interact multiplicatively [10, 12]. 
For example, a simple carcinogenesis model posits that a single cell, by 
undergoing a series of transformations, results in a cell capable of malignant 
replication; such a model is consistent with the well known power-law 
relationship for cancer incidence [10]. Since noxious exposures increase the 
probability of transformations, when they facilitate separate stages of the 
transformation to malignancy their joint effect combines multiplicatively, 
but when they facilitate the same stage, the joint effect combines additively. 
A multi-stage multiplicative model has solid empirical support for non-
hormonally dependent cancers of epithelial origin [10].
Therefore, when pathogenesis is multi-factorial and exposures affect different 
stages of disease, a multiplicative model appears to be the canonical model, 
whereas when exposures affect the same stage of disease occurrence, an 
additive model may be canonical. Whether the additive model is an additive 
rate or risk model will depend on the formulation of the underlying disease 
model, i.e. in terms of either rates or relative rates and, as we have shown, an 
addtive rate model will almost never be an additive relative rate model. In 
any case, the additive relative rate model is of some interest because of its use 
as a common model to test for additivity.
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Finally, additive and multiplicative relative rate models cannot be equal: 
each specification has different quantitative implications for outcomes. In 
particular, a multiplicative model of interaction will in general result in a 
higher rate of disease than any additive model.
Since “it is difficult to imagine situations in which typical stratifying factors 
… would be unassociated with any causal cofactors” of the exposures x, 
we propose that the additive relative rate model and the multiplicative 
relative rate model may be representing two different possible forms of 
interaction that respond to different possible models of biological interaction 
in multi-stage disease causation. As we shall see in the following section, 
this characterization offers the additional advantage that both cases can be 
characterized in terms of relative risk only.
Rate decomposition
Now we consider transition events, in particular from disease-free to 
diseased status. Transition events are modelled by rates, and are therefore 
fundamentally longitudinal. Here, to fix ideas, we focus on the case of 
hazards, i.e. instantaneous rates. 
The total population rate of transition to disease y is equal to the per-
capita rate of transition, r y, multiplied by the prevalence of the group 
without disease y, p0 (i.e. the population prevalence of the group capable of 
experiencing the transition), in other words, the quantity r y⋅p0. We write p 
with superscript 0 to emphasize the prevalence of the group without disease 
y, and we write r with superscript y to emphasize the rate of transition to y, 
respectively. Suppose that the disease-free population is furthermore divided 
into subgroups by risk-factor and stratification-variable status according 
to the methods of the previous section regarding the static problem. The 
total population transition rate r y⋅p0 must then necessarily be equal to the 
sum of the products of per-capita rates in the different subgroups and the 
prevalences of the respective subgroups. Suppose that the subgroups are 
denominated by subscripts denoting stratum/risk-factor levels and that we 
write superscripts to emphasize status with respect to disease y. When there 
are two strata (1, 2) and two risk-factor levels (a, b), we can then write 
0
,2,2
0
,1,1
0
,2,2
0
,1,1
0
b
y
bb
y
ba
y
aa
y
a
y prprprprpr ⋅+⋅+⋅+⋅=⋅Eq. (14) .
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By the methods of the static problem, above, the prevalence values in 
an equation of this type are assumed to be known. Since it is the sort of 
quantity which is in principle observable, we further suppose here that 
the total population rate, r y⋅p0, is also known. However, since there are K 
× J unknown subgroup rates, for the moment, we have only one equation 
with K × J unknowns. In the absence of (K × J) − 1 additional independent 
equations, it is clearly impossible to solve for the unknown subgroup rates. 
This is a substantially worse situation than that which was faced in the static 
problem, where we required only (K − 1) × (J − 1) additional equations, 
which we supposed were available in the form of relative risks. In other 
words, here we need K + J − 2 more equations than we needed to solve 
the static case. What can we do to make the information demands in the 
dynamic case in practice no greater than they were in the static case?
One way is to suppose that we know only a relatively small number of 
relative rates but that we know that relative rates follow a particular 
mathematical form, such as additive or multiplicative. In such a case, we 
can then solve for the different subgroup rates. In other words, if we know 
only (K − 1) + (J − 1) independent relative rates and we know a rule f(.) for 
combining relative rates, we can easily derive the additional relative rates 
required to make the system solvable. To continue the dynamic example we 
have started, above, if we know the following two relative rates
a
b
ba
a
a
a r
r
r
r
,1
,1
,1
,
,
1
,2
,21 =℘=℘ →→Eq. (15) ,
then we can easily derive the third required relative rate
),( ,1,21
,1
,2
,21 baa
a
b
ba fr
r
→→→→ ℘℘==℘Eq. (16) .
If relative rates are multiplicative, the derived relative rate is calculated
baaba →→→→ ℘⋅℘=℘ ,1,21,21Eq. (17) ,
but if relative rates are additive, the derived relative rate is calculated
1)1()1( ,1,21,21 +−℘+−℘=℘ →→→→ baabaEq. (18) .
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Following the approach for the static case, with these three relative rates it is 
possible to write enough equations in the four unknown subgroup-specific 
rates to solve for all the subgroup rates. 
While in general it is impossible to say with any confidence what is the 
correct relative risk law to apply, broad statements of the following type 
appear to be not unreasonable:
— The additive rate model is unlikely to apply since there will in general be 
interaction (i.e. the statistical association of stratification and exposure 
variables). 
— Interaction can be characterized according to two canonical forms in 
terms of relative rates (additive and multiplicative).
— Each form has specific implications for outcomes, and each can be 
related with profit to a specific part of the epidemiological literature.
— The multiplicative form for interaction of relative risk implies a larger 
subgroup risk than the additive form of interaction.
— The multiplicative form of interaction has the interpretation that 
exposures operate at different stages of pathogenesis, or, in other words, 
through different causal pathways. 
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Summary
The health of populations is a concern for both governments and civil society. 
Nevertheless, progress in the technical dimensions of health measurement 
has not been matched by progress in political and popular concepts. A lack 
of consensus regarding key methods of population health measurement has 
limited the diffusion of modern concepts. In particular, disagreements about 
how to represent age and time reflect divergent views about how to represent 
population health. We propose an approach based on the use of generic multi-
state dynamic population models and we examine whether the approach is 
feasible, whether it can be applied to real problems, and what sort of existing 
tools can be used to meet any additional data needs it entails.
In Chapter 2, we show that generic longitudinal multi-state modelling 
methods are feasible. However, their use appears to involve an increasing 
commitment to the use of mathematical tools as well as an increasing reliance 
on the ready availability of cheap computing power. Moreover, since such 
models, especially multi-state ones, are more complex than standard life 
tables, it is typically more difficult to estimate the required model parameters 
on the basis of observed epidemiological and demographic data.
The use of generic longitudinal population models as a tool for measuring 
population health benefit in an extended project of cost-effectiveness 
analysis at WHO seems notable, since it represents a significant institutional 
commitment to a form of population health measurement that is subtantially 
more sophisticated -- in terms of both the technical and conceptual aspects 
-- than either life table methods or burden of disease (“DALY”) models. These 
cost effectiveness applications, two of which are presented in Chapter 3 and 
Chapter 4, demonstrate that generic longitudinal modelling methods allow 
important policy questions to be addressed in a way that is more satisfactory 
than with non-longitudinal methods. 
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The use of generic models also facilitates comparisons across interventions 
and across disease areas in the health sector, factors that are important for 
ensuring policy relevance of population health measurements. Although the 
link between the results of the analysis of health measurement questions 
and related health policy is perhaps not always direct, the publications 
corresponding to these chapters have attracted a high level of interest. WHO 
also continues to work directly with a range of countries on projects of cost 
effectiveness and related policy development in the health sector using these 
and similar tools. 
However, generic longitudinal methods of population health measurement 
must acknowledge several serious challenges to their claims of realism and 
generality. In addition, the more widespread adoption of generic longitudinal 
models has arguably been limited by the fact that the corresponding modelling 
work is laborious and requires specialized skills. As alluded to above, supplying 
such models with input parameters can require the use of auxiliary modelling 
assumptions that can potentially militate against the desired realism and 
generality of the methods. Finally, multi-state generic longitudinal models are 
subject to model-specific sources of uncertainty that are difficult to quantify. 
To address these limitations and difficulties, a variety of methods from 
econometrics, statistics and epidemiology are in principle at the disposal of 
the modeller. The logistic family of models is one example discussed in detail 
in Chapters 5, 6 and 7. Chapter 5 presents a novel account of the logistic 
model that illuminates aspects of its wide use in epidemiology and related 
fields. When such models are used as estimation models, with age or time as 
an independent variable, they arguably constitute dynamic models. Those that 
involve age can be termed implicit dynamic methods under the assumption 
of population stationarity in the relevant outcome. Those that involve time, 
such as models of epidemic progression, are typically explicitly longitudinal. 
The use of logistic models as an auxiliary method can therefore help satisfy 
the parameter needs of generic longitudinal population models.
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However, the validity of the use of logistic and related models for this purpose 
will in general depend on the truth of a variety of assumptions. In some 
cases, the relevant assumptions will rely on the applicability to the estimation 
situation of an implicit mechanism of logistic diffusion that is described in 
Chapter 5. The work presented in Chapters 6 and 7 demonstrates in detail 
the application of these assumptions to a particular case. In addition to 
the assumption about logistic diffusion, that work relies explicitly on an 
assumption of population stationarity in the phenomenon of interest. 
These chapters show that, when used judiciously, the stationary population 
assumption, an ubiquitous and nearly unavoidable feature in the use of standard 
life table methods, can, especially when paired with standard models from 
epidemiology and related fields, provide a useful device for the exploitation 
of limited observed data for the estimation of parameters in longitudinal 
population models. Likewise, a number of common epidemiological measures, 
such as the population attributable fraction or odds ratios obtained from 
case-control studies, usually also implicitly embody a population stationarity 
assumption. 
The work presented in Chapter 7 relies on the assumption of population 
stationarity in all of these ways: stationarity in a logistic outcome, the 
interpretation of odds ratios as rate ratios and the use of population 
attributable fraction as measure of health impact. On the other hand, Chapter 
8 demonstrates the potential dangers of indiscriminately using the stationarity 
assumption by providing an example where the implications of the stationarity 
assumption can be directly compared with those from an explicitly dynamic 
(i.e. non-stationary) model using the same data set.
In order to complete the theory of the time dimension in the measurement 
of population health, the work presented here should be expanded upon and 
complemented by additional research focusing on, among other things, the 
measurement of uncertainty in longitudinal population models and on the 
implications, as model complexity increases, of the need to estimate a rapidly 
growing number of model parameters from a relatively fixed number of 
observable quantities.
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Longitudinal population models clearly represent a greater level of complexity 
than standard life table analysis. The concepts they involve, however, were all 
either implicitly or explicitly present at the birth of modern graphical methods 
of population health measurement in the later part of the 19th century. So long 
as the legitimate limitations of generic longitudinal models and their auxiliary 
methods are recognized, the availability of cheap computing power can 
provide a means of quantifying and operationalizing the original conceptual 
richness of population health measurement. 
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Samenvatting
Volksgezondheid is een zaak die zowel de overheid als de burgers aangaat. De 
ontwikkeling in de technische aspecten van volksgezondheidsmeting in de 
beleidsmatige en publieke sfeer heeft echter geen gelijke tred gehouden met die 
in de wetenschap. Een gebrek aan consensus betreffende basismethoden voor 
het meten van gezondheid op populatieniveau heeft ruime verspreiding van 
moderne begrippen in de weg gestaan. Met name uiteenlopende meningen over 
hoe rekening gehouden moet worden met leeftijd en tijd verraden verschillen 
van inzicht over hoe volksgezondheid het beste gemeten kan worden. Dit 
proefschrift stelt een benadering voor waarbij gebruik wordt gemaakt van 
zogenaamde generieke meerdimensionale dynamische bevolkingsmodellen, 
waarbij ook onderzocht wordt of de benadering uitvoerbaar is, of ze toegepast 
kan worden op problemen in de werkelijkheid, en welk type meetinstrument 
voldoet aan de datavereisten die dit met zich meebrengt. 
In Hoofdstuk 2 tonen wij de haalbaarheid aan van een aanpak die gebaseerd 
is op generieke longitudinale meerdimensionale modellen. Deze modellen 
lijken een intensieve toepassing van wiskundige methoden te vereisen, en 
zijn afhankelijk van de beschikbaarheid van goedkope rekencapaciteit. 
Omdat dergelijke modellen, met name de meerdimensionale modellen, 
complexer zijn dan standaard overlevingstafels, is het als regel moeilijker om 
de vereiste modelparameters op basis van waargenomen epidemiologische en 
demografische gegevens te schatten. 
Generieke longitudinale populatiemodellen worden onder meer voor het 
meten van gezondheidseffecten gebruikt bij kosteneffectiviteitanalyses bij 
de Wereld Gezondheids Organisatie (WHO). Dit is opvallend, omdat 
deze vorm van meten van volksgezondheid, die technisch en conceptueel 
veel verfijnder is dan methodes van overlevingstafels of ziektelast modellen 
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(„DALY“), een belangrijke inzet van de WHO vereist. Deze toepassingen 
van kosteneffectiviteitanalyse, waarvan er twee worden gepresenteerd in 
Hoofdstuk 3 en Hoofdstuk 4, tonen aan dat bij het gebruik van generieke 
longitudinale modelleringsmethoden, beleidsvragen op een bevredigender 
wijze beantwoord kunnen worden dan met niet-longitudinale methodes.
Het gebruik van generieke longitudinale populatiemodellen vergemakkelijkt 
tevens de vergelijking van verschillende interventies en van verschillende 
ziektegroepen in de gezondheidssector, wat de beleidsrelevantie vergroot. 
Ofschoon er geen direct verband is tussen de resultaten van de analyse 
van vraagstukken van gezondheidsmeting en het daarmee verbonden 
gezondheidsbeleid, hebben de publicaties waar deze hoofdstukken op zijn 
gebaseerd veel aandacht getrokken. De WHO zal met een reeks landen blijven 
samenwerken aan kosteneffectiviteitanalyses en verwante beleidsontwikkelingen 
in de gezondheidssector met gebruik van de hier beschreven technieken. 
Het realisme en de generaliseerbaarheid die worden geclaimd door de 
generieke longitudinale methodes voor de meting van de volksgezondheid, 
zijn serieus in twijfel getrokken. Bovendien zal een gebruik van dit type 
modellen vermoedelijk beperkt blijven omdat het benodigde modelleringswerk 
arbeidsintensief is en speciale vaardigheden vereist. Zoals hierboven al 
aangestipt kan het bepalen van de inputparameters van dergelijke modellen het 
gebruik vereisen van aanvullende veronderstellingen die strijdig kunnen zijn 
met gewenst realisme en generaliseerbaarheid. Tot slot zijn meerdimensionale 
generieke longitudinale modellen behept met moeilijk te kwantificeren 
oorzaken van onzekerheid.
Om deze tekortkomingen en problemen te verhelpen, heeft de modelleur 
methodes uit de econometrie, statistiek en de epidemiologie tot zijn 
beschikking. De logistische familie van modellen is een voorbeeld dat in 
detail in hoofdstukken 5, 6 en 7 wordt besproken. Hoofdstuk 5 bespreekt 
een interpretatie van het logistische model die een nieuw licht werpt op het 
wijdverspreid gebruik in de epidemiologie en verwante aandachtsgebieden. 
Wanneer dergelijke modellen als schattingsmodellen worden gebruikt, 
met leeftijd of tijd als onafhankelijke variabele, kunnen zij als dynamisch 
worden beschouwd. De modellen die rekening houden met leeftijd kunnen 
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aangeduid worden als impliciete dynamische rekenmethodes onder een 
stationariteitsaanname van de onderliggende populatie. De modellen die 
rekening houden met tijd, zoals modellen van epidemieën, zijn als regel expliciet 
longitudinaal. Logistische modellen kunnen daarom helpen te voldoen aan de 
parameterbehoeften van generieke longitudinale populatiemodellen. 
Het geldig gebruik van logistische en aanverwante modellen zal afhangen van 
de geldigheid van de onderliggende veronderstellingen. In sommige gevallen 
zullen de relevante veronderstellingen berusten op de toepasbaarheid van 
een mechanisme van logistische diffusie, zoals beschreven in Hoofdstuk 5. 
Hoofdstukken 6 en 7 beschrijven de toepassing van deze veronderstellingen 
op een specifiek voorbeeld. Naast de veronderstelling van logistische diffusie 
berust dit voorbeeld op de aanname van stationariteit van het beschreven 
fenomeen. 
Deze hoofdstukken tonen aan dat de stationaire populatie veronderstelling, 
een bijna onvermijdelijke eigenschap bij het gebruik van de standaard 
overlevingstafels, in combinatie met standaardmodellen van epidemiologie en 
verwante gebieden, van nut kan zijn voor het volledig benutten van empirische 
data voor het schatten van parameters in longitudinale populatie modellen. 
Zo wordt ook bij een aantal veel gebruikte epidemiologische maten, zoals 
de populatie attributieve fractie en de odds ratio verkregen uit case-control 
studies, meestal impliciet van een stationaire populatie uitgegaan. 
Het werk dat in Hoofdstuk 7 wordt gepresenteerd berust op de aanname van 
verschillende soorten stationariteit : stationariteit in een logistisch resultaat, 
de interpretatie van odds ratio’s als rate ratio’s en het gebruik van de populatie 
attributieve fractie als een maat van gezondheidseffect. Anderzijds toont 
Hoofdstuk 8 met een voorbeeld de potentiële gevaren van de stationaire 
populatie veronderstelling aan wanneer deze zonder onderscheid gebruikt wordt. 
In dit voorbeeld worden de implicaties van de stationariteitsveronderstelling 
duidelijk door directe vergelijking met resultaten van een expliciet dynamisch 
(d.w.z. niet-stationair) model dat dezelfde gegevens gebruikt.
Om de theorie van de tijdsdimensie bij het meten van gezondheid op 
populatie niveau te voltooien, moet het gepresenteerde werk in dit proefschrift 
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aangevuld worden met onderzoek dat gericht is op het meten van onzekerheid 
in longitudinale populatie modellen en, met gebruik van ingewikkelder 
modellen, op de implicaties voor het schatten van een toenemend aantal 
model parameters op basis van een relatief vast aantal waarneembare feiten. 
De longitudinale populatie modellen zijn duidelijk complexer dan standaard 
overlevingstafels. Echter de gebruikte begrippen waren impliciet dan wel 
expliciet aanwezig bij de geboorte van de moderne grafische methoden van 
volksgezondheidsmeting in de late 19de eeuw. Zolang er goed inzicht is in 
de bestaande tekortkomingen van generieke longitudinale modellen en hun 
hulpmethodes, kan de steeds goedkopere rekencapaciteit een middel zijn om de 
conceptuele rijkdom van het meten van de volksgezondheid te kwantificeren 
en te operationaliseren.
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